US20170065575A1 - Nampt inhibitors - Google Patents
Nampt inhibitors Download PDFInfo
- Publication number
- US20170065575A1 US20170065575A1 US15/357,383 US201615357383A US2017065575A1 US 20170065575 A1 US20170065575 A1 US 20170065575A1 US 201615357383 A US201615357383 A US 201615357383A US 2017065575 A1 US2017065575 A1 US 2017065575A1
- Authority
- US
- United States
- Prior art keywords
- nhr
- nhc
- carboxamide
- phenyl
- pyridazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 title abstract description 31
- 239000003112 inhibitor Substances 0.000 title description 17
- 102100033223 Nicotinamide phosphoribosyltransferase Human genes 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 229910003204 NH2 Inorganic materials 0.000 claims description 481
- 125000000217 alkyl group Chemical group 0.000 claims description 436
- 125000003118 aryl group Chemical group 0.000 claims description 380
- 125000000623 heterocyclic group Chemical group 0.000 claims description 326
- 125000001424 substituent group Chemical group 0.000 claims description 307
- 125000003342 alkenyl group Chemical group 0.000 claims description 282
- 125000000304 alkynyl group Chemical group 0.000 claims description 282
- 229910052731 fluorine Inorganic materials 0.000 claims description 281
- 229910052801 chlorine Inorganic materials 0.000 claims description 272
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 250
- 229910052739 hydrogen Inorganic materials 0.000 claims description 232
- 229910052740 iodine Inorganic materials 0.000 claims description 228
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 195
- 229910052794 bromium Inorganic materials 0.000 claims description 193
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 183
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 152
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 152
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 152
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 152
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 151
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 claims description 133
- 125000003545 alkoxy group Chemical group 0.000 claims description 101
- 239000001257 hydrogen Substances 0.000 claims description 99
- 125000001188 haloalkyl group Chemical group 0.000 claims description 81
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 67
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 44
- 125000004122 cyclic group Chemical group 0.000 claims description 21
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 11
- 208000030507 AIDS Diseases 0.000 claims description 10
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 206010003591 Ataxia Diseases 0.000 claims description 5
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 206010048768 Dermatosis Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 210000003679 cervix uteri Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 230000003176 fibrotic effect Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 230000037380 skin damage Effects 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 230000017423 tissue regeneration Effects 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 2
- 201000002471 spleen cancer Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 6
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 627
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 627
- 239000000460 chlorine Substances 0.000 description 249
- -1 3-propenyl Chemical group 0.000 description 84
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 62
- 150000002431 hydrogen Chemical class 0.000 description 59
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 125000006413 ring segment Chemical group 0.000 description 15
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 14
- 125000002541 furyl group Chemical group 0.000 description 14
- 125000001544 thienyl group Chemical group 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 13
- 125000004452 carbocyclyl group Chemical group 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 229910052736 halogen Inorganic materials 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 125000003367 polycyclic group Chemical group 0.000 description 8
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- IFOWYSDJMIJKDJ-HXUWFJFHSA-N (3r)-n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)[C@H]1CN(C=2N=NC=CC=2)CC1 IFOWYSDJMIJKDJ-HXUWFJFHSA-N 0.000 description 2
- VBBJAJDRGRUORG-IBGZPJMESA-N (3s)-n-[4-(1-acetylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 VBBJAJDRGRUORG-IBGZPJMESA-N 0.000 description 2
- SXTHNLLOSPXIGJ-FQEVSTJZSA-N (3s)-n-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CCC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 SXTHNLLOSPXIGJ-FQEVSTJZSA-N 0.000 description 2
- GYWXRQKDNAOXPP-IBGZPJMESA-N (3s)-n-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 GYWXRQKDNAOXPP-IBGZPJMESA-N 0.000 description 2
- IFOWYSDJMIJKDJ-FQEVSTJZSA-N (3s)-n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 IFOWYSDJMIJKDJ-FQEVSTJZSA-N 0.000 description 2
- KKSQBRLOAGOXOI-QFIPXVFZSA-N (3s)-n-[4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(CC)CC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 KKSQBRLOAGOXOI-QFIPXVFZSA-N 0.000 description 2
- QJJLHUZWDAGRQW-ZYZRXSCRSA-N (3s)-n-[4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)CC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 QJJLHUZWDAGRQW-ZYZRXSCRSA-N 0.000 description 2
- SAAOBTIKHHQBAX-FQEVSTJZSA-N (3s)-n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 SAAOBTIKHHQBAX-FQEVSTJZSA-N 0.000 description 2
- MOHGCMPCFANZHV-NRFANRHFSA-N (3s)-n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 MOHGCMPCFANZHV-NRFANRHFSA-N 0.000 description 2
- FSRCFBZVCJPYSW-NRFANRHFSA-N (3s)-n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 FSRCFBZVCJPYSW-NRFANRHFSA-N 0.000 description 2
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 2
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 2
- BYQDJIKFHYRHDC-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 BYQDJIKFHYRHDC-UHFFFAOYSA-N 0.000 description 2
- DUMIBRSKPSLVAE-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 DUMIBRSKPSLVAE-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- ZWOWADLGLVNVKW-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 ZWOWADLGLVNVKW-UHFFFAOYSA-N 0.000 description 2
- KWYZUSWHLNCMOL-UHFFFAOYSA-N n-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 KWYZUSWHLNCMOL-UHFFFAOYSA-N 0.000 description 2
- RTRWRACFWOYQKH-UHFFFAOYSA-N n-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 RTRWRACFWOYQKH-UHFFFAOYSA-N 0.000 description 2
- BGCAPKPJWNDCIN-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 BGCAPKPJWNDCIN-UHFFFAOYSA-N 0.000 description 2
- FMOFQJTWZIOQAI-UHFFFAOYSA-N n-[4-[1-(2-methoxyacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 FMOFQJTWZIOQAI-UHFFFAOYSA-N 0.000 description 2
- HNYXDRZMELIADW-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 HNYXDRZMELIADW-UHFFFAOYSA-N 0.000 description 2
- GGQIDINFYJXLSY-UHFFFAOYSA-N n-[4-[1-(2-methylsulfanylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CSC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 GGQIDINFYJXLSY-UHFFFAOYSA-N 0.000 description 2
- OGTSZEKMXKCBRT-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 OGTSZEKMXKCBRT-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- YETODIXQMRZKEG-RITPCOANSA-N (3ar,6ar)-1,2,3,3a,4,5,6,6a-octahydropyrrolo[2,3-c]pyrrole Chemical group C1NC[C@@H]2NCC[C@@H]21 YETODIXQMRZKEG-RITPCOANSA-N 0.000 description 1
- DLUDAUJQMXTXGQ-RQJHMYQMSA-N (3ar,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrole Chemical group C1CN[C@H]2CN(C)C[C@H]21 DLUDAUJQMXTXGQ-RQJHMYQMSA-N 0.000 description 1
- YQURLNGUWNDBIR-KNVOCYPGSA-N (3as,6ar)-5-methyl-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[3,4-c]pyrrole Chemical group C1NC[C@@H]2CN(C)C[C@@H]21 YQURLNGUWNDBIR-KNVOCYPGSA-N 0.000 description 1
- MFPQKBJQKBWGPN-HSZRJFAPSA-N (3r)-n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 MFPQKBJQKBWGPN-HSZRJFAPSA-N 0.000 description 1
- YAIJSHGCNRHCEX-OAQYLSRUSA-N (3r)-n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 YAIJSHGCNRHCEX-OAQYLSRUSA-N 0.000 description 1
- CFFQGPNPYLDEPC-NRFANRHFSA-N (3s)-1-(2-methylpyridin-3-yl)-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CCC(F)(F)F)CC1 CFFQGPNPYLDEPC-NRFANRHFSA-N 0.000 description 1
- LMWNYRIPGNVVPC-QFBILLFUSA-N (3s)-1-pyridazin-3-yl-n-[4-[(3r)-1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxyphenyl]pyrrolidine-3-carboxamide Chemical compound C1N(C(=O)CCC(F)(F)F)CC[C@H]1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 LMWNYRIPGNVVPC-QFBILLFUSA-N 0.000 description 1
- DUHZIIHLHNYLHI-IBGZPJMESA-N (3s)-1-pyridazin-3-yl-n-[4-[1-(1,3-thiazole-5-carbonyl)piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CN=CS1 DUHZIIHLHNYLHI-IBGZPJMESA-N 0.000 description 1
- DWGIAQXLVOURFY-SFHVURJKSA-N (3s)-1-pyridazin-3-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 DWGIAQXLVOURFY-SFHVURJKSA-N 0.000 description 1
- FUVFPAPMJBOEHR-IBGZPJMESA-N (3s)-1-pyridazin-3-yl-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 FUVFPAPMJBOEHR-IBGZPJMESA-N 0.000 description 1
- ZDOQAMDSWPCJJC-QHCPKHFHSA-N (3s)-1-pyridazin-3-yl-n-[4-[1-(4-thiophen-2-ylbutanoyl)piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CCCC1=CC=CS1 ZDOQAMDSWPCJJC-QHCPKHFHSA-N 0.000 description 1
- ODMYLZMDEIFOBB-FQEVSTJZSA-N (3s)-1-pyridazin-3-yl-n-[4-[1-(thiophene-2-carbonyl)piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CS1 ODMYLZMDEIFOBB-FQEVSTJZSA-N 0.000 description 1
- YUHHOFCNMNQSPJ-FQEVSTJZSA-N (3s)-1-pyridazin-3-yl-n-[4-[1-(thiophene-3-carbonyl)piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C=1C=CSC=1 YUHHOFCNMNQSPJ-FQEVSTJZSA-N 0.000 description 1
- CVRNXAVHZZPZEZ-QHCPKHFHSA-N (3s)-1-pyridazin-3-yl-n-[4-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 CVRNXAVHZZPZEZ-QHCPKHFHSA-N 0.000 description 1
- AXSGESNZILDYLZ-QFIPXVFZSA-N (3s)-1-pyridazin-3-yl-n-[4-[1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 AXSGESNZILDYLZ-QFIPXVFZSA-N 0.000 description 1
- JUNQYNXNWRQOAX-QFIPXVFZSA-N (3s)-1-pyridazin-3-yl-n-[4-[1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 JUNQYNXNWRQOAX-QFIPXVFZSA-N 0.000 description 1
- DRLGPYSDNFHGHK-QFIPXVFZSA-N (3s)-1-pyridazin-3-yl-n-[4-[1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]pyrrolidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 DRLGPYSDNFHGHK-QFIPXVFZSA-N 0.000 description 1
- RGVQNIDHBLQCNN-KRWDZBQOSA-N (3s)-1-pyridin-3-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxyphenyl]pyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2C=NC=CC=2)CC1 RGVQNIDHBLQCNN-KRWDZBQOSA-N 0.000 description 1
- VVLMDXHEEQFRTR-FQEVSTJZSA-N (3s)-n-[4-(1-benzoylazetidin-3-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(C1)CN1C(=O)C1=CC=CC=C1 VVLMDXHEEQFRTR-FQEVSTJZSA-N 0.000 description 1
- JBABTDOHKXMLTL-QFIPXVFZSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)oxyphenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)C=3C=CC=CC=3)=CC=2)CC1 JBABTDOHKXMLTL-QFIPXVFZSA-N 0.000 description 1
- TYCPXCSIGFNAHW-NRFANRHFSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CC=CC=C1 TYCPXCSIGFNAHW-NRFANRHFSA-N 0.000 description 1
- LGKXFNXCSXWDCA-VWLOTQADSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)CC1 LGKXFNXCSXWDCA-VWLOTQADSA-N 0.000 description 1
- DPPPEFNITFVTDY-DEOSSOPVSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound CC1=CC=NN=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)CC1 DPPPEFNITFVTDY-DEOSSOPVSA-N 0.000 description 1
- HRXSPZLJDLALOP-DEOSSOPVSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)CC1 HRXSPZLJDLALOP-DEOSSOPVSA-N 0.000 description 1
- MFPQKBJQKBWGPN-QHCPKHFHSA-N (3s)-n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 MFPQKBJQKBWGPN-QHCPKHFHSA-N 0.000 description 1
- HQSIHQMWMBQMPD-FQEVSTJZSA-N (3s)-n-[4-(1-but-3-enoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CC=C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 HQSIHQMWMBQMPD-FQEVSTJZSA-N 0.000 description 1
- KDZJXDXETFGZBH-QHCPKHFHSA-N (3s)-n-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CCCCCC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 KDZJXDXETFGZBH-QHCPKHFHSA-N 0.000 description 1
- OGGZJWFDUOTECA-QFIPXVFZSA-N (3s)-n-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CCCCC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 OGGZJWFDUOTECA-QFIPXVFZSA-N 0.000 description 1
- GWJZBTKKGCDHFZ-NRFANRHFSA-N (3s)-n-[4-(1-pent-4-enoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CCC=C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 GWJZBTKKGCDHFZ-NRFANRHFSA-N 0.000 description 1
- XKUUGBNZOSHOKT-NRFANRHFSA-N (3s)-n-[4-(1-pent-4-ynoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(CCC#C)=O)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 XKUUGBNZOSHOKT-NRFANRHFSA-N 0.000 description 1
- DAXZPWZXDMRZIJ-KRWDZBQOSA-N (3s)-n-[4-(1-propan-2-ylpyrazol-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=NN(C(C)C)C=C1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 DAXZPWZXDMRZIJ-KRWDZBQOSA-N 0.000 description 1
- OGGWMEGLSSTJCI-KRWDZBQOSA-N (3s)-n-[4-(1-tert-butylpyrazol-4-yl)phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=NN(C(C)(C)C)C=C1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 OGGWMEGLSSTJCI-KRWDZBQOSA-N 0.000 description 1
- CRFUERBUYJSPNL-FXAWDEMLSA-N (3s)-n-[4-[(3r)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1N(C(=O)C(C)(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 CRFUERBUYJSPNL-FXAWDEMLSA-N 0.000 description 1
- PTIIPNBVAYHITB-LAUBAEHRSA-N (3s)-n-[4-[(3r)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 PTIIPNBVAYHITB-LAUBAEHRSA-N 0.000 description 1
- HXGSPSSSEXICRJ-GHTZIAJQSA-N (3s)-n-[4-[(3r)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 HXGSPSSSEXICRJ-GHTZIAJQSA-N 0.000 description 1
- HXLBNBPMYBXFJV-NZQKXSOJSA-N (3s)-n-[4-[(3r)-1-(2-methylbenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 HXLBNBPMYBXFJV-NZQKXSOJSA-N 0.000 description 1
- FLRUEDGURIZVLH-GAJHUEQPSA-N (3s)-n-[4-[(3r)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 FLRUEDGURIZVLH-GAJHUEQPSA-N 0.000 description 1
- JTFMXLTVEXNWBI-WMZHIEFXSA-N (3s)-n-[4-[(3r)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 JTFMXLTVEXNWBI-WMZHIEFXSA-N 0.000 description 1
- WFABDMGANFYHQL-SIKLNZKXSA-N (3s)-n-[4-[(3r)-1-(4,4-difluorocyclohexanecarbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CC(F)(F)CCC1C(=O)N1C[C@H](OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 WFABDMGANFYHQL-SIKLNZKXSA-N 0.000 description 1
- VOGMLESXACDJDI-WMZHIEFXSA-N (3s)-n-[4-[(3r)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 VOGMLESXACDJDI-WMZHIEFXSA-N 0.000 description 1
- ZAHULVFPPGEVNG-NZQKXSOJSA-N (3s)-n-[4-[(3r)-1-benzoylpyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)[C@@H]2CN(CC2)C=2N=NC=CC=2)CN1C(=O)C1=CC=CC=C1 ZAHULVFPPGEVNG-NZQKXSOJSA-N 0.000 description 1
- CRFUERBUYJSPNL-PXNSSMCTSA-N (3s)-n-[4-[(3s)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1N(C(=O)C(C)(C)C)CC[C@@H]1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 CRFUERBUYJSPNL-PXNSSMCTSA-N 0.000 description 1
- HXGSPSSSEXICRJ-RXVVDRJESA-N (3s)-n-[4-[(3s)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1C[C@@H](OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 HXGSPSSSEXICRJ-RXVVDRJESA-N 0.000 description 1
- FLRUEDGURIZVLH-SBUREZEXSA-N (3s)-n-[4-[(3s)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2C[C@H](CC2)OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 FLRUEDGURIZVLH-SBUREZEXSA-N 0.000 description 1
- ZAHULVFPPGEVNG-REWPJTCUSA-N (3s)-n-[4-[(3s)-1-benzoylpyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C([C@@H](C1)OC2=CC=C(C=C2)NC(=O)[C@@H]2CN(CC2)C=2N=NC=CC=2)CN1C(=O)C1=CC=CC=C1 ZAHULVFPPGEVNG-REWPJTCUSA-N 0.000 description 1
- PVGXWHPOJUSYEJ-DEOSSOPVSA-N (3s)-n-[4-[1-(1-acetylpiperidine-4-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 PVGXWHPOJUSYEJ-DEOSSOPVSA-N 0.000 description 1
- AAYWMHNJDAYAKV-QHCPKHFHSA-N (3s)-n-[4-[1-(1-methylcyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CCCCC1 AAYWMHNJDAYAKV-QHCPKHFHSA-N 0.000 description 1
- GZSKHNDUONRHAI-FQEVSTJZSA-N (3s)-n-[4-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CC1 GZSKHNDUONRHAI-FQEVSTJZSA-N 0.000 description 1
- XGLBDIZFQJKQCO-DEOSSOPVSA-N (3s)-n-[4-[1-(1-phenylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1(C=2C=CC=CC=2)CC1 XGLBDIZFQJKQCO-DEOSSOPVSA-N 0.000 description 1
- MLEGTVQBGKVQFO-NRFANRHFSA-N (3s)-n-[4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 MLEGTVQBGKVQFO-NRFANRHFSA-N 0.000 description 1
- BIFYSMXQIHIVKP-KRWDZBQOSA-N (3s)-n-[4-[1-(2,2-dimethylpropanoyl)azetidin-3-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1N(C(=O)C(C)(C)C)CC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 BIFYSMXQIHIVKP-KRWDZBQOSA-N 0.000 description 1
- APNIZFPQPVBBRJ-IBGZPJMESA-N (3s)-n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxyphenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)C(C)(C)C)=CC=2)CC1 APNIZFPQPVBBRJ-IBGZPJMESA-N 0.000 description 1
- IUVIVJZWMQHAEG-SFHVURJKSA-N (3s)-n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 IUVIVJZWMQHAEG-SFHVURJKSA-N 0.000 description 1
- SZXCWTSHMDPRJZ-NRFANRHFSA-N (3s)-n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound CC1=CC=NN=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)C)CC1 SZXCWTSHMDPRJZ-NRFANRHFSA-N 0.000 description 1
- ZLYQUUMVCSOWTG-NRFANRHFSA-N (3s)-n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)C)CC1 ZLYQUUMVCSOWTG-NRFANRHFSA-N 0.000 description 1
- PHTLQBNNMPFXMM-SFHVURJKSA-N (3s)-n-[4-[1-(2,2-dimethylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=NN(CC(C)(C)C)C=C1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 PHTLQBNNMPFXMM-SFHVURJKSA-N 0.000 description 1
- GCAYZPAZTLLIEY-LJAQVGFWSA-N (3s)-n-[4-[1-(2,2-diphenylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 GCAYZPAZTLLIEY-LJAQVGFWSA-N 0.000 description 1
- VHMLKQWTFYAKKF-FQEVSTJZSA-N (3s)-n-[4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1F VHMLKQWTFYAKKF-FQEVSTJZSA-N 0.000 description 1
- REMZDKAYQKTRKZ-DEOSSOPVSA-N (3s)-n-[4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1C REMZDKAYQKTRKZ-DEOSSOPVSA-N 0.000 description 1
- MFAHTFJENFPRIR-BPARTEKVSA-N (3s)-n-[4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 MFAHTFJENFPRIR-BPARTEKVSA-N 0.000 description 1
- HVAKHEKKCFFSOT-FQEVSTJZSA-N (3s)-n-[4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 HVAKHEKKCFFSOT-FQEVSTJZSA-N 0.000 description 1
- IBVNCIAZNZYXMP-KRWDZBQOSA-N (3s)-n-[4-[1-(2,4-difluorobenzoyl)azetidin-3-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)C1 IBVNCIAZNZYXMP-KRWDZBQOSA-N 0.000 description 1
- QSRBDWRELAGTEE-FQEVSTJZSA-N (3s)-n-[4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 QSRBDWRELAGTEE-FQEVSTJZSA-N 0.000 description 1
- VGQXKAJOUDPGMH-DEOSSOPVSA-N (3s)-n-[4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 VGQXKAJOUDPGMH-DEOSSOPVSA-N 0.000 description 1
- GIGHWSVDSQKWOH-FQEVSTJZSA-N (3s)-n-[4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC=C(Cl)C(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 GIGHWSVDSQKWOH-FQEVSTJZSA-N 0.000 description 1
- IEMZPOHXSWNGPB-FQEVSTJZSA-N (3s)-n-[4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=C(F)C(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 IEMZPOHXSWNGPB-FQEVSTJZSA-N 0.000 description 1
- MVSABDIPGJIRJU-DEOSSOPVSA-N (3s)-n-[4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC=C(C)C(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 MVSABDIPGJIRJU-DEOSSOPVSA-N 0.000 description 1
- SOHFGVWDNUGDIG-DEOSSOPVSA-N (3s)-n-[4-[1-(2-benzamidoacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CNC(=O)C1=CC=CC=C1 SOHFGVWDNUGDIG-DEOSSOPVSA-N 0.000 description 1
- NOOVMLPAWNNEPZ-NRFANRHFSA-N (3s)-n-[4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 NOOVMLPAWNNEPZ-NRFANRHFSA-N 0.000 description 1
- WQOZOGDLAHBQGZ-DEOSSOPVSA-N (3s)-n-[4-[1-(2-cyclohexylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CC1CCCCC1 WQOZOGDLAHBQGZ-DEOSSOPVSA-N 0.000 description 1
- SOMZSFRQHWAPCN-QHCPKHFHSA-N (3s)-n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CC1CCCC1 SOMZSFRQHWAPCN-QHCPKHFHSA-N 0.000 description 1
- HVZNKRRQUFCPIB-QHCPKHFHSA-N (3s)-n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1C=NN=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CC1CCCC1 HVZNKRRQUFCPIB-QHCPKHFHSA-N 0.000 description 1
- WALDIRUCVXEFFT-DEOSSOPVSA-N (3s)-n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1C=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CC1CCCC1 WALDIRUCVXEFFT-DEOSSOPVSA-N 0.000 description 1
- DDVPOSFHEHXTSN-FQEVSTJZSA-N (3s)-n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CC1CC1 DDVPOSFHEHXTSN-FQEVSTJZSA-N 0.000 description 1
- CCKPIUXQTJZDQH-NRFANRHFSA-N (3s)-n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CC1CC1 CCKPIUXQTJZDQH-NRFANRHFSA-N 0.000 description 1
- IQTUQVZZBGUUNN-FQEVSTJZSA-N (3s)-n-[4-[1-(2-ethoxyacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)COCC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 IQTUQVZZBGUUNN-FQEVSTJZSA-N 0.000 description 1
- RGOKJFNLUSVDTQ-SFHVURJKSA-N (3s)-n-[4-[1-(2-fluorobenzoyl)azetidin-3-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)C1 RGOKJFNLUSVDTQ-SFHVURJKSA-N 0.000 description 1
- KOYAASRRUUELQG-FQEVSTJZSA-N (3s)-n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)C=3C(=CC=CC=3)F)=CC=2)CC1 KOYAASRRUUELQG-FQEVSTJZSA-N 0.000 description 1
- KNHZOMNAOSICGP-IBGZPJMESA-N (3s)-n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 KNHZOMNAOSICGP-IBGZPJMESA-N 0.000 description 1
- PQFYGXUEGPMBBB-QHCPKHFHSA-N (3s)-n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)CC1 PQFYGXUEGPMBBB-QHCPKHFHSA-N 0.000 description 1
- RMVLRRDBYRXBFZ-QFIPXVFZSA-N (3s)-n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)CC1 RMVLRRDBYRXBFZ-QFIPXVFZSA-N 0.000 description 1
- YAIJSHGCNRHCEX-NRFANRHFSA-N (3s)-n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 YAIJSHGCNRHCEX-NRFANRHFSA-N 0.000 description 1
- JTKSBCMIIWSPGP-SFHVURJKSA-N (3s)-n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2C=NC=CC=2)CC1 JTKSBCMIIWSPGP-SFHVURJKSA-N 0.000 description 1
- SNDWFNCSJYTUTM-IBGZPJMESA-N (3s)-n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2C=NN=CC=2)CC1 SNDWFNCSJYTUTM-IBGZPJMESA-N 0.000 description 1
- PZQWPEYEDVUKHU-KRWDZBQOSA-N (3s)-n-[4-[1-(2-hydroxy-2-methylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=NN(CC(C)(O)C)C=C1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 PZQWPEYEDVUKHU-KRWDZBQOSA-N 0.000 description 1
- IREKLUJDUJUGEX-IBGZPJMESA-N (3s)-n-[4-[1-(2-methoxyacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 IREKLUJDUJUGEX-IBGZPJMESA-N 0.000 description 1
- MKZDZWVORGTTHH-QFIPXVFZSA-N (3s)-n-[4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound COC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 MKZDZWVORGTTHH-QFIPXVFZSA-N 0.000 description 1
- JZOWVPKJMSNBDB-FQEVSTJZSA-N (3s)-n-[4-[1-(2-methylbenzoyl)azetidin-3-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC=CC=C1C(=O)N1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)C1 JZOWVPKJMSNBDB-FQEVSTJZSA-N 0.000 description 1
- BWMJZXXCIFAHPH-QHCPKHFHSA-N (3s)-n-[4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 BWMJZXXCIFAHPH-QHCPKHFHSA-N 0.000 description 1
- BNPWBIKCQPLIGU-DKTYTTGXSA-N (3s)-n-[4-[1-(2-methylcyclopropanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1CC1C(=O)N1CCC(OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 BNPWBIKCQPLIGU-DKTYTTGXSA-N 0.000 description 1
- KQAOQIGDSFZJBS-BPARTEKVSA-N (3s)-n-[4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)CCC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 KQAOQIGDSFZJBS-BPARTEKVSA-N 0.000 description 1
- MQFNXKBHWPODED-IBGZPJMESA-N (3s)-n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2C=NC=CC=2)CC1 MQFNXKBHWPODED-IBGZPJMESA-N 0.000 description 1
- RKHKJTCKKLAUKR-SFHVURJKSA-N (3s)-n-[4-[1-(2-methylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 RKHKJTCKKLAUKR-SFHVURJKSA-N 0.000 description 1
- ZWALMMFYLLORAB-MHZLTWQESA-N (3s)-n-[4-[1-(2-naphthalen-1-ylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C([C@@H](C1)C(NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC=2C3=CC=CC=C3C=CC=2)=O)CN1C1=CC=CN=N1 ZWALMMFYLLORAB-MHZLTWQESA-N 0.000 description 1
- XXGNMNXKYQBDNS-NDEPHWFRSA-N (3s)-n-[4-[1-(2-naphthalen-2-ylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C([C@@H](C1)C(NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC=2C=C3C=CC=CC3=CC=2)=O)CN1C1=CC=CN=N1 XXGNMNXKYQBDNS-NDEPHWFRSA-N 0.000 description 1
- FMJHHEWVPIRSSX-VWLOTQADSA-N (3s)-n-[4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=C(C)C(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 FMJHHEWVPIRSSX-VWLOTQADSA-N 0.000 description 1
- NRCLSAJPKCRGOK-FQEVSTJZSA-N (3s)-n-[4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 NRCLSAJPKCRGOK-FQEVSTJZSA-N 0.000 description 1
- POKWUKMYJMOQQP-KRWDZBQOSA-N (3s)-n-[4-[1-(3,5-difluorobenzoyl)azetidin-3-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CC(C2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 POKWUKMYJMOQQP-KRWDZBQOSA-N 0.000 description 1
- XBJPATISITTXDY-FQEVSTJZSA-N (3s)-n-[4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 XBJPATISITTXDY-FQEVSTJZSA-N 0.000 description 1
- OYRUSZHSNKXBFX-DEOSSOPVSA-N (3s)-n-[4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC(C)=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 OYRUSZHSNKXBFX-DEOSSOPVSA-N 0.000 description 1
- BQGQODJCVBNJDH-QFIPXVFZSA-N (3s)-n-[4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 BQGQODJCVBNJDH-QFIPXVFZSA-N 0.000 description 1
- QRGIWTBQHFRDPR-DEOSSOPVSA-N (3s)-n-[4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC(C#N)=C1 QRGIWTBQHFRDPR-DEOSSOPVSA-N 0.000 description 1
- OQTNKNLVSWHMTI-NRFANRHFSA-N (3s)-n-[4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CCOCC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 OQTNKNLVSWHMTI-NRFANRHFSA-N 0.000 description 1
- YGVMZXRPPCJECE-QFIPXVFZSA-N (3s)-n-[4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=C(F)C=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 YGVMZXRPPCJECE-QFIPXVFZSA-N 0.000 description 1
- NJJQTCLZPKGMKR-QHCPKHFHSA-N (3s)-n-[4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=C(F)C(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 NJJQTCLZPKGMKR-QHCPKHFHSA-N 0.000 description 1
- UESSHWGPPGFEFC-IBGZPJMESA-N (3s)-n-[4-[1-(3-fluorobenzoyl)azetidin-3-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CC(C2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 UESSHWGPPGFEFC-IBGZPJMESA-N 0.000 description 1
- XGOOBLBFNYDVOJ-FQEVSTJZSA-N (3s)-n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 XGOOBLBFNYDVOJ-FQEVSTJZSA-N 0.000 description 1
- MAOBLBMQRHEQRD-QFIPXVFZSA-N (3s)-n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 MAOBLBMQRHEQRD-QFIPXVFZSA-N 0.000 description 1
- IMWVXVSQJPJHTN-QHCPKHFHSA-N (3s)-n-[4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound COC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 IMWVXVSQJPJHTN-QHCPKHFHSA-N 0.000 description 1
- JZWASNRRTFSZPL-DEOSSOPVSA-N (3s)-n-[4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 JZWASNRRTFSZPL-DEOSSOPVSA-N 0.000 description 1
- UYVMUCJPTOJVRM-BPARTEKVSA-N (3s)-n-[4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)CC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 UYVMUCJPTOJVRM-BPARTEKVSA-N 0.000 description 1
- ZFUFKVSAXCZYCW-FQEVSTJZSA-N (3s)-n-[4-[1-(3-methylsulfanylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CCSC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 ZFUFKVSAXCZYCW-FQEVSTJZSA-N 0.000 description 1
- FWCOCMUSIQHBNA-NRFANRHFSA-N (3s)-n-[4-[1-(3-methylthiophene-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CSC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1C FWCOCMUSIQHBNA-NRFANRHFSA-N 0.000 description 1
- OSLZEQOOMBWQNR-QFIPXVFZSA-N (3s)-n-[4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 OSLZEQOOMBWQNR-QFIPXVFZSA-N 0.000 description 1
- PPGVCALBWIYAMZ-DEOSSOPVSA-N (3s)-n-[4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 PPGVCALBWIYAMZ-DEOSSOPVSA-N 0.000 description 1
- FYBGBSYHTZXUEJ-IBGZPJMESA-N (3s)-n-[4-[1-(4-fluorobenzoyl)azetidin-3-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)C1 FYBGBSYHTZXUEJ-IBGZPJMESA-N 0.000 description 1
- XFNKQYLFEVFTDW-FQEVSTJZSA-N (3s)-n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 XFNKQYLFEVFTDW-FQEVSTJZSA-N 0.000 description 1
- UAIGLBACRNSXIS-QFIPXVFZSA-N (3s)-n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 UAIGLBACRNSXIS-QFIPXVFZSA-N 0.000 description 1
- OOACBUXNDAJDHL-QFIPXVFZSA-N (3s)-n-[4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 OOACBUXNDAJDHL-QFIPXVFZSA-N 0.000 description 1
- YCXDYUYHKJHYPX-QHCPKHFHSA-N (3s)-n-[4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 YCXDYUYHKJHYPX-QHCPKHFHSA-N 0.000 description 1
- WLCQDNKXLSYMEC-DEOSSOPVSA-N (3s)-n-[4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 WLCQDNKXLSYMEC-DEOSSOPVSA-N 0.000 description 1
- LFELNDFSDTXTAY-QFIPXVFZSA-N (3s)-n-[4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(C)C)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 LFELNDFSDTXTAY-QFIPXVFZSA-N 0.000 description 1
- GYVNOJNHPZFKBS-SANMLTNESA-N (3s)-n-[4-[1-(4-propan-2-ylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 GYVNOJNHPZFKBS-SANMLTNESA-N 0.000 description 1
- OALIYKNNMLLLBI-VWLOTQADSA-N (3s)-n-[4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 OALIYKNNMLLLBI-VWLOTQADSA-N 0.000 description 1
- XPJVKTXEEXFWCN-QFIPXVFZSA-N (3s)-n-[4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC=C(F)C=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 XPJVKTXEEXFWCN-QFIPXVFZSA-N 0.000 description 1
- QICZZDBQWMVGIU-QHCPKHFHSA-N (3s)-n-[4-[1-(6-methylpyridine-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=NC(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 QICZZDBQWMVGIU-QHCPKHFHSA-N 0.000 description 1
- CVEPLFCCDSKCNZ-QFIPXVFZSA-N (3s)-n-[4-[1-(cyclohexanecarbonyl)piperidin-4-yl]oxyphenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1C[C@@H](C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)C3CCCCC3)=CC=2)CC1 CVEPLFCCDSKCNZ-QFIPXVFZSA-N 0.000 description 1
- WKMTWWSFGISAKZ-NRFANRHFSA-N (3s)-n-[4-[1-(cyclohexanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCCCC1 WKMTWWSFGISAKZ-NRFANRHFSA-N 0.000 description 1
- KDOXLDCUPMGCFS-QHCPKHFHSA-N (3s)-n-[4-[1-(cyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCCC1 KDOXLDCUPMGCFS-QHCPKHFHSA-N 0.000 description 1
- VUDLQJRZDRLRRI-QFIPXVFZSA-N (3s)-n-[4-[1-(cyclopentanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCC1 VUDLQJRZDRLRRI-QFIPXVFZSA-N 0.000 description 1
- LBMMSINUPHUSJI-FQEVSTJZSA-N (3s)-n-[4-[1-(cyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CC1 LBMMSINUPHUSJI-FQEVSTJZSA-N 0.000 description 1
- KMLXYBKKYONOGZ-SFHVURJKSA-N (3s)-n-[4-[1-(cyclopropylmethyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(=C1)C=NN1CC1CC1 KMLXYBKKYONOGZ-SFHVURJKSA-N 0.000 description 1
- UWHPQIHSUVEZQF-FQEVSTJZSA-N (3s)-n-[4-[1-(furan-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CO1 UWHPQIHSUVEZQF-FQEVSTJZSA-N 0.000 description 1
- GAJIULGOWKQPHO-FQEVSTJZSA-N (3s)-n-[4-[1-(furan-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C=1C=COC=1 GAJIULGOWKQPHO-FQEVSTJZSA-N 0.000 description 1
- GDJHCUBIRWZWGC-VWLOTQADSA-N (3s)-n-[4-[1-(naphthalene-1-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C([C@@H](C1)C(NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C3=CC=CC=C3C=CC=2)=O)CN1C1=CC=CN=N1 GDJHCUBIRWZWGC-VWLOTQADSA-N 0.000 description 1
- ZXGICSVNDVFDOR-YDNXMHBPSA-N (3s)-n-[4-[1-(oxan-2-ylmethyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(=C1)C=NN1CC1CCCCO1 ZXGICSVNDVFDOR-YDNXMHBPSA-N 0.000 description 1
- HDCPJCZMGTULFS-AIBWNMTMSA-N (3s)-n-[4-[1-(oxolane-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCO1 HDCPJCZMGTULFS-AIBWNMTMSA-N 0.000 description 1
- CXXQXSUJNLJEQA-XJDOXCRVSA-N (3s)-n-[4-[1-(oxolane-3-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1C=NC=CC=1)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCOC1 CXXQXSUJNLJEQA-XJDOXCRVSA-N 0.000 description 1
- VUNNOWCRBAMKKX-BGERDNNASA-N (3s)-n-[4-[1-(oxolane-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCOC1 VUNNOWCRBAMKKX-BGERDNNASA-N 0.000 description 1
- HZYPWRMJBWTVKG-RPLLCQBOSA-N (3s)-n-[4-[1-[(2r)-2-methoxy-2-phenylacetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C([C@@H](C1)C(=O)NC2=CC=C(C=C2)C2CCN(CC2)C(=O)[C@H](OC)C=2C=CC=CC=2)CN1C1=CC=CN=N1 HZYPWRMJBWTVKG-RPLLCQBOSA-N 0.000 description 1
- JLQWVRLXZPKSDZ-YADARESESA-N (3s)-n-[4-[1-[(2r)-oxolane-2-carbonyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1C=NC=CC=1)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)[C@H]1CCCO1 JLQWVRLXZPKSDZ-YADARESESA-N 0.000 description 1
- HZYPWRMJBWTVKG-IGKIAQTJSA-N (3s)-n-[4-[1-[(2s)-2-methoxy-2-phenylacetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C([C@@H](C1)C(=O)NC2=CC=C(C=C2)C2CCN(CC2)C(=O)[C@@H](OC)C=2C=CC=CC=2)CN1C1=CC=CN=N1 HZYPWRMJBWTVKG-IGKIAQTJSA-N 0.000 description 1
- IPFGVIIJEDFOSM-PMACEKPBSA-N (3s)-n-[4-[1-[(2s)-2-methylbutanoyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)[C@@H](C)CC)CCC1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2C=NC=CC=2)CC1 IPFGVIIJEDFOSM-PMACEKPBSA-N 0.000 description 1
- FZCIRDVIWIUFPI-BDYUSTAISA-N (3s)-n-[4-[1-[(2s)-2-phenylbutanoyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C([C@@H](C1)C(=O)NC2=CC=C(C=C2)C2CCN(CC2)C(=O)[C@@H](CC)C=2C=CC=CC=2)CN1C1=CC=CN=N1 FZCIRDVIWIUFPI-BDYUSTAISA-N 0.000 description 1
- JLQWVRLXZPKSDZ-CYFREDJKSA-N (3s)-n-[4-[1-[(2s)-oxolane-2-carbonyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1C=NC=CC=1)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)[C@@H]1CCCO1 JLQWVRLXZPKSDZ-CYFREDJKSA-N 0.000 description 1
- ORQCYKQFSYWGQM-FQEVSTJZSA-N (3s)-n-[4-[1-[(4-methyloxan-4-yl)methyl]pyrazol-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=C(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)C=NN1CC1(C)CCOCC1 ORQCYKQFSYWGQM-FQEVSTJZSA-N 0.000 description 1
- LVGIHRNPZQPVPN-QFIPXVFZSA-N (3s)-n-[4-[1-[2-(2,4-dichlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 LVGIHRNPZQPVPN-QFIPXVFZSA-N 0.000 description 1
- MGWGRFSKQIFVDF-NRFANRHFSA-N (3s)-n-[4-[1-[2-(2,6-dichlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1CC(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 MGWGRFSKQIFVDF-NRFANRHFSA-N 0.000 description 1
- KDQYZQLTBRZZQY-QHCPKHFHSA-N (3s)-n-[4-[1-[2-(2-chlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 KDQYZQLTBRZZQY-QHCPKHFHSA-N 0.000 description 1
- HVEBAOTUUZVXQY-QHCPKHFHSA-N (3s)-n-[4-[1-[2-(2-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 HVEBAOTUUZVXQY-QHCPKHFHSA-N 0.000 description 1
- MLFVINGOXOEYIM-NRFANRHFSA-N (3s)-n-[4-[1-[2-(2-methoxyethoxy)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CN(C(=O)COCCOC)CCC1C(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2N=NC=CC=2)CC1 MLFVINGOXOEYIM-NRFANRHFSA-N 0.000 description 1
- WZPITNACULIXDS-SANMLTNESA-N (3s)-n-[4-[1-[2-(3,5-dimethylphenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound CC1=CC(C)=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 WZPITNACULIXDS-SANMLTNESA-N 0.000 description 1
- AWDXMKAQXKIHKK-QHCPKHFHSA-N (3s)-n-[4-[1-[2-(3-chlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound ClC1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 AWDXMKAQXKIHKK-QHCPKHFHSA-N 0.000 description 1
- WXIBHKPWJYMDSG-QHCPKHFHSA-N (3s)-n-[4-[1-[2-(3-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 WXIBHKPWJYMDSG-QHCPKHFHSA-N 0.000 description 1
- NGMNGGUNEGOUDV-QHCPKHFHSA-N (3s)-n-[4-[1-[2-(4-chlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 NGMNGGUNEGOUDV-QHCPKHFHSA-N 0.000 description 1
- TWWZULWWXMAUJY-QHCPKHFHSA-N (3s)-n-[4-[1-[2-(4-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 TWWZULWWXMAUJY-QHCPKHFHSA-N 0.000 description 1
- AKTQBYCYIZTBHB-DEOSSOPVSA-N (3s)-n-[4-[1-[2-(4-methylphenoxy)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1OCC(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 AKTQBYCYIZTBHB-DEOSSOPVSA-N 0.000 description 1
- XDCUYLKPORHVHF-QFIPXVFZSA-N (3s)-n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CC1CCOCC1 XDCUYLKPORHVHF-QFIPXVFZSA-N 0.000 description 1
- GKCVPBZBEINYBK-QHCPKHFHSA-N (3s)-n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CC1CCOCC1 GKCVPBZBEINYBK-QHCPKHFHSA-N 0.000 description 1
- DBVYNWHVJBIBAS-FQEVSTJZSA-N (3s)-n-[4-[1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)=C1 DBVYNWHVJBIBAS-FQEVSTJZSA-N 0.000 description 1
- HBKKAEKHFDZJTJ-FQEVSTJZSA-N (3s)-n-[4-[1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1C(=O)N1CCC(C=2C=CC(NC(=O)[C@@H]3CN(CC3)C=3N=NC=CC=3)=CC=2)CC1 HBKKAEKHFDZJTJ-FQEVSTJZSA-N 0.000 description 1
- JCOSAUGTTNIDNV-DEOSSOPVSA-N (3s)-n-[4-[1-[3-(benzenesulfonyl)propanoyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylpyrrolidine-3-carboxamide Chemical compound O=C([C@@H]1CN(CC1)C=1N=NC=CC=1)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CCS(=O)(=O)C1=CC=CC=C1 JCOSAUGTTNIDNV-DEOSSOPVSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- RQPDLNSKAAOHTF-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydro-1,5-naphthyridine Chemical group C1CCNC2CCCNC21 RQPDLNSKAAOHTF-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- YJHSZTJRQKVYKC-UHFFFAOYSA-N 1-(2-cyanopyridin-3-yl)-n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C#N)C1 YJHSZTJRQKVYKC-UHFFFAOYSA-N 0.000 description 1
- KSBDOXBQIVLQCX-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-(1-pentanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 KSBDOXBQIVLQCX-UHFFFAOYSA-N 0.000 description 1
- SEDBIAKWSHVRAG-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-(1-propanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 SEDBIAKWSHVRAG-UHFFFAOYSA-N 0.000 description 1
- XEWDTJLLVQKUNT-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(1-methylpyrrole-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2N(C=CC=2)C)C1 XEWDTJLLVQKUNT-UHFFFAOYSA-N 0.000 description 1
- YGTAPDTUSVEKKE-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(2-morpholin-4-ylacetyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CN2CCOCC2)C1 YGTAPDTUSVEKKE-UHFFFAOYSA-N 0.000 description 1
- XFKZKJXEFHCQBM-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(2-pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CN2CCCC2)C1 XFKZKJXEFHCQBM-UHFFFAOYSA-N 0.000 description 1
- LAGSTDKHZWEKEI-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC(F)(F)F)C1 LAGSTDKHZWEKEI-UHFFFAOYSA-N 0.000 description 1
- NWIBEAVABZOJJZ-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(3-methylthiophene-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1=CSC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C(=NC=CC=3)C)=CC=2)=C1C NWIBEAVABZOJJZ-UHFFFAOYSA-N 0.000 description 1
- TVILFAZKGYNQAQ-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(3-morpholin-4-ylpropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CCN2CCOCC2)C1 TVILFAZKGYNQAQ-UHFFFAOYSA-N 0.000 description 1
- POGZZUKDQBSWLS-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(3-piperidin-1-ylpropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CCN2CCCCC2)C1 POGZZUKDQBSWLS-UHFFFAOYSA-N 0.000 description 1
- FZCQQQLSNRSDDF-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CCC(F)(F)F)C1 FZCQQQLSNRSDDF-UHFFFAOYSA-N 0.000 description 1
- IKLUXJFUWHPILN-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(5-methylthiophene-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C(=NC=CC=3)C)=CC=2)CC1 IKLUXJFUWHPILN-UHFFFAOYSA-N 0.000 description 1
- ZDZWSQGRPYXGAU-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(pyridazine-3-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2N=NC=CC=2)C1 ZDZWSQGRPYXGAU-UHFFFAOYSA-N 0.000 description 1
- SBIACOUWWHFVRP-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(thiophene-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2SC=CC=2)C1 SBIACOUWWHFVRP-UHFFFAOYSA-N 0.000 description 1
- MCEWUEKUMDXHPA-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-(thiophene-3-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C2=CSC=C2)C1 MCEWUEKUMDXHPA-UHFFFAOYSA-N 0.000 description 1
- KXHHDUGELMXENK-JOCHJYFZSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-[(2r)-5-oxopyrrolidine-2-carbonyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)[C@@H]2NC(=O)CC2)C1 KXHHDUGELMXENK-JOCHJYFZSA-N 0.000 description 1
- VSUCOSOBDAPVTG-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)CC3CCOCC3)=CC=2)C1 VSUCOSOBDAPVTG-UHFFFAOYSA-N 0.000 description 1
- DQYSOZAEYBERTP-UHFFFAOYSA-N 1-(2-methylpyridin-3-yl)-n-[4-[1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC(=CC=2)C(F)(F)F)C1 DQYSOZAEYBERTP-UHFFFAOYSA-N 0.000 description 1
- IITCHUJZTMPPHI-UHFFFAOYSA-N 1-(4-cyanopyridin-3-yl)-n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=CC=NC=2)C#N)C1 IITCHUJZTMPPHI-UHFFFAOYSA-N 0.000 description 1
- UCDMCTMBCBOXQD-UHFFFAOYSA-N 1-(4-fluoropyridin-3-yl)-n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC1=CC=NC=C1N1CC(C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)CC3CCOCC3)=CC=2)C1 UCDMCTMBCBOXQD-UHFFFAOYSA-N 0.000 description 1
- ZXSYNEUMQSAIFS-UHFFFAOYSA-N 1-(4-methylpyridin-3-yl)-n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound CC1=CC=NC=C1N1CC(C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)CC3CCOCC3)=CC=2)C1 ZXSYNEUMQSAIFS-UHFFFAOYSA-N 0.000 description 1
- FHGRYCGPSPBTLM-UHFFFAOYSA-N 1-(6-chloropyridazin-3-yl)-n-[4-[1-(2,2-dimethylpropyl)pyrazol-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1=NN(CC(C)(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(Cl)=CC=2)C1 FHGRYCGPSPBTLM-UHFFFAOYSA-N 0.000 description 1
- IXXDXUKXEALHCM-UHFFFAOYSA-N 1-(6-fluoropyridazin-3-yl)-n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(F)=CC=2)C1 IXXDXUKXEALHCM-UHFFFAOYSA-N 0.000 description 1
- SFPSCKHQDOATDU-LJQANCHMSA-N 1-(6-methylpyridazin-3-yl)-n-[4-[(3r)-1-(1,3-thiazole-4-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(O[C@H]3CN(CC3)C(=O)C=3N=CSC=3)=CC=2)C1 SFPSCKHQDOATDU-LJQANCHMSA-N 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- AFNCBWNNOVTDGK-UHFFFAOYSA-N 1-methyl-5-[4-[(1-pyridazin-3-ylazetidine-3-carbonyl)amino]phenyl]pyrazole-3-carboxylic acid Chemical compound CN1N=C(C(O)=O)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 AFNCBWNNOVTDGK-UHFFFAOYSA-N 0.000 description 1
- QDZQOXWSVADNAO-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-(3,3,3-trifluoropropylcarbamoyl)phenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(=O)NCCC(F)(F)F)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 QDZQOXWSVADNAO-UHFFFAOYSA-N 0.000 description 1
- HQCBNRVOJHOCEL-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-(thiophen-3-ylcarbamoyl)phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC=1C=CSC=1 HQCBNRVOJHOCEL-UHFFFAOYSA-N 0.000 description 1
- XWGXEVAFQZCMDR-GOSISDBHSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-(1,3-thiazole-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C1=NC=CS1 XWGXEVAFQZCMDR-GOSISDBHSA-N 0.000 description 1
- FPDIQWRPPUYEDW-GOSISDBHSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-(1,3-thiazole-4-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C1=CSC=N1 FPDIQWRPPUYEDW-GOSISDBHSA-N 0.000 description 1
- ZUTSISZQWIXDSK-QGZVFWFLSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)CC(F)(F)F)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 ZUTSISZQWIXDSK-QGZVFWFLSA-N 0.000 description 1
- AANCGDOGZVRTNO-HXUWFJFHSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-(pyridine-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C1=CC=CC=N1 AANCGDOGZVRTNO-HXUWFJFHSA-N 0.000 description 1
- CEQQHBXMYPKLSU-LJQANCHMSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-(thiophene-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C1=CC=CS1 CEQQHBXMYPKLSU-LJQANCHMSA-N 0.000 description 1
- GMVFGJUJHRIZHN-HXUWFJFHSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-(thiophene-3-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C=1C=CSC=1 GMVFGJUJHRIZHN-HXUWFJFHSA-N 0.000 description 1
- FUSJCSPNNRDEGM-HSZRJFAPSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-[2-[3-(trifluoromethyl)phenyl]acetyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 FUSJCSPNNRDEGM-HSZRJFAPSA-N 0.000 description 1
- AEMXAVSRBPRMRW-HSZRJFAPSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-[2-[4-(trifluoromethoxy)phenyl]acetyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 AEMXAVSRBPRMRW-HSZRJFAPSA-N 0.000 description 1
- GHONEAVWWIPZBH-HSZRJFAPSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-[2-[4-(trifluoromethyl)phenyl]acetyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 GHONEAVWWIPZBH-HSZRJFAPSA-N 0.000 description 1
- QGCOQILXHVXNEK-JOCHJYFZSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 QGCOQILXHVXNEK-JOCHJYFZSA-N 0.000 description 1
- FQFRFBURGHLUTC-JOCHJYFZSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 FQFRFBURGHLUTC-JOCHJYFZSA-N 0.000 description 1
- UYAZLYFSILTESV-JOCHJYFZSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 UYAZLYFSILTESV-JOCHJYFZSA-N 0.000 description 1
- SOPCLLSUJZTJQA-JOCHJYFZSA-N 1-pyridazin-3-yl-n-[4-[(3r)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 SOPCLLSUJZTJQA-JOCHJYFZSA-N 0.000 description 1
- PGGGGVOQAKJTLQ-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(1,3-thiazole-2-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=NC=CS1 PGGGGVOQAKJTLQ-UHFFFAOYSA-N 0.000 description 1
- FVBZYWXPZBXNQM-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(1,3-thiazole-4-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CSC=N1 FVBZYWXPZBXNQM-UHFFFAOYSA-N 0.000 description 1
- NOYVUCVFSRIDRJ-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(1,3-thiazole-4-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CSC=N1 NOYVUCVFSRIDRJ-UHFFFAOYSA-N 0.000 description 1
- PDHFQLSJWRMCOU-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(1,3-thiazole-5-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CN=CS1 PDHFQLSJWRMCOU-UHFFFAOYSA-N 0.000 description 1
- XLFCADNNFJKADW-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(2-pyrimidin-2-ylsulfanylacetyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CSC1=NC=CC=N1 XLFCADNNFJKADW-UHFFFAOYSA-N 0.000 description 1
- NSJJTPHYLIZZJV-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 NSJJTPHYLIZZJV-UHFFFAOYSA-N 0.000 description 1
- WZYPARPQWJGXNE-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]piperidine-4-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1C(C=C1)=CC=C1NC(=O)C1CCN(C=2N=NC=CC=2)CC1 WZYPARPQWJGXNE-UHFFFAOYSA-N 0.000 description 1
- URFLQXUCZXOTCG-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]sulfonylphenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1S(=O)(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 URFLQXUCZXOTCG-UHFFFAOYSA-N 0.000 description 1
- ZOKVQKKPRYXIAP-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(4-thiophen-2-ylbutanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CCCC1=CC=CS1 ZOKVQKKPRYXIAP-UHFFFAOYSA-N 0.000 description 1
- JZYGKULFZXXKNV-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(pyridine-2-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CC=CC=N1 JZYGKULFZXXKNV-UHFFFAOYSA-N 0.000 description 1
- DMJDEYOHKFHCHY-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(thiophene-2-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CC=CS1 DMJDEYOHKFHCHY-UHFFFAOYSA-N 0.000 description 1
- QVMRLIZYNSYVIW-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(thiophene-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CS1 QVMRLIZYNSYVIW-UHFFFAOYSA-N 0.000 description 1
- VDQXYEMIHISDGV-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(thiophene-3-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C=1C=CSC=1 VDQXYEMIHISDGV-UHFFFAOYSA-N 0.000 description 1
- NIBQTNSVJMJMLB-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-(thiophene-3-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C=1C=CSC=1 NIBQTNSVJMJMLB-UHFFFAOYSA-N 0.000 description 1
- XUKGZYYVVLLUSM-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 XUKGZYYVVLLUSM-UHFFFAOYSA-N 0.000 description 1
- HWLFUWZHJFPDCI-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 HWLFUWZHJFPDCI-UHFFFAOYSA-N 0.000 description 1
- RRNKSOBEVNNMMW-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[2-[4-(trifluoromethoxy)phenyl]acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 RRNKSOBEVNNMMW-UHFFFAOYSA-N 0.000 description 1
- OIKACWRKVPKTNA-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[2-[4-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 OIKACWRKVPKTNA-UHFFFAOYSA-N 0.000 description 1
- QWQBVIXKPUFLOS-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[2-[4-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 QWQBVIXKPUFLOS-UHFFFAOYSA-N 0.000 description 1
- SLHYEFYXDBVEEX-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 SLHYEFYXDBVEEX-UHFFFAOYSA-N 0.000 description 1
- YGAGTOYPUQZKEX-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 YGAGTOYPUQZKEX-UHFFFAOYSA-N 0.000 description 1
- FEFOQPYYRMZAOH-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 FEFOQPYYRMZAOH-UHFFFAOYSA-N 0.000 description 1
- KLUXZECIHACTFA-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 KLUXZECIHACTFA-UHFFFAOYSA-N 0.000 description 1
- GGJPUYWEGQUUNS-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl]sulfonylphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 GGJPUYWEGQUUNS-UHFFFAOYSA-N 0.000 description 1
- AVMNEPBZZLYEBD-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 AVMNEPBZZLYEBD-UHFFFAOYSA-N 0.000 description 1
- QLXOGSSLCQMYBT-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 QLXOGSSLCQMYBT-UHFFFAOYSA-N 0.000 description 1
- IHUVSKASVXEEON-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 IHUVSKASVXEEON-UHFFFAOYSA-N 0.000 description 1
- PLHQWAZZIYSTFI-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl]sulfonylphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 PLHQWAZZIYSTFI-UHFFFAOYSA-N 0.000 description 1
- SUSSZXNMTGBEGX-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[8-(4,4,4-trifluorobutanoyl)-8-azabicyclo[3.2.1]octan-3-yl]phenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)CCC(=O)N1C(C2)CCC1CC2C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 SUSSZXNMTGBEGX-UHFFFAOYSA-N 0.000 description 1
- FNJIRPBERPVIEB-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[[1-(1,3-thiazole-2-carbonyl)piperidin-4-yl]methyl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=NC=CS1 FNJIRPBERPVIEB-UHFFFAOYSA-N 0.000 description 1
- GCBDRQVMGPUMQU-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[[1-(1,3-thiazole-4-carbonyl)piperidin-4-yl]methyl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=CSC=N1 GCBDRQVMGPUMQU-UHFFFAOYSA-N 0.000 description 1
- NYVDZZHJQQOMNI-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[[1-(1,3-thiazole-5-carbonyl)piperidin-4-yl]methyl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=CN=CS1 NYVDZZHJQQOMNI-UHFFFAOYSA-N 0.000 description 1
- JHFZOXJEFUVQSB-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]methyl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 JHFZOXJEFUVQSB-UHFFFAOYSA-N 0.000 description 1
- YXWFRUDHHHOUCY-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]methyl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 YXWFRUDHHHOUCY-UHFFFAOYSA-N 0.000 description 1
- VDZUPUGEXFNUPZ-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[[1-(pyridine-2-carbonyl)piperidin-4-yl]methyl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=CC=CC=N1 VDZUPUGEXFNUPZ-UHFFFAOYSA-N 0.000 description 1
- AXEJSOCYQHOVHZ-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[[1-(thiophene-2-carbonyl)piperidin-4-yl]methyl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=CC=CS1 AXEJSOCYQHOVHZ-UHFFFAOYSA-N 0.000 description 1
- WSKUVGCKLZVEAM-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[4-[[1-(thiophene-3-carbonyl)piperidin-4-yl]methyl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C=1C=CSC=1 WSKUVGCKLZVEAM-UHFFFAOYSA-N 0.000 description 1
- KZTKJWDTHAPSDG-UHFFFAOYSA-N 1-pyridazin-3-yl-n-[6-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]pyridin-3-yl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1C(N=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 KZTKJWDTHAPSDG-UHFFFAOYSA-N 0.000 description 1
- NQPSPEZSSBCLOT-LJQANCHMSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-(1,3-thiazole-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C1=NC=CS1 NQPSPEZSSBCLOT-LJQANCHMSA-N 0.000 description 1
- MBNMRKWBHTVKMK-LJQANCHMSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-(1,3-thiazole-4-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C1=CSC=N1 MBNMRKWBHTVKMK-LJQANCHMSA-N 0.000 description 1
- NJTPJBXYOODORE-GOSISDBHSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)CC(F)(F)F)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 NJTPJBXYOODORE-GOSISDBHSA-N 0.000 description 1
- XLVCOGZOZGPAFO-OAQYLSRUSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-(pyridine-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C1=CC=CC=N1 XLVCOGZOZGPAFO-OAQYLSRUSA-N 0.000 description 1
- RWNBBSAMDAAXKE-HXUWFJFHSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-(thiophene-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C1=CC=CS1 RWNBBSAMDAAXKE-HXUWFJFHSA-N 0.000 description 1
- VNRJNABBOGQXIE-OAQYLSRUSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-(thiophene-3-carbonyl)pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C=1C=CSC=1 VNRJNABBOGQXIE-OAQYLSRUSA-N 0.000 description 1
- QIQPGOBQVVYTAW-XMMPIXPASA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-[2-[3-(trifluoromethyl)phenyl]acetyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 QIQPGOBQVVYTAW-XMMPIXPASA-N 0.000 description 1
- NYVWUUZEEVRFLK-XMMPIXPASA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-[2-[4-(trifluoromethoxy)phenyl]acetyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 NYVWUUZEEVRFLK-XMMPIXPASA-N 0.000 description 1
- ANTGJQSFLHYFRC-XMMPIXPASA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-[2-[4-(trifluoromethyl)phenyl]acetyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 ANTGJQSFLHYFRC-XMMPIXPASA-N 0.000 description 1
- BHUVJLQRBQVMOV-HSZRJFAPSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 BHUVJLQRBQVMOV-HSZRJFAPSA-N 0.000 description 1
- RXCBKVLMHOXDPE-HSZRJFAPSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 RXCBKVLMHOXDPE-HSZRJFAPSA-N 0.000 description 1
- YNIHECRRUSTSCN-HSZRJFAPSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 YNIHECRRUSTSCN-HSZRJFAPSA-N 0.000 description 1
- OXYLJUNAXXVBEU-HSZRJFAPSA-N 1-pyridazin-4-yl-n-[4-[(3r)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 OXYLJUNAXXVBEU-HSZRJFAPSA-N 0.000 description 1
- CPSIEWBKNXJQTQ-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(1,3-thiazole-2-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=NC=CS1 CPSIEWBKNXJQTQ-UHFFFAOYSA-N 0.000 description 1
- MOFOFTDAWANNQX-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(1,3-thiazole-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=NC=CS1 MOFOFTDAWANNQX-UHFFFAOYSA-N 0.000 description 1
- HDGNNGBOGZCGBV-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(1,3-thiazole-4-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CSC=N1 HDGNNGBOGZCGBV-UHFFFAOYSA-N 0.000 description 1
- GMRXCUNBMCQLFS-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(1,3-thiazole-4-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CSC=N1 GMRXCUNBMCQLFS-UHFFFAOYSA-N 0.000 description 1
- GQRMNEYDQVRTBD-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C(=O)CC(F)(F)F)CC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 GQRMNEYDQVRTBD-UHFFFAOYSA-N 0.000 description 1
- OEAVVGVCUQWZRM-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 OEAVVGVCUQWZRM-UHFFFAOYSA-N 0.000 description 1
- YNDFCRDGCGHYDN-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 YNDFCRDGCGHYDN-UHFFFAOYSA-N 0.000 description 1
- YDPXRMCDKDSMPN-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(pyridine-2-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CC=CC=N1 YDPXRMCDKDSMPN-UHFFFAOYSA-N 0.000 description 1
- WAEKDJDZSPMAGU-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(pyridine-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=N1 WAEKDJDZSPMAGU-UHFFFAOYSA-N 0.000 description 1
- FFEBFIHFFWNRJV-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(thiophene-2-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CC=CS1 FFEBFIHFFWNRJV-UHFFFAOYSA-N 0.000 description 1
- OLCIWSPWUMTFQK-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(thiophene-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CS1 OLCIWSPWUMTFQK-UHFFFAOYSA-N 0.000 description 1
- BWMYBLVSBNVPNU-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(thiophene-3-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C=1C=CSC=1 BWMYBLVSBNVPNU-UHFFFAOYSA-N 0.000 description 1
- PNDTUHFWOURBRB-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-(thiophene-3-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C=1C=CSC=1 PNDTUHFWOURBRB-UHFFFAOYSA-N 0.000 description 1
- NLSGGNGPGWQEDI-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 NLSGGNGPGWQEDI-UHFFFAOYSA-N 0.000 description 1
- BDTHZLNIUOCXSW-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[2-[3-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 BDTHZLNIUOCXSW-UHFFFAOYSA-N 0.000 description 1
- IPOCHPUPCYLUHR-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[2-[4-(trifluoromethoxy)phenyl]acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 IPOCHPUPCYLUHR-UHFFFAOYSA-N 0.000 description 1
- SFUVIPVSEDMWBN-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[2-[4-(trifluoromethoxy)phenyl]acetyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 SFUVIPVSEDMWBN-UHFFFAOYSA-N 0.000 description 1
- WXISQXPYRZIZJO-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[2-[4-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 WXISQXPYRZIZJO-UHFFFAOYSA-N 0.000 description 1
- QTSOTUVSTVWNOB-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[2-[4-(trifluoromethyl)phenyl]acetyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 QTSOTUVSTVWNOB-UHFFFAOYSA-N 0.000 description 1
- MCTLGAKEDUFYMH-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 MCTLGAKEDUFYMH-UHFFFAOYSA-N 0.000 description 1
- KQENMKIPHAPUNN-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 KQENMKIPHAPUNN-UHFFFAOYSA-N 0.000 description 1
- FXCIQAYABONGJG-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 FXCIQAYABONGJG-UHFFFAOYSA-N 0.000 description 1
- IXVQPVWRZAXOEJ-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 IXVQPVWRZAXOEJ-UHFFFAOYSA-N 0.000 description 1
- MREAIFFXWDLCPN-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 MREAIFFXWDLCPN-UHFFFAOYSA-N 0.000 description 1
- ZUSIKNSVOWBFKC-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 ZUSIKNSVOWBFKC-UHFFFAOYSA-N 0.000 description 1
- NRCOCSRZYIJHFQ-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[4-(trifluoromethyl)benzoyl]azetidin-3-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)C1 NRCOCSRZYIJHFQ-UHFFFAOYSA-N 0.000 description 1
- AJTJTMYFMCQYEJ-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 AJTJTMYFMCQYEJ-UHFFFAOYSA-N 0.000 description 1
- XRIPJYVIIGTLEY-UHFFFAOYSA-N 1-pyridazin-4-yl-n-[4-[1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 XRIPJYVIIGTLEY-UHFFFAOYSA-N 0.000 description 1
- NKTLJKVKZKWSGE-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(1,3-thiazole-2-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=NC=CS1 NKTLJKVKZKWSGE-UHFFFAOYSA-N 0.000 description 1
- QCGTXCOIGHDCFY-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(1,3-thiazole-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=NC=CS1 QCGTXCOIGHDCFY-UHFFFAOYSA-N 0.000 description 1
- FSPZMHFPYAHURK-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(2-pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CN1CCCC1 FSPZMHFPYAHURK-UHFFFAOYSA-N 0.000 description 1
- GJVSFXCIXJHYRV-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 GJVSFXCIXJHYRV-UHFFFAOYSA-N 0.000 description 1
- YOQWQAFHGPBKDR-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 YOQWQAFHGPBKDR-UHFFFAOYSA-N 0.000 description 1
- LACQUKDZSYBGBJ-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 LACQUKDZSYBGBJ-UHFFFAOYSA-N 0.000 description 1
- SXHVMXYBSAPOAP-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 SXHVMXYBSAPOAP-UHFFFAOYSA-N 0.000 description 1
- MJXBFCFSCIEOFD-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(thiophene-2-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CC=CS1 MJXBFCFSCIEOFD-UHFFFAOYSA-N 0.000 description 1
- NZOPERRMOHWTIH-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(thiophene-2-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CS1 NZOPERRMOHWTIH-UHFFFAOYSA-N 0.000 description 1
- ZAWIHBIMVZZDSQ-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(thiophene-3-carbonyl)piperidin-4-yl]oxyphenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C=1C=CSC=1 ZAWIHBIMVZZDSQ-UHFFFAOYSA-N 0.000 description 1
- GCTRCUAVBMFXCN-UHFFFAOYSA-N 1-pyridin-3-yl-n-[4-[1-(thiophene-3-carbonyl)piperidin-4-yl]phenyl]azetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C=1C=CSC=1 GCTRCUAVBMFXCN-UHFFFAOYSA-N 0.000 description 1
- JMWPSCUIQIMVQH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-pyrrolo[3,4-c]pyridine Chemical group C1NCCC2CNCC21 JMWPSCUIQIMVQH-UHFFFAOYSA-N 0.000 description 1
- QFKVQNJEBLYEAH-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-furo[3,4-b]pyrrole Chemical group C1OCC2NCCC21 QFKVQNJEBLYEAH-UHFFFAOYSA-N 0.000 description 1
- KSCPLKVBWDOSAI-UHFFFAOYSA-N 2,3,4,4a,5,6,7,7a-octahydro-1h-pyrrolo[3,4-b]pyridine Chemical group N1CCCC2CNCC21 KSCPLKVBWDOSAI-UHFFFAOYSA-N 0.000 description 1
- BEGIUDFULSWUTQ-HNNXBMFYSA-N 2-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=NC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)S1 BEGIUDFULSWUTQ-HNNXBMFYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- HQQVXVKQOPZRBJ-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-1h-furo[3,4-c]pyrrole Chemical group C1OCC2CNCC21 HQQVXVKQOPZRBJ-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical group C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- DTKQHZDTDLNUDC-UHFFFAOYSA-N 4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy-n-(1-pyridin-3-ylazetidin-3-yl)benzamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1OC1=CC=C(C(=O)NC2CN(C2)C=2C=NC=CC=2)C=C1 DTKQHZDTDLNUDC-UHFFFAOYSA-N 0.000 description 1
- WRUUVOMSYHXPKU-NRFANRHFSA-N 4-[1-(2-methylpropanoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]benzamide Chemical compound C1CN(C(=O)C(C)C)CCC1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)C=C1 WRUUVOMSYHXPKU-NRFANRHFSA-N 0.000 description 1
- PHOLNZJJRILRIU-SFHVURJKSA-N 4-[1-[(2s)-2-methylbutanoyl]piperidin-4-yl]oxy-n-(1-pyridin-3-ylazetidin-3-yl)benzamide Chemical compound C1CN(C(=O)[C@@H](C)CC)CCC1OC1=CC=C(C(=O)NC2CN(C2)C=2C=NC=CC=2)C=C1 PHOLNZJJRILRIU-SFHVURJKSA-N 0.000 description 1
- UWUVJVQEQOQPOF-UHFFFAOYSA-N 4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxy-n-(1-pyridin-3-ylazetidin-3-yl)benzamide Chemical compound C1CC(OC=2C=CC(=CC=2)C(=O)NC2CN(C2)C=2C=NC=CC=2)CCN1C(=O)CC1CCOCC1 UWUVJVQEQOQPOF-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- QHPDCLOUOXNRDK-UHFFFAOYSA-N 5-(1-benzoylpiperidin-4-yl)-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)C=2C=CC=CC=2)SC=1C(=O)NC(C1)CN1C1=CC=CN=N1 QHPDCLOUOXNRDK-UHFFFAOYSA-N 0.000 description 1
- SSNREFQEUSSNQE-FQEVSTJZSA-N 5-(1-benzoylpiperidin-4-yl)-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)C=2SC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)CN1C1=CC=CN=N1 SSNREFQEUSSNQE-FQEVSTJZSA-N 0.000 description 1
- DVXSZHDKYDILSM-UHFFFAOYSA-N 5-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound C1CC(C=2SC(=CC=2)C(=O)NC2CN(C2)C=2N=NC=CC=2)CCN1C(=O)C1(C)CC1 DVXSZHDKYDILSM-UHFFFAOYSA-N 0.000 description 1
- HKMUPBVXIHIRAN-KRWDZBQOSA-N 5-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1CC(C=2SC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)CCN1C(=O)C1(C)CC1 HKMUPBVXIHIRAN-KRWDZBQOSA-N 0.000 description 1
- LMVJVLQOVJASCO-UHFFFAOYSA-N 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1C1=CC=C(C(=O)NC2CN(C2)C=2N=NC=CC=2)S1 LMVJVLQOVJASCO-UHFFFAOYSA-N 0.000 description 1
- UGBLUDUEFHYREE-SFHVURJKSA-N 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)S1 UGBLUDUEFHYREE-SFHVURJKSA-N 0.000 description 1
- QQLVGWILUWESQL-UHFFFAOYSA-N 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C1=CC=C(C(=O)NC2CN(C2)C=2N=NC=CC=2)S1 QQLVGWILUWESQL-UHFFFAOYSA-N 0.000 description 1
- WUDJWHDCDLJCBG-KRWDZBQOSA-N 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)S1 WUDJWHDCDLJCBG-KRWDZBQOSA-N 0.000 description 1
- LBOTVJMRCZVGCQ-UHFFFAOYSA-N 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(C=2SC(=CC=2)C(=O)NC2CN(C2)C=2N=NC=CC=2)CC1 LBOTVJMRCZVGCQ-UHFFFAOYSA-N 0.000 description 1
- CWLYWUYRCNQMEN-SFHVURJKSA-N 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(C=2SC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)CC1 CWLYWUYRCNQMEN-SFHVURJKSA-N 0.000 description 1
- YIUCRJXZJVGVKT-SFHVURJKSA-N 5-[1-(2-cyclopropylacetyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1CC(C=2SC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)CCN1C(=O)CC1CC1 YIUCRJXZJVGVKT-SFHVURJKSA-N 0.000 description 1
- IQSFHIRKQXKVLR-UHFFFAOYSA-N 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2SC(=CC=2)C(=O)NC2CN(C2)C=2N=NC=CC=2)CC1 IQSFHIRKQXKVLR-UHFFFAOYSA-N 0.000 description 1
- HVFBBQNMGIUDIS-SFHVURJKSA-N 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]furan-2-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2OC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)CC1 HVFBBQNMGIUDIS-SFHVURJKSA-N 0.000 description 1
- NHUHWNXTTAFQEL-SFHVURJKSA-N 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2SC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)CC1 NHUHWNXTTAFQEL-SFHVURJKSA-N 0.000 description 1
- WZFWYQOBLBQOML-UHFFFAOYSA-N 5-[1-(2-methylbenzoyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound CC1=CC=CC=C1C(=O)N1CCC(C=2SC(=CC=2)C(=O)NC2CN(C2)C=2N=NC=CC=2)CC1 WZFWYQOBLBQOML-UHFFFAOYSA-N 0.000 description 1
- NOPJWVPQKQIKSH-NXYGQSRBSA-N 5-[1-(2-methylcyclopropanecarbonyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound CC1CC1C(=O)N1CCC(C=2SC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)CC1 NOPJWVPQKQIKSH-NXYGQSRBSA-N 0.000 description 1
- JZERVBPTZODIRY-KRWDZBQOSA-N 5-[1-(2-methylpropanoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)S1 JZERVBPTZODIRY-KRWDZBQOSA-N 0.000 description 1
- HZCUDQHQADXVAZ-UHFFFAOYSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)furan-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)NC2CN(C2)C=2N=NC=CC=2)O1 HZCUDQHQADXVAZ-UHFFFAOYSA-N 0.000 description 1
- BTCDGGJYUWBQNR-UHFFFAOYSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)NC2CN(C2)C=2N=NC=CC=2)S1 BTCDGGJYUWBQNR-UHFFFAOYSA-N 0.000 description 1
- QGMHSQUHYSXKPC-MRXNPFEDSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3r)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@H]2CN(CC2)C=2N=NC=CC=2)S1 QGMHSQUHYSXKPC-MRXNPFEDSA-N 0.000 description 1
- HPWVMXHSZCAJHV-QGZVFWFLSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3r)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-3-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC(C(=O)N[C@H]2CN(CC2)C=2N=NC=CC=2)=CS1 HPWVMXHSZCAJHV-QGZVFWFLSA-N 0.000 description 1
- DSNABZXHIMPTJG-MRXNPFEDSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3r)-1-pyridazin-4-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@H]2CN(CC2)C=2C=NN=CC=2)S1 DSNABZXHIMPTJG-MRXNPFEDSA-N 0.000 description 1
- UUXLXIGCYVBBNL-QGZVFWFLSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3r)-1-pyridazin-4-ylpyrrolidin-3-yl]thiophene-3-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC(C(=O)N[C@H]2CN(CC2)C=2C=NN=CC=2)=CS1 UUXLXIGCYVBBNL-QGZVFWFLSA-N 0.000 description 1
- VAUDOUCTDSLWBK-QGZVFWFLSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3r)-1-pyridin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@H]2CN(CC2)C=2C=NC=CC=2)S1 VAUDOUCTDSLWBK-QGZVFWFLSA-N 0.000 description 1
- NAVLRNJNFLKFPI-INIZCTEOSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]furan-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)O1 NAVLRNJNFLKFPI-INIZCTEOSA-N 0.000 description 1
- QGMHSQUHYSXKPC-INIZCTEOSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)S1 QGMHSQUHYSXKPC-INIZCTEOSA-N 0.000 description 1
- HPWVMXHSZCAJHV-KRWDZBQOSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-3-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)=CS1 HPWVMXHSZCAJHV-KRWDZBQOSA-N 0.000 description 1
- DSNABZXHIMPTJG-INIZCTEOSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3s)-1-pyridazin-4-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2C=NN=CC=2)S1 DSNABZXHIMPTJG-INIZCTEOSA-N 0.000 description 1
- VAUDOUCTDSLWBK-KRWDZBQOSA-N 5-[1-(2-methylpropyl)pyrazol-4-yl]-n-[(3s)-1-pyridin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2C=NC=CC=2)S1 VAUDOUCTDSLWBK-KRWDZBQOSA-N 0.000 description 1
- XQNXHGLNBGABJF-SFHVURJKSA-N 5-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)S1 XQNXHGLNBGABJF-SFHVURJKSA-N 0.000 description 1
- IXURGNAHAVEMFY-UHFFFAOYSA-N 5-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)C=2SC(=CC=2)C(=O)NC2CN(C2)C=2N=NC=CC=2)=C1 IXURGNAHAVEMFY-UHFFFAOYSA-N 0.000 description 1
- NFQMDWDOIDGDSH-UHFFFAOYSA-N 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2SC(=CC=2)C(=O)NC2CN(C2)C=2N=NC=CC=2)=C1 NFQMDWDOIDGDSH-UHFFFAOYSA-N 0.000 description 1
- BQGMAFHRGMSFHZ-FQEVSTJZSA-N 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2SC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)=C1 BQGMAFHRGMSFHZ-FQEVSTJZSA-N 0.000 description 1
- BXLBCAADRMSLJX-UHFFFAOYSA-N 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(C=2SC(=CC=2)C(=O)NC2CN(C2)C=2N=NC=CC=2)CC1 BXLBCAADRMSLJX-UHFFFAOYSA-N 0.000 description 1
- SWSUEKOLHMFJHF-FQEVSTJZSA-N 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(C=2SC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)CC1 SWSUEKOLHMFJHF-FQEVSTJZSA-N 0.000 description 1
- OWTPIFGSHKQPJN-UHFFFAOYSA-N 5-[1-(cyclopropanecarbonyl)piperidin-4-yl]-n-(1-pyridazin-3-ylazetidin-3-yl)thiophene-2-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)C2CC2)SC=1C(=O)NC(C1)CN1C1=CC=CN=N1 OWTPIFGSHKQPJN-UHFFFAOYSA-N 0.000 description 1
- VKSSDGRLFAWDCW-IBGZPJMESA-N 5-[1-(oxane-4-carbonyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)C=2SC(=CC=2)C2CCN(CC2)C(=O)C2CCOCC2)CN1C1=CC=CN=N1 VKSSDGRLFAWDCW-IBGZPJMESA-N 0.000 description 1
- XJZJLUCKDDBMEC-ZVAWYAOSSA-N 5-[1-(oxolane-3-carbonyl)piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)C=2SC(=CC=2)C2CCN(CC2)C(=O)C2COCC2)CN1C1=CC=CN=N1 XJZJLUCKDDBMEC-ZVAWYAOSSA-N 0.000 description 1
- NGMYPFWERBFNRJ-ZWKOTPCHSA-N 5-[1-[(2r)-oxolane-2-carbonyl]piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)C=2SC(=CC=2)C2CCN(CC2)C(=O)[C@@H]2OCCC2)CN1C1=CC=CN=N1 NGMYPFWERBFNRJ-ZWKOTPCHSA-N 0.000 description 1
- OFJUBPOJJQKBCD-NRFANRHFSA-N 5-[1-[2-(1-methylpiperidin-4-yl)acetyl]piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C1CN(C)CCC1CC(=O)N1CCC(C=2SC(=CC=2)C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)CC1 OFJUBPOJJQKBCD-NRFANRHFSA-N 0.000 description 1
- ZTJJZVQARFKLKA-OUHCFLCTSA-N 5-[1-[2-(3-bicyclo[2.2.1]heptanyl)acetyl]piperidin-4-yl]-n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]thiophene-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)C2=CC=C(S2)C2CCN(CC2)C(CC2C3CCC(C3)C2)=O)CN1C1=CC=CN=N1 ZTJJZVQARFKLKA-OUHCFLCTSA-N 0.000 description 1
- ZWONMHVYQRHJGX-UHFFFAOYSA-N 7-methyl-4,7-diazabicyclo[3.2.0]heptane Chemical group N1CCC2N(C)CC21 ZWONMHVYQRHJGX-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- ZAHXYMFVNNUHCP-UHFFFAOYSA-N Naphazoline nitrate Chemical group O[N+]([O-])=O.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 ZAHXYMFVNNUHCP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- QAOWNCQODCNURD-ZSJDYOACSA-N Sulfuric acid-d2 Chemical compound [2H]OS(=O)(=O)O[2H] QAOWNCQODCNURD-ZSJDYOACSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 description 1
- 125000004686 alkyl sulfanyl alkyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004602 benzodiazinyl group Chemical group N1=NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004599 benzpyrazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- DYGZABHKDGBCNI-UHFFFAOYSA-N benzyl 4-[4-[[1-(6-chloropyridazin-3-yl)azetidine-3-carbonyl]amino]phenyl]-4-fluoropiperidine-1-carboxylate Chemical compound C1CC(F)(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC(Cl)=CC=3)=CC=2)CCN1C(=O)OCC1=CC=CC=C1 DYGZABHKDGBCNI-UHFFFAOYSA-N 0.000 description 1
- PCOMTQQLBLSEDZ-UHFFFAOYSA-N benzyl 4-[4-[[1-(6-chloropyridazin-3-yl)azetidine-3-carbonyl]amino]phenyl]-4-hydroxypiperidine-1-carboxylate Chemical compound C1CC(O)(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC(Cl)=CC=3)=CC=2)CCN1C(=O)OCC1=CC=CC=C1 PCOMTQQLBLSEDZ-UHFFFAOYSA-N 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- PUNGVJHPDVOVFN-UHFFFAOYSA-N ethyl 1-methyl-5-[4-[(1-pyridazin-3-ylazetidine-3-carbonyl)amino]phenyl]pyrazole-3-carboxylate Chemical compound CN1N=C(C(=O)OCC)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 PUNGVJHPDVOVFN-UHFFFAOYSA-N 0.000 description 1
- MMQIIWNXZKPMJP-UHFFFAOYSA-N ethyl 1-phenyl-5-[4-[(1-pyridazin-3-ylazetidine-3-carbonyl)amino]phenyl]pyrazole-3-carboxylate Chemical compound C=1C=CC=CC=1N1N=C(C(=O)OCC)C=C1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 MMQIIWNXZKPMJP-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- NHEQIGZENDNLBN-UHFFFAOYSA-N n-(1-pyridazin-3-ylazetidin-3-yl)-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1C1=CC=C(C(=O)NC2CN(C2)C=2N=NC=CC=2)S1 NHEQIGZENDNLBN-UHFFFAOYSA-N 0.000 description 1
- DQJIVUXVGCYFOD-UHFFFAOYSA-N n-(1-pyridazin-3-ylazetidin-3-yl)-5-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]thiophene-2-carboxamide Chemical compound C1CN(C(=O)CCC(F)(F)F)CCC1C1=CC=C(C(=O)NC2CN(C2)C=2N=NC=CC=2)S1 DQJIVUXVGCYFOD-UHFFFAOYSA-N 0.000 description 1
- POVDGCUDNKFWPT-CQSZACIVSA-N n-[(3r)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)pyrazol-4-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@H]2CN(CC2)C=2C(=C(Cl)N=NC=2)Cl)S1 POVDGCUDNKFWPT-CQSZACIVSA-N 0.000 description 1
- YRNACWKXLHLJTR-OAHLLOKOSA-N n-[(3r)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)pyrazol-4-yl]thiophene-3-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC(C(=O)N[C@H]2CN(CC2)C=2C(=C(Cl)N=NC=2)Cl)=CS1 YRNACWKXLHLJTR-OAHLLOKOSA-N 0.000 description 1
- YVBQMSPZYYKPCW-OAHLLOKOSA-N n-[(3r)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)pyrazol-4-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@H]2CN(CC2)C=2N=NC(Cl)=CC=2)S1 YVBQMSPZYYKPCW-OAHLLOKOSA-N 0.000 description 1
- POVDGCUDNKFWPT-AWEZNQCLSA-N n-[(3s)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)pyrazol-4-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2C(=C(Cl)N=NC=2)Cl)S1 POVDGCUDNKFWPT-AWEZNQCLSA-N 0.000 description 1
- IPQASXRLAZHJKM-FQEVSTJZSA-N n-[(3s)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-4-[1-(2-methylpropanoyl)piperidin-4-yl]benzamide Chemical compound C1CN(C(=O)C(C)C)CCC1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC(Cl)=CC=2)C=C1 IPQASXRLAZHJKM-FQEVSTJZSA-N 0.000 description 1
- HSFIFURGEQJOKE-HNNXBMFYSA-N n-[(3s)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)pyrazol-4-yl]furan-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC(Cl)=CC=2)O1 HSFIFURGEQJOKE-HNNXBMFYSA-N 0.000 description 1
- YVBQMSPZYYKPCW-HNNXBMFYSA-N n-[(3s)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)pyrazol-4-yl]thiophene-2-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC(Cl)=CC=2)S1 YVBQMSPZYYKPCW-HNNXBMFYSA-N 0.000 description 1
- ZZNJDRZIIPOMJV-INIZCTEOSA-N n-[(3s)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)pyrazol-4-yl]thiophene-3-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C1=CC(C(=O)N[C@@H]2CN(CC2)C=2N=NC(Cl)=CC=2)=CS1 ZZNJDRZIIPOMJV-INIZCTEOSA-N 0.000 description 1
- YTQQLBNBDAWZAJ-INIZCTEOSA-N n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]-5-[1-(1,3-thiazole-4-carbonyl)piperidin-4-yl]thiophene-2-carboxamide Chemical compound C([C@@H](C1)NC(=O)C=2SC(=CC=2)C2CCN(CC2)C(=O)C=2N=CSC=2)CN1C1=CC=CN=N1 YTQQLBNBDAWZAJ-INIZCTEOSA-N 0.000 description 1
- HPRFCJZWUYICJD-HNNXBMFYSA-N n-[(3s)-1-pyridazin-3-ylpyrrolidin-3-yl]-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide Chemical compound C1CN(C(=O)CC(F)(F)F)CCC1C1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2N=NC=CC=2)S1 HPRFCJZWUYICJD-HNNXBMFYSA-N 0.000 description 1
- JCNVARZWUASKKC-UHFFFAOYSA-N n-[1-[1-(2-fluorobenzoyl)piperidin-4-yl]pyrazol-4-yl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(N2N=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=C2)CC1 JCNVARZWUASKKC-UHFFFAOYSA-N 0.000 description 1
- LVCZTNZRVBUBSZ-UHFFFAOYSA-N n-[1-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]pyrazol-4-yl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1N1N=CC(NC(=O)C2CN(C2)C=2N=NC=CC=2)=C1 LVCZTNZRVBUBSZ-UHFFFAOYSA-N 0.000 description 1
- MWKHVZBEXBGSOC-UHFFFAOYSA-N n-[2-fluoro-4-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=C(F)C(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CC1 MWKHVZBEXBGSOC-UHFFFAOYSA-N 0.000 description 1
- ZLMKDDCIAVVAPU-UHFFFAOYSA-N n-[2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2C=C(F)C(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 ZLMKDDCIAVVAPU-UHFFFAOYSA-N 0.000 description 1
- ASDMKMDWGNNTQN-UHFFFAOYSA-N n-[2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2C=C(F)C(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 ASDMKMDWGNNTQN-UHFFFAOYSA-N 0.000 description 1
- BYGGRSRUUNQQEO-UHFFFAOYSA-N n-[2-fluoro-4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=CC=C1C(=O)N1CCC(C=2C=C(F)C(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 BYGGRSRUUNQQEO-UHFFFAOYSA-N 0.000 description 1
- ATYVKMMFCKKPMK-UHFFFAOYSA-N n-[2-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1F)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 ATYVKMMFCKKPMK-UHFFFAOYSA-N 0.000 description 1
- KFANBTSPMIUTPD-UHFFFAOYSA-N n-[2-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2C=C(F)C(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 KFANBTSPMIUTPD-UHFFFAOYSA-N 0.000 description 1
- LKJGGISLYZDDKD-UHFFFAOYSA-N n-[2-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(C2CCN(CC2)C(=O)CCC(F)(F)F)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 LKJGGISLYZDDKD-UHFFFAOYSA-N 0.000 description 1
- SMINRPRBLYWXRM-UHFFFAOYSA-N n-[2-fluoro-4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(C=2C=C(F)C(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 SMINRPRBLYWXRM-UHFFFAOYSA-N 0.000 description 1
- ACZBYICAGUMQIS-UHFFFAOYSA-N n-[3-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2C(=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)F)CC1 ACZBYICAGUMQIS-UHFFFAOYSA-N 0.000 description 1
- HBGYAXWFWCKYCY-UHFFFAOYSA-N n-[3-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C(=C1)F)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 HBGYAXWFWCKYCY-UHFFFAOYSA-N 0.000 description 1
- ONDSUQAUHAUFNG-UHFFFAOYSA-N n-[3-fluoro-4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)CC(F)(F)F)C(F)=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 ONDSUQAUHAUFNG-UHFFFAOYSA-N 0.000 description 1
- UXBNFOWCYYGVAO-UHFFFAOYSA-N n-[3-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2C(=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)F)=C1 UXBNFOWCYYGVAO-UHFFFAOYSA-N 0.000 description 1
- KQJYCOVRQBGJFN-UHFFFAOYSA-N n-[3-fluoro-4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1C(C(=C1)F)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 KQJYCOVRQBGJFN-UHFFFAOYSA-N 0.000 description 1
- OGHDJCIHHSAIFO-UHFFFAOYSA-N n-[3-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)CCC(F)(F)F)C(F)=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 OGHDJCIHHSAIFO-UHFFFAOYSA-N 0.000 description 1
- SCUBXVXJCFWEEW-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 SCUBXVXJCFWEEW-UHFFFAOYSA-N 0.000 description 1
- BRNYTRFIYDNXPO-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 BRNYTRFIYDNXPO-UHFFFAOYSA-N 0.000 description 1
- XTASJBWUUHDBKQ-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 XTASJBWUUHDBKQ-UHFFFAOYSA-N 0.000 description 1
- XQYJYFKSVFZAMI-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 XQYJYFKSVFZAMI-UHFFFAOYSA-N 0.000 description 1
- SQPGJLSRZITJKT-UHFFFAOYSA-N n-[4-(1-acetylpiperidin-4-yl)phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 SQPGJLSRZITJKT-UHFFFAOYSA-N 0.000 description 1
- TTXFMASMVDAVRF-UHFFFAOYSA-N n-[4-(1-azabicyclo[2.2.2]octan-3-ylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(C(=O)NC2C3CCN(CC3)C2)C=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 TTXFMASMVDAVRF-UHFFFAOYSA-N 0.000 description 1
- CURBNDGIJLHHDY-UHFFFAOYSA-N n-[4-(1-benzoyl-4-fluoropiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(F)(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C1=CC=CC=C1 CURBNDGIJLHHDY-UHFFFAOYSA-N 0.000 description 1
- FRKCSNZIBKSUIP-UHFFFAOYSA-N n-[4-(1-benzoylazetidin-3-yl)oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(C1)CN1C(=O)C1=CC=CC=C1 FRKCSNZIBKSUIP-UHFFFAOYSA-N 0.000 description 1
- GWPPYZNJNZGPLD-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(C2CCN(CC2)C(=O)C=2C=CC=CC=2)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 GWPPYZNJNZGPLD-UHFFFAOYSA-N 0.000 description 1
- AJLAHYQSBAMJMW-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(C2CCN(CC2)C(=O)C=2C=CC=CC=2)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 AJLAHYQSBAMJMW-UHFFFAOYSA-N 0.000 description 1
- SVQMLIYLQHQBTM-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)-3-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)C=2C=CC=CC=2)C(F)=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 SVQMLIYLQHQBTM-UHFFFAOYSA-N 0.000 description 1
- LPAQODLQHMVXLX-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-cyanopyridin-3-yl)azetidine-3-carboxamide Chemical compound C1N(C=2C(=NC=CC=2)C#N)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 LPAQODLQHMVXLX-UHFFFAOYSA-N 0.000 description 1
- OJUAUJFCYYPGLV-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-fluoro-6-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound FC1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 OJUAUJFCYYPGLV-UHFFFAOYSA-N 0.000 description 1
- AEYPUVFOVVWCMP-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 AEYPUVFOVVWCMP-UHFFFAOYSA-N 0.000 description 1
- WGTLDTUCKQYSOT-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide Chemical compound CC1=NN=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 WGTLDTUCKQYSOT-UHFFFAOYSA-N 0.000 description 1
- ZHFYXBULYSSPEG-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-cyanopyridin-3-yl)azetidine-3-carboxamide Chemical compound C1N(C=2C(=CC=NC=2)C#N)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 ZHFYXBULYSSPEG-UHFFFAOYSA-N 0.000 description 1
- FHUJRSVESRDLDU-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CC=NN=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 FHUJRSVESRDLDU-UHFFFAOYSA-N 0.000 description 1
- CUTZPQDHZGWHMS-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-cyanopyridin-3-yl)azetidine-3-carboxamide Chemical compound C1N(C=2C=C(C=NC=2)C#N)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 CUTZPQDHZGWHMS-UHFFFAOYSA-N 0.000 description 1
- RYTOFSKAMVCQRI-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-fluoropyridin-3-yl)azetidine-3-carboxamide Chemical compound FC1=CN=CC(N2CC(C2)C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)=C1 RYTOFSKAMVCQRI-UHFFFAOYSA-N 0.000 description 1
- AKMQGPDGYFVBNR-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CN=CC(N2CC(C2)C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)=C1 AKMQGPDGYFVBNR-UHFFFAOYSA-N 0.000 description 1
- QDAUTOGWKLGJOZ-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-4-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CC(F)=NC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 QDAUTOGWKLGJOZ-UHFFFAOYSA-N 0.000 description 1
- ANBICJLAOHZPHN-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-5-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound N1=C(F)C(C)=CC(N2CC(C2)C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)=C1 ANBICJLAOHZPHN-UHFFFAOYSA-N 0.000 description 1
- UIIWQNMWUGKRQO-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(F)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 UIIWQNMWUGKRQO-UHFFFAOYSA-N 0.000 description 1
- ALSZCAJBHOIQPC-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 ALSZCAJBHOIQPC-UHFFFAOYSA-N 0.000 description 1
- JPHIUQBTGPZROV-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC=CC=2)C1 JPHIUQBTGPZROV-UHFFFAOYSA-N 0.000 description 1
- AQKKCKJCBQCNBW-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 AQKKCKJCBQCNBW-UHFFFAOYSA-N 0.000 description 1
- GUMNKBVOVMAXOL-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylpiperidine-4-carboxamide Chemical compound C1CN(C=2N=NC=CC=2)CCC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 GUMNKBVOVMAXOL-UHFFFAOYSA-N 0.000 description 1
- FWQVINRMPLYEIJ-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC=C1 FWQVINRMPLYEIJ-UHFFFAOYSA-N 0.000 description 1
- OTAVOOZOTHOQLM-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1S(=O)(=O)C(CC1)CCN1C(=O)C1=CC=CC=C1 OTAVOOZOTHOQLM-UHFFFAOYSA-N 0.000 description 1
- SAEVXAKMQNJMJD-UHFFFAOYSA-N n-[4-(1-benzoylpiperidin-4-yl)sulfonylphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1S(=O)(=O)C(CC1)CCN1C(=O)C1=CC=CC=C1 SAEVXAKMQNJMJD-UHFFFAOYSA-N 0.000 description 1
- NOCPLAOTYXMRDR-UHFFFAOYSA-N n-[4-(1-but-3-enoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC=C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 NOCPLAOTYXMRDR-UHFFFAOYSA-N 0.000 description 1
- BYBDZWXVAGMQJS-UHFFFAOYSA-N n-[4-(1-butanoylpiperidin-4-yl)oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 BYBDZWXVAGMQJS-UHFFFAOYSA-N 0.000 description 1
- AAFKUGOODNIZRH-UHFFFAOYSA-N n-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 AAFKUGOODNIZRH-UHFFFAOYSA-N 0.000 description 1
- MOHNGOQABSDQFF-UHFFFAOYSA-N n-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 MOHNGOQABSDQFF-UHFFFAOYSA-N 0.000 description 1
- QUTQDKKDXLISBR-UHFFFAOYSA-N n-[4-(1-butylpiperidin-4-yl)phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CCCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 QUTQDKKDXLISBR-UHFFFAOYSA-N 0.000 description 1
- SIFBFNUBRNGBIK-UHFFFAOYSA-N n-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCCCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 SIFBFNUBRNGBIK-UHFFFAOYSA-N 0.000 description 1
- MUGMCERVDGMUDU-UHFFFAOYSA-N n-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 MUGMCERVDGMUDU-UHFFFAOYSA-N 0.000 description 1
- UKIQLBANSWSHNB-UHFFFAOYSA-N n-[4-(1-pent-4-enoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC=C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 UKIQLBANSWSHNB-UHFFFAOYSA-N 0.000 description 1
- AQTMWMLLJWJXBO-UHFFFAOYSA-N n-[4-(1-pent-4-ynoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(CCC#C)=O)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 AQTMWMLLJWJXBO-UHFFFAOYSA-N 0.000 description 1
- LVNNTHFOEPXRHC-UHFFFAOYSA-N n-[4-(1-pentanoylazetidin-3-yl)oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)CCCC)CC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 LVNNTHFOEPXRHC-UHFFFAOYSA-N 0.000 description 1
- RATCBMOITYIYPQ-UHFFFAOYSA-N n-[4-(1-pentanoylpiperidin-4-yl)oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 RATCBMOITYIYPQ-UHFFFAOYSA-N 0.000 description 1
- ZCSFYYQMWNYVSZ-UHFFFAOYSA-N n-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 ZCSFYYQMWNYVSZ-UHFFFAOYSA-N 0.000 description 1
- DSLMXFJGIXCMLJ-UHFFFAOYSA-N n-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 DSLMXFJGIXCMLJ-UHFFFAOYSA-N 0.000 description 1
- OWRHIVXYKLYQJI-UHFFFAOYSA-N n-[4-(1-propanoylpiperidin-4-yl)oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 OWRHIVXYKLYQJI-UHFFFAOYSA-N 0.000 description 1
- CGZJXZIYSCLTOJ-UHFFFAOYSA-N n-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 CGZJXZIYSCLTOJ-UHFFFAOYSA-N 0.000 description 1
- OOVDKQFDEHFOSS-UHFFFAOYSA-N n-[4-(1-propylpiperidin-4-yl)oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CCC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 OOVDKQFDEHFOSS-UHFFFAOYSA-N 0.000 description 1
- CKYAPQAQVAGBOR-UHFFFAOYSA-N n-[4-(1-propylpiperidin-4-yl)phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 CKYAPQAQVAGBOR-UHFFFAOYSA-N 0.000 description 1
- RXUCCPZPSHJOQC-UHFFFAOYSA-N n-[4-(2,2-dimethylpropylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)NCC(C)(C)C)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 RXUCCPZPSHJOQC-UHFFFAOYSA-N 0.000 description 1
- FAPQWHARYOGMII-UHFFFAOYSA-N n-[4-(2-butyl-5-tert-butylpyrazol-3-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CCCCN1N=C(C(C)(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 FAPQWHARYOGMII-UHFFFAOYSA-N 0.000 description 1
- IPLKILOWWXLZJH-UHFFFAOYSA-N n-[4-(2-cyclopropylethylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NCCC1CC1 IPLKILOWWXLZJH-UHFFFAOYSA-N 0.000 description 1
- GHZIRRSHNRBZBC-UHFFFAOYSA-N n-[4-(2-methoxyethylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)NCCOC)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 GHZIRRSHNRBZBC-UHFFFAOYSA-N 0.000 description 1
- MXDKEFYKDZNHOZ-UHFFFAOYSA-N n-[4-(5-cyclopropyl-2-methylpyrazol-3-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CN1N=C(C2CC2)C=C1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 MXDKEFYKDZNHOZ-UHFFFAOYSA-N 0.000 description 1
- UTAWSRGGBHODOY-UHFFFAOYSA-N n-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O1C(CCC)=NC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=N1 UTAWSRGGBHODOY-UHFFFAOYSA-N 0.000 description 1
- LYTNFFUSHTXWKY-UHFFFAOYSA-N n-[4-(8-benzoyl-8-azabicyclo[3.2.1]octan-3-yl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(C1)CC2CCC1N2C(=O)C1=CC=CC=C1 LYTNFFUSHTXWKY-UHFFFAOYSA-N 0.000 description 1
- GLYXKTKPAKCGEI-UHFFFAOYSA-N n-[4-(benzylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NCC1=CC=CC=C1 GLYXKTKPAKCGEI-UHFFFAOYSA-N 0.000 description 1
- VJPUGANMCSEGMP-UHFFFAOYSA-N n-[4-(butylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)NCCCC)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 VJPUGANMCSEGMP-UHFFFAOYSA-N 0.000 description 1
- IXNVFSCVXJJXHS-UHFFFAOYSA-N n-[4-(cyclobutylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC1CCC1 IXNVFSCVXJJXHS-UHFFFAOYSA-N 0.000 description 1
- HLYWKIWZYHMYLG-UHFFFAOYSA-N n-[4-(cyclobutylmethylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NCC1CCC1 HLYWKIWZYHMYLG-UHFFFAOYSA-N 0.000 description 1
- NWMBTVDDDFDWBL-UHFFFAOYSA-N n-[4-(cyclopentylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC1CCCC1 NWMBTVDDDFDWBL-UHFFFAOYSA-N 0.000 description 1
- WPPCYCWZGBPSOW-UHFFFAOYSA-N n-[4-(cyclopropylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC1CC1 WPPCYCWZGBPSOW-UHFFFAOYSA-N 0.000 description 1
- WKFPXYDBUJQPOG-UHFFFAOYSA-N n-[4-(cyclopropylmethylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NCC1CC1 WKFPXYDBUJQPOG-UHFFFAOYSA-N 0.000 description 1
- SFZYMFWYNWJSHW-UHFFFAOYSA-N n-[4-(oxan-4-ylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC1CCOCC1 SFZYMFWYNWJSHW-UHFFFAOYSA-N 0.000 description 1
- VWKFRJOBRBFGNW-UHFFFAOYSA-N n-[4-(oxan-4-ylmethylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NCC1CCOCC1 VWKFRJOBRBFGNW-UHFFFAOYSA-N 0.000 description 1
- HLGXLGGDXYXIFK-UHFFFAOYSA-N n-[4-(oxetan-3-ylmethylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NCC1COC1 HLGXLGGDXYXIFK-UHFFFAOYSA-N 0.000 description 1
- GPHPVMKHBUWVIA-UHFFFAOYSA-N n-[4-(oxolan-3-ylmethylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NCC1CCOC1 GPHPVMKHBUWVIA-UHFFFAOYSA-N 0.000 description 1
- JWPLXQJKYCOOTB-UHFFFAOYSA-N n-[4-(phenylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1 JWPLXQJKYCOOTB-UHFFFAOYSA-N 0.000 description 1
- PEWWNRDHKNVMCB-UHFFFAOYSA-N n-[4-(prop-2-enylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)NCC=C)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 PEWWNRDHKNVMCB-UHFFFAOYSA-N 0.000 description 1
- PNJSSSVOKFULLV-UHFFFAOYSA-N n-[4-(propylcarbamoyl)phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)NCCC)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 PNJSSSVOKFULLV-UHFFFAOYSA-N 0.000 description 1
- DTUKNFOMCSVZBI-UHFFFAOYSA-N n-[4-[(1-acetylpiperidin-4-yl)methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 DTUKNFOMCSVZBI-UHFFFAOYSA-N 0.000 description 1
- WOCNMVJWFXTBRS-UHFFFAOYSA-N n-[4-[(1-benzoylpiperidin-4-yl)methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=CC=CC=C1 WOCNMVJWFXTBRS-UHFFFAOYSA-N 0.000 description 1
- MGPZFEOITYLSIS-UHFFFAOYSA-N n-[4-[(1-but-3-enoylpiperidin-4-yl)methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC=C)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 MGPZFEOITYLSIS-UHFFFAOYSA-N 0.000 description 1
- NVCBLTXNPSTJRW-UHFFFAOYSA-N n-[4-[(1-butanoylpiperidin-4-yl)methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 NVCBLTXNPSTJRW-UHFFFAOYSA-N 0.000 description 1
- VKSAZBHXCQSXAC-UHFFFAOYSA-N n-[4-[(1-cyclopropylcyclopropyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC1(C2CC2)CC1 VKSAZBHXCQSXAC-UHFFFAOYSA-N 0.000 description 1
- VASZDCGNKKYKKD-UHFFFAOYSA-N n-[4-[(1-hexanoylpiperidin-4-yl)methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCCC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 VASZDCGNKKYKKD-UHFFFAOYSA-N 0.000 description 1
- AYGCCJBGCRDTAT-UHFFFAOYSA-N n-[4-[(1-methylcyclobutyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(NC(=O)C2CN(C2)C=2N=NC=CC=2)C=CC=1C(=O)NC1(C)CCC1 AYGCCJBGCRDTAT-UHFFFAOYSA-N 0.000 description 1
- MXQUNAKFQHFLDT-UHFFFAOYSA-N n-[4-[(1-methylcyclopropyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(NC(=O)C2CN(C2)C=2N=NC=CC=2)C=CC=1C(=O)NC1(C)CC1 MXQUNAKFQHFLDT-UHFFFAOYSA-N 0.000 description 1
- MNDWGHIMTLIXRA-UHFFFAOYSA-N n-[4-[(1-methylpiperidin-3-yl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C)CCCC1NC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 MNDWGHIMTLIXRA-UHFFFAOYSA-N 0.000 description 1
- RAULFTWNLMFGGB-UHFFFAOYSA-N n-[4-[(1-methylpiperidin-3-yl)methylcarbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C)CCCC1CNC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 RAULFTWNLMFGGB-UHFFFAOYSA-N 0.000 description 1
- GIJRUPKZTWOJER-UHFFFAOYSA-N n-[4-[(1-methylpiperidin-4-yl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 GIJRUPKZTWOJER-UHFFFAOYSA-N 0.000 description 1
- AIULZPZGQYPOAE-UHFFFAOYSA-N n-[4-[(1-pent-4-ynoylpiperidin-4-yl)methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(CCC#C)=O)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 AIULZPZGQYPOAE-UHFFFAOYSA-N 0.000 description 1
- RLANDZTZQPZBID-UHFFFAOYSA-N n-[4-[(1-pentanoylpiperidin-4-yl)methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCCC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 RLANDZTZQPZBID-UHFFFAOYSA-N 0.000 description 1
- PRZVVOQUYFMCFY-UHFFFAOYSA-N n-[4-[(1-propanoylpiperidin-4-yl)methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 PRZVVOQUYFMCFY-UHFFFAOYSA-N 0.000 description 1
- WFJFXGLQCHWGLA-UHFFFAOYSA-N n-[4-[(2,2-dimethyloxan-4-yl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1COC(C)(C)CC1NC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 WFJFXGLQCHWGLA-UHFFFAOYSA-N 0.000 description 1
- OXBFJCBEFPPARY-UHFFFAOYSA-N n-[4-[(2-fluorophenyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 OXBFJCBEFPPARY-UHFFFAOYSA-N 0.000 description 1
- NNBZXVXSIIOQRV-UHFFFAOYSA-N n-[4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)NCC(C)(C)OC)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 NNBZXVXSIIOQRV-UHFFFAOYSA-N 0.000 description 1
- LHQGTJPMMQFUGR-UHFFFAOYSA-N n-[4-[(2-methylcyclopropyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1CC1NC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 LHQGTJPMMQFUGR-UHFFFAOYSA-N 0.000 description 1
- OVFZPKLSZBSDGC-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(NC(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 OVFZPKLSZBSDGC-UHFFFAOYSA-N 0.000 description 1
- MMFUZGCRHXTITB-UHFFFAOYSA-N n-[4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)NCC(C)(C)COC)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 MMFUZGCRHXTITB-UHFFFAOYSA-N 0.000 description 1
- AZAWPMBTDKQHKP-UHFFFAOYSA-N n-[4-[(3-methyloxetan-3-yl)methylcarbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(NC(=O)C2CN(C2)C=2N=NC=CC=2)C=CC=1C(=O)NCC1(C)COC1 AZAWPMBTDKQHKP-UHFFFAOYSA-N 0.000 description 1
- ZPMQMEHUVVURFE-JOCHJYFZSA-N n-[4-[(3r)-1-(2,2-difluoro-2-phenylacetyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O([C@@H]1CCN(C1)C(=O)C(F)(F)C=1C=CC=CC=1)C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 ZPMQMEHUVVURFE-JOCHJYFZSA-N 0.000 description 1
- LYTXXXNSTKEKPR-HSZRJFAPSA-N n-[4-[(3r)-1-(2,2-difluoro-2-phenylacetyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound O([C@@H]1CCN(C1)C(=O)C(F)(F)C=1C=CC=CC=1)C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 LYTXXXNSTKEKPR-HSZRJFAPSA-N 0.000 description 1
- MKFVXOTVPGMBMB-HXUWFJFHSA-N n-[4-[(3r)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)(C)CC)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 MKFVXOTVPGMBMB-HXUWFJFHSA-N 0.000 description 1
- ZIBXYXVLVCXJEY-OAQYLSRUSA-N n-[4-[(3r)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)(C)CC)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 ZIBXYXVLVCXJEY-OAQYLSRUSA-N 0.000 description 1
- FZTAFTSRRBHURU-LJQANCHMSA-N n-[4-[(3r)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 FZTAFTSRRBHURU-LJQANCHMSA-N 0.000 description 1
- FRMGRUFSMXHOLS-HXUWFJFHSA-N n-[4-[(3r)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 FRMGRUFSMXHOLS-HXUWFJFHSA-N 0.000 description 1
- NGAIVUVMXLVKBX-OAQYLSRUSA-N n-[4-[(3r)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(O[C@H]3CN(CC3)C(=O)C=3C(=CC(F)=CC=3)F)=CC=2)C1 NGAIVUVMXLVKBX-OAQYLSRUSA-N 0.000 description 1
- JFHXWHHRWGQPQL-HXUWFJFHSA-N n-[4-[(3r)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 JFHXWHHRWGQPQL-HXUWFJFHSA-N 0.000 description 1
- NVAMKSHLADCJPS-OAQYLSRUSA-N n-[4-[(3r)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 NVAMKSHLADCJPS-OAQYLSRUSA-N 0.000 description 1
- DLTSGPFPVJDBJR-HXUWFJFHSA-N n-[4-[(3r)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 DLTSGPFPVJDBJR-HXUWFJFHSA-N 0.000 description 1
- WNBMFMGSAQWQRP-OAQYLSRUSA-N n-[4-[(3r)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 WNBMFMGSAQWQRP-OAQYLSRUSA-N 0.000 description 1
- AXQXMMSOXVXIPH-HXUWFJFHSA-N n-[4-[(3r)-1-(2-cyclopropylacetyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C([C@@H](CC1)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)N1C(=O)CC1CC1 AXQXMMSOXVXIPH-HXUWFJFHSA-N 0.000 description 1
- VCSROFMXVCYPTB-OAQYLSRUSA-N n-[4-[(3r)-1-(2-cyclopropylacetyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C([C@@H](CC1)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)N1C(=O)CC1CC1 VCSROFMXVCYPTB-OAQYLSRUSA-N 0.000 description 1
- IDGILAXQPPSXHA-HXUWFJFHSA-N n-[4-[(3r)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 IDGILAXQPPSXHA-HXUWFJFHSA-N 0.000 description 1
- BICIWUJCTFKSMC-OAQYLSRUSA-N n-[4-[(3r)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 BICIWUJCTFKSMC-OAQYLSRUSA-N 0.000 description 1
- DWMNGWWPMNYCOD-GOSISDBHSA-N n-[4-[(3r)-1-(2-methoxyacetyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)COC)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 DWMNGWWPMNYCOD-GOSISDBHSA-N 0.000 description 1
- SQVBPEHNFXPHLZ-LJQANCHMSA-N n-[4-[(3r)-1-(2-methoxyacetyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)COC)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 SQVBPEHNFXPHLZ-LJQANCHMSA-N 0.000 description 1
- ARKVOMYJKVFQQD-XMMPIXPASA-N n-[4-[(3r)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O([C@@H]1CCN(C1)C(=O)C(C)(C)C=1C=CC=CC=1)C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 ARKVOMYJKVFQQD-XMMPIXPASA-N 0.000 description 1
- UNJUEMGJMCPQPD-RUZDIDTESA-N n-[4-[(3r)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound O([C@@H]1CCN(C1)C(=O)C(C)(C)C=1C=CC=CC=1)C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 UNJUEMGJMCPQPD-RUZDIDTESA-N 0.000 description 1
- VZHXYPACFAWTBE-HXUWFJFHSA-N n-[4-[(3r)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(C)=CC=2)C1 VZHXYPACFAWTBE-HXUWFJFHSA-N 0.000 description 1
- VTTZMXZNLUOFMQ-LJQANCHMSA-N n-[4-[(3r)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 VTTZMXZNLUOFMQ-LJQANCHMSA-N 0.000 description 1
- URYAEWLKDSPDLX-HXUWFJFHSA-N n-[4-[(3r)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 URYAEWLKDSPDLX-HXUWFJFHSA-N 0.000 description 1
- RFZGSMKNRCSXPM-HXUWFJFHSA-N n-[4-[(3r)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 RFZGSMKNRCSXPM-HXUWFJFHSA-N 0.000 description 1
- HQRBTNJCOSMRTD-OAQYLSRUSA-N n-[4-[(3r)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 HQRBTNJCOSMRTD-OAQYLSRUSA-N 0.000 description 1
- QCVNUKMYMOTJTO-JOCHJYFZSA-N n-[4-[(3r)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 QCVNUKMYMOTJTO-JOCHJYFZSA-N 0.000 description 1
- SLEQQKOVVQQCJJ-HSZRJFAPSA-N n-[4-[(3r)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 SLEQQKOVVQQCJJ-HSZRJFAPSA-N 0.000 description 1
- QLIPJWFKWPHQJO-JOCHJYFZSA-N n-[4-[(3r)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 QLIPJWFKWPHQJO-JOCHJYFZSA-N 0.000 description 1
- FMHOAVFLMBXGTD-HSZRJFAPSA-N n-[4-[(3r)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 FMHOAVFLMBXGTD-HSZRJFAPSA-N 0.000 description 1
- DBSJJFKLOFTMTJ-JOCHJYFZSA-N n-[4-[(3r)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 DBSJJFKLOFTMTJ-JOCHJYFZSA-N 0.000 description 1
- TYVLZYYPYFICNH-HSZRJFAPSA-N n-[4-[(3r)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 TYVLZYYPYFICNH-HSZRJFAPSA-N 0.000 description 1
- LYXIEYYBYYKXIJ-OAQYLSRUSA-N n-[4-[(3r)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxyphenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound C1N(C(=O)CC(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(C)=CC=2)C1 LYXIEYYBYYKXIJ-OAQYLSRUSA-N 0.000 description 1
- FGIAKKMIELWYPK-HXUWFJFHSA-N n-[4-[(3r)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)CC(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 FGIAKKMIELWYPK-HXUWFJFHSA-N 0.000 description 1
- FGEPCTDBXAIUGD-OAQYLSRUSA-N n-[4-[(3r)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)CC(C)C)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 FGEPCTDBXAIUGD-OAQYLSRUSA-N 0.000 description 1
- YRZWOUSOFDVJJL-OAQYLSRUSA-N n-[4-[(3r)-1-(4,4-difluorocyclohexanecarbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(F)(F)CCC1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 YRZWOUSOFDVJJL-OAQYLSRUSA-N 0.000 description 1
- HHQOQHQLGDCSRW-JOCHJYFZSA-N n-[4-[(3r)-1-(4,4-difluorocyclohexanecarbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CC(F)(F)CCC1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 HHQOQHQLGDCSRW-JOCHJYFZSA-N 0.000 description 1
- XDKQDPUQCUYLIT-JOCHJYFZSA-N n-[4-[(3r)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 XDKQDPUQCUYLIT-JOCHJYFZSA-N 0.000 description 1
- CPSZAOSOYUUKQF-HSZRJFAPSA-N n-[4-[(3r)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 CPSZAOSOYUUKQF-HSZRJFAPSA-N 0.000 description 1
- NFGACCSMOSQEOO-JOCHJYFZSA-N n-[4-[(3r)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 NFGACCSMOSQEOO-JOCHJYFZSA-N 0.000 description 1
- LZHMFXGONVIUIY-HSZRJFAPSA-N n-[4-[(3r)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 LZHMFXGONVIUIY-HSZRJFAPSA-N 0.000 description 1
- BTEHTTGRMAGXFY-HXUWFJFHSA-N n-[4-[(3r)-1-(5-methylthiophene-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 BTEHTTGRMAGXFY-HXUWFJFHSA-N 0.000 description 1
- MCSXXGFEEOIMTE-OAQYLSRUSA-N n-[4-[(3r)-1-(5-methylthiophene-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 MCSXXGFEEOIMTE-OAQYLSRUSA-N 0.000 description 1
- AYUFKGLFXYVBAQ-LJQANCHMSA-N n-[4-[(3r)-1-(cyclopropanecarbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C1CC1 AYUFKGLFXYVBAQ-LJQANCHMSA-N 0.000 description 1
- FJZUCMOVYLZKND-HXUWFJFHSA-N n-[4-[(3r)-1-(cyclopropanecarbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C1CC1 FJZUCMOVYLZKND-HXUWFJFHSA-N 0.000 description 1
- UAQISLARNNCIRS-OAQYLSRUSA-N n-[4-[(3r)-1-(oxane-4-carbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C1CCOCC1 UAQISLARNNCIRS-OAQYLSRUSA-N 0.000 description 1
- SXPWUZYNLCVDNT-JOCHJYFZSA-N n-[4-[(3r)-1-(oxane-4-carbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C1CCOCC1 SXPWUZYNLCVDNT-JOCHJYFZSA-N 0.000 description 1
- SLZYAESYRKBVSB-FIWHBWSRSA-N n-[4-[(3r)-1-(oxolane-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C1CCCO1 SLZYAESYRKBVSB-FIWHBWSRSA-N 0.000 description 1
- VMASEUIPOKKPIL-VQCQRNETSA-N n-[4-[(3r)-1-(oxolane-2-carbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C1CCCO1 VMASEUIPOKKPIL-VQCQRNETSA-N 0.000 description 1
- FSNKFQPZKKRIET-OTOKDRCRSA-N n-[4-[(3r)-1-(oxolane-3-carbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2N=NC=CC=2)CN1C(=O)C1CCOC1 FSNKFQPZKKRIET-OTOKDRCRSA-N 0.000 description 1
- XQXXIFKPBFGBRN-CAWMZFRYSA-N n-[4-[(3r)-1-(oxolane-3-carbonyl)pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C([C@H](C1)OC2=CC=C(C=C2)NC(=O)C2CN(C2)C=2C=NN=CC=2)CN1C(=O)C1CCOC1 XQXXIFKPBFGBRN-CAWMZFRYSA-N 0.000 description 1
- OLVKYVSBWGWDOH-OXJNMPFZSA-N n-[4-[(3r)-1-[(2s)-2-methylbutanoyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)[C@@H](C)CC)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 OLVKYVSBWGWDOH-OXJNMPFZSA-N 0.000 description 1
- GLFSHUDBBZQQJH-HRAATJIYSA-N n-[4-[(3r)-1-[(2s)-2-methylbutanoyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)[C@@H](C)CC)CC[C@H]1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 GLFSHUDBBZQQJH-HRAATJIYSA-N 0.000 description 1
- FHGXAKKXVVDXTA-JOCHJYFZSA-N n-[4-[(3r)-1-[2-(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 FHGXAKKXVVDXTA-JOCHJYFZSA-N 0.000 description 1
- GWPKMVDCYJIGHY-HSZRJFAPSA-N n-[4-[(3r)-1-[2-(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 GWPKMVDCYJIGHY-HSZRJFAPSA-N 0.000 description 1
- VCBJGBUDHVYDIC-JOCHJYFZSA-N n-[4-[(3r)-1-[2-(2-fluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 VCBJGBUDHVYDIC-JOCHJYFZSA-N 0.000 description 1
- XVARPTUDAQSYKH-HSZRJFAPSA-N n-[4-[(3r)-1-[2-(2-fluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 XVARPTUDAQSYKH-HSZRJFAPSA-N 0.000 description 1
- ZITMZTRJOJGPOB-HSZRJFAPSA-N n-[4-[(3r)-1-[2-(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(CC(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 ZITMZTRJOJGPOB-HSZRJFAPSA-N 0.000 description 1
- JZBPIXMPYZCGRV-XMMPIXPASA-N n-[4-[(3r)-1-[2-(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(CC(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 JZBPIXMPYZCGRV-XMMPIXPASA-N 0.000 description 1
- GANCWVSAXNJMMT-HSZRJFAPSA-N n-[4-[(3r)-1-[2-(3-fluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 GANCWVSAXNJMMT-HSZRJFAPSA-N 0.000 description 1
- NTNRNRSSRHXOCO-XMMPIXPASA-N n-[4-[(3r)-1-[2-(3-fluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2C[C@@H](CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 NTNRNRSSRHXOCO-XMMPIXPASA-N 0.000 description 1
- JKBRGPGUHSZGSJ-HSZRJFAPSA-N n-[4-[(3r)-1-[2-(4-fluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 JKBRGPGUHSZGSJ-HSZRJFAPSA-N 0.000 description 1
- KTQRZXLQQYDFFS-XMMPIXPASA-N n-[4-[(3r)-1-[2-(4-fluorophenyl)acetyl]pyrrolidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1C[C@H](OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 KTQRZXLQQYDFFS-XMMPIXPASA-N 0.000 description 1
- HWJSJYLZIJEGIQ-UHFFFAOYSA-N n-[4-[(4-fluorophenyl)carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 HWJSJYLZIJEGIQ-UHFFFAOYSA-N 0.000 description 1
- ZFGRMXBQWPLJIL-UHFFFAOYSA-N n-[4-[1-(1-acetylpiperidine-4-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C)CCC1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 ZFGRMXBQWPLJIL-UHFFFAOYSA-N 0.000 description 1
- UUYCQDCRFWQNGV-UHFFFAOYSA-N n-[4-[1-(1-methylcyclohexanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CCCCC1 UUYCQDCRFWQNGV-UHFFFAOYSA-N 0.000 description 1
- GCBNTOWXXWSKSI-UHFFFAOYSA-N n-[4-[1-(1-methylcyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C2(C)CCCCC2)C1 GCBNTOWXXWSKSI-UHFFFAOYSA-N 0.000 description 1
- ILLSLDGZEGJRAG-UHFFFAOYSA-N n-[4-[1-(1-methylcyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CCCCC1 ILLSLDGZEGJRAG-UHFFFAOYSA-N 0.000 description 1
- WTSIVAFTURIECL-UHFFFAOYSA-N n-[4-[1-(1-methylcyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CCCCC1 WTSIVAFTURIECL-UHFFFAOYSA-N 0.000 description 1
- WGTPFYYOMRZTIC-UHFFFAOYSA-N n-[4-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CC1 WGTPFYYOMRZTIC-UHFFFAOYSA-N 0.000 description 1
- YUOHHPZCMPYCOQ-UHFFFAOYSA-N n-[4-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C2(C)CC2)C1 YUOHHPZCMPYCOQ-UHFFFAOYSA-N 0.000 description 1
- PIGWSAPNRYPZEA-UHFFFAOYSA-N n-[4-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CC1 PIGWSAPNRYPZEA-UHFFFAOYSA-N 0.000 description 1
- SDBXJTPHMLDBFN-UHFFFAOYSA-N n-[4-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CC1 SDBXJTPHMLDBFN-UHFFFAOYSA-N 0.000 description 1
- ZDKQPKOWIYFMLO-UHFFFAOYSA-N n-[4-[1-(1-methylpyrrole-2-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CC1 ZDKQPKOWIYFMLO-UHFFFAOYSA-N 0.000 description 1
- QFADOXALYOFACL-UHFFFAOYSA-N n-[4-[1-(1-methylpyrrole-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CC1 QFADOXALYOFACL-UHFFFAOYSA-N 0.000 description 1
- ZFLLEQFGMOYCPR-UHFFFAOYSA-N n-[4-[1-(1-phenylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1(C=2C=CC=CC=2)CC1 ZFLLEQFGMOYCPR-UHFFFAOYSA-N 0.000 description 1
- BPIXPEYDDRNSQQ-UHFFFAOYSA-N n-[4-[1-(1-phenylcyclopropanecarbonyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1S(=O)(=O)C(CC1)CCN1C(=O)C1(C=2C=CC=CC=2)CC1 BPIXPEYDDRNSQQ-UHFFFAOYSA-N 0.000 description 1
- HVWKWHCSBFLMOD-UHFFFAOYSA-N n-[4-[1-(2,2-difluoro-2-phenylacetyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1C(F)(F)C(=O)N(C1)CC1OC(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 HVWKWHCSBFLMOD-UHFFFAOYSA-N 0.000 description 1
- CQWYEADGLKUHIT-UHFFFAOYSA-N n-[4-[1-(2,2-difluoro-2-phenylacetyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1C(F)(F)C(=O)N(CC1)CCC1OC(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 CQWYEADGLKUHIT-UHFFFAOYSA-N 0.000 description 1
- GDPFDUJXJOUKJK-UHFFFAOYSA-N n-[4-[1-(2,2-difluoro-2-phenylacetyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1C(F)(F)C(=O)N(CC1)CCC1OC(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 GDPFDUJXJOUKJK-UHFFFAOYSA-N 0.000 description 1
- YOANTULQWPDKMK-UHFFFAOYSA-N n-[4-[1-(2,2-difluoro-2-phenylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1C(F)(F)C(=O)N(CC1)CCC1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 YOANTULQWPDKMK-UHFFFAOYSA-N 0.000 description 1
- ZQGUWCPQIDGDFV-UHFFFAOYSA-N n-[4-[1-(2,2-dimethyl-3-piperazin-1-ylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)C=NN1CC(C)(C)CN1CCNCC1 ZQGUWCPQIDGDFV-UHFFFAOYSA-N 0.000 description 1
- GGHFRAAUNBOBMQ-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 GGHFRAAUNBOBMQ-UHFFFAOYSA-N 0.000 description 1
- FNGOYSLIRUFABC-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 FNGOYSLIRUFABC-UHFFFAOYSA-N 0.000 description 1
- UWAJSOKGLDGZLL-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 UWAJSOKGLDGZLL-UHFFFAOYSA-N 0.000 description 1
- YOZLCPKRAGNSCD-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 YOZLCPKRAGNSCD-UHFFFAOYSA-N 0.000 description 1
- MQHKVXDTYIEKAD-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 MQHKVXDTYIEKAD-UHFFFAOYSA-N 0.000 description 1
- XJJLZVPCMDPJNM-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 XJJLZVPCMDPJNM-UHFFFAOYSA-N 0.000 description 1
- WYHPESHNWYPNBW-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(C)(C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 WYHPESHNWYPNBW-UHFFFAOYSA-N 0.000 description 1
- HAAMYMAJBYQDMK-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylbutyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(C)(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 HAAMYMAJBYQDMK-UHFFFAOYSA-N 0.000 description 1
- IFWHWRZBLFMJIR-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)-4-fluoropiperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1(F)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 IFWHWRZBLFMJIR-UHFFFAOYSA-N 0.000 description 1
- YROSXMQSUNSXAE-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)-4-hydroxypiperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1(O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 YROSXMQSUNSXAE-UHFFFAOYSA-N 0.000 description 1
- VUTZFWNBWWJUIJ-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1F)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 VUTZFWNBWWJUIJ-UHFFFAOYSA-N 0.000 description 1
- CUENRYFKWXCYPG-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1F)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 CUENRYFKWXCYPG-UHFFFAOYSA-N 0.000 description 1
- WFTSDXYIKLLINQ-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-3-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C(=C1)F)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 WFTSDXYIKLLINQ-UHFFFAOYSA-N 0.000 description 1
- LTZYVTQLWYWKCN-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 LTZYVTQLWYWKCN-UHFFFAOYSA-N 0.000 description 1
- ZPJLACHULHYHTM-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 ZPJLACHULHYHTM-UHFFFAOYSA-N 0.000 description 1
- JICPTSGKZAPVRE-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 JICPTSGKZAPVRE-UHFFFAOYSA-N 0.000 description 1
- SJEKTXYPKWKYSF-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)C)C1 SJEKTXYPKWKYSF-UHFFFAOYSA-N 0.000 description 1
- MNAPTKLAMZJYCE-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(F)=CC=2)C1 MNAPTKLAMZJYCE-UHFFFAOYSA-N 0.000 description 1
- WVVPZDOEXIEHRW-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)C)C1 WVVPZDOEXIEHRW-UHFFFAOYSA-N 0.000 description 1
- GQQNBJXSKGVHCY-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpiperidine-4-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CCN(C=2N=NC=CC=2)CC1 GQQNBJXSKGVHCY-UHFFFAOYSA-N 0.000 description 1
- GMHUCHWWRYJCLU-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 GMHUCHWWRYJCLU-UHFFFAOYSA-N 0.000 description 1
- AFBZJUDOWVNWAL-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 AFBZJUDOWVNWAL-UHFFFAOYSA-N 0.000 description 1
- PBPGVXMWVMKMIU-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1S(=O)(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 PBPGVXMWVMKMIU-UHFFFAOYSA-N 0.000 description 1
- IBLCWZWALWZRLC-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropyl)imidazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC(C)(C)CN1C=NC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 IBLCWZWALWZRLC-UHFFFAOYSA-N 0.000 description 1
- GCUQUMBHMQCHLJ-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 GCUQUMBHMQCHLJ-UHFFFAOYSA-N 0.000 description 1
- QNUPXEVKEHZIGA-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropyl)pyrazol-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2=CN(CC(C)(C)C)N=C2)C1 QNUPXEVKEHZIGA-UHFFFAOYSA-N 0.000 description 1
- QOMIPYCQXFBFNM-UHFFFAOYSA-N n-[4-[1-(2,2-dimethylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=NN(CC(C)(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 QOMIPYCQXFBFNM-UHFFFAOYSA-N 0.000 description 1
- JSJWNWWMBAQWLP-UHFFFAOYSA-N n-[4-[1-(2,2-diphenylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 JSJWNWWMBAQWLP-UHFFFAOYSA-N 0.000 description 1
- ZKXXJIWIZAOFGK-UHFFFAOYSA-N n-[4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1F ZKXXJIWIZAOFGK-UHFFFAOYSA-N 0.000 description 1
- PAEGZTZWWFAJBF-UHFFFAOYSA-N n-[4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1F PAEGZTZWWFAJBF-UHFFFAOYSA-N 0.000 description 1
- CLGNGUIYWHGVMI-UHFFFAOYSA-N n-[4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1C CLGNGUIYWHGVMI-UHFFFAOYSA-N 0.000 description 1
- ZIXUYYZYVOESOI-UHFFFAOYSA-N n-[4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=CC(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1C ZIXUYYZYVOESOI-UHFFFAOYSA-N 0.000 description 1
- IJYFVUZUYOLQDQ-UHFFFAOYSA-N n-[4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 IJYFVUZUYOLQDQ-UHFFFAOYSA-N 0.000 description 1
- ZCODHRWWMZHIDU-UHFFFAOYSA-N n-[4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 ZCODHRWWMZHIDU-UHFFFAOYSA-N 0.000 description 1
- ASFASXZLQNEVSA-UHFFFAOYSA-N n-[4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 ASFASXZLQNEVSA-UHFFFAOYSA-N 0.000 description 1
- OGQIUWRYBUIRQH-UHFFFAOYSA-N n-[4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 OGQIUWRYBUIRQH-UHFFFAOYSA-N 0.000 description 1
- OLJVJORGIWJCGU-UHFFFAOYSA-N n-[4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 OLJVJORGIWJCGU-UHFFFAOYSA-N 0.000 description 1
- KOSPEVRIRFYQLK-UHFFFAOYSA-N n-[4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 KOSPEVRIRFYQLK-UHFFFAOYSA-N 0.000 description 1
- AREXQHLBGVHKKQ-UHFFFAOYSA-N n-[4-[1-(2,4-difluorobenzoyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)C1 AREXQHLBGVHKKQ-UHFFFAOYSA-N 0.000 description 1
- BELKOROCMGUIDL-UHFFFAOYSA-N n-[4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(C=2C=C(F)C(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 BELKOROCMGUIDL-UHFFFAOYSA-N 0.000 description 1
- ARRRTOYWFXNISC-UHFFFAOYSA-N n-[4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 ARRRTOYWFXNISC-UHFFFAOYSA-N 0.000 description 1
- BGUYJUXMQZLUFS-UHFFFAOYSA-N n-[4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 BGUYJUXMQZLUFS-UHFFFAOYSA-N 0.000 description 1
- LJPGOLZCQDCCDS-UHFFFAOYSA-N n-[4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 LJPGOLZCQDCCDS-UHFFFAOYSA-N 0.000 description 1
- LJBVCKZSVWYHFG-UHFFFAOYSA-N n-[4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 LJBVCKZSVWYHFG-UHFFFAOYSA-N 0.000 description 1
- WAGOFAXZVZEARS-UHFFFAOYSA-N n-[4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WAGOFAXZVZEARS-UHFFFAOYSA-N 0.000 description 1
- PETSDCLANWYDKQ-UHFFFAOYSA-N n-[4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 PETSDCLANWYDKQ-UHFFFAOYSA-N 0.000 description 1
- LIVBXGBOGLMDRI-UHFFFAOYSA-N n-[4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=C(Cl)C(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 LIVBXGBOGLMDRI-UHFFFAOYSA-N 0.000 description 1
- JUZFLNZVQRTCOT-UHFFFAOYSA-N n-[4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=C(F)C(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 JUZFLNZVQRTCOT-UHFFFAOYSA-N 0.000 description 1
- FUGQWTKOOBTWFL-UHFFFAOYSA-N n-[4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=C(F)C(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 FUGQWTKOOBTWFL-UHFFFAOYSA-N 0.000 description 1
- YEBBVPJRQSPEOW-UHFFFAOYSA-N n-[4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=C(C)C(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 YEBBVPJRQSPEOW-UHFFFAOYSA-N 0.000 description 1
- ILSFPSKITVJYLT-UHFFFAOYSA-N n-[4-[1-(2,5-dimethylfuran-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O1C(C)=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1C ILSFPSKITVJYLT-UHFFFAOYSA-N 0.000 description 1
- YADLYZTUOHENJF-UHFFFAOYSA-N n-[4-[1-(2-amino-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(N)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 YADLYZTUOHENJF-UHFFFAOYSA-N 0.000 description 1
- HVUCKHUYCQBHJZ-UHFFFAOYSA-N n-[4-[1-(2-aminopyridine-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound NC1=NC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 HVUCKHUYCQBHJZ-UHFFFAOYSA-N 0.000 description 1
- CFYSFWMAPQSKQO-UHFFFAOYSA-N n-[4-[1-(2-benzamidoacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CNC(=O)C1=CC=CC=C1 CFYSFWMAPQSKQO-UHFFFAOYSA-N 0.000 description 1
- ACEMHWIMTOYZEL-UHFFFAOYSA-N n-[4-[1-(2-chlorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 ACEMHWIMTOYZEL-UHFFFAOYSA-N 0.000 description 1
- LIMLFNOLLVGKTE-UHFFFAOYSA-N n-[4-[1-(2-chlorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 LIMLFNOLLVGKTE-UHFFFAOYSA-N 0.000 description 1
- LXMDESIWPXPBER-UHFFFAOYSA-N n-[4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)Cl)C1 LXMDESIWPXPBER-UHFFFAOYSA-N 0.000 description 1
- AXXFKHKQVBWIRL-UHFFFAOYSA-N n-[4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 AXXFKHKQVBWIRL-UHFFFAOYSA-N 0.000 description 1
- AJKPIVVLPSRLCL-UHFFFAOYSA-N n-[4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 AJKPIVVLPSRLCL-UHFFFAOYSA-N 0.000 description 1
- YZSSOWJRFYNHAO-UHFFFAOYSA-N n-[4-[1-(2-chlorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 YZSSOWJRFYNHAO-UHFFFAOYSA-N 0.000 description 1
- WQFKGWMUQDZLSL-UHFFFAOYSA-N n-[4-[1-(2-cyclohexylacetyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CC1CCCCC1 WQFKGWMUQDZLSL-UHFFFAOYSA-N 0.000 description 1
- VYSOZPSULFZLTN-UHFFFAOYSA-N n-[4-[1-(2-cyclohexylacetyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC2CCCCC2)C1 VYSOZPSULFZLTN-UHFFFAOYSA-N 0.000 description 1
- PFZSZKUUVWGRGE-UHFFFAOYSA-N n-[4-[1-(2-cyclohexylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CC1CCCCC1 PFZSZKUUVWGRGE-UHFFFAOYSA-N 0.000 description 1
- DKAOZDKTGALDEB-UHFFFAOYSA-N n-[4-[1-(2-cyclohexylacetyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CC1CCCCC1 DKAOZDKTGALDEB-UHFFFAOYSA-N 0.000 description 1
- AOKCKXYGQVACFY-UHFFFAOYSA-N n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CC1CCCC1 AOKCKXYGQVACFY-UHFFFAOYSA-N 0.000 description 1
- YOWBVLPPRHZPPD-UHFFFAOYSA-N n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC2CCCC2)C1 YOWBVLPPRHZPPD-UHFFFAOYSA-N 0.000 description 1
- JXRKYCKNXWVFOA-UHFFFAOYSA-N n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CC1CCCC1 JXRKYCKNXWVFOA-UHFFFAOYSA-N 0.000 description 1
- BRCGJPQWVCYZFK-UHFFFAOYSA-N n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CCN1C(=O)CC1CCCC1 BRCGJPQWVCYZFK-UHFFFAOYSA-N 0.000 description 1
- FMQGKMLEWULXTP-UHFFFAOYSA-N n-[4-[1-(2-cyclopentylacetyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CC1CCCC1 FMQGKMLEWULXTP-UHFFFAOYSA-N 0.000 description 1
- DXJGGNGIRPFQTH-UHFFFAOYSA-N n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]-2-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(C2CCN(CC2)C(=O)CC2CC2)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 DXJGGNGIRPFQTH-UHFFFAOYSA-N 0.000 description 1
- BZBJQYFHHXZZIG-UHFFFAOYSA-N n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]-3-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)CC2CC2)C(F)=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 BZBJQYFHHXZZIG-UHFFFAOYSA-N 0.000 description 1
- ALPOPIBWFIQQMW-UHFFFAOYSA-N n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CC1CC1 ALPOPIBWFIQQMW-UHFFFAOYSA-N 0.000 description 1
- NUTMPGPCKSPIHT-UHFFFAOYSA-N n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CCN1C(=O)CC1CC1 NUTMPGPCKSPIHT-UHFFFAOYSA-N 0.000 description 1
- CIXKGDOZODOEJH-UHFFFAOYSA-N n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CC1CC1 CIXKGDOZODOEJH-UHFFFAOYSA-N 0.000 description 1
- HURNUQCKGMQILX-UHFFFAOYSA-N n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CCN1C(=O)CC1CC1 HURNUQCKGMQILX-UHFFFAOYSA-N 0.000 description 1
- KZTQXLGWVVSFCY-UHFFFAOYSA-N n-[4-[1-(2-cyclopropylacetyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CC1CC1 KZTQXLGWVVSFCY-UHFFFAOYSA-N 0.000 description 1
- ICFIERZPASIVAT-UHFFFAOYSA-N n-[4-[1-(2-cyclopropylethyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1CCC1CC1 ICFIERZPASIVAT-UHFFFAOYSA-N 0.000 description 1
- WHNYMVMEKMMZCB-UHFFFAOYSA-N n-[4-[1-(2-ethoxyacetyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COCC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 WHNYMVMEKMMZCB-UHFFFAOYSA-N 0.000 description 1
- CRGKAPKNSBAUDW-UHFFFAOYSA-N n-[4-[1-(2-ethoxyacetyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)COCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 CRGKAPKNSBAUDW-UHFFFAOYSA-N 0.000 description 1
- INXIFWYIAUZDED-UHFFFAOYSA-N n-[4-[1-(2-ethoxyacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 INXIFWYIAUZDED-UHFFFAOYSA-N 0.000 description 1
- DHQREBKPCIAWQE-UHFFFAOYSA-N n-[4-[1-(2-ethoxyacetyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 DHQREBKPCIAWQE-UHFFFAOYSA-N 0.000 description 1
- DACQESBPRDQXEW-UHFFFAOYSA-N n-[4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(CC)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC(F)=CC=2)C1 DACQESBPRDQXEW-UHFFFAOYSA-N 0.000 description 1
- QTFRAAFAIFTDGH-UHFFFAOYSA-N n-[4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(CC)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 QTFRAAFAIFTDGH-UHFFFAOYSA-N 0.000 description 1
- KRXUTZOOJXNVRH-UHFFFAOYSA-N n-[4-[1-(2-ethylbutyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(CC)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 KRXUTZOOJXNVRH-UHFFFAOYSA-N 0.000 description 1
- ACMHITBXTDYNCJ-UHFFFAOYSA-N n-[4-[1-(2-ethylbutyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(CC)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 ACMHITBXTDYNCJ-UHFFFAOYSA-N 0.000 description 1
- KELNJBPGCFEVLJ-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(O)(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C1=CC=CC=C1F KELNJBPGCFEVLJ-UHFFFAOYSA-N 0.000 description 1
- WRMMCKWUUDCZAC-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WRMMCKWUUDCZAC-UHFFFAOYSA-N 0.000 description 1
- ALDYRVBEIUGSNK-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 ALDYRVBEIUGSNK-UHFFFAOYSA-N 0.000 description 1
- QFAMAWMJJYMGJV-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C1 QFAMAWMJJYMGJV-UHFFFAOYSA-N 0.000 description 1
- FQJKMPGDXXVFOQ-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide Chemical compound CC1=NN=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C1 FQJKMPGDXXVFOQ-UHFFFAOYSA-N 0.000 description 1
- JCJNNKHGEGGRDE-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(F)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C1 JCJNNKHGEGGRDE-UHFFFAOYSA-N 0.000 description 1
- VUZFFXIHMDVURC-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)C1 VUZFFXIHMDVURC-UHFFFAOYSA-N 0.000 description 1
- WOHCEHMJNGBZEH-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WOHCEHMJNGBZEH-UHFFFAOYSA-N 0.000 description 1
- GAPHYIURLIDGAJ-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylpiperidine-4-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CCN(CC3)C=3N=NC=CC=3)=CC=2)CC1 GAPHYIURLIDGAJ-UHFFFAOYSA-N 0.000 description 1
- NCUQMQJLYPXDMS-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 NCUQMQJLYPXDMS-UHFFFAOYSA-N 0.000 description 1
- WJMSMKUPFUTAOV-UHFFFAOYSA-N n-[4-[1-(2-fluorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WJMSMKUPFUTAOV-UHFFFAOYSA-N 0.000 description 1
- NNGCIPBKKUGJGW-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)(O)C)CC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 NNGCIPBKKUGJGW-UHFFFAOYSA-N 0.000 description 1
- JJWQTTRHCVZEIE-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 JJWQTTRHCVZEIE-UHFFFAOYSA-N 0.000 description 1
- ONWURVDIDPOPEM-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(2-methoxypyridin-3-yl)azetidine-3-carboxamide Chemical compound COC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)O)C1 ONWURVDIDPOPEM-UHFFFAOYSA-N 0.000 description 1
- TXYCVDYUTCHHNH-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)O)C1 TXYCVDYUTCHHNH-UHFFFAOYSA-N 0.000 description 1
- FDNOQIWAKNGCIY-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(4-methoxypyridin-3-yl)azetidine-3-carboxamide Chemical compound COC1=CC=NC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)O)C1 FDNOQIWAKNGCIY-UHFFFAOYSA-N 0.000 description 1
- KYOTZCGBZNGMGM-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(4-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CC=NC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C(C)(C)O)C1 KYOTZCGBZNGMGM-UHFFFAOYSA-N 0.000 description 1
- WIPKYKAHKUQLMQ-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 WIPKYKAHKUQLMQ-UHFFFAOYSA-N 0.000 description 1
- UHXDVHWGMVVVJN-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 UHXDVHWGMVVVJN-UHFFFAOYSA-N 0.000 description 1
- LXXZFZHXRBKOTB-UHFFFAOYSA-N n-[4-[1-(2-hydroxy-2-methylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=NN(CC(C)(O)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 LXXZFZHXRBKOTB-UHFFFAOYSA-N 0.000 description 1
- GAZGWGBLKZEJOY-UHFFFAOYSA-N n-[4-[1-(2-hydroxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound OC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 GAZGWGBLKZEJOY-UHFFFAOYSA-N 0.000 description 1
- ORDNWROUDGXXIY-UHFFFAOYSA-N n-[4-[1-(2-methoxyacetyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 ORDNWROUDGXXIY-UHFFFAOYSA-N 0.000 description 1
- IPBJTUIZDNUOSF-UHFFFAOYSA-N n-[4-[1-(2-methoxyacetyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 IPBJTUIZDNUOSF-UHFFFAOYSA-N 0.000 description 1
- LKDDINYUXUIDDL-UHFFFAOYSA-N n-[4-[1-(2-methoxyacetyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 LKDDINYUXUIDDL-UHFFFAOYSA-N 0.000 description 1
- CCEONCYARQZNEM-UHFFFAOYSA-N n-[4-[1-(2-methoxyacetyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 CCEONCYARQZNEM-UHFFFAOYSA-N 0.000 description 1
- WWWUFRBXZOWSHM-UHFFFAOYSA-N n-[4-[1-(2-methoxyacetyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 WWWUFRBXZOWSHM-UHFFFAOYSA-N 0.000 description 1
- QRWYEAPOHNDJST-UHFFFAOYSA-N n-[4-[1-(2-methoxyacetyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 QRWYEAPOHNDJST-UHFFFAOYSA-N 0.000 description 1
- DHKXEMPRAPFYMO-UHFFFAOYSA-N n-[4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound COC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 DHKXEMPRAPFYMO-UHFFFAOYSA-N 0.000 description 1
- PQVVFOMLNQVLGO-UHFFFAOYSA-N n-[4-[1-(2-methoxybenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound COC1=CC=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 PQVVFOMLNQVLGO-UHFFFAOYSA-N 0.000 description 1
- SZUMQRPOGYACSX-UHFFFAOYSA-N n-[4-[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1C(C)(C)C(=O)N(CC1)CCC1OC(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 SZUMQRPOGYACSX-UHFFFAOYSA-N 0.000 description 1
- LRZRJIKUIMEKAQ-UHFFFAOYSA-N n-[4-[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1C(C)(C)C(=O)N(CC1)CCC1OC(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 LRZRJIKUIMEKAQ-UHFFFAOYSA-N 0.000 description 1
- ASEQDESJJWMBHL-UHFFFAOYSA-N n-[4-[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1C(C)(C)C(=O)N(CC1)CCC1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=NN=C1 ASEQDESJJWMBHL-UHFFFAOYSA-N 0.000 description 1
- ITFIIXUWODNJQY-UHFFFAOYSA-N n-[4-[1-(2-methyl-2-piperazin-1-ylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C(C)(C)N1CCNCC1 ITFIIXUWODNJQY-UHFFFAOYSA-N 0.000 description 1
- KEOZUICOYMFHMX-UHFFFAOYSA-N n-[4-[1-(2-methyl-2-piperazin-1-ylpropanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)C(C)(C)N1CCNCC1 KEOZUICOYMFHMX-UHFFFAOYSA-N 0.000 description 1
- SBBFBQORFMEENT-UHFFFAOYSA-N n-[4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 SBBFBQORFMEENT-UHFFFAOYSA-N 0.000 description 1
- LEBILIKDZRPBMQ-UHFFFAOYSA-N n-[4-[1-(2-methylbenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 LEBILIKDZRPBMQ-UHFFFAOYSA-N 0.000 description 1
- SHXQNYGXOIOFBN-UHFFFAOYSA-N n-[4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 SHXQNYGXOIOFBN-UHFFFAOYSA-N 0.000 description 1
- XAPPMSHVXFLCBK-UHFFFAOYSA-N n-[4-[1-(2-methylbutyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 XAPPMSHVXFLCBK-UHFFFAOYSA-N 0.000 description 1
- CYSIZTSIHHINFQ-UHFFFAOYSA-N n-[4-[1-(2-methylcyclopropanecarbonyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound CC1CC1C(=O)N1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)C1 CYSIZTSIHHINFQ-UHFFFAOYSA-N 0.000 description 1
- ZROKLTPQQVZRJN-UHFFFAOYSA-N n-[4-[1-(2-methylcyclopropanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound CC1CC1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CC1 ZROKLTPQQVZRJN-UHFFFAOYSA-N 0.000 description 1
- OFHYLBPCWHAGRQ-UHFFFAOYSA-N n-[4-[1-(2-methylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1CC1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C(=NC=CC=3)C)=CC=2)CC1 OFHYLBPCWHAGRQ-UHFFFAOYSA-N 0.000 description 1
- XFCSBZIIVSPLDG-UHFFFAOYSA-N n-[4-[1-(2-methylcyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound CC1CC1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CC1 XFCSBZIIVSPLDG-UHFFFAOYSA-N 0.000 description 1
- WWXYZXNTSQVQGW-UHFFFAOYSA-N n-[4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)CCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 WWXYZXNTSQVQGW-UHFFFAOYSA-N 0.000 description 1
- GIZCHRYTWSJWGR-UHFFFAOYSA-N n-[4-[1-(2-methylpentyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(C)CCC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 GIZCHRYTWSJWGR-UHFFFAOYSA-N 0.000 description 1
- OUONWGLBCPKWCI-UHFFFAOYSA-N n-[4-[1-(2-methylpentyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(C)CCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 OUONWGLBCPKWCI-UHFFFAOYSA-N 0.000 description 1
- DSVVKBIDHWKLOR-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)C(C)C)CC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 DSVVKBIDHWKLOR-UHFFFAOYSA-N 0.000 description 1
- XFYRRAUUKREWSJ-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 XFYRRAUUKREWSJ-UHFFFAOYSA-N 0.000 description 1
- PYGKYEAUUYDYPT-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 PYGKYEAUUYDYPT-UHFFFAOYSA-N 0.000 description 1
- ZCGABGKYDTUBPW-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 ZCGABGKYDTUBPW-UHFFFAOYSA-N 0.000 description 1
- CGMMOCAINOCYJN-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 CGMMOCAINOCYJN-UHFFFAOYSA-N 0.000 description 1
- URFVUNFBOOFZQJ-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 URFVUNFBOOFZQJ-UHFFFAOYSA-N 0.000 description 1
- PLUBLXFPSJRKDT-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 PLUBLXFPSJRKDT-UHFFFAOYSA-N 0.000 description 1
- OLYXVAYLIPHBMC-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1S(=O)(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 OLYXVAYLIPHBMC-UHFFFAOYSA-N 0.000 description 1
- IWZPMMMUQDAHSF-UHFFFAOYSA-N n-[4-[1-(2-methylpropanoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1S(=O)(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 IWZPMMMUQDAHSF-UHFFFAOYSA-N 0.000 description 1
- LVLJHKFFARWTBT-UHFFFAOYSA-N n-[4-[1-(2-methylpropyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 LVLJHKFFARWTBT-UHFFFAOYSA-N 0.000 description 1
- UGKJHLVKAGLOPS-UHFFFAOYSA-N n-[4-[1-(2-methylpropyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 UGKJHLVKAGLOPS-UHFFFAOYSA-N 0.000 description 1
- VMKWXXICDHUSCJ-UHFFFAOYSA-N n-[4-[1-(2-methylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=NN(CC(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 VMKWXXICDHUSCJ-UHFFFAOYSA-N 0.000 description 1
- MRVYICSPRGHGPD-UHFFFAOYSA-N n-[4-[1-(2-morpholin-4-ylacetyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CN1CCOCC1 MRVYICSPRGHGPD-UHFFFAOYSA-N 0.000 description 1
- FMCZFGPUAPWSGS-UHFFFAOYSA-N n-[4-[1-(2-morpholin-4-ylacetyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CN1CCOCC1 FMCZFGPUAPWSGS-UHFFFAOYSA-N 0.000 description 1
- ZSFYTFFSMCSABI-UHFFFAOYSA-N n-[4-[1-(2-naphthalen-1-ylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)CC=2C3=CC=CC=C3C=CC=2)C=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 ZSFYTFFSMCSABI-UHFFFAOYSA-N 0.000 description 1
- LDJWYYGGXPHCBR-UHFFFAOYSA-N n-[4-[1-(2-naphthalen-2-ylacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)CC=2C=C3C=CC=CC3=CC=2)C=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 LDJWYYGGXPHCBR-UHFFFAOYSA-N 0.000 description 1
- YTQODDBHRMXELF-UHFFFAOYSA-N n-[4-[1-(2-oxopropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(=O)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 YTQODDBHRMXELF-UHFFFAOYSA-N 0.000 description 1
- PLKYYABEUQAHFN-UHFFFAOYSA-N n-[4-[1-(2-phenylacetyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1S(=O)(=O)C(CC1)CCN1C(=O)CC1=CC=CC=C1 PLKYYABEUQAHFN-UHFFFAOYSA-N 0.000 description 1
- TXYBUGWCJOLJJY-UHFFFAOYSA-N n-[4-[1-(2-phenylmethoxyacetyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)COCC1=CC=CC=C1 TXYBUGWCJOLJJY-UHFFFAOYSA-N 0.000 description 1
- POCZFDPDAPSDQL-UHFFFAOYSA-N n-[4-[1-(2-piperazin-1-ylethyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=C1)C=NN1CCN1CCNCC1 POCZFDPDAPSDQL-UHFFFAOYSA-N 0.000 description 1
- MOVUMDBWQRRUJU-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)CC(C)(C)C)CC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 MOVUMDBWQRRUJU-UHFFFAOYSA-N 0.000 description 1
- PRJROJSTIQVMQH-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(C=C1F)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 PRJROJSTIQVMQH-UHFFFAOYSA-N 0.000 description 1
- GHYWYTHZWKXXEY-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(C=C1F)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 GHYWYTHZWKXXEY-UHFFFAOYSA-N 0.000 description 1
- ZVBQZXRPWNFVBI-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-3-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(C(=C1)F)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 ZVBQZXRPWNFVBI-UHFFFAOYSA-N 0.000 description 1
- BZHVROCKCOKYCC-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 BZHVROCKCOKYCC-UHFFFAOYSA-N 0.000 description 1
- LTECCAKTTPRKSL-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 LTECCAKTTPRKSL-UHFFFAOYSA-N 0.000 description 1
- LGJFWBTZEBAAEB-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC(C)(C)C)C1 LGJFWBTZEBAAEB-UHFFFAOYSA-N 0.000 description 1
- XDFDTJBORCYWPW-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound CC1=CC=NN=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)CC(C)(C)C)C1 XDFDTJBORCYWPW-UHFFFAOYSA-N 0.000 description 1
- PJDMVILSUUAZFA-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 PJDMVILSUUAZFA-UHFFFAOYSA-N 0.000 description 1
- XUGJEZSXRDTUQX-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 XUGJEZSXRDTUQX-UHFFFAOYSA-N 0.000 description 1
- ONLMBHLWPSHSQB-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 ONLMBHLWPSHSQB-UHFFFAOYSA-N 0.000 description 1
- FZXMBFKFOAZVLB-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1S(=O)(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 FZXMBFKFOAZVLB-UHFFFAOYSA-N 0.000 description 1
- ARHXWVWJNGMVSB-UHFFFAOYSA-N n-[4-[1-(3,3-dimethylbutyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CCC(C)(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 ARHXWVWJNGMVSB-UHFFFAOYSA-N 0.000 description 1
- UROXYRMUUBLULQ-UHFFFAOYSA-N n-[4-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 UROXYRMUUBLULQ-UHFFFAOYSA-N 0.000 description 1
- OTKUFRUXEHGWHI-UHFFFAOYSA-N n-[4-[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 OTKUFRUXEHGWHI-UHFFFAOYSA-N 0.000 description 1
- IWOOXRHZUZNFKO-UHFFFAOYSA-N n-[4-[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 IWOOXRHZUZNFKO-UHFFFAOYSA-N 0.000 description 1
- MTDOFQSQIUPLKM-UHFFFAOYSA-N n-[4-[1-(3,4-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 MTDOFQSQIUPLKM-UHFFFAOYSA-N 0.000 description 1
- JSWITHKYFKTOKR-UHFFFAOYSA-N n-[4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(C)C(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 JSWITHKYFKTOKR-UHFFFAOYSA-N 0.000 description 1
- FSNHAYQFYVSIPH-UHFFFAOYSA-N n-[4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=C(Cl)C=C(Cl)C=2)C1 FSNHAYQFYVSIPH-UHFFFAOYSA-N 0.000 description 1
- VCDTXLXWQXSICC-UHFFFAOYSA-N n-[4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 VCDTXLXWQXSICC-UHFFFAOYSA-N 0.000 description 1
- UBAFMJOIUIDSOC-UHFFFAOYSA-N n-[4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)C=2C=C(F)C(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 UBAFMJOIUIDSOC-UHFFFAOYSA-N 0.000 description 1
- MTVRNTLRXIAFOQ-UHFFFAOYSA-N n-[4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 MTVRNTLRXIAFOQ-UHFFFAOYSA-N 0.000 description 1
- ZRQHHYDALCAFRI-UHFFFAOYSA-N n-[4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 ZRQHHYDALCAFRI-UHFFFAOYSA-N 0.000 description 1
- UYXOVJRQOZFBHZ-UHFFFAOYSA-N n-[4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 UYXOVJRQOZFBHZ-UHFFFAOYSA-N 0.000 description 1
- ONELBAIKVAWWMS-UHFFFAOYSA-N n-[4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 ONELBAIKVAWWMS-UHFFFAOYSA-N 0.000 description 1
- YLRYXXPTLQVXEY-UHFFFAOYSA-N n-[4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 YLRYXXPTLQVXEY-UHFFFAOYSA-N 0.000 description 1
- HULKZSKPBISWEU-UHFFFAOYSA-N n-[4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC(C)=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 HULKZSKPBISWEU-UHFFFAOYSA-N 0.000 description 1
- RSQNGTRYXLVVAQ-UHFFFAOYSA-N n-[4-[1-(3-amino-2,2-dimethylpropyl)pyrazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=NN(CC(C)(CN)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 RSQNGTRYXLVVAQ-UHFFFAOYSA-N 0.000 description 1
- XCLNQYQBOSLGKB-UHFFFAOYSA-N n-[4-[1-(3-chlorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 XCLNQYQBOSLGKB-UHFFFAOYSA-N 0.000 description 1
- LLKVRIBUMODBFQ-UHFFFAOYSA-N n-[4-[1-(3-chlorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 LLKVRIBUMODBFQ-UHFFFAOYSA-N 0.000 description 1
- SDGUKRUVWBNSBZ-UHFFFAOYSA-N n-[4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=C(Cl)C=CC=2)C1 SDGUKRUVWBNSBZ-UHFFFAOYSA-N 0.000 description 1
- PYYVSGRXNRZHJB-UHFFFAOYSA-N n-[4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 PYYVSGRXNRZHJB-UHFFFAOYSA-N 0.000 description 1
- IGOWZCWCNDSMOB-UHFFFAOYSA-N n-[4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 IGOWZCWCNDSMOB-UHFFFAOYSA-N 0.000 description 1
- RFJVXNQQTGVVKU-UHFFFAOYSA-N n-[4-[1-(3-chlorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 RFJVXNQQTGVVKU-UHFFFAOYSA-N 0.000 description 1
- MYLOUFQIADVQIE-UHFFFAOYSA-N n-[4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CC(C#N)=C1 MYLOUFQIADVQIE-UHFFFAOYSA-N 0.000 description 1
- XAYBMISTFOMGOW-UHFFFAOYSA-N n-[4-[1-(3-ethoxypropanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCOCC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 XAYBMISTFOMGOW-UHFFFAOYSA-N 0.000 description 1
- RJMFBKOZLRYVNA-UHFFFAOYSA-N n-[4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCOCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 RJMFBKOZLRYVNA-UHFFFAOYSA-N 0.000 description 1
- MJPXMIMFHIURIU-UHFFFAOYSA-N n-[4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCOCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 MJPXMIMFHIURIU-UHFFFAOYSA-N 0.000 description 1
- BMTHYQBKBMAOPW-UHFFFAOYSA-N n-[4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCOCC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 BMTHYQBKBMAOPW-UHFFFAOYSA-N 0.000 description 1
- QEVMAAPVUGFPPZ-UHFFFAOYSA-N n-[4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=C(F)C=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 QEVMAAPVUGFPPZ-UHFFFAOYSA-N 0.000 description 1
- KJNQLEZDUXCWHU-UHFFFAOYSA-N n-[4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(F)C(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 KJNQLEZDUXCWHU-UHFFFAOYSA-N 0.000 description 1
- PCVYXYGHDFIHTG-UHFFFAOYSA-N n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 PCVYXYGHDFIHTG-UHFFFAOYSA-N 0.000 description 1
- MXLYALNLPSSAKC-UHFFFAOYSA-N n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 MXLYALNLPSSAKC-UHFFFAOYSA-N 0.000 description 1
- NPVOUGYCIIPRND-UHFFFAOYSA-N n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=C(F)C=CC=2)C1 NPVOUGYCIIPRND-UHFFFAOYSA-N 0.000 description 1
- FKVWWZMETAYNHW-UHFFFAOYSA-N n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 FKVWWZMETAYNHW-UHFFFAOYSA-N 0.000 description 1
- RSSGGHWVDHKPGE-UHFFFAOYSA-N n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 RSSGGHWVDHKPGE-UHFFFAOYSA-N 0.000 description 1
- CCKSRUBQWONREA-UHFFFAOYSA-N n-[4-[1-(3-fluorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 CCKSRUBQWONREA-UHFFFAOYSA-N 0.000 description 1
- WPHIWHPWAHYIKE-UHFFFAOYSA-N n-[4-[1-(3-hydroxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound OC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 WPHIWHPWAHYIKE-UHFFFAOYSA-N 0.000 description 1
- PYYAXLDGRKGKAN-UHFFFAOYSA-N n-[4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound COC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 PYYAXLDGRKGKAN-UHFFFAOYSA-N 0.000 description 1
- GXWBMRJGNREDQT-UHFFFAOYSA-N n-[4-[1-(3-methoxybenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound COC1=CC=CC(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 GXWBMRJGNREDQT-UHFFFAOYSA-N 0.000 description 1
- VENDDNJGLBIDQM-UHFFFAOYSA-N n-[4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=CC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 VENDDNJGLBIDQM-UHFFFAOYSA-N 0.000 description 1
- MADSOPQNHBSZIH-UHFFFAOYSA-N n-[4-[1-(3-methylbenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=CC(C(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 MADSOPQNHBSZIH-UHFFFAOYSA-N 0.000 description 1
- VJBZBNYUSFNHSH-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 VJBZBNYUSFNHSH-UHFFFAOYSA-N 0.000 description 1
- XDDFATAJVQTJAM-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 XDDFATAJVQTJAM-UHFFFAOYSA-N 0.000 description 1
- RTJQCKLYUHEOQO-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 RTJQCKLYUHEOQO-UHFFFAOYSA-N 0.000 description 1
- KUQUMTFKLDZYBL-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 KUQUMTFKLDZYBL-UHFFFAOYSA-N 0.000 description 1
- ZJFWMOLRIYRRIE-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 ZJFWMOLRIYRRIE-UHFFFAOYSA-N 0.000 description 1
- XPXAWFCUYACVLE-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 XPXAWFCUYACVLE-UHFFFAOYSA-N 0.000 description 1
- XGCUSBYETSOXBZ-UHFFFAOYSA-N n-[4-[1-(3-methylbutanoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1S(=O)(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 XGCUSBYETSOXBZ-UHFFFAOYSA-N 0.000 description 1
- FWRJVIZBENRIGR-UHFFFAOYSA-N n-[4-[1-(3-methylbutyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CCC(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 FWRJVIZBENRIGR-UHFFFAOYSA-N 0.000 description 1
- CPQCITIKIYRFPY-UHFFFAOYSA-N n-[4-[1-(3-methylbutyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(CCC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 CPQCITIKIYRFPY-UHFFFAOYSA-N 0.000 description 1
- GELABBDKXLEOEC-UHFFFAOYSA-N n-[4-[1-(3-methylpentanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 GELABBDKXLEOEC-UHFFFAOYSA-N 0.000 description 1
- LGEVKWMQIDPBNB-UHFFFAOYSA-N n-[4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 LGEVKWMQIDPBNB-UHFFFAOYSA-N 0.000 description 1
- DDZXCUSZEXZPFS-UHFFFAOYSA-N n-[4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 DDZXCUSZEXZPFS-UHFFFAOYSA-N 0.000 description 1
- NZPSOLOJHGKDLP-UHFFFAOYSA-N n-[4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 NZPSOLOJHGKDLP-UHFFFAOYSA-N 0.000 description 1
- TUEPGGYXNJWGRY-UHFFFAOYSA-N n-[4-[1-(3-methylsulfanylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCSC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 TUEPGGYXNJWGRY-UHFFFAOYSA-N 0.000 description 1
- OACWVOGTDPBSKJ-UHFFFAOYSA-N n-[4-[1-(3-methylthiophene-2-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1=CSC(C(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)=C1C OACWVOGTDPBSKJ-UHFFFAOYSA-N 0.000 description 1
- VWBLWDCAYISRJF-UHFFFAOYSA-N n-[4-[1-(3-methylthiophene-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1=CSC(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)=C1C VWBLWDCAYISRJF-UHFFFAOYSA-N 0.000 description 1
- WTSUZXXBNUGCCG-UHFFFAOYSA-N n-[4-[1-(3-morpholin-4-ylpropanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CCN1CCOCC1 WTSUZXXBNUGCCG-UHFFFAOYSA-N 0.000 description 1
- AFKPCYUJYAAFFK-UHFFFAOYSA-N n-[4-[1-(3-nitropropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC[N+](=O)[O-])CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 AFKPCYUJYAAFFK-UHFFFAOYSA-N 0.000 description 1
- KCZDRMFKTYLTCY-UHFFFAOYSA-N n-[4-[1-(3-phenylpropanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CCC1=CC=CC=C1 KCZDRMFKTYLTCY-UHFFFAOYSA-N 0.000 description 1
- MHDHOBUHRFQDEA-UHFFFAOYSA-N n-[4-[1-(3-piperidin-1-ylpropanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CCN1CCCCC1 MHDHOBUHRFQDEA-UHFFFAOYSA-N 0.000 description 1
- VEZVKSDGIRDTQO-UHFFFAOYSA-N n-[4-[1-(4,4-difluorocyclohexanecarbonyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CC(F)(F)CCC1C(=O)N1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)C1 VEZVKSDGIRDTQO-UHFFFAOYSA-N 0.000 description 1
- WLAZIQWBDPOAHR-UHFFFAOYSA-N n-[4-[1-(4,4-difluorocyclohexanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(F)(F)CCC1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WLAZIQWBDPOAHR-UHFFFAOYSA-N 0.000 description 1
- YALYFDJCPSDGTB-UHFFFAOYSA-N n-[4-[1-(4,4-difluorocyclohexanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CC(F)(F)CCC1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 YALYFDJCPSDGTB-UHFFFAOYSA-N 0.000 description 1
- RNSYJENPDCASHR-UHFFFAOYSA-N n-[4-[1-(4,4-difluorocyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CC(F)(F)CCC1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 RNSYJENPDCASHR-UHFFFAOYSA-N 0.000 description 1
- KCAFBUCTKYVPOH-UHFFFAOYSA-N n-[4-[1-(4-chlorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 KCAFBUCTKYVPOH-UHFFFAOYSA-N 0.000 description 1
- AZBOITOSLLZBKG-UHFFFAOYSA-N n-[4-[1-(4-chlorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 AZBOITOSLLZBKG-UHFFFAOYSA-N 0.000 description 1
- UAKAQUZVKRRALQ-UHFFFAOYSA-N n-[4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC(Cl)=CC=2)C1 UAKAQUZVKRRALQ-UHFFFAOYSA-N 0.000 description 1
- ISCHIZXPFGUUPV-UHFFFAOYSA-N n-[4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 ISCHIZXPFGUUPV-UHFFFAOYSA-N 0.000 description 1
- HZNOGMUDPKPMAH-UHFFFAOYSA-N n-[4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 HZNOGMUDPKPMAH-UHFFFAOYSA-N 0.000 description 1
- WXYCFZUPRQKSCL-UHFFFAOYSA-N n-[4-[1-(4-chlorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WXYCFZUPRQKSCL-UHFFFAOYSA-N 0.000 description 1
- IOWHZOMIFZXECE-UHFFFAOYSA-N n-[4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 IOWHZOMIFZXECE-UHFFFAOYSA-N 0.000 description 1
- NUOMCZUKRNSXDO-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)C1 NUOMCZUKRNSXDO-UHFFFAOYSA-N 0.000 description 1
- VNTDEWNZKMSVBU-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 VNTDEWNZKMSVBU-UHFFFAOYSA-N 0.000 description 1
- QAMZCVLMMBIHBZ-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 QAMZCVLMMBIHBZ-UHFFFAOYSA-N 0.000 description 1
- UHNXYSLZXVKQDW-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2C=CC(F)=CC=2)C1 UHNXYSLZXVKQDW-UHFFFAOYSA-N 0.000 description 1
- VWHHEZYBJLELQW-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC(F)=CC=3)=CC=2)CC1 VWHHEZYBJLELQW-UHFFFAOYSA-N 0.000 description 1
- IYRQXAHNLFNXQH-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 IYRQXAHNLFNXQH-UHFFFAOYSA-N 0.000 description 1
- FQZWIVPRXMVZTH-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 FQZWIVPRXMVZTH-UHFFFAOYSA-N 0.000 description 1
- LPSKHMIENYKEBZ-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 LPSKHMIENYKEBZ-UHFFFAOYSA-N 0.000 description 1
- WWRVLMJYPVMOFU-UHFFFAOYSA-N n-[4-[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 WWRVLMJYPVMOFU-UHFFFAOYSA-N 0.000 description 1
- RUHWKPRJWILGBY-UHFFFAOYSA-N n-[4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(O)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 RUHWKPRJWILGBY-UHFFFAOYSA-N 0.000 description 1
- GCCYRHOKPLZOIK-UHFFFAOYSA-N n-[4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 GCCYRHOKPLZOIK-UHFFFAOYSA-N 0.000 description 1
- MBCHCUHWOKUGAJ-UHFFFAOYSA-N n-[4-[1-(4-methoxybenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 MBCHCUHWOKUGAJ-UHFFFAOYSA-N 0.000 description 1
- JIRXPKBYNPXBEQ-UHFFFAOYSA-N n-[4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 JIRXPKBYNPXBEQ-UHFFFAOYSA-N 0.000 description 1
- WAFZVPJSPYPSAH-UHFFFAOYSA-N n-[4-[1-(4-methylbenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WAFZVPJSPYPSAH-UHFFFAOYSA-N 0.000 description 1
- XUQXVQOMXXDOPP-UHFFFAOYSA-N n-[4-[1-(4-methylpentanoyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)CCC(C)C)CC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 XUQXVQOMXXDOPP-UHFFFAOYSA-N 0.000 description 1
- AXYOSCRJVOVFPC-UHFFFAOYSA-N n-[4-[1-(4-methylpentanoyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 AXYOSCRJVOVFPC-UHFFFAOYSA-N 0.000 description 1
- ZXLHXQKBAPKWGB-UHFFFAOYSA-N n-[4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 ZXLHXQKBAPKWGB-UHFFFAOYSA-N 0.000 description 1
- RZCKOJGEGHUCLA-UHFFFAOYSA-N n-[4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 RZCKOJGEGHUCLA-UHFFFAOYSA-N 0.000 description 1
- BFRLKXRQJUZVAC-UHFFFAOYSA-N n-[4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 BFRLKXRQJUZVAC-UHFFFAOYSA-N 0.000 description 1
- HJZIDWOLYRIHKI-UHFFFAOYSA-N n-[4-[1-(4-methylpentanoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(C)C)CCC1S(=O)(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 HJZIDWOLYRIHKI-UHFFFAOYSA-N 0.000 description 1
- UZAAGVJTDIFIJU-UHFFFAOYSA-N n-[4-[1-(4-propan-2-ylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 UZAAGVJTDIFIJU-UHFFFAOYSA-N 0.000 description 1
- MPUWNFBODHMZNT-UHFFFAOYSA-N n-[4-[1-(4-propan-2-ylbenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 MPUWNFBODHMZNT-UHFFFAOYSA-N 0.000 description 1
- SVEZVRSVPUADMK-UHFFFAOYSA-N n-[4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 SVEZVRSVPUADMK-UHFFFAOYSA-N 0.000 description 1
- PZUPYTLIVMSQEO-UHFFFAOYSA-N n-[4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 PZUPYTLIVMSQEO-UHFFFAOYSA-N 0.000 description 1
- KTPFIFBLFAAYCN-UHFFFAOYSA-N n-[4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=C(F)C=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 KTPFIFBLFAAYCN-UHFFFAOYSA-N 0.000 description 1
- XMPXCXWSDVZIBN-UHFFFAOYSA-N n-[4-[1-(5-methylpyrazine-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=NC(C)=CN=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 XMPXCXWSDVZIBN-UHFFFAOYSA-N 0.000 description 1
- UMFQDRRJXPDBTC-UHFFFAOYSA-N n-[4-[1-(5-methylthiophene-2-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 UMFQDRRJXPDBTC-UHFFFAOYSA-N 0.000 description 1
- LXBBUWWNCIPPEG-UHFFFAOYSA-N n-[4-[1-(5-methylthiophene-2-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 LXBBUWWNCIPPEG-UHFFFAOYSA-N 0.000 description 1
- DXEDUWNBGUAHKF-UHFFFAOYSA-N n-[4-[1-(5-methylthiophene-2-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CC1 DXEDUWNBGUAHKF-UHFFFAOYSA-N 0.000 description 1
- DKWFMTXHSKVJIN-UHFFFAOYSA-N n-[4-[1-(5-methylthiophene-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 DKWFMTXHSKVJIN-UHFFFAOYSA-N 0.000 description 1
- RZGXPKUPXDMVSJ-UHFFFAOYSA-N n-[4-[1-(5-methylthiophene-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 RZGXPKUPXDMVSJ-UHFFFAOYSA-N 0.000 description 1
- KMIUULCUIGOSLP-UHFFFAOYSA-N n-[4-[1-(5-methylthiophene-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound S1C(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CC1 KMIUULCUIGOSLP-UHFFFAOYSA-N 0.000 description 1
- QFAAMIVIRUOAJI-UHFFFAOYSA-N n-[4-[1-(6-methylpyridine-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=NC(C)=CC=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 QFAAMIVIRUOAJI-UHFFFAOYSA-N 0.000 description 1
- BGRDUORZCNKPKY-UHFFFAOYSA-N n-[4-[1-(cyclobutanecarbonyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(C1)CN1C(=O)C1CCC1 BGRDUORZCNKPKY-UHFFFAOYSA-N 0.000 description 1
- BNDXRXUIJWLSDC-UHFFFAOYSA-N n-[4-[1-(cyclobutanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCC1 BNDXRXUIJWLSDC-UHFFFAOYSA-N 0.000 description 1
- WOODFSOAZKFRKW-UHFFFAOYSA-N n-[4-[1-(cyclohexanecarbonyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(C1)CN1C(=O)C1CCCCC1 WOODFSOAZKFRKW-UHFFFAOYSA-N 0.000 description 1
- JIAYURNSJHNPGC-UHFFFAOYSA-N n-[4-[1-(cyclohexanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCCCC1 JIAYURNSJHNPGC-UHFFFAOYSA-N 0.000 description 1
- DGDNKHALRZWLTB-UHFFFAOYSA-N n-[4-[1-(cyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C2CCCCC2)C1 DGDNKHALRZWLTB-UHFFFAOYSA-N 0.000 description 1
- CNSBCUBLZDYZGA-UHFFFAOYSA-N n-[4-[1-(cyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCCC1 CNSBCUBLZDYZGA-UHFFFAOYSA-N 0.000 description 1
- ASYPEWJJUYKKLI-UHFFFAOYSA-N n-[4-[1-(cyclohexanecarbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCCC1 ASYPEWJJUYKKLI-UHFFFAOYSA-N 0.000 description 1
- DIYHTOZEGIMNTC-UHFFFAOYSA-N n-[4-[1-(cyclohexanecarbonyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1S(=O)(=O)C(CC1)CCN1C(=O)C1CCCCC1 DIYHTOZEGIMNTC-UHFFFAOYSA-N 0.000 description 1
- UEYZEQLBBAQNGO-UHFFFAOYSA-N n-[4-[1-(cyclohexylmethyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1CC1CCCCC1 UEYZEQLBBAQNGO-UHFFFAOYSA-N 0.000 description 1
- YNEVPFKOLZXPOD-UHFFFAOYSA-N n-[4-[1-(cyclopentanecarbonyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(C1)CN1C(=O)C1CCCC1 YNEVPFKOLZXPOD-UHFFFAOYSA-N 0.000 description 1
- DYUJBMLNZBUBGV-UHFFFAOYSA-N n-[4-[1-(cyclopentanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCCC1 DYUJBMLNZBUBGV-UHFFFAOYSA-N 0.000 description 1
- UPYIGYUEFBJBNF-UHFFFAOYSA-N n-[4-[1-(cyclopentanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCC1 UPYIGYUEFBJBNF-UHFFFAOYSA-N 0.000 description 1
- HMNDAEIMUCCFAL-UHFFFAOYSA-N n-[4-[1-(cyclopentanecarbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCC1 HMNDAEIMUCCFAL-UHFFFAOYSA-N 0.000 description 1
- KKERQHOFWYVSLY-UHFFFAOYSA-N n-[4-[1-(cyclopentanecarbonyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1S(=O)(=O)C(CC1)CCN1C(=O)C1CCCC1 KKERQHOFWYVSLY-UHFFFAOYSA-N 0.000 description 1
- DIXQJQMMUSWRMM-UHFFFAOYSA-N n-[4-[1-(cyclopentanecarbonyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1S(=O)(=O)C(CC1)CCN1C(=O)C1CCCC1 DIXQJQMMUSWRMM-UHFFFAOYSA-N 0.000 description 1
- LKDMDDASRMMCCQ-UHFFFAOYSA-N n-[4-[1-(cyclopentylmethyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1CC1CCCC1 LKDMDDASRMMCCQ-UHFFFAOYSA-N 0.000 description 1
- ZNJCOEUDTAXZKD-UHFFFAOYSA-N n-[4-[1-(cyclopropanecarbonyl)piperidin-4-yl]-2-fluorophenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(C2CCN(CC2)C(=O)C2CC2)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 ZNJCOEUDTAXZKD-UHFFFAOYSA-N 0.000 description 1
- ITCYNCZSUAOBBY-UHFFFAOYSA-N n-[4-[1-(cyclopropanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CC1 ITCYNCZSUAOBBY-UHFFFAOYSA-N 0.000 description 1
- SJTBXUGXQFGCNN-UHFFFAOYSA-N n-[4-[1-(cyclopropanecarbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CC1 SJTBXUGXQFGCNN-UHFFFAOYSA-N 0.000 description 1
- QYTIEQFWEKFSMQ-UHFFFAOYSA-N n-[4-[1-(cyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CC1 QYTIEQFWEKFSMQ-UHFFFAOYSA-N 0.000 description 1
- DFIBTZCOFASLGQ-UHFFFAOYSA-N n-[4-[1-(cyclopropanecarbonyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CC1 DFIBTZCOFASLGQ-UHFFFAOYSA-N 0.000 description 1
- WUWFNNPRNMARPG-UHFFFAOYSA-N n-[4-[1-(cyclopropanecarbonyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1S(=O)(=O)C(CC1)CCN1C(=O)C1CC1 WUWFNNPRNMARPG-UHFFFAOYSA-N 0.000 description 1
- KQPQCYIUJRVXIZ-UHFFFAOYSA-N n-[4-[1-(cyclopropylmethyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1CC1CC1 KQPQCYIUJRVXIZ-UHFFFAOYSA-N 0.000 description 1
- XAPNZFWSSVTMGS-UHFFFAOYSA-N n-[4-[1-(furan-2-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1=CC=CO1 XAPNZFWSSVTMGS-UHFFFAOYSA-N 0.000 description 1
- BGTKMXXAQGGZOO-UHFFFAOYSA-N n-[4-[1-(furan-2-carbonyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C=2OC=CC=2)C1 BGTKMXXAQGGZOO-UHFFFAOYSA-N 0.000 description 1
- AQUZIRBXLSWVAP-UHFFFAOYSA-N n-[4-[1-(furan-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CO1 AQUZIRBXLSWVAP-UHFFFAOYSA-N 0.000 description 1
- FHMCCBZEVDUAPO-UHFFFAOYSA-N n-[4-[1-(furan-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1=CC=CO1 FHMCCBZEVDUAPO-UHFFFAOYSA-N 0.000 description 1
- RJXFDMQSASAZLT-UHFFFAOYSA-N n-[4-[1-(furan-3-carbonyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(C1)CN1C(=O)C=1C=COC=1 RJXFDMQSASAZLT-UHFFFAOYSA-N 0.000 description 1
- ABAGYZYIOYDGGY-UHFFFAOYSA-N n-[4-[1-(furan-3-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C=1C=COC=1 ABAGYZYIOYDGGY-UHFFFAOYSA-N 0.000 description 1
- LKCZWLNGHDBOAX-UHFFFAOYSA-N n-[4-[1-(furan-3-carbonyl)piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound CC1=NC=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2CCN(CC2)C(=O)C2=COC=C2)C1 LKCZWLNGHDBOAX-UHFFFAOYSA-N 0.000 description 1
- PHJPQTVEPULGLV-UHFFFAOYSA-N n-[4-[1-(furan-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C=1C=COC=1 PHJPQTVEPULGLV-UHFFFAOYSA-N 0.000 description 1
- GPECLFQTVMZDQV-UHFFFAOYSA-N n-[4-[1-(furan-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C=1C=COC=1 GPECLFQTVMZDQV-UHFFFAOYSA-N 0.000 description 1
- YJAPSZJILOVYGI-UHFFFAOYSA-N n-[4-[1-(naphthalene-1-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(C2CCN(CC2)C(=O)C=2C3=CC=CC=C3C=CC=2)C=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 YJAPSZJILOVYGI-UHFFFAOYSA-N 0.000 description 1
- MKIWBWLKFBLMOS-UHFFFAOYSA-N n-[4-[1-(naphthalene-1-carbonyl)piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=C(S(=O)(=O)C2CCN(CC2)C(=O)C=2C3=CC=CC=C3C=CC=2)C=CC=1NC(=O)C(C1)CN1C1=CC=CN=N1 MKIWBWLKFBLMOS-UHFFFAOYSA-N 0.000 description 1
- NUDOCHMVDBZEKF-UHFFFAOYSA-N n-[4-[1-(oxane-4-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCOCC1 NUDOCHMVDBZEKF-UHFFFAOYSA-N 0.000 description 1
- YKDXBAQQBCSPOK-UHFFFAOYSA-N n-[4-[1-(oxane-4-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCOCC1 YKDXBAQQBCSPOK-UHFFFAOYSA-N 0.000 description 1
- TZVOYZYJTBAMJT-UHFFFAOYSA-N n-[4-[1-(oxane-4-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCOCC1 TZVOYZYJTBAMJT-UHFFFAOYSA-N 0.000 description 1
- VALBWHLJYHBNCU-UHFFFAOYSA-N n-[4-[1-(oxolan-3-ylmethyl)piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1CC1CCOC1 VALBWHLJYHBNCU-UHFFFAOYSA-N 0.000 description 1
- TVETXMXDXZMYBY-UHFFFAOYSA-N n-[4-[1-(oxolane-2-carbonyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(C1)CN1C(=O)C1CCCO1 TVETXMXDXZMYBY-UHFFFAOYSA-N 0.000 description 1
- WIJOVJYIVVJIBD-UHFFFAOYSA-N n-[4-[1-(oxolane-2-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCCO1 WIJOVJYIVVJIBD-UHFFFAOYSA-N 0.000 description 1
- VQMRNINGJDNQTH-UHFFFAOYSA-N n-[4-[1-(oxolane-2-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCCO1 VQMRNINGJDNQTH-UHFFFAOYSA-N 0.000 description 1
- RWYPQIADEHGLSW-UHFFFAOYSA-N n-[4-[1-(oxolane-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCO1 RWYPQIADEHGLSW-UHFFFAOYSA-N 0.000 description 1
- GCWRHXJFHCPEAI-UHFFFAOYSA-N n-[4-[1-(oxolane-2-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCCO1 GCWRHXJFHCPEAI-UHFFFAOYSA-N 0.000 description 1
- RNLQSZYSNOSEIR-UHFFFAOYSA-N n-[4-[1-(oxolane-3-carbonyl)azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(C1)CN1C(=O)C1CCOC1 RNLQSZYSNOSEIR-UHFFFAOYSA-N 0.000 description 1
- HECGPAHVTOXFQL-UHFFFAOYSA-N n-[4-[1-(oxolane-3-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCOC1 HECGPAHVTOXFQL-UHFFFAOYSA-N 0.000 description 1
- SMDOGYURIZFLNQ-UHFFFAOYSA-N n-[4-[1-(oxolane-3-carbonyl)piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)C1CCOC1 SMDOGYURIZFLNQ-UHFFFAOYSA-N 0.000 description 1
- SAVDHNGDKCHGEW-UHFFFAOYSA-N n-[4-[1-(oxolane-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCOC1 SAVDHNGDKCHGEW-UHFFFAOYSA-N 0.000 description 1
- DNEYYNHMAMACMU-UHFFFAOYSA-N n-[4-[1-(oxolane-3-carbonyl)piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NN=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)C1CCOC1 DNEYYNHMAMACMU-UHFFFAOYSA-N 0.000 description 1
- NSAJQXYHAHXPQL-AREMUKBSSA-N n-[4-[1-[(2r)-2-methoxy-2-phenylacetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC1)CCC1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 NSAJQXYHAHXPQL-AREMUKBSSA-N 0.000 description 1
- RDTYQTHYMFXAHH-JOCHJYFZSA-N n-[4-[1-[(2r)-5-oxopyrrolidine-2-carbonyl]piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)[C@H]1CCC(=O)N1 RDTYQTHYMFXAHH-JOCHJYFZSA-N 0.000 description 1
- NSAJQXYHAHXPQL-SANMLTNESA-N n-[4-[1-[(2s)-2-methoxy-2-phenylacetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O=C([C@@H](OC)C=1C=CC=CC=1)N(CC1)CCC1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 NSAJQXYHAHXPQL-SANMLTNESA-N 0.000 description 1
- AJIPOLMEJQYVEP-HNNXBMFYSA-N n-[4-[1-[(2s)-2-methylbutanoyl]azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1N(C(=O)[C@@H](C)CC)CC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 AJIPOLMEJQYVEP-HNNXBMFYSA-N 0.000 description 1
- XOIGUAZJHJDNND-KRWDZBQOSA-N n-[4-[1-[(2s)-2-methylbutanoyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)[C@@H](C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 XOIGUAZJHJDNND-KRWDZBQOSA-N 0.000 description 1
- WTPJNDKPKHYMJU-KRWDZBQOSA-N n-[4-[1-[(2s)-2-methylbutanoyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)[C@@H](C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 WTPJNDKPKHYMJU-KRWDZBQOSA-N 0.000 description 1
- WBXCCUUHAWITQP-SFHVURJKSA-N n-[4-[1-[(2s)-2-methylbutanoyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)[C@@H](C)CC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 WBXCCUUHAWITQP-SFHVURJKSA-N 0.000 description 1
- GLZLLHVLRRCYDN-KRWDZBQOSA-N n-[4-[1-[(2s)-2-methylbutanoyl]piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)[C@@H](C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NN=CC=2)C1 GLZLLHVLRRCYDN-KRWDZBQOSA-N 0.000 description 1
- ZVWCBSUHZPSGTJ-SFHVURJKSA-N n-[4-[1-[(2s)-2-methylbutanoyl]piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)[C@@H](C)CC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 ZVWCBSUHZPSGTJ-SFHVURJKSA-N 0.000 description 1
- IMMPEDFODHQUON-SANMLTNESA-N n-[4-[1-[(2s)-2-phenylbutanoyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)N(CC1)CCC1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 IMMPEDFODHQUON-SANMLTNESA-N 0.000 description 1
- XQXCZNYKDBTWEW-SANMLTNESA-N n-[4-[1-[(2s)-2-phenylbutanoyl]piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O=C([C@@H](CC)C=1C=CC=CC=1)N(CC1)CCC1S(=O)(=O)C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 XQXCZNYKDBTWEW-SANMLTNESA-N 0.000 description 1
- ZGOPSFPGYYSMBV-QHCPKHFHSA-N n-[4-[1-[(2s)-oxolane-2-carbonyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1OC(CC1)CCN1C(=O)[C@@H]1CCCO1 ZGOPSFPGYYSMBV-QHCPKHFHSA-N 0.000 description 1
- HQXVZSLRDPWEAI-QHCPKHFHSA-N n-[4-[1-[(2s)-oxolane-2-carbonyl]piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2C=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)[C@@H]1CCCO1 HQXVZSLRDPWEAI-QHCPKHFHSA-N 0.000 description 1
- JJZLTOGPBZIIKU-UHFFFAOYSA-N n-[4-[1-[(4-methyloxan-4-yl)methyl]pyrazol-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2=CN(CC3(C)CCOCC3)N=C2)C1 JJZLTOGPBZIIKU-UHFFFAOYSA-N 0.000 description 1
- YKLHZQKBJAGVQP-UHFFFAOYSA-N n-[4-[1-[(4-methyloxan-4-yl)methyl]pyrazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)C=NN1CC1(C)CCOCC1 YKLHZQKBJAGVQP-UHFFFAOYSA-N 0.000 description 1
- RQHPOAQEPDJKDO-UHFFFAOYSA-N n-[4-[1-[(4-methylpiperidin-4-yl)methyl]pyrazol-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)C=NN1CC1(C)CCNCC1 RQHPOAQEPDJKDO-UHFFFAOYSA-N 0.000 description 1
- FTWMBFYRZSEFNV-UHFFFAOYSA-N n-[4-[1-[(4-methylpiperidin-4-yl)methyl]pyrazol-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1=C(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)C=NN1CC1(C)CCNCC1 FTWMBFYRZSEFNV-UHFFFAOYSA-N 0.000 description 1
- DXCUHZONKSPNIU-UHFFFAOYSA-N n-[4-[1-[2-(2,3-difluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1F DXCUHZONKSPNIU-UHFFFAOYSA-N 0.000 description 1
- GDLNHUPUJIFPRF-UHFFFAOYSA-N n-[4-[1-[2-(2,4-dichlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 GDLNHUPUJIFPRF-UHFFFAOYSA-N 0.000 description 1
- FUMPVTOSMWPJPU-UHFFFAOYSA-N n-[4-[1-[2-(2,4-difluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 FUMPVTOSMWPJPU-UHFFFAOYSA-N 0.000 description 1
- XDYGJMQKTAMATI-UHFFFAOYSA-N n-[4-[1-[2-(2,4-difluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 XDYGJMQKTAMATI-UHFFFAOYSA-N 0.000 description 1
- XFZISOQMJOMQBA-UHFFFAOYSA-N n-[4-[1-[2-(2,4-difluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 XFZISOQMJOMQBA-UHFFFAOYSA-N 0.000 description 1
- SOVRUSKMRAWJPU-UHFFFAOYSA-N n-[4-[1-[2-(2,5-difluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=C(F)C(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 SOVRUSKMRAWJPU-UHFFFAOYSA-N 0.000 description 1
- ZMKNQUQYXUOGSP-UHFFFAOYSA-N n-[4-[1-[2-(2,6-dichlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 ZMKNQUQYXUOGSP-UHFFFAOYSA-N 0.000 description 1
- RLADXEDSRWYBGK-UHFFFAOYSA-N n-[4-[1-[2-(2-chlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 RLADXEDSRWYBGK-UHFFFAOYSA-N 0.000 description 1
- XFGZJWMTQGQFIM-UHFFFAOYSA-N n-[4-[1-[2-(2-fluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 XFGZJWMTQGQFIM-UHFFFAOYSA-N 0.000 description 1
- RDBOOAVHRBJNGL-UHFFFAOYSA-N n-[4-[1-[2-(2-fluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 RDBOOAVHRBJNGL-UHFFFAOYSA-N 0.000 description 1
- FVVMGTKMYRTBSY-UHFFFAOYSA-N n-[4-[1-[2-(2-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 FVVMGTKMYRTBSY-UHFFFAOYSA-N 0.000 description 1
- QMDVZKBWKKYFCU-UHFFFAOYSA-N n-[4-[1-[2-(2-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 QMDVZKBWKKYFCU-UHFFFAOYSA-N 0.000 description 1
- WSMXOMYURZBMAN-UHFFFAOYSA-N n-[4-[1-[2-(2-fluorophenyl)acetyl]piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1CC(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WSMXOMYURZBMAN-UHFFFAOYSA-N 0.000 description 1
- WTJWKATVIMODKO-UHFFFAOYSA-N n-[4-[1-[2-(2-methoxyethoxy)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COCCOC)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 WTJWKATVIMODKO-UHFFFAOYSA-N 0.000 description 1
- UTUAAVYKNQAIKM-UHFFFAOYSA-N n-[4-[1-[2-(2-methoxyethoxy)acetyl]piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)COCCOC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 UTUAAVYKNQAIKM-UHFFFAOYSA-N 0.000 description 1
- CELAHJSLBQTAOM-UHFFFAOYSA-N n-[4-[1-[2-(2-methoxyethoxy)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COCCOC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 CELAHJSLBQTAOM-UHFFFAOYSA-N 0.000 description 1
- VPUOYCHPHWXQJR-UHFFFAOYSA-N n-[4-[1-[2-(2-methoxyethoxy)acetyl]piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COCCOC)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 VPUOYCHPHWXQJR-UHFFFAOYSA-N 0.000 description 1
- QVBJHQZFXNNDQC-UHFFFAOYSA-N n-[4-[1-[2-(3,4-dichlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 QVBJHQZFXNNDQC-UHFFFAOYSA-N 0.000 description 1
- XQRPLQJTYAPQCX-UHFFFAOYSA-N n-[4-[1-[2-(3,5-difluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(CC(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 XQRPLQJTYAPQCX-UHFFFAOYSA-N 0.000 description 1
- KAEJQZMRGVJJLC-UHFFFAOYSA-N n-[4-[1-[2-(3,5-difluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(CC(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 KAEJQZMRGVJJLC-UHFFFAOYSA-N 0.000 description 1
- ZKHKZZNXVADPOV-UHFFFAOYSA-N n-[4-[1-[2-(3,5-difluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 ZKHKZZNXVADPOV-UHFFFAOYSA-N 0.000 description 1
- DNEBJCDXFBHJEZ-UHFFFAOYSA-N n-[4-[1-[2-(3,5-difluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 DNEBJCDXFBHJEZ-UHFFFAOYSA-N 0.000 description 1
- LODGUMWNBGPPCI-UHFFFAOYSA-N n-[4-[1-[2-(3,5-difluorophenyl)acetyl]piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC(F)=CC(CC(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 LODGUMWNBGPPCI-UHFFFAOYSA-N 0.000 description 1
- KWUFLJCDPSLCEG-UHFFFAOYSA-N n-[4-[1-[2-(3,5-dimethylphenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC(C)=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 KWUFLJCDPSLCEG-UHFFFAOYSA-N 0.000 description 1
- APZANVOUQXXZFN-UHFFFAOYSA-N n-[4-[1-[2-(3-chlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound ClC1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 APZANVOUQXXZFN-UHFFFAOYSA-N 0.000 description 1
- PDAPIXFLHIYBIE-UHFFFAOYSA-N n-[4-[1-[2-(3-fluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 PDAPIXFLHIYBIE-UHFFFAOYSA-N 0.000 description 1
- FNLXKWFTWGDQMW-UHFFFAOYSA-N n-[4-[1-[2-(3-fluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2CCC(CC2)OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 FNLXKWFTWGDQMW-UHFFFAOYSA-N 0.000 description 1
- YFRLXLQNHOAWKA-UHFFFAOYSA-N n-[4-[1-[2-(3-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 YFRLXLQNHOAWKA-UHFFFAOYSA-N 0.000 description 1
- VJWYPLRPCISZJC-UHFFFAOYSA-N n-[4-[1-[2-(3-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)=C1 VJWYPLRPCISZJC-UHFFFAOYSA-N 0.000 description 1
- NDHXEHUOGPHQMQ-UHFFFAOYSA-N n-[4-[1-[2-(3-fluorophenyl)acetyl]piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC(CC(=O)N2CCC(CC2)S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 NDHXEHUOGPHQMQ-UHFFFAOYSA-N 0.000 description 1
- UGHSBVRLTQZJHA-UHFFFAOYSA-N n-[4-[1-[2-(4-chlorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 UGHSBVRLTQZJHA-UHFFFAOYSA-N 0.000 description 1
- RUXVJODPDMUQRJ-UHFFFAOYSA-N n-[4-[1-[2-(4-fluorophenyl)acetyl]azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)C1 RUXVJODPDMUQRJ-UHFFFAOYSA-N 0.000 description 1
- WENXVIGTHHONLP-UHFFFAOYSA-N n-[4-[1-[2-(4-fluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WENXVIGTHHONLP-UHFFFAOYSA-N 0.000 description 1
- HSBMCGOLOMTVSP-UHFFFAOYSA-N n-[4-[1-[2-(4-fluorophenyl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1CCC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 HSBMCGOLOMTVSP-UHFFFAOYSA-N 0.000 description 1
- MFKFOTRIVYBDAO-UHFFFAOYSA-N n-[4-[1-[2-(4-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 MFKFOTRIVYBDAO-UHFFFAOYSA-N 0.000 description 1
- JWWKRQSCJNGMIO-UHFFFAOYSA-N n-[4-[1-[2-(4-fluorophenyl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CC1 JWWKRQSCJNGMIO-UHFFFAOYSA-N 0.000 description 1
- ZBFQBCNSQLSVRW-UHFFFAOYSA-N n-[4-[1-[2-(4-fluorophenyl)acetyl]piperidin-4-yl]sulfonylphenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)N1CCC(S(=O)(=O)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 ZBFQBCNSQLSVRW-UHFFFAOYSA-N 0.000 description 1
- WVXXFHSKJNXUEW-UHFFFAOYSA-N n-[4-[1-[2-(4-methylphenoxy)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1OCC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WVXXFHSKJNXUEW-UHFFFAOYSA-N 0.000 description 1
- GARAKMWZZXCQRF-UHFFFAOYSA-N n-[4-[1-[2-(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C)CCN1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C(=NC=CC=3)C)=CC=2)CC1 GARAKMWZZXCQRF-UHFFFAOYSA-N 0.000 description 1
- KYBKWFVHIPWJSF-UHFFFAOYSA-N n-[4-[1-[2-(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C)CCN1CC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CC1 KYBKWFVHIPWJSF-UHFFFAOYSA-N 0.000 description 1
- OMZOTXZKLWBTAE-UHFFFAOYSA-N n-[4-[1-[2-(furan-2-carbonylamino)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CNC(=O)C1=CC=CO1 OMZOTXZKLWBTAE-UHFFFAOYSA-N 0.000 description 1
- PFGGEYQSKXXTOJ-UHFFFAOYSA-N n-[4-[1-[2-(oxan-4-yl)acetyl]azetidin-3-yl]oxyphenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1C(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CN1C(=O)CC1CCOCC1 PFGGEYQSKXXTOJ-UHFFFAOYSA-N 0.000 description 1
- FCRPLUUACJZYJR-UHFFFAOYSA-N n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxyphenyl]-1-[2-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=NC=CC=C1N1CC(C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)CC3CCOCC3)=CC=2)C1 FCRPLUUACJZYJR-UHFFFAOYSA-N 0.000 description 1
- QEYPHDJUVXBWKY-UHFFFAOYSA-N n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxyphenyl]-1-[4-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=NC=C1N1CC(C(=O)NC=2C=CC(OC3CCN(CC3)C(=O)CC3CCOCC3)=CC=2)C1 QEYPHDJUVXBWKY-UHFFFAOYSA-N 0.000 description 1
- KEDXIFMYQSFKIR-UHFFFAOYSA-N n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(OC=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CC1CCOCC1 KEDXIFMYQSFKIR-UHFFFAOYSA-N 0.000 description 1
- OLXZKNFWCMFGCD-UHFFFAOYSA-N n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]phenyl]-1-pyridazin-4-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NN=CC=3)=CC=2)CCN1C(=O)CC1CCOCC1 OLXZKNFWCMFGCD-UHFFFAOYSA-N 0.000 description 1
- LRVHHXWIWAOROQ-UHFFFAOYSA-N n-[4-[1-[2-(oxan-4-yl)acetyl]piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CCN1C(=O)CC1CCOCC1 LRVHHXWIWAOROQ-UHFFFAOYSA-N 0.000 description 1
- BUPRCMZDFBMWES-LKXRKSRJSA-N n-[4-[1-[2-[(1r,4s)-3-bicyclo[2.2.1]heptanyl]acetyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1([C@@]2([H])CC[C@](C2)(C1)[H])CC(=O)N(CC1)CCC1OC(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=C1 BUPRCMZDFBMWES-LKXRKSRJSA-N 0.000 description 1
- GOOHQYQJMZXCOU-DJJHXFJNSA-N n-[4-[1-[2-[(1r,4s)-3-bicyclo[2.2.1]heptanyl]acetyl]piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1([C@@]2([H])CC[C@](C2)(C1)[H])CC(=O)N(CC1)CCC1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=C1C GOOHQYQJMZXCOU-DJJHXFJNSA-N 0.000 description 1
- VAOMYBVMJHIUHC-FQCAPJHASA-N n-[4-[1-[2-[(1r,4s)-3-bicyclo[2.2.1]heptanyl]acetyl]piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1([C@@]2([H])CC[C@](C2)(C1)[H])CC(=O)N(CC1)CCC1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=C1 VAOMYBVMJHIUHC-FQCAPJHASA-N 0.000 description 1
- BQIPPCTTWIWSAP-UHFFFAOYSA-N n-[4-[1-[2-[(4-methylphenyl)sulfonylamino]acetyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCC(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 BQIPPCTTWIWSAP-UHFFFAOYSA-N 0.000 description 1
- RFWRCSAPZOUNCM-UHFFFAOYSA-N n-[4-[1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)N2CCC(CC2)C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=C1 RFWRCSAPZOUNCM-UHFFFAOYSA-N 0.000 description 1
- DRBIJJOXNJUMIB-UHFFFAOYSA-N n-[4-[1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 DRBIJJOXNJUMIB-UHFFFAOYSA-N 0.000 description 1
- VJHOYYWFVOANQQ-UHFFFAOYSA-N n-[4-[1-[3-(benzenesulfonyl)propanoyl]piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(CC1)CCN1C(=O)CCS(=O)(=O)C1=CC=CC=C1 VJHOYYWFVOANQQ-UHFFFAOYSA-N 0.000 description 1
- WHPALTVCSUCKIQ-UHFFFAOYSA-N n-[4-[1-[3-(dimethylamino)propanoyl]piperidin-4-yl]oxyphenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCN(C)C)CCC1OC(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 WHPALTVCSUCKIQ-UHFFFAOYSA-N 0.000 description 1
- HISJSRRLOWXXGB-UHFFFAOYSA-N n-[4-[1-[3-(dimethylamino)propanoyl]piperidin-4-yl]phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide Chemical compound C1CN(C(=O)CCN(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C(=NC=CC=2)C)C1 HISJSRRLOWXXGB-UHFFFAOYSA-N 0.000 description 1
- AVQOBSPONLTQRJ-UHFFFAOYSA-N n-[4-[1-[3-(dimethylamino)propanoyl]piperidin-4-yl]phenyl]-1-pyridin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCN(C)C)CCC1C(C=C1)=CC=C1NC(=O)C1CN(C=2C=NC=CC=2)C1 AVQOBSPONLTQRJ-UHFFFAOYSA-N 0.000 description 1
- DNRPUTUVROBYLW-UHFFFAOYSA-N n-[4-[1-[[4-methyl-1-(oxetan-3-yl)piperidin-4-yl]methyl]pyrazol-4-yl]phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide Chemical compound N1=NC(C)=CC=C1N1CC(C(=O)NC=2C=CC(=CC=2)C2=CN(CC3(C)CCN(CC3)C3COC3)N=C2)C1 DNRPUTUVROBYLW-UHFFFAOYSA-N 0.000 description 1
- LLKHEPHEWVGGFH-UHFFFAOYSA-N n-[4-[2-(2-ethylpiperidin-1-yl)ethylcarbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CCC1CCCCN1CCNC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 LLKHEPHEWVGGFH-UHFFFAOYSA-N 0.000 description 1
- SVYJIGQWOIXHPN-UHFFFAOYSA-N n-[4-[2-(2-methoxyethyl)-5-(2-methylpropyl)pyrazol-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound COCCN1N=C(CC(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 SVYJIGQWOIXHPN-UHFFFAOYSA-N 0.000 description 1
- MXJNONOTNVXYIA-UHFFFAOYSA-N n-[4-[2-(n-methylanilino)ethylcarbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1N(C)CCNC(=O)C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 MXJNONOTNVXYIA-UHFFFAOYSA-N 0.000 description 1
- HDBLVWPOKXWNNB-UHFFFAOYSA-N n-[4-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CN1N=C(C(F)(F)F)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 HDBLVWPOKXWNNB-UHFFFAOYSA-N 0.000 description 1
- SMAQQQRQAKPMAZ-UHFFFAOYSA-N n-[4-[2-phenyl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C=1C=CC=CC=1N1N=C(C(F)(F)F)C=C1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 SMAQQQRQAKPMAZ-UHFFFAOYSA-N 0.000 description 1
- UPHOIDJJMLFTQE-UHFFFAOYSA-N n-[4-[4-fluoro-1-(2-fluorobenzoyl)piperidin-4-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(F)(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 UPHOIDJJMLFTQE-UHFFFAOYSA-N 0.000 description 1
- SZWPDADYQXZGMU-UHFFFAOYSA-N n-[4-[5-(2,2-dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O1C(CC(C)(C)C)=NC(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)=N1 SZWPDADYQXZGMU-UHFFFAOYSA-N 0.000 description 1
- WMAAITUHASFPEQ-UHFFFAOYSA-N n-[4-[5-(2,2-dimethylpropyl)-1,3,4-oxadiazol-2-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound O1C(CC(C)(C)C)=NN=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 WMAAITUHASFPEQ-UHFFFAOYSA-N 0.000 description 1
- BPJNFSDUBYQUQQ-UHFFFAOYSA-N n-[4-[5-cyclopropyl-2-(2-hydroxyethyl)pyrazol-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound OCCN1N=C(C2CC2)C=C1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 BPJNFSDUBYQUQQ-UHFFFAOYSA-N 0.000 description 1
- ZZPULQMUGMAFGJ-UHFFFAOYSA-N n-[4-[5-cyclopropyl-2-(2-methoxyethyl)pyrazol-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound COCCN1N=C(C2CC2)C=C1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 ZZPULQMUGMAFGJ-UHFFFAOYSA-N 0.000 description 1
- LLYWJLRHIPRURN-UHFFFAOYSA-N n-[4-[5-tert-butyl-2-(2-methoxyethyl)pyrazol-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound COCCN1N=C(C(C)(C)C)C=C1C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 LLYWJLRHIPRURN-UHFFFAOYSA-N 0.000 description 1
- BLFVGPXUSHUHNC-UHFFFAOYSA-N n-[4-[5-tert-butyl-2-(oxan-4-ylmethyl)pyrazol-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1COCCC1CN1N=C(C(C)(C)C)C=C1C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 BLFVGPXUSHUHNC-UHFFFAOYSA-N 0.000 description 1
- VLSVCZQZCIKKRR-UHFFFAOYSA-N n-[4-[8-(1-methylcyclopropanecarbonyl)-8-azabicyclo[3.2.1]octan-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1C(C=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC2CCC1N2C(=O)C1(C)CC1 VLSVCZQZCIKKRR-UHFFFAOYSA-N 0.000 description 1
- JSMVGFUUSZXKOU-UHFFFAOYSA-N n-[4-[8-(2,2-dimethylpropanoyl)-8-azabicyclo[3.2.1]octan-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC(C)(C)C(=O)N1C(C2)CCC1CC2C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 JSMVGFUUSZXKOU-UHFFFAOYSA-N 0.000 description 1
- CARMBNREWCQIAB-UHFFFAOYSA-N n-[4-[8-(2-fluorobenzoyl)-8-azabicyclo[3.2.1]octan-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1C2CCC1CC(C=1C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=1)C2 CARMBNREWCQIAB-UHFFFAOYSA-N 0.000 description 1
- KXJVNAXGFUGFCL-UHFFFAOYSA-N n-[4-[8-(2-methylpropanoyl)-8-azabicyclo[3.2.1]octan-3-yl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC(C)C(=O)N1C(C2)CCC1CC2C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 KXJVNAXGFUGFCL-UHFFFAOYSA-N 0.000 description 1
- RAEYPCTZUYHACZ-CYBMUJFWSA-N n-[4-[[(1r)-1-cyclopropylethyl]carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound N([C@H](C)C1CC1)C(=O)C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 RAEYPCTZUYHACZ-CYBMUJFWSA-N 0.000 description 1
- RAEYPCTZUYHACZ-ZDUSSCGKSA-N n-[4-[[(1s)-1-cyclopropylethyl]carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound N([C@@H](C)C1CC1)C(=O)C(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 RAEYPCTZUYHACZ-ZDUSSCGKSA-N 0.000 description 1
- QBSQQSTXAYUEGC-CYBMUJFWSA-N n-[4-[[(2r)-butan-2-yl]carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)N[C@H](C)CC)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 QBSQQSTXAYUEGC-CYBMUJFWSA-N 0.000 description 1
- PGSSZRQBMRAYBV-QGZVFWFLSA-N n-[4-[[(2r)-oxolan-2-yl]methylcarbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC[C@H]1CCCO1 PGSSZRQBMRAYBV-QGZVFWFLSA-N 0.000 description 1
- QBSQQSTXAYUEGC-ZDUSSCGKSA-N n-[4-[[(2s)-butan-2-yl]carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(C(=O)N[C@@H](C)CC)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 QBSQQSTXAYUEGC-ZDUSSCGKSA-N 0.000 description 1
- PGSSZRQBMRAYBV-KRWDZBQOSA-N n-[4-[[(2s)-oxolan-2-yl]methylcarbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)NC[C@@H]1CCCO1 PGSSZRQBMRAYBV-KRWDZBQOSA-N 0.000 description 1
- BOEXBBNZZFVSIZ-MRXNPFEDSA-N n-[4-[[(3r)-oxolan-3-yl]carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)N[C@@H]1CCOC1 BOEXBBNZZFVSIZ-MRXNPFEDSA-N 0.000 description 1
- BOEXBBNZZFVSIZ-INIZCTEOSA-N n-[4-[[(3s)-oxolan-3-yl]carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1C(=O)N[C@H]1CCOC1 BOEXBBNZZFVSIZ-INIZCTEOSA-N 0.000 description 1
- QTKKQIJJDHRACX-UHFFFAOYSA-N n-[4-[[1-(1,2-oxazole-5-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=CC=NO1 QTKKQIJJDHRACX-UHFFFAOYSA-N 0.000 description 1
- NBZOKCZXNCBOHS-UHFFFAOYSA-N n-[4-[[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(CC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)C1(C)CC1 NBZOKCZXNCBOHS-UHFFFAOYSA-N 0.000 description 1
- KXVAXFVUTILHEH-UHFFFAOYSA-N n-[4-[[1-(1-methylpyrrole-2-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCC(CC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 KXVAXFVUTILHEH-UHFFFAOYSA-N 0.000 description 1
- XDPZNRSRGAHWHA-UHFFFAOYSA-N n-[4-[[1-(1h-pyrazole-4-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C=1C=NNC=1 XDPZNRSRGAHWHA-UHFFFAOYSA-N 0.000 description 1
- VXZLOBOXQNRAQG-UHFFFAOYSA-N n-[4-[[1-(1h-pyrazole-5-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=CC=NN1 VXZLOBOXQNRAQG-UHFFFAOYSA-N 0.000 description 1
- VZQMMUFIFDFBFF-UHFFFAOYSA-N n-[4-[[1-(2,2-dimethylbutanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)CC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 VZQMMUFIFDFBFF-UHFFFAOYSA-N 0.000 description 1
- HTJLEUQIDRKZKP-UHFFFAOYSA-N n-[4-[[1-(2,2-dimethylpropanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)(C)C)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 HTJLEUQIDRKZKP-UHFFFAOYSA-N 0.000 description 1
- WQVNROSJYBJTSF-UHFFFAOYSA-N n-[4-[[1-(2-cyclopentylacetyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(CC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CC1CCCC1 WQVNROSJYBJTSF-UHFFFAOYSA-N 0.000 description 1
- RCLOPMXIIUJCMY-UHFFFAOYSA-N n-[4-[[1-(2-cyclopropylacetyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CC(CC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CCN1C(=O)CC1CC1 RCLOPMXIIUJCMY-UHFFFAOYSA-N 0.000 description 1
- KRTBCHJBAJUCKV-UHFFFAOYSA-N n-[4-[[1-(2-ethoxyacetyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COCC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 KRTBCHJBAJUCKV-UHFFFAOYSA-N 0.000 description 1
- IABHCYHAVJEZKP-UHFFFAOYSA-N n-[4-[[1-(2-ethylbutanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(CC)CC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 IABHCYHAVJEZKP-UHFFFAOYSA-N 0.000 description 1
- FCMQCVATOMBOGC-UHFFFAOYSA-N n-[4-[[1-(2-fluorobenzoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(CC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 FCMQCVATOMBOGC-UHFFFAOYSA-N 0.000 description 1
- LZKQZYJDMAIRPC-UHFFFAOYSA-N n-[4-[[1-(2-methoxyacetyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 LZKQZYJDMAIRPC-UHFFFAOYSA-N 0.000 description 1
- WCGVGPZQUNCJLI-UHFFFAOYSA-N n-[4-[[1-(2-methylbenzoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1=CC=CC=C1C(=O)N1CCC(CC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WCGVGPZQUNCJLI-UHFFFAOYSA-N 0.000 description 1
- COBMQUIWWIXOLI-UHFFFAOYSA-N n-[4-[[1-(2-methylbutanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)CC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 COBMQUIWWIXOLI-UHFFFAOYSA-N 0.000 description 1
- WPSUBGYOONUNBI-UHFFFAOYSA-N n-[4-[[1-(2-methylcyclopropanecarbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound CC1CC1C(=O)N1CCC(CC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 WPSUBGYOONUNBI-UHFFFAOYSA-N 0.000 description 1
- QKQDWAKVIXJBBS-UHFFFAOYSA-N n-[4-[[1-(2-methylpentanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)CCC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 QKQDWAKVIXJBBS-UHFFFAOYSA-N 0.000 description 1
- HEIQRPDLCDMOIF-UHFFFAOYSA-N n-[4-[[1-(2-methylpropanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)C(C)C)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 HEIQRPDLCDMOIF-UHFFFAOYSA-N 0.000 description 1
- RGTIWJDEZIDZNH-UHFFFAOYSA-N n-[4-[[1-(2-methylsulfanylacetyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CSC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 RGTIWJDEZIDZNH-UHFFFAOYSA-N 0.000 description 1
- DGERAZIKTMGBRT-UHFFFAOYSA-N n-[4-[[1-(3,3-dimethylbutanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 DGERAZIKTMGBRT-UHFFFAOYSA-N 0.000 description 1
- AGQGIUTXQRDLOM-UHFFFAOYSA-N n-[4-[[1-(3-methylbutanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)C)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 AGQGIUTXQRDLOM-UHFFFAOYSA-N 0.000 description 1
- VZEISKVWJORPPQ-UHFFFAOYSA-N n-[4-[[1-(3-methylpentanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)CC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 VZEISKVWJORPPQ-UHFFFAOYSA-N 0.000 description 1
- GBIKOMKLXYMHBW-UHFFFAOYSA-N n-[4-[[1-(3-methylsulfanylpropanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCSC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 GBIKOMKLXYMHBW-UHFFFAOYSA-N 0.000 description 1
- YFJAKQLCFOTEPQ-UHFFFAOYSA-N n-[4-[[1-(3-methylthiophene-2-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CSC(C(=O)N2CCC(CC=3C=CC(NC(=O)C4CN(C4)C=4N=NC=CC=4)=CC=3)CC2)=C1C YFJAKQLCFOTEPQ-UHFFFAOYSA-N 0.000 description 1
- WCHCFEAYCPSFQD-UHFFFAOYSA-N n-[4-[[1-(4-methylpentanoyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CCC(C)C)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 WCHCFEAYCPSFQD-UHFFFAOYSA-N 0.000 description 1
- JJJKTNCVLBNLQB-UHFFFAOYSA-N n-[4-[[1-(6-methylpyridine-3-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=NC(C)=CC=C1C(=O)N1CCC(CC=2C=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 JJJKTNCVLBNLQB-UHFFFAOYSA-N 0.000 description 1
- YUEMSAAWROKFJT-UHFFFAOYSA-N n-[4-[[1-(cyclobutanecarbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1CCC1 YUEMSAAWROKFJT-UHFFFAOYSA-N 0.000 description 1
- UMRVCCNYLSEAPW-UHFFFAOYSA-N n-[4-[[1-(cyclohexanecarbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1CCCCC1 UMRVCCNYLSEAPW-UHFFFAOYSA-N 0.000 description 1
- XBKIYXRWWSHPGV-UHFFFAOYSA-N n-[4-[[1-(cyclopentanecarbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1CCCC1 XBKIYXRWWSHPGV-UHFFFAOYSA-N 0.000 description 1
- IBFBPSTWZPLYCS-UHFFFAOYSA-N n-[4-[[1-(cyclopropanecarbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1CC1 IBFBPSTWZPLYCS-UHFFFAOYSA-N 0.000 description 1
- JOOQSRNIIBCQFX-UHFFFAOYSA-N n-[4-[[1-(furan-2-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1=CC=CO1 JOOQSRNIIBCQFX-UHFFFAOYSA-N 0.000 description 1
- IIWABFOUDMSMPJ-UHFFFAOYSA-N n-[4-[[1-(furan-3-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C=1C=COC=1 IIWABFOUDMSMPJ-UHFFFAOYSA-N 0.000 description 1
- LDXLVXSZJOCRKJ-UHFFFAOYSA-N n-[4-[[1-(oxolane-2-carbonyl)piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1N(C=2N=NC=CC=2)CC1C(=O)NC(C=C1)=CC=C1CC(CC1)CCN1C(=O)C1CCCO1 LDXLVXSZJOCRKJ-UHFFFAOYSA-N 0.000 description 1
- COBMQUIWWIXOLI-SFHVURJKSA-N n-[4-[[1-[(2s)-2-methylbutanoyl]piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)[C@@H](C)CC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 COBMQUIWWIXOLI-SFHVURJKSA-N 0.000 description 1
- GBRVXGMIGYKJIJ-UHFFFAOYSA-N n-[4-[[1-[2-(2-methoxyethoxy)acetyl]piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)COCCOC)CCC1CC(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 GBRVXGMIGYKJIJ-UHFFFAOYSA-N 0.000 description 1
- OPSFRHNYRQHSTM-NHIDMIJISA-N n-[4-[[1-[2-[(1r,4s)-3-bicyclo[2.2.1]heptanyl]acetyl]piperidin-4-yl]methyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1([C@@]2([H])CC[C@](C2)(C1)[H])CC(=O)N(CC1)CCC1CC(C=C1)=CC=C1NC(=O)C(C1)CN1C1=CC=CN=N1 OPSFRHNYRQHSTM-NHIDMIJISA-N 0.000 description 1
- ZLAITLCESWJREO-UHFFFAOYSA-N n-[4-[[4-[2-(dimethylamino)ethyl]phenyl]carbamoyl]phenyl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=CC(CCN(C)C)=CC=C1NC(=O)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 ZLAITLCESWJREO-UHFFFAOYSA-N 0.000 description 1
- IPGLSVORNHTMFS-UHFFFAOYSA-N n-[6-[1-(2,2-dimethylpropyl)pyrazol-4-yl]pyridin-3-yl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=NN(CC(C)(C)C)C=C1C(N=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 IPGLSVORNHTMFS-UHFFFAOYSA-N 0.000 description 1
- BRGRHXKWJZVJHQ-UHFFFAOYSA-N n-[6-[1-(2-fluorobenzoyl)piperidin-4-yl]pyridin-3-yl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound FC1=CC=CC=C1C(=O)N1CCC(C=2N=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)CC1 BRGRHXKWJZVJHQ-UHFFFAOYSA-N 0.000 description 1
- YXJYSBXWDSOOFJ-UHFFFAOYSA-N n-[6-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]pyridin-3-yl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1CN(C(=O)CC(C)(C)C)CCC1C(N=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 YXJYSBXWDSOOFJ-UHFFFAOYSA-N 0.000 description 1
- VSKZTJMGLQHZMV-UHFFFAOYSA-N n-[6-[1-[(4-methylpiperidin-4-yl)methyl]pyrazol-4-yl]pyridin-3-yl]-1-pyridazin-3-ylazetidine-3-carboxamide Chemical compound C1=C(C=2N=CC(NC(=O)C3CN(C3)C=3N=NC=CC=3)=CC=2)C=NN1CC1(C)CCNCC1 VSKZTJMGLQHZMV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000005731 poly ADP ribosylation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- KWDMBZLLUYYWSQ-UHFFFAOYSA-N tert-butyl 4-[2-methyl-1-oxo-1-[4-[4-[(1-pyridin-3-ylazetidine-3-carbonyl)amino]phenyl]piperidin-1-yl]propan-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(C)(C)C(=O)N1CCC(C=2C=CC(NC(=O)C3CN(C3)C=3C=NC=CC=3)=CC=2)CC1 KWDMBZLLUYYWSQ-UHFFFAOYSA-N 0.000 description 1
- VPYVQKVVWMYDPA-UHFFFAOYSA-N tert-butyl 4-[4-[(1-pyridazin-3-ylazetidin-3-yl)carbamoyl]phenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=C(C(=O)NC2CN(C2)C=2N=NC=CC=2)C=C1 VPYVQKVVWMYDPA-UHFFFAOYSA-N 0.000 description 1
- ZKYPYNXMXMHOAO-UHFFFAOYSA-N tert-butyl 4-[4-[(1-pyridazin-3-ylazetidine-3-carbonyl)amino]pyrazol-1-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1N=CC(NC(=O)C2CN(C2)C=2N=NC=CC=2)=C1 ZKYPYNXMXMHOAO-UHFFFAOYSA-N 0.000 description 1
- SVKSSULLZAGJKB-HXUWFJFHSA-N tert-butyl 4-[4-[[(3r)-1-pyridin-3-ylpyrrolidin-3-yl]carbamoyl]phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(C(=O)N[C@H]2CN(CC2)C=2C=NC=CC=2)C=C1 SVKSSULLZAGJKB-HXUWFJFHSA-N 0.000 description 1
- YIEAAUASLNJQMX-LJQANCHMSA-N tert-butyl 4-[4-[[(3r)-1-pyridin-3-ylpyrrolidine-3-carbonyl]amino]phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)[C@H]1CN(C=2C=NC=CC=2)CC1 YIEAAUASLNJQMX-LJQANCHMSA-N 0.000 description 1
- SVKSSULLZAGJKB-FQEVSTJZSA-N tert-butyl 4-[4-[[(3s)-1-pyridin-3-ylpyrrolidin-3-yl]carbamoyl]phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(C(=O)N[C@@H]2CN(CC2)C=2C=NC=CC=2)C=C1 SVKSSULLZAGJKB-FQEVSTJZSA-N 0.000 description 1
- YIEAAUASLNJQMX-IBGZPJMESA-N tert-butyl 4-[4-[[(3s)-1-pyridin-3-ylpyrrolidine-3-carbonyl]amino]phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC(C=C1)=CC=C1NC(=O)[C@@H]1CN(C=2C=NC=CC=2)CC1 YIEAAUASLNJQMX-IBGZPJMESA-N 0.000 description 1
- IVZKOHAEEPHJKV-UHFFFAOYSA-N tert-butyl 4-[5-[(1-pyridazin-3-ylazetidin-3-yl)carbamoyl]thiophen-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=C(C(=O)NC2CN(C2)C=2N=NC=CC=2)S1 IVZKOHAEEPHJKV-UHFFFAOYSA-N 0.000 description 1
- DVJPOTPRGMBOFD-UHFFFAOYSA-N tert-butyl 4-fluoro-4-[4-[(1-pyridazin-3-ylazetidine-3-carbonyl)amino]phenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(F)C(C=C1)=CC=C1NC(=O)C1CN(C=2N=NC=CC=2)C1 DVJPOTPRGMBOFD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000005032 thiofuranyl group Chemical group S1C(=CC=C1)* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- This invention pertains to compounds which inhibit the activity of NAMPT, compositions containing the compounds, and methods of treating diseases during which NAMPT is expressed.
- NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that plays a critical role in many physiologically essential processes (Ziegkel, M. Eur. J. Biochem. 267, 1550-1564, 2000). NAD is necessary for several signaling pathways including among others poly ADP-ribosylation in DNA repair, mono-ADP-ribosylation in both the immune system and G-protein-coupled signaling, and NAD is also required by sirtuins for their deacetylase activity (Garten, A. et al Trends in Endocrinology and Metabolism, 20, 130-138, 2008).
- NAMPT also known as pre-B-cell-colony-enhancing factor (PBEF) and visfatin
- PBEF pre-B-cell-colony-enhancing factor
- visfatin is an enzyme that catalyzes the phosphoribosylation of nicotinamide and is the rate-limiting enzyme in one of two pathways that salvage NAD.
- NAMPT inhibitors have potential as anticancer agents. Cancer cells have a higher basal turnover of NAD and also display higher energy requirements compared with normal cells. Additionally, increased NAMPT expression has been reported in colorectal cancer (Van Beijnum, J. R. et al Int. J. Cancer 101, 118-127, 2002) and NAMPT is involved in angiogenesis (Kim, S. R. et al. Biochem. Biophys. Res. Commun. 357, 150-156, 2007). Small-molecule inhibitors of NAMPT have been shown to cause depletion of intracellular NAD+ levels and ultimately induce tumor cell death (Hansen, C M et al. Anticancer Res. 20, 42111-4220, 2000) as well as inhibit tumor growth in xenograft models (Olese, U. H. et al. Mol Cancer Ther. 9, 1609-1617, 2010).
- NAMPT inhibitors also have potential as therapeutic agents in inflammatory and metabolic disorders (Galli, M. et al Cancer Res. 70, 8-11, 2010).
- NAMPT is the predominant enzyme in T and B lymphocytes.
- Selective inhibition of NAMPT leads to NAD+ depletion in lymphocytes blocking the expansion that accompanies autoimmune disease progression whereas cell types expressing the other NAD+ generating pathways might be spared.
- a small molecule NAMPT inhibitor (FK866) has been shown to selectively block proliferation and induce apoptosis of activated T cells and was efficacious in animal models of arthritis (collagen-induced arthritis) (Busso, N. et al. Plos One 3, e2267, 2008).
- FK866 ameliorated the manifestations of experimental autoimmune encephalomyelitis (EAE), a model of T-cell mediated autoimmune disorders.
- EAE experimental autoimmune encephalomyelitis
- NaMPT activity increases NF-kB transcriptional activity in human vascular endothelial cell, resulting in MMP-2 and MMP-9 activation, suggesting a role for NAMPT inhibitors in the prevention of inflammatory mediated complications of obesity and type 2 diabetes (Adya, R. et. Al. Diabetes Care, 31, 758-760, 2008).
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IC)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 10 wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 2 is pyrrolyl; the R 2 pyrrolyl is not substituted with two alkyl groups.
- Z 1 is
- Y 1 is C(O)NH
- X 1 is N and X 2 is CR 1 ;
- R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 ;
- R 1 at each occurrence, is hydrogen; and
- R 4 at each occurrence, is heterocyclyl.
- Z 1 is
- Y 1 is C(O)NH
- X 1 is N and X 2 is CR 1
- R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 ; and R 1 , at each occurrence, is hydrogen; and R 4 , at each occurrence, is heterocyclyl.
- Still another embodiment pertains to compounds, which are
- Still another embodiment pertains to compounds of Formula (1A), selected from the group consisting of
- Another embodiment pertains to a composition for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic upus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress
- Another embodiment pertains to a method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult
- Another embodiment pertains to a method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult
- alkyl (alone or in combination with another term(s)) means a straight- or branched-chain saturated hydrocarbyl substituent typically containing from 1 to about 10 carbon atoms; or in another embodiment, from 1 to about 8 carbon atoms; in another embodiment, from 1 to about 6 carbon atoms; and in another embodiment, from 1 to about 4 carbon atoms.
- substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, and hexyl and the like.
- alkenyl (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more double bonds and typically from 2 to about 10 carbon atoms; or in another embodiment, from 2 to about 8 carbon atoms; in another embodiment, from 2 to about 6 carbon atoms; and in another embodiment, from 2 to about 4 carbon atoms.
- substituents include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, and 3-butenyl and the like.
- alkynyl (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more triple bonds and typically from 2 to about 10 carbon atoms; or in another embodiment, from 2 to about 8 carbon atoms; in another embodiment, from 2 to about 6 carbon atoms; and in another embodiment, from 2 to about 4 carbon atoms.
- substituents include ethynyl, 2-propynyl, 3-propynyl, 2-butynyl, and 3-butynyl and the like.
- carbocyclyl (alone or in combination with another term(s)) means a saturated cyclic (i.e., “cycloalkyl”), partially saturated cyclic (i.e., “cycloalkenyl”), or completely unsaturated (i.e., “aryl”) hydrocarbyl substituent containing from 3 to 14 carbon ring atoms (“ring atoms” are the atoms bound together to form the ring or rings of a cyclic substituent).
- a carbocyclyl may be a single-ring (monocyclic) or polycyclic ring structure.
- a carbocyclyl may be a single ring structure, which typically contains from 3 to 8 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms.
- Examples of such single-ring carbocyclyls include cyclopropyl (cyclopropanyl), cyclobutyl (cyclobutanyl), cyclopentyl (cyclopentanyl), cyclopentenyl, cyclopentadienyl, cyclohexyl (cyclohexanyl), cyclohexenyl, cyclohexadienyl, and phenyl.
- a carbocyclyl may alternatively be polycyclic (i.e., may contain more than one ring).
- polycyclic carbocyclyls include bridged, fused, and spirocyclic carbocyclyls.
- a spirocyclic carbocyclyl one atom is common to two different rings.
- An example of a spirocyclic carbocyclyl is spiropentanyl.
- a bridged carbocyclyl the rings share at least two common non-adjacent atoms.
- bridged carbocyclyls include bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]hept-2-enyl, and adamantanyl.
- two or more rings may be fused together, such that two rings share one common bond.
- Examples of two- or three-fused ring carbocyclyls include naphthalenyl, tetrahydronaphthalenyl (tetralinyl), indenyl, indanyl (dihydroindenyl), anthracenyl, phenanthrenyl, and decalinyl.
- cycloalkyl (alone or in combination with another term(s)) means a saturated cyclic hydrocarbyl substituent containing from 3 to 14 carbon ring atoms.
- a cycloalkyl may be a single carbon ring, which typically contains from 3 to 8 carbon ring atoms and more typically from 3 to 6 ring atoms.
- single-ring cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- a cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused, and spirocyclic carbocyclyls.
- aryl (alone or in combination with another term(s)) means an aromatic carbocyclyl containing from 6 to 14 carbon ring atoms.
- An aryl may be monocyclic or polycyclic (i.e., may contain more than one ring). In the case of polycyclic aromatic rings, only one ring the polycyclic system is required to be unsaturated while the remaining ring(s) may be saturated, partially saturated or unsaturated.
- aryls include phenyl, naphthalenyl, indenyl, indanyl, and tetrahydronapthyl.
- the number of carbon atoms in a hydrocarbyl substituent is indicated by the prefix “C x -C y -”, wherein x is the minimum and y is the maximum number of carbon atoms in the substituent.
- C 1 -C 6 -alkyl refers to an alkyl substituent containing from 1 to 6 carbon atoms.
- C 3 -C 5 -cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 8 carbon ring atoms.
- hydrogen (alone or in combination with another term(s)) means a hydrogen radical, and may be depicted as —H.
- hydroxy (alone or in combination with another term(s)) means —OH.
- amino (alone or in combination with another term(s)) means —NH 2 .
- halogen or “halo” (alone or in combination with another term(s)) means a fluorine radical (which may be depicted as —F), chlorine radical (which may be depicted as —Cl), bromine radical (which may be depicted as —Br), or iodine radical (which may be depicted as —I).
- a non-hydrogen radical is in the place of hydrogen radical on a carbon or nitrogen of the substituent.
- a substituted alkyl substituent is an alkyl substituent in which at least one non-hydrogen radical is in the place of a hydrogen radical on the alkyl substituent.
- monofluoroalkyl is alkyl substituted with a fluoro radical
- difluoroalkyl is alkyl substituted with two fluoro radicals. It should be recognized that if there are more than one substitution on a substituent, each non-hydrogen radical may be identical or different (unless otherwise stated).
- substituent may be either (1) not substituted or (2) substituted. If a substituent is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen radicals as the heteroaryl has substitutable positions.
- tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical.
- an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical.
- a substituent is described as being optionally substituted with one or more non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to the maximum number of substitutable positions on the substituent.
- any heteroaryl with 3 substitutable positions would be optionally substituted by one, two or three non-hydrogen radicals.
- tetrazolyl which has only one substitutable position
- haloalkyl means an alkyl substituent in which at least one hydrogen radical is replaced with a halogen radical.
- haloalkyls include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).
- the prefix “perhalo” indicates that every hydrogen radical on the substituent to which the prefix is attached is replaced with independently selected halogen radicals, i.e., each hydrogen radical on the substituent is replaced with a halogen radical. If all the halogen radicals are identical, the prefix typically will identify the halogen radical. Thus, for example, the term “perfluoro” means that every hydrogen radical on the substituent to which the prefix is attached is substituted with a fluorine radical. To illustrate, the term “perfluoroalkyl” means an alkyl substituent wherein a fluorine radical is in the place of each hydrogen radical.
- carbonyl (alone or in combination with another term(s)) means —C(O)—.
- aminocarbonyl (alone or in combination with another term(s)) means —C(O)—NH 2 .
- oxy (alone or in combination with another term(s)) means an ether substituent, and may be depicted as —O—.
- alkylhydroxy (alone or in combination with another term(s)) means -alkyl-OH.
- alkylamino (alone or in combination with another term(s)) means -alkyl-NH 2 .
- alkyloxy (alone or in combination with another term(s)) means an alkylether substituent, i.e., —O-alkyl.
- alkylether substituent i.e., —O-alkyl.
- substituents include methoxy (—O—CH 3 ), ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy.
- alkylcarbonyl (alone or in combination with another term(s)) means —C(O)-alkyl.
- aminoalkylcarbonyl (alone or in combination with another term(s)) means —C(O)-alkyl-NH 2 .
- alkyloxycarbonyl (alone or in combination with another term(s)) means —C(O)—O-alkyl.
- carbocyclylcarbonyl (alone or in combination with another term(s)) means —C(O)-carbocyclyl.
- heterocyclylcarbonyl (alone or in combination with another term(s)) means —C(O)-heterocyclyl.
- carbocyclylalkylcarbonyl (alone or in combination with another term(s)) means —C(O)-alkyl-carbocyclyl.
- heterocyclylalkylcarbonyl (alone or in combination with another term(s)) means —C(O)-alkyl-heterocyclyl.
- carbocyclyloxycarbonyl (alone or in combination with another term(s)) means —C(O)—O-carbocyclyl.
- carbocyclylalkyloxycarbonyl (alone or in combination with another term(s)) means —C(O)—O-alkyl-carbocyclyl.
- thio or “thia” (alone or in combination with another term(s)) means a thiaether substituent, i.e., an ether substituent wherein a divalent sulfur atom is in the place of the ether oxygen atom. Such a substituent may be depicted as —S—.
- alkyl-thio-alkyl means alkyl-S-alkyl (alkyl-sulfanyl-alkyl).
- thiol or “sulfhydryl” (alone or in combination with another term(s)) means a sulfhydryl substituent, and may be depicted as —SH.
- (thiocarbonyl) (alone or in combination with another term(s)) means a carbonyl wherein the oxygen atom has been replaced with a sulfur. Such a substituent may be depicted as —C(S)—.
- sulfonyl (alone or in combination with another term(s)) means —S(O) 2 —.
- aminosulfonyl (alone or in combination with another term(s)) means —S(O) 2 —NH 2 .
- sulfinyl or “sulfoxido” (alone or in combination with another term(s)) means —S(O)—.
- heterocyclyl (alone or in combination with another term(s)) means a saturated (i.e., “heterocycloalkyl”), partially saturated (i.e., “heterocycloalkenyl”), or completely unsaturated (i.e., “heteroaryl”) ring structure containing a total of 3 to 14 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
- a heterocyclyl may be a single-ring (monocyclic) or polycyclic ring structure.
- a heterocyclyl may be a single ring, which typically contains from 3 to 7 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms.
- single-ring heterocyclyls include 1,2,3,6-tetrahydropyridine, thiomorpholinyl, tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl (thiofuranyl), dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, oxazolyl, oxazolidinyl, isoxazolidinyl, isox
- a heterocyclyl may alternatively be polycyclic (i.e., may contain more than one ring).
- polycyclic heterocyclyls include bridged, fused, and spirocyclic heterocyclyls.
- a spirocyclic heterocyclyl one atom is common to two different rings.
- a bridged heterocyclyl the rings share at least two common non-adjacent atoms.
- two or more rings may be fused together, such that two rings share one common bond.
- fused-ring heterocyclyls include hexahydro-furo[3,4-c]pyrrole, hexahydro-furo[3,4-b]pyrrole, octahydro-pyrrolo[3,4-b]pyridine, octahydro-pyrrolo[3,4-c]pyridine, (3aR,6aR)-5-methyl-octahydro-pyrrolo[3,4-b]pyrrole, (3aR,6aR)-octahydro-pyrrolo[3,4-b]pyrrole, 6-methyl-2,6-diaza-bicyclo[3.2.0]heptane, (3aS,6aR)-2-methyl-octahydro-pyrrolo[3,4-c]pyrrole, decahydro-[1,5]naphthyridine, 2,3-dihydrobenzofuranyl, 2,3,4,9-tetrahydro-1H-pyrido[3,
- fused-ring heterocyclyls include benzo-fused heterocyclyls, such as benzimidazolyl, benzo[d][1,3]dioxolyl, indolyl, isoindolyl (isobenzazolyl, pseudoisoindolyl), indoleninyl (pseudoindolyl), isoindazolyl (benzpyrazolyl), benzazinyl (including quinolinyl (1-benzazinyl) or isoquinolinyl (2-benzazinyl)), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl (1,2-benzodiazinyl) or quinazolinyl (1,3-benzodiazinyl)), benzopyranyl (including chromanyl or isochromanyl), benzoxazinyl (including 1,3,2-benzoxazinyl,
- 5-6 membered heteroaryl (alone or in combination with another term(s)) means aromatic heterocyclyl containing a total of 5 to 6 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
- a heteroatom i.e., oxygen, nitrogen, or sulfur
- heterocycloalkyl (alone or in combination with another term(s)) means a saturated heterocyclyl.
- heteroaryl (alone or in combination with another term(s)) means an aromatic heterocyclyl containing from 5 to 14 ring atoms.
- a heteroaryl may be a single ring or 2 or 3 fused rings.
- heteroaryl substituents include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, pyridazinyl, and 1,3,5-, 1,2,4- or 1,2,3-triazinyl; 5-membered ring substituents such as imidazyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, benzisoxazolyl, benzoxazoly
- alkylcycloalkyl contains two components: alkyl and cycloalkyl.
- the C 1 -C 6 - prefix on C 1 -C 6 -alkylcycloalkyl means that the alkyl component of the alkylcycloalkyl contains from 1 to 6 carbon atoms; the C 1 -C 6 -prefix does not describe the cycloalkyl component.
- the prefix “halo” on haloalkyloxyalkyl indicates that only the alkyloxy component of the alkyloxyalkyl substituent is substituted with one or more halogen radicals.
- halogen substitution may alternatively or additionally occur on the alkyl component, the substituent would instead be described as “halogen-substituted alkyloxyalkyl” rather than “haloalkyloxyalkyl.” And finally, if the halogen substitution may only occur on the alkyl component, the substituent would instead be described as “alkyloxyhaloalkyl.”
- treat refers to a method of alleviating or abrogating a disease and/or its attendant symptoms.
- prevent refers to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease.
- prevent also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring a disease.
- terapéuticaally effective amount refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.
- modulate refers to the ability of a compound to increase or decrease the function, or activity, of a kinase.
- “Modulation”, as used herein in its various forms, is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism of the activity associated with kinase.
- Kinase inhibitors are compounds that, e.g., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate signal transduction.
- Kinase activators are compounds that, e.g., bind to, stimulate, increase, open, activate, facilitate, enhance activation, sensitize or up regulate signal transduction.
- composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the “subject” is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human.
- Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature.
- Isotopes can be radioactive or non-radioactive isotopes.
- Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 32 P, 35 S, 18 F, 36 Cl, and 125 I.
- Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
- the isotope-labeled compounds contain deuterium ( 2 H), tritium ( 3 H) or 14 C isotopes.
- Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope-labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope-labeled reagent for a non-labeled reagent.
- compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D 2 SO 4 /D 2 O.
- a deuteric acid such as D 2 SO 4 /D 2 O.
- the isotope-labeled compounds of the invention may be used as standards to determine the effectiveness in binding assays.
- Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)).
- Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut., 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77, 79-88 (1999).
- non-radio active isotope containing drugs such as deuterated drugs called “heavy drugs,” can be used for the treatment of diseases and conditions related to NAMPT activity.
- Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment.
- Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %.
- Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.
- Suitable groups for X 1 , X 2 , Y 1 , Z 1 , R 1 , and R 2 in compounds of all Formulas are independently selected.
- the described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention.
- embodiments for any of X 1 , X 2 , Y 1 , Z 1 , R 1 , and R 2 can be combined with embodiments defined for any other of X 1 , X 2 , Y 1 , Z 1 , R 1 , and R 2 .
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (I)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 ,
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 2 is pyrrolyl; the R 2 pyrrolyl is not substituted with two alkyl groups.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F.
- R 1 at each occurrence, is hydrogen.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (I), Y 1 is C(O)NH. In another embodiment of Formula (I), Y 1 is NHC(O).
- Z 1 is
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 ,
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is furanyl or thiophenyl; wherein each R 2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2
- each R 4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 , C(O)NHR 10 , C(O)NHR 10
- each R 4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (I)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , and OR 4 ;
- R 4 at each occurrence, is heterocyclyl
- R 4 wherein the cyclic moiety represented by R 4 is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , and CO(O)R 10 ;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (I), which includes Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114
- the present invention provides compounds of Formula (II)
- One embodiment of this invention pertains to compounds of Formula (II) and pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 10 wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F.
- R 1 at each occurrence, is hydrogen.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (II), Y 1 is C(O)NH. In another embodiment of Formula (II), Y 1 is NHC(O).
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NR 3 S(O)
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is furanyl or thiophenyl; wherein each R 2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2
- each R 4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 , C(O)NHR 10 ,
- each R 4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (II)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , and OR 4 ;
- R 4 at each occurrence, is heterocyclyl
- R 4 wherein the cyclic moiety represented by R 4 is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , and CO(O)R 10 ;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (II), which includes Examples 1, 2, 3, 4, 5, 6, 7, 10, 20, 21, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118
- the present invention provides compounds of Formula (III)
- One embodiment of this invention pertains to compounds of Formula (III) or pharmaceutically acceptable salts thereof;
- Y 1 is C(O)NH, or NHC(O);
- R 4x is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4 , C(O)NHSO 2 R 4 ,
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (III), Y 1 is C(O)NH. In another embodiment of Formula (III), Y is NHC(O).
- R 4x is selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4 , C(O)NHNHOR 4 , C(
- R 4x is selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I. In another embodiment of Formula (III), R 4x is selected from the group consisting of R 4 , SO 2 R 4 , and OR 4 .
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2
- each R 4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 , C(O)NHR 10 , C(O)NHR 10
- each R 4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (III)
- Y 1 is C(O)NH, or NHC(O);
- R 4x is independently selected from the group consisting of R 4 , SO 2 R 4 , and OR 4 ;
- R 4 at each occurrence, is heterocyclyl
- R 4 wherein the cyclic moiety represented by R 4 is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , and CO(O)R 10 ;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (III), which includes Examples 1, 2, 3, 4, 5, 6, 7, 10, 20, 21, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118,
- the present invention provides compounds of Formula (IV)
- One embodiment of this invention pertains to compounds of Formula (IV) and pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 ,
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F.
- R 1 at each occurrence, is hydrogen.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IV), Y 1 is C(O)NH. In another embodiment of Formula (IV), Y 1 is NHC(O).
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 ,
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is furanyl or thiophenyl; wherein each R 2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2
- each R 4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 , C(O)NHR 10 , C(O)NHR 10
- each R 4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IV)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , and OR 4 ;
- R 4 at each occurrence, is heterocyclyl
- R 4 wherein the cyclic moiety represented by R 4 is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , and CO(O)R 10 ;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl;
- Still another embodiment pertains to compounds having Formula (IV), which includes Examples 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 27, 28, 141, 142, 204, 310, 311, 312, 313, and pharmaceutically acceptable salts thereof.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IA)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 ,
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 2 is pyrrolyl; the R 2 pyrrolyl is not substituted with two alkyl groups.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IA), R 1 , at each occurrence, is hydrogen.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IA), Y 1 is C(O)NH. In another embodiment of Formula (IA), Y 1 is NHC(O).
- Z 1 is
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NR 3 S(O)
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is furanyl or thiophenyl; wherein each R 2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)NHR 7 , C(O)NHR 7 ,
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IA), R 7 , at each occurrence, is heterocyclyl.
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 , C(O)N
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , OH, F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IA)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , and F;
- R 4 at each occurrence, is alkyl or heterocyclyl; wherein each R 4 alkyl is optionally substituted with R 7 ;
- R 7 at each occurrence, is independently heterocyclyl
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 1 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl;
- R 2 is pyrrolyl; the R 2 pyrrolyl is not substituted with two alkyl groups.
- Still another embodiment pertains to compounds having Formula (IA), which includes Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113,
- Still another embodiment pertains to compounds of Formula (1A), selected from the group consisting of Examples 147, 310, 313, 316, 317, 320, 332, 333, 334, 402, 433, 440, 658, 681, 691, 706, 707, 723, 736, 795, and pharmaceutically acceptable salts thereof.
- the present invention provides compounds of Formula (IIA)
- One embodiment of this invention pertains to compounds of Formula (IIA) and pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl
- R 9 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IIA), Y 1 is C(O)NH. In another embodiment of Formula (IIA), Y 1 is NHC(O).
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- the present invention provides compounds of Formula (IIB),
- R 1 and R 2 are as described herein for Formula (IA).
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIA) and (IIB), R 1 , at each occurrence, is hydrogen.
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is furanyl or thiophenyl; wherein each R 2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NR 7 C(O)OR 7 ,
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IIA) and (IIB), R 7 , at each occurrence, is heterocyclyl.
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , OH, F, Cl, Br and I;
- R 10 at each occurrence is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 1 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IIA)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , and F;
- R 4 at each occurrence, is alkyl or heterocyclyl; wherein each R 4 alkyl is optionally substituted with R 7 ;
- R 7 at each occurrence, is independently heterocyclyl
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (IIA), which includes Examples 1, 2, 3, 4, 5, 6, 7, 10, 20, 21, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117,
- the present invention provides compounds of Formula (IIIA)
- One embodiment of this invention pertains to compounds of Formula (IIIA) or pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4 , C(O)NHSO 2 R 4 ,
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IIIA), Y 1 is C(O)NH. In another embodiment of Formula (IIIA), Y 1 is NHC(O).
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- the present invention provides compounds of Formula (IIIB),
- R 1 is described herein for Formula (IA) and R 4x is as described herein for substituents on R 2 when R 2 is aryl in Formula (IA).
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIIA) and (IIIB), R 1 , at each occurrence, is hydrogen.
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)N
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IIIA) and (IIIB), R 7 , at each occurrence, is heterocyclyl.
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 ,
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , OH, F, Cl, Br and I;
- R 10 at each occurrence is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cyclo
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IIIA)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 4X is independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , and F;
- R 4 at each occurrence, is alkyl or heterocyclyl; wherein each R 4 alkyl is optionally substituted with R 7 ;
- R 7 at each occurrence, is independently heterocyclyl
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 2 , OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (IIIA), which includes Examples 1, 2, 3, 4, 5, 6, 7, 10, 20, 22, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119
- the present invention provides compounds of Formula (IVA)
- One embodiment of this invention pertains to compounds of Formula (IVA) and pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8 ,
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 10 wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IVA), Y 1 is C(O)NH. In another embodiment of Formula (IVA), Y 1 is NHC(O).
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- the present invention provides compounds of Formula (IVB),
- R 1 and R 2 are as described herein for Formula (IA).
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IVA) and (IVB), R 1 , at each occurrence, is hydrogen.
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 2 is furanyl or thiophenyl; wherein each R 2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)N
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IVA) and (IVB), R 7 , at each occurrence, is heterocyclyl.
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 ,
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , OH, F, Cl, Br and I;
- R 10 at each occurrence is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 1 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cyclo
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IVA)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , and F;
- R 4 at each occurrence, is alkyl or heterocyclyl; wherein each R 4 alkyl is optionally substituted with R 7 ;
- R 7 at each occurrence, is independently heterocyclyl
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl;
- Still another embodiment pertains to compounds having Formula (IVA), which includes Examples 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 27, 28, 141, 142, 204, 310, 311, 312, 313, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 6
- the present invention provides compounds of Formula (VA)
- One embodiment of this invention pertains to compounds of Formula (VA) or pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4 , C(O)NHSO 2 R 4 ,
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 10 wherein the cyclic moieties represented by R 4 , and R 7 , are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 )
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (VA), Y 1 is C(O)NH. In another embodiment of Formula (VA), Y 1 is NHC(O).
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- the present invention provides compounds of Formula (VB),
- R 1 is described herein for Formula (IA) and R 4x is as described herein for substituents on R 2 when R 2 is aryl in Formula (IA).
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (VA) and (VB), R 1 , at each occurrence, is hydrogen.
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4 ,
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , F, Cl, and I. In another embodiment of Formula (VA) and (VB), R 4X is independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)NHR 7
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (VA) and (VB), R 7 , at each occurrence, is heterocyclyl.
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 , C(
- each R 4 and R 7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , OH, F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cyclo
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (VA)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 4X is independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , and F;
- R 4 at each occurrence, is alkyl or heterocyclyl; wherein each R 4 alkyl is optionally substituted with R 7 ;
- R 7 at each occurrence, is independently heterocyclyl
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (VA), which includes Examples 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 27, 28, 141, 142, 204, 310, 311, 312, 313, 614, 615, 616, 617, 625, 626, 627, 628, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IC)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 10 wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 2 is pyrrolyl; the R 2 pyrrolyl is not substituted with two alkyl groups.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- R 1 at each occurrence, is hydrogen.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IC), Y 1 is C(O)NH. In another embodiment of Formula (IC), Y 1 is NHC(O).
- Z 1 is
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 ,
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is pyridinyl, furanyl, thiophenyl, pyrazole, or thiazolyl; wherein each R 2 pyridinyl, furanyl, thiophenyl, pyrazole, and thiazolyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)NHR 7 , C(O)NHR 7 ,
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IC), R 7 , at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 , C(O)N
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , CO(O)H, OH, F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IC)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , C(O)NHR 4 , and F;
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , and F;
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , C(O)OH, OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , NH 2 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl;
- R 2 is pyrrolyl; the R 2 pyrrolyl is not substituted with two alkyl groups.
- Still another embodiment pertains to compounds having Formula (IC), which include
- Still another embodiment pertains to compounds of Formula (1A), selected from the group consisting of
- the present invention provides compounds of Formula (IIC)
- One embodiment of this invention pertains to compounds of Formula (IIC) and pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 10 wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IIC), Y 1 is C(O)NH. In another embodiment of Formula (IIC), Y 1 is NHC(O).
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- the present invention provides compounds of Formula (IID),
- R 1 and R 2 are as described herein for Formula (IC).
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIC) and (IID), R 1 , at each occurrence, is hydrogen.
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is pyridinyl, furanyl, thiophenyl, pyrazole, or thiazolyl; wherein each R 2 pyridinyl, furanyl, thiophenyl, pyrazole, and thiazolyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl.
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)N
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , F, Cl, Br and I.
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IIC) and (IID), R 7 , at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , CO(O)H, OH, F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IIC)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , C(O)NHR 4 , and F;
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , and F;
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , C(O)OH, OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , NH 2 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (IIC), which includes
- the present invention provides compounds of Formula (IIIC)
- One embodiment of this invention pertains to compounds of Formula (IIIC) or pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4 , C(O)NHSO 2 R 4 ,
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R 4 and R 7 , are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IIIC), Y 1 is C(O)NH. In another embodiment of Formula (IIIC), Y 1 is NHC(O).
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- the present invention provides compounds of Formula (IIID),
- R 1 is described herein for Formula (IC) and R 4x is as described herein for substituents on R 2 when R 2 is aryl in Formula (IC).
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIIC) and (IIID), R 1 , at each occurrence, is hydrogen.
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , F, Cl, and I.
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl.
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)N
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , F, Cl, Br and I.
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IIIC) and (IIID), R 7 , at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , CO(O)H, OH, F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IIIC)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 4X is independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , and F;
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , and F;
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , C(O)OH, OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , NH 2 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (IIIC), which include
- the present invention provides compounds of Formula (IVC)
- One embodiment of this invention pertains to compounds of Formula (IVC) and pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O) 2 R 3 , NHC(O)OR 3
- R 3 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R 3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 5 , OR 5 , SR 5 , S(O)R 5 , SO 2 R 5 , C(O)R 5 , CO(O)R 5 , OC(O)R 5 , OC(O)OR 5 , NH 2 , NHR 5 , N(R 5 ) 2 , NHC(O)R 5 , NR 5 C(O)R 5 , NHS(O) 2 R 5 , NR 5 S(O) 2 R 5 , NHC(O)OR 5 , NR 5 C(O)OR 5 , NHC(O)NH 2 , NHC(O)NHR
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 5 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 8 , OR 8 , SR 8 , S(O)R 8 , SO 2 R 8 , NHR 8 , N(R 8 ) 2 , C(O)R 8 , C(O)NH 2 , C(O)NHR 8 , C(O)N(R 8 ) 2 , NHC(O)R 8 , NR 8 C(O)R 8 , NHSO 2 R 8 , NHC(O)OR 8 , SO 2 NH 2 , SO 2 NHR 8 , SO 2 N(R 8 ) 2 , NHC(O)NH 2 , NHC(O)NHR 8
- R 6 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 9 , OR 9 , SR 9 , S(O)R 9 , SO 2 R 9 , NHR 9 , N(R 9 ) 2 , C(O)R 9 , C(O)NH 2 , C(O)NHR 9 , C(O)N(R 9 ) 2 , NHC(O)R 9 , NR 9 C(O)R 9 , NHSO 2 R 9 , NHC(O)OR 9 , SO 2 NH 2 , SO 2 NHR 9 , SO 2 N(R 9 ) 2 , NHC(O)NH 2 , NHC(O)NHR 9
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 8 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 10 wherein the cyclic moieties represented by R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (IVC), Y 1 is C(O)NH. In another embodiment of Formula (IVC), Y 1 is NHC(O).
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- the present invention provides compounds of Formula (IVD),
- R 1 and R 2 are as described herein for Formula (IC).
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IVC) and (IVD), R 1 , at each occurrence, is hydrogen.
- R 2 is independently selected from the group consisting of C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, C 4 -C 6 -alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R 2 C 4 -C 6 -alkyl, C 4 -C 6 -alkenyl, and C 4 -C 6 -alkynyl is substituted with one or more substituents independently selected from the group consisting of R 3 , OR 3 , SR 3 , S(O)R 3 , SO 2 R 3 , C(O)R 3 , CO(O)R 3 , OC(O)R 3 , OC(O)OR 3 , NH 2 , NHR 3 , N(R 3 ) 2 , NHC(O)R 3 , NR 3 C(O)R 3 , NHS(O) 2 R 3 , NR 3 S(O
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , F, Cl, and I.
- R 2 is aryl; wherein each R 2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is phenyl; wherein each R 2 phenyl is substituted with one substituent independently selected from the group consisting of R 4 , OR 4 , and SO 2 R 4 .
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , F, Cl, and I.
- R 2 is 5-6 membered heteroaryl; wherein each R 2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 2 is pyridinyl, furanyl, thiophenyl, pyrazole, or thiazolyl; wherein each R 2 pyridinyl, furanyl, thiophenyl, pyrazole, and thiazolyl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl.
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)N
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , F, Cl, Br and I.
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IVC) and (IVD), R 7 , at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , CO(O)H, OH, F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 1 , OH, NO 2 , and F; wherein each R 10 aryl
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IVC)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 2 is aryl or 5-6 membered heteroaryl wherein each R 2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , C(O)NHR 4 , and F;
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , and F;
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , C(O)OH, OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 12 , OR 12 , C(O)R 12 , NH 2 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl;
- Still another embodiment pertains to compounds having Formula (IV), which include
- the present invention provides compounds of Formula (VC)
- One embodiment of this invention pertains to compounds of Formula (VC) or pharmaceutically acceptable salts thereof;
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I;
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4 , C(O)NHSO 2 R 4 ,
- R 4 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR
- R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R 4 , and R 7 , are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , C(O)C(O)R 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , S(O)R 11 , SO 2 R 11 , C(O)R 11 , CO(O)R 11 , OC(O)R 11 , OC(O)OR 11 , NH 2 , NHR 11 , N(R 11 ) 2 , NHC(O)R 11 , NR 11 C(O)R 11 , NHS(O) 2 R 11 , NR 11 S(O) 2 R 11 , NHC(O)OR 11 , NR 11 C(O)OR 11 , NHC(O)NH 2 , NHC(O)NHR
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , OR 13 , C(O)OR 13 , OCF 3 , CF 3 , F, Cl, Br and I;
- R 12 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- X 1 is N and X 2 is CR 1 ; or X 1 is CR 1 and X 2 is N; or X 1 is CR 1 and X 2 is CR 1 .
- X 1 is N and X 2 is CR 1 .
- X 1 is CR 1 and X 2 is N.
- X 1 is CR 1 and X 2 is CR 1 .
- Y 1 is C(O)NH, or NHC(O). In another embodiment of Formula (VC), Y 1 is C(O)NH. In another embodiment of Formula (VC), Y 1 is NHC(O).
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl.
- X 1 is CR 1 and X 2 is CR 1 ; and R 1 , at each occurrence, is hydrogen.
- the present invention provides compounds of Formula (VD),
- R 1 is described herein for Formula (IC) and R 4x is as described herein for substituents on R 2 when R 2 is aryl in Formula (IC).
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH 2 , CN, NO 2 , F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I.
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (VC) and (VD), R 1 , at each occurrence, is hydrogen.
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SR 4 , S(O)R 4 , SO 2 R 4 , C(O)R 4 , OC(O)OR 4 , NH 2 , NHR 4 , N(R 4 ) 2 , NHC(O)R 4 , NR 4 C(O)R 4 , NHS(O) 2 R 4 , NR 4 S(O) 2 R 4 , NHC(O)OR 4 , NR 4 C(O)OR 4 , NHC(O)NH 2 , NHC(O)NHR 4 , NHC(O)N(R 4 ) 2 , NR 4 C(O)NHR 4 , NR 4 C(O)N(R 4 ) 2 , C(O)NH 2 , C(O)NHR 4 , C(O)N(R 4 ) 2 , C(O)NHOH, C(O)NHOR 4 ,
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , F, Cl, and I.
- R 4X is independently selected from the group consisting of R 4 , OR 4 , SO 2 R 4 , C(O)NHR 4 , and F.
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R 4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , SR 7 , S(O)R 7 , SO 2 R 7 , C(O)R 7 , CO(O)R 7 , OC(O)R 7 , OC(O)OR 7 , NH 2 , NHR 7 , N(R 7 ) 2 , NHC(O)R 7 , NR 7 C(O)R 7 , NHS(O) 2 R 7 , NR 7 S(O) 2 R 7 , NHC(O)OR 7 , NR 7 C(O)OR 7 , NHC(O)NH 2 , NHC(O)NHR 7 , NHC(O)N(R 7 ) 2 , NR 7 C(O)NHR 7 , NR 7 C(O)N(R 7 ) 2 , C(O)NH 2 , C(O)NHR
- each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , F, Cl, Br and I.
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (VC) and (VD), R 7 , at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , OR 10 , SR 10 , S(O)R 10 , SO 2 R 10 , C(O)R 10 , CO(O)R 10 , OC(O)R 10 , OC(O)OR 10 , NH 2 , NHR 10 , N(R 10 ) 2 , NHC(O)R 10 , NR 10 C(O)R 10 , NHS(O) 2 R 10 , NR 10 S(O) 2 R 10 , NHC(O)OR 10 , NR 10 C(O)OR 10 , NHC(O)NH 2 , NHC(O)NHR 10 , NHC(O)N(R 10 ) 2 , NR 10 C(O)NHR 10 , NR 10 C(O)N(R 10 ) 2 , C(O)NH 2 ,
- each R 4 and R 7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , CO(O)R 10 , C(O)C(O)R 10 , CO(O)H, OH, F, Cl, Br and I;
- R 10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R 1 , OR 1 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl,
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (VC)
- X 1 is N and X 2 is CR 1 ;
- X 1 is CR 1 and X 2 is N;
- X 1 is CR 1 and X 2 is CR 1 ;
- Y 1 is C(O)NH, or NHC(O);
- R 1 at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R 4X is independently selected from the group consisting of R 4 , SO 2 R 4 , OR 4 , and F;
- R 4 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 7 , OR 7 , N(R 7 ) 2 , and F;
- R 7 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- cyclic moieties represented by R 4 and R 7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R 10 , C(O)R 10 , C(O)C(O)R 10 , CO(O)R 10 , C(O)OH, OH and F;
- R 10 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R 11 , OR 11 , SR 11 , SO 2 R 11 , NH 2 , N(R 11 ) 2 , NHC(O)R 11 , NHS(O) 2 R 11 , OH, NO 2 , and F; wherein each R 10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R 2 , OR 12 , C(O)R 12 , NH 2 , OH, CN, CF 3 , OCF 3 , F, and Cl;
- R 11 at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R 11 alkyl is optionally substituted with alkoxy or aryl; wherein each R 11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R 13 , C(O)OR 13 , OCF 3 , CF 3 , F, and Cl;
- R 12 at each occurrence, is independently selected from the group consisting of alkyl, and aryl;
- R 13 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (VC), which include
- Another embodiment comprises pharmaceutical compositions comprising a compound having Formula (I) and an excipient.
- Still another embodiment comprises methods of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having Formula (I).
- compositions for treating diseases during which NAMPT is expressed comprising an excipient and a therapeutically effective amount of the compound having Formula (I).
- Still another embodiment pertains to methods of treating disease in a patient during which NAMPT is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).
- Still another embodiment pertains to compositions for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult
- Still another embodiment pertains to methods of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory
- compositions for treating diseases during which NAMPT is expressed comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
- Still another embodiment pertains to methods of treating disease in a patient during which NAMPT is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
- Still another embodiment pertains to compositions for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult
- Still another embodiment pertains to methods of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory
- Metabolites of compounds having Formula (I), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with NAMPT.
- Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having Formula (I) may also have utility for treating diseases associated with NAMPT.
- Compounds having Formula (I) may exist as acid addition salts, basic addition salts or zwitterions. Salts of the compounds are prepared during isolation or following purification of the compounds. Acid addition salts of the compounds are those derived from the reaction of the compounds with an acid.
- the compounds having Formula (I) may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperitoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally or vaginally.
- Therapeutically effective amounts of compounds having Formula (I) depend on the recipient of the treatment, the disorder being treated and the severity thereof, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the compound potency, its rate of clearance and whether or not another drug is co-administered.
- the amount of a compound of this invention having Formula (I) used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight.
- Single dose compositions contain these amounts or a combination of submultiples thereof.
- Compounds having Formula (I) may be administered with or without an excipient.
- Excipients include, for example, encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof.
- encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof.
- Excipients for preparation of compositions comprising a compound having Formula (I) to be administered orally in solid dosage form include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl cellulose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ring
- Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered ophthalmically or orally in liquid dosage forms include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof.
- Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered osmotically include, for example, chlorofluorohydrocarbons, ethanol, water and mixtures thereof.
- Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water and mixtures thereof.
- Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered rectally or vaginally include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof.
- Compounds having Formula (I) are expected to be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, antivirals, aurora kinase inhibitors, apoptosis promoters (for example, Bcl-xL, Bcl-w and Bfl-1) inhibitors, activators of death receptor pathway, Bcr-Abl kinase inhibitors, BiTE (Bi-Specific T cell Engager) antibodies, antibody drug conjugates, biologic response modifiers, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, DVDs, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors, hormonal therapies, immunologicals, inhibitors of inhibitors of apoptosis proteins (IAPs), intercalating antibiotics,
- BiTE antibodies are bi-specific antibodies that direct T-cells to attack cancer cells by simultaneously binding the two cells. The T-cell then attacks the target cancer cell.
- Examples of BiTE antibodies include adecatumumab (Micromet MT201), blinatumomab (Micromet MT103) and the like.
- adecatumumab Mert MT201
- blinatumomab Mcromet MT103
- one of the mechanisms by which T-cells elicit apoptosis of the target cancer cell is by exocytosis of cytolytic granule components, which include perforin and granzyme B.
- SiRNAs are molecules having endogenous RNA bases or chemically modified nucleotides. The modifications do not abolish cellular activity, but rather impart increased stability and/or increased cellular potency. Examples of chemical modifications include phosphorothioate groups, 2′-deoxynucleotide, 2′-OCH 3 -containing ribonucleotides, 2′-F-ribonucleotides, 2′-methoxyethyl ribonucleotides, combinations thereof and the like.
- the siRNA can have varying lengths (e.g., 10-200 bps) and structures (e.g., hairpins, single/double strands, bulges, nicks/gaps, mismatches) and are processed in cells to provide active gene silencing.
- a double-stranded siRNA can have the same number of nucleotides on each strand (blunt ends) or asymmetric ends (overhangs). The overhang of 1-2 nucleotides can be present on the sense and/or the antisense strand, as well as present on the 5′- and/or the 3′-ends of a given strand.
- Multivalent binding proteins are binding proteins comprising two or more antigen binding sites. Multivalent binding proteins are engineered to have the three or more antigen binding sites and are generally not naturally occurring antibodies.
- the term “multispecific binding protein” means a binding protein capable of binding two or more related or unrelated targets.
- Dual variable domain (DVD) binding proteins are tetravalent or multivalent binding proteins binding proteins comprising two or more antigen binding sites. Such DVDs may be monospecific (i.e., capable of binding one antigen) or multispecific (i.e., capable of binding two or more antigens). DVD binding proteins comprising two heavy chain DVD polypeptides and two light chain DVD polypeptides are referred to as DVD Ig's.
- Each half of a DVD Ig comprises a heavy chain DVD polypeptide, a light chain DVD polypeptide, and two antigen binding sites.
- Each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen binding per antigen binding site.
- Alkylating agents include altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, CLORETAZINE® (laromustine, VNP 40101M), cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, TREANDA® (bendamustine), treosulfan, trofosfamide and the like.
- Angiogenesis inhibitors include endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogs, vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors and the like.
- Tie-2 endothelial-specific receptor tyrosine kinase
- EGFR epidermal growth factor receptor
- IGFR-2 insulin growth factor-2 receptor
- MMP-2 matrix metalloproteinase-2
- MMP-9 matrix metalloproteinase-9
- PDGFR platelet-derived growth factor receptor
- VEGFR vascular endothelial growth factor receptor tyrosine
- Antimetabolites include ALIMTA® (pemetrexed disodium, LY231514, MTA), 5-azacitidine, XELODA® (capecitabine), carmofur, LEUSTAT® (cladribine), clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR (5-ethynyl-1- ⁇ -D-ribofuranosylimidazole-4-carboxamide), enocitabine, ethnylcytidine, fludarabine, 5-fluorouracil alone or in combination with leucovorin, GEMZAR® (gemcitabine), hydroxyurea, ALKERAN®(melphalan), mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nel
- Antivirals include ritonavir, hydroxychloroquine and the like.
- Aurora kinase inhibitors include ABT-348, AZD-1152, MLN-8054, VX-680, Aurora A-specific kinase inhibitors, Aurora B-specific kinase inhibitors and pan-Aurora kinase inhibitors and the like.
- Bcl-2 protein inhibitors include AT-101 (( ⁇ )gossypol), GENASENSE® (G3139 or oblimersen (Bcl-2-targeting antisense oligonucleotide)), IPI-194, IPI-565, N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((pheny
- CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.
- COX-2 inhibitors include ABT-963, ARCOXIA® (etoricoxib), BEXTRA® (valdecoxib), BMS347070, CELEBREX® (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX® (deracoxib), JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX® (rofecoxib) and the like.
- EGFR inhibitors include ABX-EGF, anti-EGFR immunoliposomes, EGF-vaccine, EMD-7200, ERBITUX® (cetuximab), HR3, IgA antibodies, IRESSA® (gefitinib), TARCEVA® (erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB® (lapatinib) and the like.
- ErbB2 receptor inhibitors include CP-724-714, CI-1033 (canertinib), HERCEPTIN® (trastuzumab), TYKERB® (lapatinib), OMNITARG® (2C4, petuzumab), TAK-165, GW-572016 (ionafarnib), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB AR-209, mAB 2B-1 and the like.
- Histone deacetylase inhibitors include depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproic acid and the like.
- HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB® (human recombinant antibody to HSP-90), NCS-683664, PU24FC1, PU-3, radicicol, SNX-2112, STA-9090 VER49009 and the like.
- Inhibitors of inhibitors of apoptosis proteins include HGS 1029, GDC-0145, GDC-0152, LCL-161, LBW-242 and the like.
- Antibody drug conjugates include anti-CD22-MC-MMAF, anti-CD22-MC-MMAE, anti-CD22-MCC-DM1, CR-011-vcMMAE, PSMA-ADC, MEDI-547, SGN-19Am SGN-35, SGN-75 and the like
- Activators of death receptor pathway include TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., DR4 and DR5) such as Apomab, conatumumab, ETR2-ST01, GDC0145 (lexatumumab), HGS-1029, LBY-135, PRO-1762 and trastuzumab.
- Kinesin inhibitors include Eg5 inhibitors such as AZD4877, ARRY-520; CENPE inhibitors such as GSK923295A and the like.
- JAK-2 inhibitors include CEP-701 (lesaurtinib), XL019 and 1NCB018424 and the like.
- MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like.
- mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1/TORC2 inhibitors, including PI-103, PP242, PP30, Torin 1 and the like.
- Non-steroidal anti-inflammatory drugs include AMIGESIC® (salsalate), DOLOBID® (diflunisal), MOTRIN® (ibuprofen), ORUDIS® (ketoprofen), RELAFEN® (nabumetone), FELDENE® (piroxicam), ibuprofen cream, ALEVE® (naproxen) and NAPROSYN® (naproxen), VOLTAREN® (diclofenac), INDOCIN® (indomethacin), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE® (etodolac), TORADOL® (ketorolac), DAYPRO® (oxaprozin) and the like.
- PDGFR inhibitors include C-451, CP-673, CP-868596 and the like.
- Platinum chemotherapeutics include cisplatin, ELOXATIN® (oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN® (carboplatin), satraplatin, picoplatin and the like.
- Polo-like kinase inhibitors include BI-2536 and the like.
- Phosphoinositide-3 kinase (PI3K) inhibitors include wortmannin, LY294002, XL-147, CAL-120, ONC-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, XL765 and the like.
- Thrombospondin analogs include ABT-510, ABT-567, ABT-898, TSP-1 and the like.
- VEGFR inhibitors include AVASTIN® (bevacizumab), ABT-869, AEE-788, ANGIOZYMETM (a ribozyme that inhibits angiogenesis (Ribozyme Pharmaceuticals (Boulder, Colo.) and Chiron, (Emeryville, Calif.)), axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, MACUGEN (pegaptamib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), vatalanib (PTK-787, ZK-222584), SUTENT® (sunitinib, SU-11248), VEGF trap, ZACTIMATM (vandetanib, ZD-6474) and the like.
- Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE® (bleomycin), daunorubicin, CAELYX® or MYOCET® (liposomal doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS® (idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, VALSTAR® (valrubicin), zinostatin and the like.
- Topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, CAMPTOSAR® (irinotecan hydrochloride), camptothecin, CARDIOXANE® (dexrazoxine), diflomotecan, edotecarin, ELLENCE® or PHARMORUBICIN® (epirubicin), etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan and the like.
- Antibodies include AVASTIN® (bevacizumab), CD40-specific antibodies, chTNT-1/B, denosumab, ERBITUX® (cetuximab), HUMAX-CD4® (zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX® (edrecolomab), RENCAREX® (WX G250), RITUXAN® (rituximab), ticilimumab, trastuzimab, CD20 antibodies types I and II and the like.
- Hormonal therapies include ARIMIDEX® (anastrozole), AROMASIN® (exemestane), arzoxifene, CASODEX® (bicalutamide), CETROTIDE® (cetrorelix), degarelix, deslorelin, DESOPAN® (trilostane), dexamethasone, DROGENIL® (flutamide), EVISTA® (raloxifene), AFEMATM (fadrozole), FARESTON® (toremifene), FASLODEX® (fulvestrant), FEMARA® (letrozole), formestane, glucocorticoids, HECTOROL® (doxercalciferol), RENAGEL® (sevelamer carbonate), lasofoxifene, leuprolide acetate, MEGACE® (megesterol), MIFEPREX® (mifepristone), NILANDRONTM (nilutamide), NOLVADEX® (tamoxifen cit
- Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexacalcitrol (KH1060), fenretinide, PANRETIN® (aliretinoin), ATRAGEN® (liposomal tretinoin), TARGRETIN® (bexarotene), LGD-1550 and the like.
- PARP inhibitors include ABT-888 (veliparib), olaparib, KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, ONO-2231 and the like.
- Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like.
- Proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171 and the like.
- immunologicals include interferons and other immune-enhancing agents.
- Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-la, ACTIMMUNE® (interferon gamma-1b) or interferon gamma-n1, combinations thereof and the like.
- agents include ALFAFERONE®, (IFN- ⁇ ), BAM-002 (oxidized glutathione), BEROMUN® (tasonermin), BEXXAR® (tositumomab), CAMPATH® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE® (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010 (anti-CTLA-4), melanoma vaccine, mitumomab, molgramostim, MYLOTARGTM (gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OVAREX® (oregovomab), pemtumomab (Y-muHMFG1), PROVENGE® (sipuleucel-T), sargaramostim, sizo
- Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth or differentiation of tissue cells to direct them to have anti-tumor activity and include krestin, lentinan, sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and the like.
- Pyrimidine analogs include cytarabine (ara C or Arabinoside C), cytosine arabinoside, doxifluridine, FLUDARA® (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR® (gemcitabine), TOMUDEX® (ratitrexed), TROXATYLTM (triacetyluridine troxacitabine) and the like.
- Purine analogs include LANVIS® (thioguanine) and PURI-NETHOL® (mercaptopurine).
- Antimitotic agents include batabulin, epothilone D (KOS-862), N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE® (docetaxel), PNU100940 (109881), patupilone, XRP-9881 (larotaxel), vinflunine, ZK-EPO (synthetic epothilone) and the like.
- Ubiquitin ligase inhibitors include MDM2 inhibitors, such as nutlins, NEDD8 inhibitors such as MLN4924 and the like.
- Radiosensitizers that enhance the efficacy of radiotherapy.
- radiotherapy include external beam radiotherapy, teletherapy, brachytherapy and sealed, unsealed source radiotherapy and the like.
- compounds having Formula (I) may be combined with other chemotherapeutic agents such as ABRAXANETM (ABI-007), ABT-100 (farnesyl transferase inhibitor), ADVEXIN® (Ad5CMV-p53 vaccine), ALTOCOR® or MEVACOR® (lovastatin), AMPLIGEN® (poly I:poly C12U, a synthetic RNA), APTOSYN® (exisulind), AREDIA® (pamidronic acid), arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE® (tazarotene), AVE-8062 (combreastatin derivative) BEC2 (mitumomab), cachectin or cachexin (tumor necrosis factor), canvaxin (vaccine), CEAVAC® (cancer vaccine), CELEUK® (celmoleukin), CEPLENE® (histamine di
- TR-FRET Time-Resolved Fluorescence Resonance Energy Transfer
- TR-FRET Fluorescence Resonance Energy Transfer
- Test compounds were serially diluted (typically 11 half log dilutions) in neat DMSO to 50 ⁇ final concentrations prior to dilution with assay buffer (50 mM HEPES (NaOH), pH 7.5, 100 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 1% Glycerol) to 3 ⁇ and 6% DMSO.
- assay buffer 50 mM HEPES (NaOH), pH 7.5, 100 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 1% Glycerol.
- 6 ⁇ L were transferred to 384-well low-volume plates (Owens Corning #3673). To this, 12 ⁇ L of a 1.5 ⁇ solution containing enzyme, probe and antibody were added.
- TR-FRET Time-Resolved Fluorescence Resonance Energy Transfer
- Table 1 shows the utility of compounds having Formula I to functionally inhibit NAMPT.
- PC3 cells were seeded in 96-well black plates (Corning #3904) at 500 cells/well in 90 ⁇ l of RPMI media containing 10% heat-inactivated FBS and incubated overnight at 37° C. and 5% CO 2 to allow cells to attach to wells.
- test compounds were serially diluted in neat DMSO to 1000 ⁇ final concentrations prior to dilution with RPMI media to 10 ⁇ and 1% DMSO.
- Ten ⁇ L of the 10 ⁇ compounds were then transferred to wells containing cells to produce a dose response of 10-fold dilutions from 10 ⁇ M to 1 ⁇ 10 ⁇ 5 ⁇ M. Cells were incubated for 5 days at 37° C.
- cell viability was measured using Cell Titer Glo reagent (Promega #G7571). Percent inhibition values were calculated and fitted to a sigmoidal dose response curves using Assay Explorer software to determine IC50s. To assess whether inhibition of cell viability was due to NAMPT inhibition, the proliferation assay was also performed in the presence of 0.3 mM nicotinamide mononucleotide.
- Table 2 shows the results of the cell proliferation assay.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
Description
- This application is a continuation of U.S. patent application Ser. No. 14/603,832, filed Jan. 23, 2015, which is a divisional of U.S. Pat. No. 8,975,398, granted Mar. 10, 2015, which claims priority to U.S. Provisional Application Ser. No. 61/645,692, filed May 11, 2012, U.S. Provisional Application Ser. No. 61/719,013, filed Oct. 26, 2012, and U.S. Provisional Application Ser. No. 61/779,756, filed Mar. 13, 2013, which are incorporated by reference in their entirety.
- This invention pertains to compounds which inhibit the activity of NAMPT, compositions containing the compounds, and methods of treating diseases during which NAMPT is expressed.
- NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that plays a critical role in many physiologically essential processes (Ziegkel, M. Eur. J. Biochem. 267, 1550-1564, 2000). NAD is necessary for several signaling pathways including among others poly ADP-ribosylation in DNA repair, mono-ADP-ribosylation in both the immune system and G-protein-coupled signaling, and NAD is also required by sirtuins for their deacetylase activity (Garten, A. et al Trends in Endocrinology and Metabolism, 20, 130-138, 2008).
- NAMPT (also known as pre-B-cell-colony-enhancing factor (PBEF) and visfatin) is an enzyme that catalyzes the phosphoribosylation of nicotinamide and is the rate-limiting enzyme in one of two pathways that salvage NAD.
- Increasing evidence suggests that NAMPT inhibitors have potential as anticancer agents. Cancer cells have a higher basal turnover of NAD and also display higher energy requirements compared with normal cells. Additionally, increased NAMPT expression has been reported in colorectal cancer (Van Beijnum, J. R. et al Int. J. Cancer 101, 118-127, 2002) and NAMPT is involved in angiogenesis (Kim, S. R. et al. Biochem. Biophys. Res. Commun. 357, 150-156, 2007). Small-molecule inhibitors of NAMPT have been shown to cause depletion of intracellular NAD+ levels and ultimately induce tumor cell death (Hansen, C M et al. Anticancer Res. 20, 42111-4220, 2000) as well as inhibit tumor growth in xenograft models (Olese, U. H. et al. Mol Cancer Ther. 9, 1609-1617, 2010).
- NAMPT inhibitors also have potential as therapeutic agents in inflammatory and metabolic disorders (Galli, M. et al Cancer Res. 70, 8-11, 2010). For example, NAMPT is the predominant enzyme in T and B lymphocytes. Selective inhibition of NAMPT leads to NAD+ depletion in lymphocytes blocking the expansion that accompanies autoimmune disease progression whereas cell types expressing the other NAD+ generating pathways might be spared. A small molecule NAMPT inhibitor (FK866) has been shown to selectively block proliferation and induce apoptosis of activated T cells and was efficacious in animal models of arthritis (collagen-induced arthritis) (Busso, N. et al. Plos One 3, e2267, 2008). FK866 ameliorated the manifestations of experimental autoimmune encephalomyelitis (EAE), a model of T-cell mediated autoimmune disorders. (Bruzzone, S et al. Plos One 4, e7897, 2009). NaMPT activity increases NF-kB transcriptional activity in human vascular endothelial cell, resulting in MMP-2 and MMP-9 activation, suggesting a role for NAMPT inhibitors in the prevention of inflammatory mediated complications of obesity and type 2 diabetes (Adya, R. et. Al. Diabetes Care, 31, 758-760, 2008).
- One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IC)
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R>)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); Z1 is - and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups. In another embodiment of Formula (IC), Z1 is
- wherein indicates the point of attachment to Y1 and indicates the point of attachment to the nitrogen containing heteroaryl; Y1 is C(O)NH; X1 is N and X2 is CR1; wherein R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4. In another embodiment of Formula (IC), Z1 is
- wherein indicates the point of attachment to Y1 and indicates the point of attachment to the nitrogen containing heteroaryl; Y1 is C(O)NH; X1 is N and X2 is CR1; wherein R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4. In another embodiment of Formula (IC), Z1 is
- wherein indicates the point of attachment to Y1 and indicates the point of attachment to the nitrogen containing heteroaryl; Y1 is C(O)NH; X1 is N and X2 is CR1; wherein R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4; and R1, at each occurrence, is hydrogen. In another embodiment of Formula (IC), Z1 is
- wherein indicates the point of attachment to Y1 and indicates the point of attachment to the nitrogen containing heteroaryl; Y1 is C(O)NH; X1 is N and X2 is CR1; wherein R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4; and R1, at each occurrence, is hydrogen. In another embodiment of Formula (IC), Z1 is
- wherein indicates the point of attachment to Y1 and indicates the point of attachment to the nitrogen containing heteroaryl; Y1 is C(O)NH; X1 is N and X2 is CR1; wherein R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4; R1, at each occurrence, is hydrogen; and R4, at each occurrence, is heterocyclyl. In another embodiment of Formula IC), Z1 is
- wherein indicates the point of attachment to Y1 and indicates the point of attachment to the nitrogen containing heteroaryl; Y1 is C(O)NH; X1 is N and X2 is CR1; wherein R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4; and R1, at each occurrence, is hydrogen; and R4, at each occurrence, is heterocyclyl.
- Still another embodiment pertains to compounds, which are
- 1-(pyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(2-cyanopyridin-3-yl)-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-[2-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(4-methylpyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(4-fluoropyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-[4-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide;
- tert-butyl 4-[4-({[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate;
- tert-butyl 4-[4-({[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate;
- 1-(pyridin-3-yl)-N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[1-(pyridin-3-yl)azetidin-3-yl]-4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}benzamide;
- N-(4-{1-[(2S)-2-methylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)-N-[1-(pyridin-3-yl)azetidin-3-yl]benzamide;
- 4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}-N-[1-(pyridin-3-yl)azetidin-3-yl]benzamide;
- 1-(pyridin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-(4-{[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbamoyl}phenoxy)piperidine-1-carboxylate;
- tert-butyl 4-(4-{[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbamoyl}phenoxy)piperidine-1-carboxylate;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-ethoxypropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-butanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(N-acetyl-L-leucyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methoxypyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpentyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-ethylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylmethyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylmethyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpentyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methoxypyridin-3-yl)azetidine-3-carboxamide;
- 1-(4-cyanopyridin-3-yl)-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(5-oxo-D-prolyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(5-oxo-L-prolyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-[4-(1-pentanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(5-oxo-D-prolyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(5-oxo-L-prolyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-[4-(1-propanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]azetidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-{4-[(1-benzoylazetidin-3-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-hydroxy-2-methylpropanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-pentanoylazetidin-3-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]furan-2-carboxamide;
- (3S)—N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- tert-butyl 4-(4-{[1-(pyridazin-3-yl)azetidin-3-yl]carbamoyl}phenyl)piperidine-1-carboxylate;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(methylsulfanyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-nitropropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[(pyrimidin-2-ylsulfanyl)acetyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[N-(furan-2-ylcarbonyl)glycyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(benzyloxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl)butanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclobutylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-{N-[(4-methylphenyl)sulfonyl]glycyl}piperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,3-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-phenylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2,5-dimethylfuran-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-oxopropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(pyridin-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[3-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(pyridin-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[3-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3, 5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-(4-{1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[difluoro(phenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-tert-butylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]sulfonyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,5-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-dimethylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-dichlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(phenylacetyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylalanyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-4-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-4-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- tert-butyl 4-(2-methyl-1-oxo-1-{4-[4-({[1-(pyridin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidin-1-yl}propan-2-yl)piperazine-1-carboxylate;
- N-(4-{1-[2-methyl-2-(piperazin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[(3R)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3R)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3R)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-4-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}piperidine-4-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl)butanoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-5-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-fluoropyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-fluoro-6-methylpyridin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-methylpyridin-3-yl)azetidine-3-carboxamide;
- 2-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-1,3-thiazole-5-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(2-methylpyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]furan-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]furan-2-carboxamide;
- N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-4-[1-(2-methylpropanoyl)piperidin-4-yl]benzamide;
- N-(4-{1-[2-(piperazin-1-yl)ethyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 4-[1-(2-methylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]benzamide;
- N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- (3S)—N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- 5-[1-(2-methylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-(1-benzoylpiperidin-4-yl)-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}thiophene-2-carboxamide;
- 5-{1-[(1-methylpiperidin-4-yl)acetyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- (3S)—N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(propan-2-yl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-2-ylmethyl)-1H-pyrazol-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-tert-butyl-1H-pyrazol-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-benzoylpyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2-methylbenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylazetidin-3-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-difluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-difluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,3,4-oxadiazol-2-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-imidazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-(5-{[1-(pyridazin-3-yl)azetidin-3-yl]carbamoyl}thiophen-2-yl)piperidine-1-carboxylate;
- tert-butyl 4-fluoro-4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidine-1-carboxylate;
- 5-(1-benzoylpiperidin-4-yl)-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylbenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-fluoropyridazin-3-yl)-N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-benzoylpyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[8-(2-methylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[8-(4,4,4-trifluorobutanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(8-benzoyl-8-azabicyclo[3.2.1]oct-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2-fluorobenzoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2,2-dimethylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{8-[(1-methylcyclopropyl)carbonyl]-8-azabicyclo[3.2.1]oct-3-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxyethyl)-3-(2-methylpropyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-fluoropiperidine-1-carboxylate;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-hydroxypiperidine-1-carboxylate;
- N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[4-fluoro-1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(2-fluoro-4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoyl-4-fluoropiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-fluoropiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butyl-3-tert-butyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-chloropyridazin-3-yl)-N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-3-fluorophenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-hydroxypiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-methylpyridazin-3-yl)-N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-{[4-methyl-1-(oxetan-3-yl)piperidin-4-yl]methyl}-1H-pyrazol-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]furan-2-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-aminopyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-methyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylic acid;
- ethyl 1-methyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylate;
- ethyl 1-phenyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylate;
- N-{6-[1-(2-fluorobenzoyl)piperidin-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-methylpyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{6-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]pyridin-3-yl}azetidine-3-carboxamide;
- N-{6-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{6-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)-1H-pyrazol-1-yl]piperidine-1-carboxylate;
- N-(6-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}pyridin-3-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(1H-pyrazol-4-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(methylsulfanyl)acetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(1H-pyrazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(pent-4-ynoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-hexanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(but-3-enoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-butanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-pentanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{1-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-1H-pyrazol-4-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{1-[1-(2-fluorobenzoyl)piperidin-4-yl]-1H-pyrazol-4-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(phenylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-cyclopropylethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[2-(2-ethylpiperidin-1-yl)ethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(cyclobutylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(butylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({2-[methyl(phenyl)amino]ethyl}carbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1,1′-bi(cyclopropyl)-1-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(thiophen-3-ylcarbamoyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylpiperidin-4-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-azabicyclo[2.2.2]oct-3-ylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(oxetan-3-ylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-methylcyclopropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclobutylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylcyclopropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3,3,3-trifluoropropyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(1-methylpiperidin-3-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[(1-methylpiperidin-3-yl)methyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclopropylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclopentylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(benzylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(propylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylcyclobutyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(prop-2-en-1-ylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(cyclopropylacetyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(bicyclo[2.2.1]hept-2-ylacetyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}azetidine-3-carboxamide;
- N-[4-({4-[2-(dimethylamino)ethyl]phenyl}carbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-amino-2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2,2-dimethyl-3-(piperazin-1-yl)propyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-methyl-2-(piperazin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- Still another embodiment pertains to compounds of Formula (1A), selected from the group consisting of
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(methylsulfanyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- Another embodiment pertains to a composition for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic upus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said composition comprising an excipient and a therapeutically effective amount of a compound of Formula (IC), or pharmaceutically acceptable salts thereof.
- Another embodiment pertains to a method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula (IC), or pharmaceutically acceptable salts thereof.
- Another embodiment pertains to a method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (IC), or pharmaceutically acceptable salts thereof; and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
- This detailed description is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This description and its specific examples are intended for purposes of illustration only. This invention, therefore, is not limited to the embodiments described in this patent application, and may be variously modified.
- Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. With reference to the use of the words “comprise” or “comprises” or “comprising” in this patent application (including the claims), Applicants note that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that Applicants intend each of those words to be so interpreted in construing this patent application, including the claims below. For a variable that occurs more than one time in any substituent or in the compound of the invention or any other formulae herein, its definition on each occurrence is independent of its definition at every other occurrence. Combinations of substituents are permissible only if such combinations result in stable compounds. Stable compounds are compounds which can be isolated in a useful degree of purity from a reaction mixture.
- It is meant to be understood that proper valences are maintained for all combinations herein, that monovalent moieties having more than one atom are attached through their left ends, and that divalent moieties are drawn from left to right.
- As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated:
- The term “alkyl” (alone or in combination with another term(s)) means a straight- or branched-chain saturated hydrocarbyl substituent typically containing from 1 to about 10 carbon atoms; or in another embodiment, from 1 to about 8 carbon atoms; in another embodiment, from 1 to about 6 carbon atoms; and in another embodiment, from 1 to about 4 carbon atoms. Examples of such substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, and hexyl and the like.
- The term “alkenyl” (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more double bonds and typically from 2 to about 10 carbon atoms; or in another embodiment, from 2 to about 8 carbon atoms; in another embodiment, from 2 to about 6 carbon atoms; and in another embodiment, from 2 to about 4 carbon atoms. Examples of such substituents include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, and 3-butenyl and the like.
- The term “alkynyl” (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more triple bonds and typically from 2 to about 10 carbon atoms; or in another embodiment, from 2 to about 8 carbon atoms; in another embodiment, from 2 to about 6 carbon atoms; and in another embodiment, from 2 to about 4 carbon atoms. Examples of such substituents include ethynyl, 2-propynyl, 3-propynyl, 2-butynyl, and 3-butynyl and the like.
- The term “carbocyclyl” (alone or in combination with another term(s)) means a saturated cyclic (i.e., “cycloalkyl”), partially saturated cyclic (i.e., “cycloalkenyl”), or completely unsaturated (i.e., “aryl”) hydrocarbyl substituent containing from 3 to 14 carbon ring atoms (“ring atoms” are the atoms bound together to form the ring or rings of a cyclic substituent). A carbocyclyl may be a single-ring (monocyclic) or polycyclic ring structure.
- A carbocyclyl may be a single ring structure, which typically contains from 3 to 8 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms. Examples of such single-ring carbocyclyls include cyclopropyl (cyclopropanyl), cyclobutyl (cyclobutanyl), cyclopentyl (cyclopentanyl), cyclopentenyl, cyclopentadienyl, cyclohexyl (cyclohexanyl), cyclohexenyl, cyclohexadienyl, and phenyl. A carbocyclyl may alternatively be polycyclic (i.e., may contain more than one ring). Examples of polycyclic carbocyclyls include bridged, fused, and spirocyclic carbocyclyls. In a spirocyclic carbocyclyl, one atom is common to two different rings. An example of a spirocyclic carbocyclyl is spiropentanyl. In a bridged carbocyclyl, the rings share at least two common non-adjacent atoms. Examples of bridged carbocyclyls include bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]hept-2-enyl, and adamantanyl. In a fused-ring carbocyclyl system, two or more rings may be fused together, such that two rings share one common bond. Examples of two- or three-fused ring carbocyclyls include naphthalenyl, tetrahydronaphthalenyl (tetralinyl), indenyl, indanyl (dihydroindenyl), anthracenyl, phenanthrenyl, and decalinyl.
- The term “cycloalkyl” (alone or in combination with another term(s)) means a saturated cyclic hydrocarbyl substituent containing from 3 to 14 carbon ring atoms. A cycloalkyl may be a single carbon ring, which typically contains from 3 to 8 carbon ring atoms and more typically from 3 to 6 ring atoms. Examples of single-ring cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. A cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused, and spirocyclic carbocyclyls.
- The term “aryl” (alone or in combination with another term(s)) means an aromatic carbocyclyl containing from 6 to 14 carbon ring atoms. An aryl may be monocyclic or polycyclic (i.e., may contain more than one ring). In the case of polycyclic aromatic rings, only one ring the polycyclic system is required to be unsaturated while the remaining ring(s) may be saturated, partially saturated or unsaturated. Examples of aryls include phenyl, naphthalenyl, indenyl, indanyl, and tetrahydronapthyl.
- In some instances, the number of carbon atoms in a hydrocarbyl substituent (e.g., alkyl, alkenyl, alkynyl, or cycloalkyl) is indicated by the prefix “Cx-Cy-”, wherein x is the minimum and y is the maximum number of carbon atoms in the substituent. Thus, for example, “C1-C6-alkyl” refers to an alkyl substituent containing from 1 to 6 carbon atoms. Illustrating further, C3-C5-cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 8 carbon ring atoms.
- The term “hydrogen” (alone or in combination with another term(s)) means a hydrogen radical, and may be depicted as —H.
- The term “hydroxy” (alone or in combination with another term(s)) means —OH.
- The term “carboxy” (alone or in combination with another term(s)) means —C(O)—OH.
- The term “amino” (alone or in combination with another term(s)) means —NH2.
- The term “halogen” or “halo” (alone or in combination with another term(s)) means a fluorine radical (which may be depicted as —F), chlorine radical (which may be depicted as —Cl), bromine radical (which may be depicted as —Br), or iodine radical (which may be depicted as —I).
- If a substituent is described as being “substituted”, a non-hydrogen radical is in the place of hydrogen radical on a carbon or nitrogen of the substituent. Thus, for example, a substituted alkyl substituent is an alkyl substituent in which at least one non-hydrogen radical is in the place of a hydrogen radical on the alkyl substituent. To illustrate, monofluoroalkyl is alkyl substituted with a fluoro radical, and difluoroalkyl is alkyl substituted with two fluoro radicals. It should be recognized that if there are more than one substitution on a substituent, each non-hydrogen radical may be identical or different (unless otherwise stated).
- If a substituent is described as being “optionally substituted”, the substituent may be either (1) not substituted or (2) substituted. If a substituent is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen radicals as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical. If a substituent is described as being optionally substituted with one or more non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to the maximum number of substitutable positions on the substituent. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with one or more non-hydrogen radicals, then any heteroaryl with 3 substitutable positions would be optionally substituted by one, two or three non-hydrogen radicals. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical.
- This patent application uses the terms “substituent” and “radical” interchangeably.
- The prefix “halo” indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example, haloalkyl means an alkyl substituent in which at least one hydrogen radical is replaced with a halogen radical. Examples of haloalkyls include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).
- The prefix “perhalo” indicates that every hydrogen radical on the substituent to which the prefix is attached is replaced with independently selected halogen radicals, i.e., each hydrogen radical on the substituent is replaced with a halogen radical. If all the halogen radicals are identical, the prefix typically will identify the halogen radical. Thus, for example, the term “perfluoro” means that every hydrogen radical on the substituent to which the prefix is attached is substituted with a fluorine radical. To illustrate, the term “perfluoroalkyl” means an alkyl substituent wherein a fluorine radical is in the place of each hydrogen radical.
- The term “carbonyl” (alone or in combination with another term(s)) means —C(O)—.
- The term “aminocarbonyl” (alone or in combination with another term(s)) means —C(O)—NH2.
- The term “oxo” (alone or in combination with another term(s)) means (═O).
- The term “oxy” (alone or in combination with another term(s)) means an ether substituent, and may be depicted as —O—.
- The term “alkylhydroxy” (alone or in combination with another term(s)) means -alkyl-OH.
- The term “alkylamino” (alone or in combination with another term(s)) means -alkyl-NH2.
- The term “alkyloxy” (alone or in combination with another term(s)) means an alkylether substituent, i.e., —O-alkyl. Examples of such a substituent include methoxy (—O—CH3), ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy.
- The term “alkylcarbonyl” (alone or in combination with another term(s)) means —C(O)-alkyl.
- The term “aminoalkylcarbonyl” (alone or in combination with another term(s)) means —C(O)-alkyl-NH2.
- The term “alkyloxycarbonyl” (alone or in combination with another term(s)) means —C(O)—O-alkyl.
- The term “carbocyclylcarbonyl” (alone or in combination with another term(s)) means —C(O)-carbocyclyl.
- Similarly, the term “heterocyclylcarbonyl” (alone or in combination with another term(s)) means —C(O)-heterocyclyl.
- The term “carbocyclylalkylcarbonyl” (alone or in combination with another term(s)) means —C(O)-alkyl-carbocyclyl.
- Similarly, the term “heterocyclylalkylcarbonyl” (alone or in combination with another term(s)) means —C(O)-alkyl-heterocyclyl.
- The term “carbocyclyloxycarbonyl” (alone or in combination with another term(s)) means —C(O)—O-carbocyclyl.
- The term “carbocyclylalkyloxycarbonyl” (alone or in combination with another term(s)) means —C(O)—O-alkyl-carbocyclyl.
- The term “thio” or “thia” (alone or in combination with another term(s)) means a thiaether substituent, i.e., an ether substituent wherein a divalent sulfur atom is in the place of the ether oxygen atom. Such a substituent may be depicted as —S—. This, for example, “alkyl-thio-alkyl” means alkyl-S-alkyl (alkyl-sulfanyl-alkyl).
- The term “thiol” or “sulfhydryl” (alone or in combination with another term(s)) means a sulfhydryl substituent, and may be depicted as —SH.
- The term “(thiocarbonyl)” (alone or in combination with another term(s)) means a carbonyl wherein the oxygen atom has been replaced with a sulfur. Such a substituent may be depicted as —C(S)—.
- The term “sulfonyl” (alone or in combination with another term(s)) means —S(O)2—.
- The term “aminosulfonyl” (alone or in combination with another term(s)) means —S(O)2—NH2.
- The term “sulfinyl” or “sulfoxido” (alone or in combination with another term(s)) means —S(O)—.
- The term “heterocyclyl” (alone or in combination with another term(s)) means a saturated (i.e., “heterocycloalkyl”), partially saturated (i.e., “heterocycloalkenyl”), or completely unsaturated (i.e., “heteroaryl”) ring structure containing a total of 3 to 14 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur. A heterocyclyl may be a single-ring (monocyclic) or polycyclic ring structure.
- A heterocyclyl may be a single ring, which typically contains from 3 to 7 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms. Examples of single-ring heterocyclyls include 1,2,3,6-tetrahydropyridine, thiomorpholinyl, tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl (thiofuranyl), dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, oxazolyl, oxazolidinyl, isoxazolidinyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl (furazanyl), or 1,3,4-oxadiazolyl), oxatriazolyl (including 1,2,3,4-oxatriazolyl or 1,2,3,5-oxatriazolyl), dioxazolyl (including 1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, or 1,3,4-dioxazolyl), oxathiazolyl, oxathiolyl, oxathiolanyl, pyranyl, dihydropyranyl, thiopyranyl, tetrahydrothiopyranyl, pyridinyl (azinyl), piperidinyl, diazinyl (including pyridazinyl (1,2-diazinyl), pyrimidinyl (1,3-diazinyl), or pyrazinyl (1,4-diazinyl)), piperazinyl, pyrrolidin-2-only, triazinyl (including 1,3,5-triazinyl, 1,2,4-triazinyl, and 1,2,3-triazinyl)), oxazinyl (including 1,2-oxazinyl, 1,3-oxazinyl, or 1,4-oxazinyl)), oxathiazinyl (including 1,2,3-oxathiazinyl, 1,2,4-oxathiazinyl, 1,2,5-oxathiazinyl, or 1,2,6-oxathiazinyl)), oxadiazinyl (including 1,2,3-oxadiazinyl, 1,2,4-oxadiazinyl, 1,4,2-oxadiazinyl, or 1,3,5-oxadiazinyl)), morpholinyl, azepinyl, oxepinyl, thiepinyl, and diazepinyl.
- A heterocyclyl may alternatively be polycyclic (i.e., may contain more than one ring). Examples of polycyclic heterocyclyls include bridged, fused, and spirocyclic heterocyclyls. In a spirocyclic heterocyclyl, one atom is common to two different rings. In a bridged heterocyclyl, the rings share at least two common non-adjacent atoms. In a fused-ring heterocyclyl, two or more rings may be fused together, such that two rings share one common bond. Examples of fused-ring heterocyclyls include hexahydro-furo[3,4-c]pyrrole, hexahydro-furo[3,4-b]pyrrole, octahydro-pyrrolo[3,4-b]pyridine, octahydro-pyrrolo[3,4-c]pyridine, (3aR,6aR)-5-methyl-octahydro-pyrrolo[3,4-b]pyrrole, (3aR,6aR)-octahydro-pyrrolo[3,4-b]pyrrole, 6-methyl-2,6-diaza-bicyclo[3.2.0]heptane, (3aS,6aR)-2-methyl-octahydro-pyrrolo[3,4-c]pyrrole, decahydro-[1,5]naphthyridine, 2,3-dihydrobenzofuranyl, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indolyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, (trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1 (2H)-onyl, 1,2,3,4-tetrahydroisoquinolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, indolizinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl (including pyrido[3,4-b]-pyridinyl, pyrido[3,2-b]-pyridinyl, or pyrido[4,3-b]-pyridinyl), and pteridinyl. Other examples of fused-ring heterocyclyls include benzo-fused heterocyclyls, such as benzimidazolyl, benzo[d][1,3]dioxolyl, indolyl, isoindolyl (isobenzazolyl, pseudoisoindolyl), indoleninyl (pseudoindolyl), isoindazolyl (benzpyrazolyl), benzazinyl (including quinolinyl (1-benzazinyl) or isoquinolinyl (2-benzazinyl)), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl (1,2-benzodiazinyl) or quinazolinyl (1,3-benzodiazinyl)), benzopyranyl (including chromanyl or isochromanyl), benzoxazinyl (including 1,3,2-benzoxazinyl, 1,4,2-benzoxazinyl, 2,3,1-benzoxazinyl, or 3,1,4-benzoxazinyl), and benzisoxazinyl (including 1,2-benzisoxazinyl or 1,4-benzisoxazinyl). Examples of spirocyclic heterocyclyls include 1,4-dioxa-8-azaspiro[4.5]decanyl.
- The term “5-6 membered heteroaryl” (alone or in combination with another term(s)) means aromatic heterocyclyl containing a total of 5 to 6 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
- The term “heterocycloalkyl” (alone or in combination with another term(s)) means a saturated heterocyclyl.
- The term “heteroaryl” (alone or in combination with another term(s)) means an aromatic heterocyclyl containing from 5 to 14 ring atoms. A heteroaryl may be a single ring or 2 or 3 fused rings. Examples of heteroaryl substituents include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, pyridazinyl, and 1,3,5-, 1,2,4- or 1,2,3-triazinyl; 5-membered ring substituents such as imidazyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, benzisoxazolyl, benzoxazolyl, and purinyl; and 6/6-membered fused rings such as benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and benzoxazinyl.
- A prefix attached to a multi-component substituent only applies to the first component. To illustrate, the term “alkylcycloalkyl” contains two components: alkyl and cycloalkyl. Thus, the C1-C6- prefix on C1-C6-alkylcycloalkyl means that the alkyl component of the alkylcycloalkyl contains from 1 to 6 carbon atoms; the C1-C6-prefix does not describe the cycloalkyl component. To illustrate further, the prefix “halo” on haloalkyloxyalkyl indicates that only the alkyloxy component of the alkyloxyalkyl substituent is substituted with one or more halogen radicals. If halogen substitution may alternatively or additionally occur on the alkyl component, the substituent would instead be described as “halogen-substituted alkyloxyalkyl” rather than “haloalkyloxyalkyl.” And finally, if the halogen substitution may only occur on the alkyl component, the substituent would instead be described as “alkyloxyhaloalkyl.”
- The terms “treat”, “treating” and “treatment” refer to a method of alleviating or abrogating a disease and/or its attendant symptoms.
- The terms “prevent”, “preventing” and “prevention” refer to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease. As used herein, “prevent”, “preventing” and “prevention” also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring a disease.
- The term “therapeutically effective amount” refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.
- The term “modulate” refers to the ability of a compound to increase or decrease the function, or activity, of a kinase. “Modulation”, as used herein in its various forms, is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism of the activity associated with kinase. Kinase inhibitors are compounds that, e.g., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate signal transduction. Kinase activators are compounds that, e.g., bind to, stimulate, increase, open, activate, facilitate, enhance activation, sensitize or up regulate signal transduction.
- The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- The “subject” is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human.
- Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 32P, 35S, 18F, 36Cl, and 125I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
- In another embodiment, the isotope-labeled compounds contain deuterium (2H), tritium (3H) or 14C isotopes. Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope-labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope-labeled reagent for a non-labeled reagent. In some instances, compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D2SO4/D2O. In addition to the above, relevant procedures and intermediates are disclosed, for instance, in Lizondo, J et al., Drugs Fut, 21(11), 1116 (1996); Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, B et al., Org Lett, 5(7), 963 (2003); PCT publications WO1997010223, WO2005099353, WO1995007271, WO2006008754; U.S. Pat. Nos. 7,538,189; 7,534,814; 7,531,685; 7,528,131; 7,521,421; 7,514,068; 7,511,013; and US Patent Application Publication Nos. 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416; and 20090082471, the methods are hereby incorporated by reference.
- The isotope-labeled compounds of the invention may be used as standards to determine the effectiveness in binding assays. Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut., 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77, 79-88 (1999).
- In addition, non-radio active isotope containing drugs, such as deuterated drugs called “heavy drugs,” can be used for the treatment of diseases and conditions related to NAMPT activity. Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment. Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %. Replacement of up to about 15% of normal atom with a heavy isotope has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201: 357). Acute replacement of as high as 15%-23% in human fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in “Dosimetry & Treatment Planning for Neutron Capture Therapy”, Zamenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp. 125-134; Diabetes Metab. 23: 251 (1997)).
- Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.
- Suitable groups for X1, X2, Y1, Z1, R1, and R2 in compounds of all Formulas are independently selected. The described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention. For example, it is contemplated that embodiments for any of X1, X2, Y1, Z1, R1, and R2 can be combined with embodiments defined for any other of X1, X2, Y1, Z1, R1, and R2.
- One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (I)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- Z1 is
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); Z1 is - and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups.
- In one embodiment of Formula (I), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (I), X1 is N and X2 is CR1. In another embodiment of Formula (I), X1 is CR1 and X2 is N. In another embodiment of Formula (I), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (I), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (I), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (I), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F. In another embodiment of Formula (I), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (I), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (I), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (I), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F. In another embodiment of Formula (I), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (I), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (I), Y1 is C(O)NH. In another embodiment of Formula (I), Y1 is NHC(O).
- In one embodiment of Formula (I), Z1 is
- In one embodiment of Formula (I), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (I), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (I), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4. In another embodiment of Formula (I), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (I), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (I), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4. In another embodiment of Formula (I), R2 is furanyl or thiophenyl; wherein each R2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4.
- In one embodiment of Formula (I), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (I), R4, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (I), each R4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with alkyl or alkoxy; and R12, at each occurrence, is independently selected alkyl. In another embodiment of Formula (I), each R4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (I)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- Z1 is
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, and OR4;
- R4, at each occurrence, is heterocyclyl;
- wherein the cyclic moiety represented by R4 is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, and CO(O)R10;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12 OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (I), which includes Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (II)
- and pharmaceutically acceptable salts thereof; wherein X1, X2, Y1, R1, and R2 are as described herein for Formula (I).
- One embodiment of this invention pertains to compounds of Formula (II) and pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (II), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (II), X1 is N and X2 is CR1. In another embodiment of Formula (II), X1 is CR1 and X2 is N. In another embodiment of Formula (II), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (II), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (II), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (II), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F. In another embodiment of Formula (II), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (II), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (II), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (II), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F. In another embodiment of Formula (II), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (II), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (II), Y1 is C(O)NH. In another embodiment of Formula (II), Y1 is NHC(O).
- In one embodiment of Formula (II), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (II), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (II), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4. In another embodiment of Formula (II), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (II), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (II), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4. In another embodiment of Formula (II), R2 is furanyl or thiophenyl; wherein each R2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4.
- In one embodiment of Formula (II), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (II), R4, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (II), each R4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with alkyl or alkoxy; and R12, at each occurrence, is independently selected alkyl. In another embodiment of Formula (II), each R4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (II)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, and OR4;
- R4, at each occurrence, is heterocyclyl;
- wherein the cyclic moiety represented by R4 is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, and CO(O)R10;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (II), which includes Examples 1, 2, 3, 4, 5, 6, 7, 10, 20, 21, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 609, 610, 611, 612, 613, and
- pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (III)
- and pharmaceutically acceptable salts thereof; wherein Y1 is as described in Formula (I) herein and R4x is as described herein for substituents on R2 when R2 is aryl in Formula (I).
- One embodiment of this invention pertains to compounds of Formula (III) or pharmaceutically acceptable salts thereof;
- wherein
- Y1 is C(O)NH, or NHC(O);
- R4x is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (III), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (III), Y1 is C(O)NH. In another embodiment of Formula (III), Y is NHC(O).
- In one embodiment of Formula (III), R4x is selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (III), R4x is selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (III), R4x is selected from the group consisting of R4, SO2R4, and OR4.
- In one embodiment of Formula (III), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (III), R4, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (III), each R4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with alkyl or alkoxy; and R12, at each occurrence, is independently selected alkyl. In another embodiment of Formula (III), each R4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R2, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (III)
- wherein
- Y1 is C(O)NH, or NHC(O);
- R4x is independently selected from the group consisting of R4, SO2R4, and OR4;
- R4, at each occurrence, is heterocyclyl;
- wherein the cyclic moiety represented by R4 is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, and CO(O)R10;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (III), which includes Examples 1, 2, 3, 4, 5, 6, 7, 10, 20, 21, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 602, 609, 610, and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (IV)
- and pharmaceutically acceptable salts thereof; wherein X1, X2, Y1, R1, and R2 are as described herein for Formula (I).
- One embodiment of this invention pertains to compounds of Formula (IV) and pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (IV), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IV), X1 is N and X2 is CR1. In another embodiment of Formula (IV), X1 is CR1 and X2 is N. In another embodiment of Formula (IV), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IV), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IV), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IV), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F. In another embodiment of Formula (IV), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IV), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IV), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IV), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F. In another embodiment of Formula (IV), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IV), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IV), Y1 is C(O)NH. In another embodiment of Formula (IV), Y1 is NHC(O).
- In one embodiment of Formula (IV), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IV), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IV), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4. In another embodiment of Formula (IV), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (IV), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IV), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4. In another embodiment of Formula (IV), R2 is furanyl or thiophenyl; wherein each R2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, and SO2R4.
- In one embodiment of Formula (IV), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IV), R4, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (IV), each R4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with alkyl or alkoxy; and R12, at each occurrence, is independently selected alkyl. In another embodiment of Formula (IV), each R4 heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IV)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, and OR4;
- R4, at each occurrence, is heterocyclyl;
- wherein the cyclic moiety represented by R4 is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, and CO(O)R10;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, and heterocyclyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups. - Still another embodiment pertains to compounds having Formula (IV), which includes Examples 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 27, 28, 141, 142, 204, 310, 311, 312, 313, and pharmaceutically acceptable salts thereof.
- One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IA)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- Z1 is
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); Z1 is - and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups.
- In one embodiment of Formula (IA), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IA), X1 is N and X2 is CR1. In another embodiment of Formula (IA), X1 is CR1 and X2 is N. In another embodiment of Formula (IA), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IA), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IA), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IA), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IA), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IA), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IA), Y1 is C(O)NH. In another embodiment of Formula (IA), Y1 is NHC(O).
- In one embodiment of Formula (IA), Z1 is
- In one embodiment of Formula (IA), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IA), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IA), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IA), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IA), R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (IA), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IA), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IA), R2 is furanyl or thiophenyl; wherein each R2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F.
- In one embodiment of Formula (IA), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IA), R4, at each occurrence, is alkyl or heterocyclyl.
- In one embodiment of Formula (IA), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IA), each R4 alkyl is optionally substituted with one R7.
- In one embodiment of Formula (IA), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IA), R7, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (IA), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (IA), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, OH, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl and haloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IA)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- Z1 is
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, OR4, and F;
- R4, at each occurrence, is alkyl or heterocyclyl; wherein each R4 alkyl is optionally substituted with R7;
- R7, at each occurrence, is independently heterocyclyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR1, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl;
- with the proviso that
- when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); Z1 is
- and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups.
- Still another embodiment pertains to compounds having Formula (IA), which includes Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, and pharmaceutically acceptable salts thereof.
- Still another embodiment pertains to compounds of Formula (1A), selected from the group consisting of Examples 147, 310, 313, 316, 317, 320, 332, 333, 334, 402, 433, 440, 658, 681, 691, 706, 707, 723, 736, 795, and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (IIA)
- and pharmaceutically acceptable salts thereof; wherein X1, X2, Y1, R1, and R2 are as described herein for Formula (IA).
- One embodiment of this invention pertains to compounds of Formula (IIA) and pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (IIA), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IIA), X1 is N and X2 is CR1. In another embodiment of Formula (IIA), X1 is CR1 and X2 is N. In another embodiment of Formula (IIA), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IIA), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IIA), Y1 is C(O)NH. In another embodiment of Formula (IIA), Y1 is NHC(O).
- In one embodiment of Formula (IIA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IIA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IIA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In another aspect, the present invention provides compounds of Formula (IIB),
- and pharmaceutically acceptable salts thereof; wherein R1 and R2 are as described herein for Formula (IA).
- In one embodiment of Formula (IIA) and (IIB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IIA) and (IIB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IIA) and (IIB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIA) and (IIB), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IIA) and (IIB), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IIA) and (IIB), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IIA) and (IIB), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IIA) and (IIB), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IIA) and (IIB), R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (IIA) and (IIB), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IIA) and (IIB), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IIA) and (IIB), R2 is furanyl or thiophenyl; wherein each R2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F.
- In one embodiment of Formula (IIA) and (IIB), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IIA) and (IIB), R4, at each occurrence, is alkyl or heterocyclyl.
- In one embodiment of Formula (IIA) and (IIB), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (I), each R4 alkyl is optionally substituted with one R7.
- In one embodiment of Formula (IIA) and (IIB), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IIA) and (IIB), R7, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (IIA) and (IIB), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (IIA) and (IIB), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, OH, F, Cl, Br and I; R10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR1, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl and haloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IIA)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, OR4, and F;
- R4, at each occurrence, is alkyl or heterocyclyl; wherein each R4 alkyl is optionally substituted with R7;
- R7, at each occurrence, is independently heterocyclyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (IIA), which includes Examples 1, 2, 3, 4, 5, 6, 7, 10, 20, 21, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 609, 610, 611, 612, 613, 614, 615, 616, 617, 665, 666, 667, 668, 737, 738, 739, 740, 741, 748, 750, 751, 753, 784, 803, 804, 805, 806, 807, 809, 817, 818, 819, 820, 821, 822, 823, 828, 829, 830, 831, 832, 833, 834, 835, 840, 841, 842, 843, 844, 845, 846, 851, 852, 853, 854, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (IIIA)
- and pharmaceutically acceptable salts thereof; wherein X1, X2, R1, and Y1 are as described in Formula (IA) herein and R4x is as described herein for substituents on R2 when R2 is aryl in Formula (IA).
- One embodiment of this invention pertains to compounds of Formula (IIIA) or pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R4X is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- wherein the cyclic moieties represented by R4 and R7, are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (IIIA), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IIIA), X1 is N and X2 is CR1. In another embodiment of Formula (IIIA), X1 is CR1 and X2 is N. In another embodiment of Formula (IIIA), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IIIA), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IIIA), Y1 is C(O)NH. In another embodiment of Formula (IIIA), Y1 is NHC(O).
- In one embodiment of Formula (IIIA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IIIA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IIIA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIIA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In another aspect, the present invention provides compounds of Formula (IIIB),
- and pharmaceutically acceptable salts thereof; wherein R1 is described herein for Formula (IA) and R4x is as described herein for substituents on R2 when R2 is aryl in Formula (IA).
- In one embodiment of Formula (IIIA) and (IIIB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IIIA) and (IIIB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IIIA) and (IIIB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIIA) and (IIIB), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IIIA) and (IIIB), R4X is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IIIA) and (IIIB), R4X is independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IIIA) and (IIIB), R4X is independently selected from the group consisting of R4, OR4, SO2R4, and F.
- In one embodiment of Formula (IIIA) and (IIIB), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IIIA) and (IIIB), R4, at each occurrence, is alkyl or heterocyclyl.
- In one embodiment of Formula (IIIA) and (IIIB), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IIIA) and (IIIB), each R4 alkyl is optionally substituted with one R7.
- In one embodiment of Formula (IIIA) and (IIIB), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IIIA) and (IIIB), R7, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (IIIA) and (IIIB), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (IIIA) and (IIIB), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, OH, F, Cl, Br and I; R10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl and haloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IIIA)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R4X is independently selected from the group consisting of R4, SO2R4, OR4, and F;
- R4, at each occurrence, is alkyl or heterocyclyl; wherein each R4 alkyl is optionally substituted with R7;
- R7, at each occurrence, is independently heterocyclyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R2, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (IIIA), which includes Examples 1, 2, 3, 4, 5, 6, 7, 10, 20, 22, 25, 26, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 609, 610, 611, 612, 613, 614, 615, 616, 617, 665, 666, 667, 668, 737, 738, 739, 740, 741, 748, 750, 751, 753, 784, 803, 804, 805, 806, 807, 809, 817, 818, 819, 820, 821, 822, 823, 840, 841, 842, 843, 844, 845, 846, 851, 852, 853, 854, 857, 863, 864, 865, 866, 867, and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (IVA)
- and pharmaceutically acceptable salts thereof; wherein each X1, X2, Y1, R1, and R2 are as described herein for Formula (I).
- One embodiment of this invention pertains to compounds of Formula (IVA) and pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups. - In one embodiment of Formula (IVA), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IVA), X1 is N and X2 is CR1. In another embodiment of Formula (IVA), X1 is CR1 and X2 is N. In another embodiment of Formula (IVA), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IVA), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IVA), Y1 is C(O)NH. In another embodiment of Formula (IVA), Y1 is NHC(O).
- In one embodiment of Formula (IVA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IVA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IVA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IVA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In another aspect, the present invention provides compounds of Formula (IVB),
- and pharmaceutically acceptable salts thereof; wherein R1 and R2 are as described herein for Formula (IA).
- In one embodiment of Formula (IVA) and (IVB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IVA) and (IVB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IVA) and (IVB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IVA) and (IVB), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IVA) and (IVB), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IVA) and (IVB), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IVA) and (IVB), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IVA) and (IVB), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IVA) and (IVB), R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (IVA) and (IVB), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (IVA) and (IVB), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F. In another embodiment of Formula (IVA) and (IVB), R2 is furanyl or thiophenyl; wherein each R2 furanyl and thiophenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, and F.
- In one embodiment of Formula (IVA) and (IVB), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IVA) and (IVB), R4, at each occurrence, is alkyl or heterocyclyl.
- In one embodiment of Formula (IVA) and (IVB), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IVA) and (IVB), each R4 alkyl is optionally substituted with one R7.
- In one embodiment of Formula (IVA) and (IVB), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IVA) and (IVB), R7, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (IVA) and (IVB), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (IVA) and (IVB), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, OH, F, Cl, Br and I; R10 at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR1, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl and haloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IVA)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, OR4, and F;
- R4, at each occurrence, is alkyl or heterocyclyl; wherein each R4 alkyl is optionally substituted with R7;
- R7, at each occurrence, is independently heterocyclyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups. - Still another embodiment pertains to compounds having Formula (IVA), which includes Examples 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 27, 28, 141, 142, 204, 310, 311, 312, 313, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (VA)
- and pharmaceutically acceptable salts thereof; wherein X1, X2, R1, and Y1 are as described in Formula (IA) herein and R4x is as described herein for substituents on R2 when R2 is aryl in Formula (IA).
- One embodiment of this invention pertains to compounds of Formula (VA) or pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R4X is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- wherein the cyclic moieties represented by R4, and R7, are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (VA), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (VA), X1 is N and X2 is CR1. In another embodiment of Formula (VA), X1 is CR1 and X2 is N. In another embodiment of Formula (VA), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (VA), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (VA), Y1 is C(O)NH. In another embodiment of Formula (VA), Y1 is NHC(O).
- In one embodiment of Formula (VA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (VA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (VA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (VA), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In another aspect, the present invention provides compounds of Formula (VB),
- and pharmaceutically acceptable salts thereof; wherein R1 is described herein for Formula (IA) and R4x is as described herein for substituents on R2 when R2 is aryl in Formula (IA).
- In one embodiment of Formula (VA) and (VB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (VA) and (VB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (VA) and (VB), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (VA) and (VB), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (VA) and (VB), R4X is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (VA) and (VB), R4X is independently selected from the group consisting of R4, OR4, SO2R4, F, Cl, and I. In another embodiment of Formula (VA) and (VB), R4X is independently selected from the group consisting of R4, OR4, SO2R4, and F.
- In one embodiment of Formula (VA) and (VB), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (VA) and (VB), R4, at each occurrence, is alkyl or heterocyclyl.
- In one embodiment of Formula (VA) and (VB), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (I), each R4 alkyl is optionally substituted with one R7.
- In one embodiment of Formula (VA) and (VB), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (VA) and (VB), R7, at each occurrence, is heterocyclyl.
- In one embodiment of Formula (VA) and (VB), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (VA) and (VB), each R4 and R7 heterocyclyl is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, OH, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl and haloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (VA)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R4X is independently selected from the group consisting of R4, SO2R4, OR4, and F;
- R4, at each occurrence, is alkyl or heterocyclyl; wherein each R4 alkyl is optionally substituted with R7;
- R7, at each occurrence, is independently heterocyclyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (VA), which includes Examples 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 27, 28, 141, 142, 204, 310, 311, 312, 313, 614, 615, 616, 617, 625, 626, 627, 628, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 743, 744, 745, 748, 749, 750, 751, 752, 753, 756, 757, 759, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, and pharmaceutically acceptable salts thereof.
- One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IC)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- Z1 is
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); Z1 is - and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups.
- In one embodiment of Formula (IC), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IC), X1 is N and X2 is CR1. In another embodiment of Formula (IC), X1 is CR1 and X2 is N. In another embodiment of Formula (IC), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IC), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IC), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IC), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IC), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IC), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IC), Y1 is C(O)NH. In another embodiment of Formula (IC), Y1 is NHC(O).
- In one embodiment of Formula (IC), Z1 is
- In one embodiment of Formula (IC), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IC), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, F, Cl, and I. In another embodiment of Formula (IC), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IC), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IC), R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (IC), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, F, Cl, and I. In another embodiment of Formula (IC), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IC), R2 is pyridinyl, furanyl, thiophenyl, pyrazole, or thiazolyl; wherein each R2 pyridinyl, furanyl, thiophenyl, pyrazole, and thiazolyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F.
- In one embodiment of Formula (IC), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IC), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (IC), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IC), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, F, Cl, Br and I.
- In one embodiment of Formula (IC), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IC), R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (IC), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (IC), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, CO(O)H, OH, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R2, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IC)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- Z1 is
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, OR4, C(O)NHR4, and F;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, and F;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, C(O)OH, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl;
- with the proviso that
- when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); Z1 is
- and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups.
- Still another embodiment pertains to compounds having Formula (IC), which include
- 1-(pyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(2-cyanopyridin-3-yl)-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-[2-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(4-methylpyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(4-fluoropyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-[4-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide;
- tert-butyl 4-[4-({[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate;
- tert-butyl 4-[4-({[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate;
- 1-(pyridin-3-yl)-N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[1-(pyridin-3-yl)azetidin-3-yl]-4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}benzamide;
- N-(4-{1-[(2S)-2-methylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)-N-[1-(pyridin-3-yl)azetidin-3-yl]benzamide;
- 4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}-N-[1-(pyridin-3-yl)azetidin-3-yl]benzamide;
- 1-(pyridin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-(4-{[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbamoyl}phenoxy)piperidine-1-carboxylate;
- tert-butyl 4-(4-{[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbamoyl}phenoxy)piperidine-1-carboxylate;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-ethoxypropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-butanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(N-acetyl-L-leucyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methoxypyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpentyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-ethylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylmethyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylmethyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpentyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methoxypyridin-3-yl)azetidine-3-carboxamide;
- 1-(4-cyanopyridin-3-yl)-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(5-oxo-D-prolyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(5-oxo-L-prolyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-[4-(1-pentanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(5-oxo-D-prolyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(5-oxo-L-prolyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-[4-(1-propanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]azetidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-{4-[(1-benzoylazetidin-3-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-hydroxy-2-methylpropanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-pentanoylazetidin-3-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]furan-2-carboxamide;
- (3S)—N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- tert-butyl 4-(4-{[1-(pyridazin-3-yl)azetidin-3-yl]carbamoyl}phenyl)piperidine-1-carboxylate;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(methylsulfanyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-nitropropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[(pyrimidin-2-ylsulfanyl)acetyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[N-(furan-2-ylcarbonyl)glycyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(benzyloxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl)butanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclobutylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-{N-[(4-methylphenyl)sulfonyl]glycyl}piperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,3-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-phenylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2,5-dimethylfuran-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-oxopropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(pyridin-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[3-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(pyridin-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[3-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-(4-{1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[difluoro(phenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-tert-butylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]sulfonyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,5-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-dimethylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-dichlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(phenylacetyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylalanyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-4-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-4-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- tert-butyl 4-(2-methyl-1-oxo-1-{4-[4-({[1-(pyridin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidin-1-yl}propan-2-yl)piperazine-1-carboxylate;
- N-(4-{1-[2-methyl-2-(piperazin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[(3R)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3R)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3R)-1-(5, 6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-4-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}piperidine-4-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl)butanoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-5-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-fluoropyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-fluoro-6-methylpyridin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-methylpyridin-3-yl)azetidine-3-carboxamide;
- 2-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-1,3-thiazole-5-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(2-methylpyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]furan-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]furan-2-carboxamide;
- N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-4-[1-(2-methylpropanoyl)piperidin-4-yl]benzamide;
- N-(4-{1-[2-(piperazin-1-yl)ethyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 4-[1-(2-methylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]benzamide;
- N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- (3S)—N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- 5-[1-(2-methylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-(1-benzoylpiperidin-4-yl)-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}thiophene-2-carboxamide;
- 5-{1-[(1-methylpiperidin-4-yl)acetyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- (3S)—N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(propan-2-yl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-2-ylmethyl)-1H-pyrazol-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-tert-butyl-1H-pyrazol-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-benzoylpyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2-methylbenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylazetidin-3-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-difluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-difluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,3,4-oxadiazol-2-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-imidazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-(5-{[1-(pyridazin-3-yl)azetidin-3-yl]carbamoyl}thiophen-2-yl)piperidine-1-carboxylate;
- tert-butyl 4-fluoro-4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidine-1-carboxylate;
- 5-(1-benzoylpiperidin-4-yl)-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylbenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-fluoropyridazin-3-yl)-N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-benzoylpyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[8-(2-methylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[8-(4,4,4-trifluorobutanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(8-benzoyl-8-azabicyclo[3.2.1]oct-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2-fluorobenzoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2,2-dimethylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{8-[(1-methylcyclopropyl)carbonyl]-8-azabicyclo[3.2.1]oct-3-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxyethyl)-3-(2-methylpropyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-fluoropiperidine-1-carboxylate;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-hydroxypiperidine-1-carboxylate;
- N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[4-fluoro-1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(2-fluoro-4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoyl-4-fluoropiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-fluoropiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butyl-3-tert-butyl-H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-chloropyridazin-3-yl)-N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-3-fluorophenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-hydroxypiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-methylpyridazin-3-yl)-N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-{[4-methyl-1-(oxetan-3-yl)piperidin-4-yl]methyl}-1H-pyrazol-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]furan-2-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-aminopyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-methyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylic acid;
- ethyl 1-methyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylate;
- ethyl 1-phenyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylate;
- N-{6-[1-(2-fluorobenzoyl)piperidin-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-methylpyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{6-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]pyridin-3-yl}azetidine-3-carboxamide;
- N-{6-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{6-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)-1H-pyrazol-1-yl]piperidine-1-carboxylate;
- N-(6-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}pyridin-3-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(1H-pyrazol-4-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(methylsulfanyl)acetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(1H-pyrazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(pent-4-ynoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-hexanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(but-3-enoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-butanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-pentanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{1-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-1H-pyrazol-4-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{1-[1-(2-fluorobenzoyl)piperidin-4-yl]-1H-pyrazol-4-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(phenylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-cyclopropylethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[2-(2-ethylpiperidin-1-yl)ethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(cyclobutylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(butylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({2-[methyl(phenyl)amino]ethyl}carbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1,1′-bi(cyclopropyl)-1-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(thiophen-3-ylcarbamoyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylpiperidin-4-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-azabicyclo[2.2.2]oct-3-ylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(oxetan-3-ylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-methylcyclopropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclobutylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylcyclopropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3,3,3-trifluoropropyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(1-methylpiperidin-3-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[(1-methylpiperidin-3-yl)methyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclopropylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclopentylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(benzylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(propylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylcyclobutyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(prop-2-en-1-ylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(cyclopropylacetyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(bicyclo[2.2.1]hept-2-ylacetyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}azetidine-3-carboxamide;
- N-[4-({4-[2-(dimethylamino)ethyl]phenyl}carbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-amino-2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2,2-dimethyl-3-(piperazin-1-yl)propyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-methyl-2-(piperazin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- Still another embodiment pertains to compounds of Formula (1A), selected from the group consisting of
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(methylsulfanyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (IIC)
- and pharmaceutically acceptable salts thereof; wherein X1, X2, Y1, R1, and R2 are as described herein for Formula (IC).
- One embodiment of this invention pertains to compounds of Formula (IIC) and pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (IIC), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IIC), X1 is N and X2 is CR1. In another embodiment of Formula (IIC), X1 is CR1 and X2 is N. In another embodiment of Formula (IIC), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IIC), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IIC), Y1 is C(O)NH. In another embodiment of Formula (IIC), Y1 is NHC(O).
- In one embodiment of Formula (IIC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IIC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IIC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In another aspect, the present invention provides compounds of Formula (IID),
- and pharmaceutically acceptable salts thereof; wherein R1 and R2 are as described herein for Formula (IC).
- In one embodiment of Formula (IIC) and (IID), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IIC) and (IID), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IIC) and (IID), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIC) and (IID), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IIC) and (IID), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IIC) and (IID), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, F, Cl, and I. In another embodiment of Formula (IIC) and (IID), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IIC) and (IID), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IIC) and (IID), R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (IIC) and (IID), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, F, Cl, and I. In another embodiment of Formula (IIC) and (IID), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IIC) and (IID), R2 is pyridinyl, furanyl, thiophenyl, pyrazole, or thiazolyl; wherein each R2 pyridinyl, furanyl, thiophenyl, pyrazole, and thiazolyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F.
- In one embodiment of Formula (IIC) and (IID), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IIC) and (IID), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (IIC) and (IID), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IIC) and (IID), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, F, Cl, Br and I.
- In one embodiment of Formula (IIC) and (IID), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IIC) and (IID), R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (IIC) and (IID), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (IIC) and (IID), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, CO(O)H, OH, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IIC)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, OR4, C(O)NHR4, and F;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, and F;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, C(O)OH, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (IIC), which includes
- 1-(pyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(2-cyanopyridin-3-yl)-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-[2-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(4-methylpyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(4-fluoropyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-[4-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[1-(pyridin-3-yl)azetidin-3-yl]-4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}benzamide;
- N-(4-{1-[(2S)-2-methylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)-N-[1-(pyridin-3-yl)azetidin-3-yl]benzamide;
- 4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}-N-[1-(pyridin-3-yl)azetidin-3-yl]benzamide;
- 1-(pyridin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-ethoxypropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-butanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(N-acetyl-L-leucyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methoxypyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpentyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-ethylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylmethyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylmethyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpentyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methoxypyridin-3-yl)azetidine-3-carboxamide;
- 1-(4-cyanopyridin-3-yl)-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(5-oxo-D-prolyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(5-oxo-L-prolyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-[4-(1-pentanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(5-oxo-D-prolyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(5-oxo-L-prolyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-[4-(1-propanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]azetidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-{4-[(1-benzoylazetidin-3-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-hydroxy-2-methylpropanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-pentanoylazetidin-3-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]furan-2-carboxamide;
- tert-butyl 4-(4-{[1-(pyridazin-3-yl)azetidin-3-yl]carbamoyl}phenyl)piperidine-1-carboxylate;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(methylsulfanyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-nitropropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[(pyrimidin-2-ylsulfanyl)acetyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[N-(furan-2-ylcarbonyl)glycyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(benzyloxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl)butanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclobutylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-{N-[(4-methylphenyl)sulfonyl]glycyl}piperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,3-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-phenylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2,5-dimethylfuran-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-oxopropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(pyridin-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[3-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3, 5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(pyridin-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[3-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-(4-{1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[difluoro(phenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-tert-butylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]sulfonyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,5-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-dimethylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-dichlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(phenylacetyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylalanyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-(2-methyl-1-oxo-1-{4-[4-({[1-(pyridin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidin-1-yl}propan-2-yl)piperazine-1-carboxylate;
- N-(4-{1-[2-methyl-2-(piperazin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-5-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-fluoropyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-fluoro-6-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-(piperazin-1-yl)ethyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,3,4-oxadiazol-2-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-imidazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-fluoro-4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidine-1-carboxylate;
- N-{4-[3-cyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-fluoropyridazin-3-yl)-N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2-methylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[8-(4,4,4-trifluorobutanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(8-benzoyl-8-azabicyclo[3.2.1]oct-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2-fluorobenzoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2,2-dimethylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{8-[(1-methylcyclopropyl)carbonyl]-8-azabicyclo[3.2.1]oct-3-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxyethyl)-3-(2-methylpropyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-fluoropiperidine-1-carboxylate;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-hydroxypiperidine-1-carboxylate;
- N-{4-[4-fluoro-1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(2-fluoro-4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoyl-4-fluoropiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-fluoropiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butyl-3-tert-butyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-chloropyridazin-3-yl)-N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-3-fluorophenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{3-fluoro-4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-3-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-hydroxypiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-methylpyridazin-3-yl)-N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-{[4-methyl-1-(oxetan-3-yl)piperidin-4-yl]methyl}-1H-pyrazol-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-aminopyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-methyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylic acid;
- ethyl 1-methyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylate;
- ethyl 1-phenyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylate;
- N-{6-[1-(2-fluorobenzoyl)piperidin-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-methylpyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{6-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]pyridin-3-yl}azetidine-3-carboxamide;
- N-{6-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{6-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridin-3-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)-1H-pyrazol-1-yl]piperidine-1-carboxylate;
- N-(6-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}pyridin-3-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(1H-pyrazol-4-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(methylsulfanyl)acetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(1H-pyrazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(pent-4-ynoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-hexanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(but-3-enoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-butanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-pentanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{1-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-1H-pyrazol-4-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{1-[1-(2-fluorobenzoyl)piperidin-4-yl]-1H-pyrazol-4-yl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(phenylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-cyclopropylethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[2-(2-ethylpiperidin-1-yl)ethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(cyclobutylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(butylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({2-[methyl(phenyl)amino]ethyl}carbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1,1′-bi(cyclopropyl)-1-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(thiophen-3-ylcarbamoyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylpiperidin-4-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-azabicyclo[2.2.2]oct-3-ylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(oxetan-3-ylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-methylcyclopropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclobutylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylcyclopropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3,3,3-trifluoropropyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(1-methylpiperidin-3-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[(1-methylpiperidin-3-yl)methyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclopropylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclopentylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(benzylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(propylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylcyclobutyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(prop-2-en-1-ylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}azetidine-3-carboxamide;
- N-[4-({4-[2-(dimethylamino)ethyl]phenyl}carbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-amino-2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2,2-dimethyl-3-(piperazin-1-yl)propyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-methyl-2-(piperazin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (IIIC)
- and pharmaceutically acceptable salts thereof; wherein X1, X2, R1, and Y1 are as described in Formula (IC) herein and R4x is as described herein for substituents on R2 when R2 is aryl in Formula (IC).
- One embodiment of this invention pertains to compounds of Formula (IIIC) or pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R4X is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R4 and R7, are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (IIIC), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IIIC), X1 is N and X2 is CR1. In another embodiment of Formula (IIIC), X1 is CR1 and X2 is N. In another embodiment of Formula (IIIC), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IIIC), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IIIC), Y1 is C(O)NH. In another embodiment of Formula (IIIC), Y1 is NHC(O).
- In one embodiment of Formula (IIIC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IIIC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IIIC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIIC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In another aspect, the present invention provides compounds of Formula (IIID),
- and pharmaceutically acceptable salts thereof; wherein R1 is described herein for Formula (IC) and R4x is as described herein for substituents on R2 when R2 is aryl in Formula (IC).
- In one embodiment of Formula (IIIC) and (IIID), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IIIC) and (IIID), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IIIC) and (IIID), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IIIC) and (IIID), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IIIC) and (IIID), R4X is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IIIC) and (IIID), R4X is independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, F, Cl, and I. In another embodiment of Formula (IIIC) and (IIID), R4X is independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F.
- In one embodiment of Formula (IIIC) and (IIID), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IIIC) and (IIID), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (IIIC) and (IIID), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IIIC) and (IIID), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, F, Cl, Br and I.
- In one embodiment of Formula (IIIC) and (IIID), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IIIC) and (IIID), R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (IIIC) and (IIID), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (IIIC) and (IIID), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, CO(O)H, OH, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R2, NH2, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R2, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IIIC)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R4X is independently selected from the group consisting of R4, SO2R4, OR4, and F;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, and F;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, C(O)OH, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (IIIC), which include
- 1-(pyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(2-cyanopyridin-3-yl)-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-[2-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(4-methylpyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(4-fluoropyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-[4-(trifluoromethyl)pyridin-3-yl]azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-ethoxypropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-butanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(N-acetyl-L-leucyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propanoylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methoxypyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylmethyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpentyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-ethylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propylpiperidin-4-yl)oxy]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylmethyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylmethyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpentyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methoxypyridin-3-yl)azetidine-3-carboxamide;
- 1-(4-cyanopyridin-3-yl)-N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(5-oxo-D-prolyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(5-oxo-L-prolyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- 1-(pyridin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-[4-(1-pentanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(5-oxo-D-prolyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(N,N-dimethyl-beta-alanyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(5-oxo-L-prolyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-[4-(1-propanoylpiperidin-4-yl)phenyl]azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[3-(morpholin-4-yl)propanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- 1-(2-methylpyridin-3-yl)-N-(4-{1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]azetidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-{4-[(1-benzoylazetidin-3-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-hydroxy-2-methylpropanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-pentanoylazetidin-3-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)azetidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]azetidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(methylsulfanyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-nitropropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[(pyrimidin-2-ylsulfanyl)acetyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[N-(furan-2-ylcarbonyl)glycyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(benzyloxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl)butanoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclobutylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-{N-[(4-methylphenyl)sulfonyl]glycyl}piperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,3-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-phenylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(2,5-dimethylfuran-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-oxopropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(pyridin-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[3-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(pyridin-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[3-(trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3, 5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4-(trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4-(trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-(4-{1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-(4-{1-[difluoro(phenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[4-(trifluoromethoxy)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-4-yl)-N-[4-(1-{[4-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-tert-butylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]sulfonyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2,5-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-dimethylbenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3-carboxamide;
- N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenylsulfonylphenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,3-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,4-dichlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methoxybenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(phenylacetyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methylalanyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-(2-methyl-1-oxo-1-{4-[4-({[1-(pyridin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidin-1-yl}propan-2-yl)piperazine-1-carboxylate;
- N-(4-{1-[2-methyl-2-(piperazin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-5-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-fluoropyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-fluoro-6-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-(piperazin-1-yl)ethyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,3,4-oxadiazol-2-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-imidazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-fluoro-4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidine-1-carboxylate;
- N-{4-[3-cyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-fluoropyridazin-3-yl)-N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2-methylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[8-(4,4,4-trifluorobutanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(8-benzoyl-8-azabicyclo[3.2.1]oct-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2-fluorobenzoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2,2-dimethylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{8-[(1-methylcyclopropyl)carbonyl]-8-azabicyclo[3.2.1]oct-3-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxyethyl)-3-(2-methylpropyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-fluoropiperidine-1-carboxylate;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-hydroxypiperidine-1-carboxylate;
- N-{4-[4-fluoro-1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoyl-4-fluoropiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-fluoropiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butyl-3-tert-butyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-chloropyridazin-3-yl)-N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-hydroxypiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-methylpyridazin-3-yl)-N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-acetylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-{[4-methyl-1-(oxetan-3-yl)piperidin-4-yl]methyl}-1H-pyrazol-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(3-methylpyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{1-[(2-aminopyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-methyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylic acid;
- ethyl 1-methyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylate;
- ethyl 1-phenyl-5-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-1H-pyrazole-3-carboxylate;
- N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-methylpyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3-carboxamide;
- N-{4-[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(1H-pyrazol-4-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(methylsulfanyl)acetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(1H-pyrazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(pent-4-ynoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(methoxyacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-{4-[(1-hexanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(but-3-enoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-propanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-butanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-pentanoylpiperidin-4-yl)methyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]methyl}phenyl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(phenylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-cyclopropylethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[2-(2-ethylpiperidin-1-yl)ethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(cyclobutylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(butylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-({2-[methyl(phenyl)amino]ethyl}carbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1,1′-bi(cyclopropyl)-1-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(thiophen-3-ylcarbamoyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylpiperidin-4-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-azabicyclo[2.2.2]oct-3-ylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(oxetan-3-ylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-methylcyclopropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclobutylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylcyclopropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3,3,3-trifluoropropyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(1-methylpiperidin-3-yl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]azetidine-3-carboxamide;
- N-(4-{[(1-methylpiperidin-3-yl)methyl]carbamoyl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclopropylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(cyclopentylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(benzylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(propylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[(1-methylcyclobutyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(prop-2-en-1-ylcarbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}azetidine-3-carboxamide;
- N-[4-({4-[2-(dimethylamino)ethyl]phenyl}carbamoyl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}azetidine-3-carboxamide;
- N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3-amino-2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2,2-dimethyl-3-(piperazin-1-yl)propyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{1-[2-methyl-2-(piperazin-1-yl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (IVC)
- and pharmaceutically acceptable salts thereof; wherein each X1, X2, Y1, R1, and R2 are as described herein for Formula (I).
- One embodiment of this invention pertains to compounds of Formula (IVC) and pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
- R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups. - In one embodiment of Formula (IVC), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (IVC), X1 is N and X2 is CR1. In another embodiment of Formula (IVC), X1 is CR1 and X2 is N. In another embodiment of Formula (IVC), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (IVC), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (IVC), Y1 is C(O)NH. In another embodiment of Formula (IVC), Y1 is NHC(O).
- In one embodiment of Formula (IVC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IVC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IVC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IVC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In another aspect, the present invention provides compounds of Formula (IVD),
- and pharmaceutically acceptable salts thereof; wherein R1 and R2 are as described herein for Formula (IC).
- In one embodiment of Formula (IVC) and (IVD), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (IVC) and (IVD), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (IVC) and (IVD), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (IVC) and (IVD), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (IVC) and (IVD), R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (IVC) and (IVD), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, F, Cl, and I. In another embodiment of Formula (IVC) and (IVD), R2 is aryl; wherein each R2 aryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IVC) and (IVD), R2 is phenyl; wherein each R2 phenyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IVC) and (IVD), R2 is phenyl; wherein each R2 phenyl is substituted with one substituent independently selected from the group consisting of R4, OR4, and SO2R4.
- In another embodiment of Formula (IVC) and (IVD), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, F, Cl, and I. In another embodiment of Formula (IVC) and (IVD), R2 is 5-6 membered heteroaryl; wherein each R2 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F. In another embodiment of Formula (IVC) and (IVD), R2 is pyridinyl, furanyl, thiophenyl, pyrazole, or thiazolyl; wherein each R2 pyridinyl, furanyl, thiophenyl, pyrazole, and thiazolyl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F.
- In one embodiment of Formula (IVC) and (IVD), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IVC) and (IVD), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (IVC) and (IVD), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (IVC) and (IVD), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, F, Cl, Br and I.
- In one embodiment of Formula (IVC) and (IVD), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (IVC) and (IVD), R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (IVC) and (IVD), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (IVC) and (IVD), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, CO(O)H, OH, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R1, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (IVC)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R2 is aryl or 5-6 membered heteroaryl wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, SO2R4, OR4, C(O)NHR4, and F;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, and F;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, C(O)OH, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R12, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl;
- with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups. - Still another embodiment pertains to compounds having Formula (IV), which include
- tert-butyl 4-[4-({[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate;
- tert-butyl 4-[4-({[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- tert-butyl 4-(4-{[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbamoyl}phenoxy)piperidine-1-carboxylate;
- tert-butyl 4-(4-{[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbamoyl}phenoxy)piperidine-1-carboxylate;
- (3S)—N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[(3R)-1-(5, 6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3R)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide;
- N-[(3R)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3R)-1-(pyridazin-4-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidi4-yl]phenyl}-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}piperidine-4-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl)butanoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-5-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-fluoropyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-fluoro-6-methylpyridin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-methylpyridin-3-yl)azetidine-3-carboxamide;
- 2-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-1,3-thiazole-5-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(2-methylpyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]furan-2-carboxamide;
- 5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]furan-2-carboxamide;
- N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-4-[1-(2-methylpropanoyl)piperidin-4-yl]benzamide;
- N-(4-{1-[2-(piperazin-1-yl)ethyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 4-[1-(2-methylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]benzamide;
- N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- (3S)—N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- 5-[1-(2-methylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-(1-benzoylpiperidin-4-yl)-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}thiophene-2-carboxamide;
- 5-{1-[(1-methylpiperidin-4-yl)acetyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(1,3-thiazol-4-ylcarbonyl)piperidin-4-yl]thiophene-2-carboxamide;
- (3S)—N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(propan-2-yl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-2-ylmethyl)-1H-pyrazol-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-tert-butyl-1H-pyrazol-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-benzoylpyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2-methylbenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylazetidin-3-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-difluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-difluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,3,4-oxadiazol-2-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-imidazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-(5-{[1-(pyridazin-3-yl)azetidin-3-yl]carbamoyl}thiophen-2-yl)piperidine-1-carboxylate;
- tert-butyl 4-fluoro-4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidine-1-carboxylate;
- 5-(1-benzoylpiperidin-4-yl)-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylbenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-fluoropyridazin-3-yl)-N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-benzoylpyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[8-(2-methylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[8-(4,4,4-trifluorobutanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(8-benzoyl-8-azabicyclo[3.2.1]oct-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2-fluorobenzoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2,2-dimethylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{8-[(1-methylcyclopropyl)carbonyl]-8-azabicyclo[3.2.1]oct-3-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxyethyl)-3-(2-methylpropyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-fluoropiperidine-1-carboxylate;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-hydroxypiperidine-1-carboxylate;
- N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[4-fluoro-1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(2-fluoro-4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoyl-4-fluoropiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-fluoropiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butyl-3-tert-butyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]furan-2-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(cyclopropylacetyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(bicyclo[2.2.1]hept-2-ylacetyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2-carboxamide; and pharmaceutically acceptable salts thereof.
- In another aspect, the present invention provides compounds of Formula (VC)
- and pharmaceutically acceptable salts thereof; wherein X1, X2, R1, and Y1 are as described in Formula (IC) herein and R4X is as described herein for substituents on R2 when R2 is aryl in Formula (IC).
- One embodiment of this invention pertains to compounds of Formula (VC) or pharmaceutically acceptable salts thereof;
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
- R4X is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein the cyclic moieties represented by R4, and R7, are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In one embodiment of Formula (VC), X1 is N and X2 is CR1; or X1 is CR1 and X2 is N; or X1 is CR1 and X2 is CR1. In another embodiment of Formula (VC), X1 is N and X2 is CR1. In another embodiment of Formula (VC), X1 is CR1 and X2 is N. In another embodiment of Formula (VC), X1 is CR1 and X2 is CR1.
- In one embodiment of Formula (VC), Y1 is C(O)NH, or NHC(O). In another embodiment of Formula (VC), Y1 is C(O)NH. In another embodiment of Formula (VC), Y1 is NHC(O).
- In one embodiment of Formula (VC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (VC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (VC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (VC), X1 is CR1 and X2 is CR1; and R1, at each occurrence, is hydrogen.
- In another aspect, the present invention provides compounds of Formula (VD),
- and pharmaceutically acceptable salts thereof; wherein R1 is described herein for Formula (IC) and R4x is as described herein for substituents on R2 when R2 is aryl in Formula (IC).
- In one embodiment of Formula (VC) and (VD), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I. In another embodiment of Formula (VC) and (VD), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, Cl, Br and I. In another embodiment of Formula (VC) and (VD), R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, F, and Cl. In another embodiment of Formula (VC) and (VD), R1, at each occurrence, is hydrogen.
- In one embodiment of Formula (VC) and (VD), R4X is independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I. In another embodiment of Formula (VC) and (VD), R4X is independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, F, Cl, and I. In another embodiment of Formula (VC) and (VD), R4X is independently selected from the group consisting of R4, OR4, SO2R4, C(O)NHR4, and F.
- In one embodiment of Formula (VC) and (VD), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (VC) and (VD), R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (VC) and (VD), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I. In another embodiment of Formula (VC) and (VD), each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, F, Cl, Br and I.
- In one embodiment of Formula (VC) and (VD), R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl. In another embodiment of Formula (VC) and (VD), R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl.
- In one embodiment of Formula (VC) and (VD), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I; R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I; R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl.
- In another embodiment of Formula (VC) and (VD), each R4 and R7 cyclic moiety is independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, CO(O)R10, C(O)C(O)R10, CO(O)H, OH, F, Cl, Br and I; R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl, alkenyl, and alkynyl, are optionally substituted with one or more substituents independently selected from the group consisting of R1, OR1, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl; R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, CF3, F, and Cl; R12, at each occurrence, is independently selected from the group consisting of alkyl and aryl; and R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.
- One embodiment of this invention pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (VC)
- wherein
- X1 is N and X2 is CR1; or
- X1 is CR1 and X2 is N; or
- X1 is CR1 and X2 is CR1;
- Y1 is C(O)NH, or NHC(O);
- R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, CN, Cl, and F;
- R4X is independently selected from the group consisting of R4, SO2R4, OR4, and F;
- R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, aryl, heterocyclyl, and cycloalkyl; wherein each R4 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, N(R7)2, and F;
- R7, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl;
- wherein the cyclic moieties represented by R4 and R7 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, C(O)R10, C(O)C(O)R10, CO(O)R10, C(O)OH, OH and F;
- R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and cycloalkyl; wherein each R10 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, SO2R11, NH2, N(R11)2, NHC(O)R11, NHS(O)2R11, OH, NO2, and F; wherein each R10 aryl, heterocyclyl and cycloalkyl is optionally substituted with one or more R2, OR12, C(O)R12, NH2, OH, CN, CF3, OCF3, F, and Cl;
- R11, at each occurrence, is independently selected from the group consisting of alkyl, aryl, heterocyclyl, and cycloalkyl; wherein each R11 alkyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, C(O)OR13, OCF3, CF3, F, and Cl;
- R12, at each occurrence, is independently selected from the group consisting of alkyl, and aryl; and
- R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, cycloalkyl, and heterocyclyl.
- Still another embodiment pertains to compounds having Formula (VC), which include
- tert-butyl 4-[4-({[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate;
- tert-butyl 4-[4-({[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- tert-butyl 4-(4-{[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbamoyl}phenoxy)piperidine-1-carboxylate;
- tert-butyl 4-(4-{[(3R)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbamoyl}phenoxy)piperidine-1-carboxylate;
- (3S)—N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]sulfonyl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidi4-yl]phenyl}-1-(pyridazin-3-yl)piperidine-4-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}piperidine-4-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl)butanoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl)phenyl]acetyl}piperidin-4-yl)phenyl]pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-5-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-fluoropyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-fluoro-6-methylpyridin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-methylthiophen-2-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl)benzoyl]piperidin-4-yl}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoro-4-methylpyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-cyanopyridin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5-methylpyridin-3-yl)azetidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(2-methylpyridin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine-3-carboxamide;
- N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-4-[1-(2-methylpropanoyl)piperidin-4-yl]benzamide;
- N-(4-{1-[2-(piperazin-1-yl)ethyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 4-[1-(2-methylpropanoyl)piperidin-4-yl]-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]benzamide;
- N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(propan-2-yl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran-2-ylmethyl)-1H-pyrazol-4-yl]phenyl}pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-tert-butyl-1H-pyrazol-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-benzoylpyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2-methylbenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)-1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(4-fluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylazetidin-3-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(3,5-difluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2-methylbenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,4-difluorobenzoyl)azetidin-3-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3R)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,3,4-oxadiazol-2-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropyl)-1H-imidazol-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[5-(2,2-dimethylpropyl)-1,2,4-oxadiazol-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- tert-butyl 4-(5-{[1-(pyridazin-3-yl)azetidin-3-yl]carbamoyl}thiophen-2-yl)piperidine-1-carboxylate;
- tert-butyl 4-fluoro-4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidine-1-carboxylate;
- 5-(1-benzoylpiperidin-4-yl)-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2-methylbenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[3-cyclopropyl-1-(2-hydroxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- 1-(6-fluoropyridazin-3-yl)-N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide;
- N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-benzoylpyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[(3S)-1-(2,2-dimethylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- (3S)—N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- N-{4-[8-(2-methylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 1-(pyridazin-3-yl)-N-{4-[8-(4,4,4-trifluorobutanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}azetidine-3-carboxamide;
- N-[4-(8-benzoyl-8-azabicyclo[3.2.1]oct-3-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2-fluorobenzoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[8-(2,2-dimethylpropanoyl)-8-azabicyclo[3.2.1]oct-3-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(4-{8-[(1-methylcyclopropyl)carbonyl]-8-azabicyclo[3.2.1]oct-3-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2-methoxyethyl)-3-(2-methylpropyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-fluoropiperidine-1-carboxylate;
- benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-hydroxypiperidine-1-carboxylate;
- N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]thiophene-2-carboxamide;
- 5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide;
- N-{4-[4-fluoro-1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-(2-fluoro-4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoyl-4-fluoropiperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)-4-fluoropiperidin-4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-[4-(1-butyl-3-tert-butyl-1H-pyrazol-5-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{4-[3-tert-butyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazol-5-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-fluorophenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- N-{2-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide;
- (3S)—N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide;
- (3S)—N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamide; and pharmaceutically acceptable salts thereof.
- Another embodiment comprises pharmaceutical compositions comprising a compound having Formula (I) and an excipient.
- Still another embodiment comprises methods of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having Formula (I).
- Still another embodiment pertains to compositions for treating diseases during which NAMPT is expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).
- Still another embodiment pertains to methods of treating disease in a patient during which NAMPT is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).
- Still another embodiment pertains to compositions for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).
- Still another embodiment pertains to methods of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).
- Still another embodiment pertains to compositions for treating diseases during which NAMPT is expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
- Still another embodiment pertains to methods of treating disease in a patient during which NAMPT is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
- Still another embodiment pertains to compositions for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
- Still another embodiment pertains to methods of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said methods comprising administering to the patient a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
- Metabolites of compounds having Formula (I), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with NAMPT.
- Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having Formula (I) may also have utility for treating diseases associated with NAMPT.
- Compounds having Formula (I) may exist as acid addition salts, basic addition salts or zwitterions. Salts of the compounds are prepared during isolation or following purification of the compounds. Acid addition salts of the compounds are those derived from the reaction of the compounds with an acid. For example, the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate, and undecanoate salts of the compounds are contemplated as being embraced by this invention. Basic addition salts of the compounds are those derived from the reaction of the compounds with the hydroxide, carbonate or bicarbonate of cations such as lithium, sodium, potassium, calcium, and magnesium.
- The compounds having Formula (I) may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperitoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally or vaginally.
- Therapeutically effective amounts of compounds having Formula (I) depend on the recipient of the treatment, the disorder being treated and the severity thereof, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the compound potency, its rate of clearance and whether or not another drug is co-administered. The amount of a compound of this invention having Formula (I) used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof.
- Compounds having Formula (I) may be administered with or without an excipient. Excipients include, for example, encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof.
- Excipients for preparation of compositions comprising a compound having Formula (I) to be administered orally in solid dosage form include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl cellulose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water, and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered ophthalmically or orally in liquid dosage forms include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered osmotically include, for example, chlorofluorohydrocarbons, ethanol, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered rectally or vaginally include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof.
- Compounds having Formula (I) are expected to be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, antivirals, aurora kinase inhibitors, apoptosis promoters (for example, Bcl-xL, Bcl-w and Bfl-1) inhibitors, activators of death receptor pathway, Bcr-Abl kinase inhibitors, BiTE (Bi-Specific T cell Engager) antibodies, antibody drug conjugates, biologic response modifiers, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, DVDs, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors, hormonal therapies, immunologicals, inhibitors of inhibitors of apoptosis proteins (IAPs), intercalating antibiotics, kinase inhibitors, kinesin inhibitors, Jak2 inhibitors, mammalian target of rapamycin inhibitors, microRNA's, mitogen-activated extracellular signal-regulated kinase inhibitors, multivalent binding proteins, non-steroidal anti-inflammatory drugs (NSAIDs), poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, proteosome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, small inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors, ubiquitin ligase inhibitors, and the like, and in combination with one or more of these agents.
- BiTE antibodies are bi-specific antibodies that direct T-cells to attack cancer cells by simultaneously binding the two cells. The T-cell then attacks the target cancer cell. Examples of BiTE antibodies include adecatumumab (Micromet MT201), blinatumomab (Micromet MT103) and the like. Without being limited by theory, one of the mechanisms by which T-cells elicit apoptosis of the target cancer cell is by exocytosis of cytolytic granule components, which include perforin and granzyme B.
- SiRNAs are molecules having endogenous RNA bases or chemically modified nucleotides. The modifications do not abolish cellular activity, but rather impart increased stability and/or increased cellular potency. Examples of chemical modifications include phosphorothioate groups, 2′-deoxynucleotide, 2′-OCH3-containing ribonucleotides, 2′-F-ribonucleotides, 2′-methoxyethyl ribonucleotides, combinations thereof and the like. The siRNA can have varying lengths (e.g., 10-200 bps) and structures (e.g., hairpins, single/double strands, bulges, nicks/gaps, mismatches) and are processed in cells to provide active gene silencing. A double-stranded siRNA (dsRNA) can have the same number of nucleotides on each strand (blunt ends) or asymmetric ends (overhangs). The overhang of 1-2 nucleotides can be present on the sense and/or the antisense strand, as well as present on the 5′- and/or the 3′-ends of a given strand.
- Multivalent binding proteins are binding proteins comprising two or more antigen binding sites. Multivalent binding proteins are engineered to have the three or more antigen binding sites and are generally not naturally occurring antibodies. The term “multispecific binding protein” means a binding protein capable of binding two or more related or unrelated targets. Dual variable domain (DVD) binding proteins are tetravalent or multivalent binding proteins binding proteins comprising two or more antigen binding sites. Such DVDs may be monospecific (i.e., capable of binding one antigen) or multispecific (i.e., capable of binding two or more antigens). DVD binding proteins comprising two heavy chain DVD polypeptides and two light chain DVD polypeptides are referred to as DVD Ig's. Each half of a DVD Ig comprises a heavy chain DVD polypeptide, a light chain DVD polypeptide, and two antigen binding sites. Each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen binding per antigen binding site.
- Alkylating agents include altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, CLORETAZINE® (laromustine, VNP 40101M), cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, TREANDA® (bendamustine), treosulfan, trofosfamide and the like.
- Angiogenesis inhibitors include endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogs, vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors and the like.
- Antimetabolites include ALIMTA® (pemetrexed disodium, LY231514, MTA), 5-azacitidine, XELODA® (capecitabine), carmofur, LEUSTAT® (cladribine), clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide), enocitabine, ethnylcytidine, fludarabine, 5-fluorouracil alone or in combination with leucovorin, GEMZAR® (gemcitabine), hydroxyurea, ALKERAN®(melphalan), mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosfate, pelitrexol, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, UFT and the like.
- Antivirals include ritonavir, hydroxychloroquine and the like.
- Aurora kinase inhibitors include ABT-348, AZD-1152, MLN-8054, VX-680, Aurora A-specific kinase inhibitors, Aurora B-specific kinase inhibitors and pan-Aurora kinase inhibitors and the like.
- Bcl-2 protein inhibitors include AT-101 ((−)gossypol), GENASENSE® (G3139 or oblimersen (Bcl-2-targeting antisense oligonucleotide)), IPI-194, IPI-565, N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263), GX-070 (obatoclax) and the like. Bcr-Abl kinase inhibitors include DASATINIB® (BMS-354825), GLEEVEC® (imatinib) and the like.
- CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.
- COX-2 inhibitors include ABT-963, ARCOXIA® (etoricoxib), BEXTRA® (valdecoxib), BMS347070, CELEBREX® (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX® (deracoxib), JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX® (rofecoxib) and the like.
- EGFR inhibitors include ABX-EGF, anti-EGFR immunoliposomes, EGF-vaccine, EMD-7200, ERBITUX® (cetuximab), HR3, IgA antibodies, IRESSA® (gefitinib), TARCEVA® (erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB® (lapatinib) and the like.
- ErbB2 receptor inhibitors include CP-724-714, CI-1033 (canertinib), HERCEPTIN® (trastuzumab), TYKERB® (lapatinib), OMNITARG® (2C4, petuzumab), TAK-165, GW-572016 (ionafarnib), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB AR-209, mAB 2B-1 and the like.
- Histone deacetylase inhibitors include depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproic acid and the like.
- HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB® (human recombinant antibody to HSP-90), NCS-683664, PU24FC1, PU-3, radicicol, SNX-2112, STA-9090 VER49009 and the like.
- Inhibitors of inhibitors of apoptosis proteins include HGS 1029, GDC-0145, GDC-0152, LCL-161, LBW-242 and the like.
- Antibody drug conjugates include anti-CD22-MC-MMAF, anti-CD22-MC-MMAE, anti-CD22-MCC-DM1, CR-011-vcMMAE, PSMA-ADC, MEDI-547, SGN-19Am SGN-35, SGN-75 and the like
- Activators of death receptor pathway include TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., DR4 and DR5) such as Apomab, conatumumab, ETR2-ST01, GDC0145 (lexatumumab), HGS-1029, LBY-135, PRO-1762 and trastuzumab.
- Kinesin inhibitors include Eg5 inhibitors such as AZD4877, ARRY-520; CENPE inhibitors such as GSK923295A and the like.
- JAK-2 inhibitors include CEP-701 (lesaurtinib), XL019 and 1NCB018424 and the like.
- MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like.
- mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1/TORC2 inhibitors, including PI-103, PP242, PP30, Torin 1 and the like.
- Non-steroidal anti-inflammatory drugs include AMIGESIC® (salsalate), DOLOBID® (diflunisal), MOTRIN® (ibuprofen), ORUDIS® (ketoprofen), RELAFEN® (nabumetone), FELDENE® (piroxicam), ibuprofen cream, ALEVE® (naproxen) and NAPROSYN® (naproxen), VOLTAREN® (diclofenac), INDOCIN® (indomethacin), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE® (etodolac), TORADOL® (ketorolac), DAYPRO® (oxaprozin) and the like.
- PDGFR inhibitors include C-451, CP-673, CP-868596 and the like.
- Platinum chemotherapeutics include cisplatin, ELOXATIN® (oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN® (carboplatin), satraplatin, picoplatin and the like.
- Polo-like kinase inhibitors include BI-2536 and the like.
- Phosphoinositide-3 kinase (PI3K) inhibitors include wortmannin, LY294002, XL-147, CAL-120, ONC-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, XL765 and the like.
- Thrombospondin analogs include ABT-510, ABT-567, ABT-898, TSP-1 and the like.
- VEGFR inhibitors include AVASTIN® (bevacizumab), ABT-869, AEE-788, ANGIOZYME™ (a ribozyme that inhibits angiogenesis (Ribozyme Pharmaceuticals (Boulder, Colo.) and Chiron, (Emeryville, Calif.)), axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, MACUGEN (pegaptamib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), vatalanib (PTK-787, ZK-222584), SUTENT® (sunitinib, SU-11248), VEGF trap, ZACTIMA™ (vandetanib, ZD-6474) and the like.
- Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE® (bleomycin), daunorubicin, CAELYX® or MYOCET® (liposomal doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS® (idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, VALSTAR® (valrubicin), zinostatin and the like.
- Topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, CAMPTOSAR® (irinotecan hydrochloride), camptothecin, CARDIOXANE® (dexrazoxine), diflomotecan, edotecarin, ELLENCE® or PHARMORUBICIN® (epirubicin), etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan and the like.
- Antibodies include AVASTIN® (bevacizumab), CD40-specific antibodies, chTNT-1/B, denosumab, ERBITUX® (cetuximab), HUMAX-CD4® (zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX® (edrecolomab), RENCAREX® (WX G250), RITUXAN® (rituximab), ticilimumab, trastuzimab, CD20 antibodies types I and II and the like.
- Hormonal therapies include ARIMIDEX® (anastrozole), AROMASIN® (exemestane), arzoxifene, CASODEX® (bicalutamide), CETROTIDE® (cetrorelix), degarelix, deslorelin, DESOPAN® (trilostane), dexamethasone, DROGENIL® (flutamide), EVISTA® (raloxifene), AFEMA™ (fadrozole), FARESTON® (toremifene), FASLODEX® (fulvestrant), FEMARA® (letrozole), formestane, glucocorticoids, HECTOROL® (doxercalciferol), RENAGEL® (sevelamer carbonate), lasofoxifene, leuprolide acetate, MEGACE® (megesterol), MIFEPREX® (mifepristone), NILANDRON™ (nilutamide), NOLVADEX® (tamoxifen citrate), PLENAXIS™ (abarelix), prednisone, PROPECIA® (finasteride), rilostane, SUPREFACT® (buserelin), TRELSTAR® (luteinizing hormone releasing hormone (LHRH)), VANTAS® (Histrelin implant), VETORYL® (trilostane or modrastane), ZOLADEX® (fosrelin, goserelin) and the like.
- Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexacalcitrol (KH1060), fenretinide, PANRETIN® (aliretinoin), ATRAGEN® (liposomal tretinoin), TARGRETIN® (bexarotene), LGD-1550 and the like.
- PARP inhibitors include ABT-888 (veliparib), olaparib, KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, ONO-2231 and the like.
- Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like.
- Proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171 and the like.
- Examples of immunologicals include interferons and other immune-enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-la, ACTIMMUNE® (interferon gamma-1b) or interferon gamma-n1, combinations thereof and the like. Other agents include ALFAFERONE®, (IFN-α), BAM-002 (oxidized glutathione), BEROMUN® (tasonermin), BEXXAR® (tositumomab), CAMPATH® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE® (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010 (anti-CTLA-4), melanoma vaccine, mitumomab, molgramostim, MYLOTARG™ (gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OVAREX® (oregovomab), pemtumomab (Y-muHMFG1), PROVENGE® (sipuleucel-T), sargaramostim, sizofilan, teceleukin, THERACYS® (Bacillus Calmette-Guerin), ubenimex, VIRULIZIN® (immunotherapeutic, Lorus Pharmaceuticals), Z-100 (Specific Substance of Maruyama (SSM)), WF-10 (Tetrachlorodecaoxide (TCDO)), PROLEUKIN® (aldesleukin), ZADAXIN® (thymalfasin), ZENAPAX® (daclizumab), ZEVALIN® (90Y-Ibritumomab tiuxetan) and the like.
- Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth or differentiation of tissue cells to direct them to have anti-tumor activity and include krestin, lentinan, sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and the like.
- Pyrimidine analogs include cytarabine (ara C or Arabinoside C), cytosine arabinoside, doxifluridine, FLUDARA® (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR® (gemcitabine), TOMUDEX® (ratitrexed), TROXATYL™ (triacetyluridine troxacitabine) and the like.
- Purine analogs include LANVIS® (thioguanine) and PURI-NETHOL® (mercaptopurine).
- Antimitotic agents include batabulin, epothilone D (KOS-862), N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE® (docetaxel), PNU100940 (109881), patupilone, XRP-9881 (larotaxel), vinflunine, ZK-EPO (synthetic epothilone) and the like.
- Ubiquitin ligase inhibitors include MDM2 inhibitors, such as nutlins, NEDD8 inhibitors such as MLN4924 and the like.
- Compounds of this invention can also be used as radiosensitizers that enhance the efficacy of radiotherapy. Examples of radiotherapy include external beam radiotherapy, teletherapy, brachytherapy and sealed, unsealed source radiotherapy and the like.
- Additionally, compounds having Formula (I) may be combined with other chemotherapeutic agents such as ABRAXANE™ (ABI-007), ABT-100 (farnesyl transferase inhibitor), ADVEXIN® (Ad5CMV-p53 vaccine), ALTOCOR® or MEVACOR® (lovastatin), AMPLIGEN® (poly I:poly C12U, a synthetic RNA), APTOSYN® (exisulind), AREDIA® (pamidronic acid), arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE® (tazarotene), AVE-8062 (combreastatin derivative) BEC2 (mitumomab), cachectin or cachexin (tumor necrosis factor), canvaxin (vaccine), CEAVAC® (cancer vaccine), CELEUK® (celmoleukin), CEPLENE® (histamine dihydrochloride), CERVARIX® (human papillomavirus vaccine), CHOP® (C: CYTOXAN® (cyclophosphamide); H: ADRIAMYCIN® (hydroxydoxorubicin); O: Vincristine (ONCOVIN®); P: prednisone), CYPAT™ (cyproterone acetate), combrestatin A4P, DAB(389)EGF (catalytic and translocation domains of diphtheria toxin fused via a His-Ala linker to human epidermal growth factor) or TransMID-107R™ (diphtheria toxins), dacarbazine, dactinomycin, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), eniluracil, EVIZON™ (squalamine lactate), DIMERICINE® (T4N5 liposome lotion), discodermolide, DX-8951f (exatecan mesylate), enzastaurin, EP0906 (epithilone B), GARDASIL® (quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine), GASTRIMMUNE®, GENASENSE®, GMK (ganglioside conjugate vaccine), GVAX® (prostate cancer vaccine), halofuginone, histerelin, hydroxycarbamide, ibandronic acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-pseudomonas exotoxin, interferon-α, interferon-γ, JUNOVAN™ or MEPACT™ (mifamurtide), lonafarnib, 5,10-methylenetetrahydrofolate, miltefosine (hexadecylphosphocholine), NEOVASTAT®(AE-941), NEUTREXIN® (trimetrexate glucuronate), NIPENT® (pentostatin), ONCONASE® (a ribonuclease enzyme), ONCOPHAGE® (melanoma vaccine treatment), ONCOVAX® (IL-2 Vaccine), ORATHECIN™ (rubitecan), OSIDEM® (antibody-based cell drug), OVAREX® MAb (murine monoclonal antibody), paclitaxel, PANDIMEX™ (aglycone saponins from ginseng comprising 20(S)protopanaxadiol (aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab, PANVAC®-VF (investigational cancer vaccine), pegaspargase, PEG Interferon A, phenoxodiol, procarbazine, rebimastat, REMOVAB® (catumaxomab), REVLIMID® (lenalidomide), RSR13 (efaproxiral), SOMATULINE® LA (lanreotide), SORIATANE®(acitretin), staurosporine (Streptomyces staurospores), talabostat (PT100), TARGRETIN® (bexarotene), TAXOPREXIN® (DHA-paclitaxel), TELCYTA® (canfosfamide, TLK286), temilifene, TEMODAR® (temozolomide), tesmilifene, thalidomide, THERATOPE® (STn-KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline dihydrochloride), TNFERADE™ (adenovector: DNA carrier containing the gene for tumor necrosis factor-α), TRACLEER® or ZAVESCA® (bosentan), tretinoin (Retin-A), tetrandrine, TRISENOX® (arsenic trioxide), VIRULIZIN®, ukrain (derivative of alkaloids from the greater celandine plant), vitaxin (anti-alphavbeta3 antibody), XCYTRIN® (motexafin gadolinium), XINLAY™ (atrasentan), XYOTAX™ (paclitaxel poliglumex), YONDELIS® (trabectedin), ZD-6126, ZINECARD® (dexrazoxane), ZOMETA® (zolendronic acid), zorubicin and the like.
- Determination of the utility of compounds having Formula (I) as binders to and inhibitors of NAMPT was performed using Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) binding assays.
- Test compounds were serially diluted (typically 11 half log dilutions) in neat DMSO to 50× final concentrations prior to dilution with assay buffer (50 mM HEPES (NaOH), pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, 1% Glycerol) to 3× and 6% DMSO. Six μL were transferred to 384-well low-volume plates (Owens Corning #3673). To this, 12 μL of a 1.5× solution containing enzyme, probe and antibody were added. Final concentrations in the 18 μL reactions were 1× assay buffer, 2% DMSO, 6.8 nM NAMPT (human, recombinant, C-terminally His-tagged), 200 nM probe (a potent nicotinamide-competitive inhibitor conjugated to Oregon Green 488) and 1 nM Tb-anti-His antibody (Invitrogen # PV5895). Reactions were equilibrated at room temperature for 3 hours prior to reading on an Envision multi-label plate reader (Perkin Elmer; Ex=337 nm, Em=520 and 495 nm). Time-resolved FRET ratios (Em520/Em495) were normalized to controls, plotted as a function of compound concentration and fit with the four-parameter logistic equation to determine IC50s.
- Compound handling and data processing were identical to the assay in the absence of substrates (above). Final concentrations were 1× assay buffer, 2% DMSO, 2 nM NAMPT, 2 nM probe, 1 nM Tb-anti-His antibody (Invitrogen # PV5895), 200 μM PRPP and 2.5 mM ATP. Reactions were equilibrated for 16 hours prior to measurement to allow for potential enzymatic modification of test compounds.
- Table 1 shows the utility of compounds having Formula I to functionally inhibit NAMPT.
-
TABLE 1 TR-FRET Binding- TR-FRET IC50 Binding- (with IC50 PRPP) Example (μM) (μM) 1 0.120000 0.000386 2 0.022300 0.020000 3 0.357000 0.019200 4 0.424000 0.024000 5 0.107000 0.010200 6 0.544000 0.002340 7 0.104000 0.084700 8 3.360000 0.005300 9 8.620000 0.017200 10 0.034500 0.000518 11 2.370000 0.001930 12 1.410000 0.002050 13 0.858000 0.002880 14 3.840000 0.003080 15 1.660000 0.002490 16 2.480000 0.004130 17 3.510000 0.002360 18 2.740000 0.005320 19 1.170000 0.000554 20 0.006740 0.000296 21 7.380000 0.000507 22 0.011700 0.000169 23 1.950000 0.000610 24 5.880000 0.000861 25 0.028100 0.000598 26 0.005050 0.000761 27 nd 0.011200 28 nd 0.002510 29 0.079800 0.016700 30 0.015000 0.000267 31 0.135000 0.000693 32 0.010200 0.000284 33 0.109000 0.000342 34 0.071400 0.000886 35 0.091600 0.000866 36 0.040100 0.000882 37 0.068900 0.000983 38 0.046500 0.000900 39 0.104000 0.001050 40 0.042800 0.000490 41 0.069200 0.000780 42 0.226000 0.002390 43 0.086500 0.000803 44 0.138000 0.001010 45 0.087300 0.001080 46 0.093400 0.001020 47 0.080500 0.001780 48 0.112000 0.000861 49 0.066100 0.001020 50 0.063500 0.001100 51 0.109000 0.001170 52 0.051000 0.000696 53 0.025600 0.000689 54 0.072100 0.000806 55 0.168000 0.002220 56 0.360000 0.000812 57 0.180000 0.001070 58 0.059500 0.000683 59 0.027900 0.000606 60 0.150000 0.001010 61 0.033700 0.000675 62 0.041600 0.000666 63 0.052700 0.000514 64 0.055200 0.000927 65 0.121000 0.000704 66 0.056600 0.000535 67 0.452000 0.000497 68 0.080600 0.000569 69 0.068600 0.000918 70 0.035700 0.000742 71 0.041200 0.014600 72 0.006540 0.007340 73 0.224000 0.071100 74 0.911000 0.000666 75 1.340000 0.000719 76 1.920000 0.000440 77 3.010000 0.000832 78 0.265000 0.000632 79 2.690000 0.000824 80 1.600000 0.000686 81 3.720000 0.001130 82 0.955000 0.000526 83 1.210000 0.000503 84 6.070000 0.001810 85 0.032200 0.017000 86 1.260000 0.000833 87 1.390000 0.001270 88 0.574000 0.000640 89 2.000000 0.000647 90 1.410000 0.000902 91 0.992000 0.000868 92 0.784000 0.000548 93 1.220000 0.001250 94 2.270000 0.001030 95 1.360000 0.001020 96 0.115000 0.282000 97 0.036600 0.131000 98 0.013000 0.000209 99 0.013500 0.000169 100 0.030600 0.000497 101 0.016500 0.000486 102 0.008840 0.000210 103 0.056200 0.000493 104 0.001200 0.000193 105 0.296000 0.000244 106 0.160000 0.000221 107 0.163000 0.000169 108 0.003330 0.000176 109 0.005030 0.000398 110 0.006630 0.000169 111 0.002840 0.000199 112 0.040200 0.000362 113 0.060600 0.000254 114 0.083900 0.000247 115 0.048200 0.000178 116 0.026500 0.000204 117 0.006270 0.000355 118 0.014100 0.000169 119 0.006120 0.000169 120 0.011600 0.000294 121 0.009940 0.000169 122 0.007940 0.000169 123 0.065600 0.000282 124 0.123000 0.000278 125 0.015400 0.000518 126 0.014900 0.000359 127 0.003640 0.000391 128 0.008360 0.000610 129 0.004490 0.000367 130 0.288000 0.000535 131 0.069900 0.000474 132 0.008460 0.000441 133 0.012000 0.000626 134 0.016900 0.000361 135 0.033900 0.000293 136 0.020400 0.000635 137 0.017600 0.000459 138 0.021800 0.000445 139 0.012000 0.000473 140 0.011000 0.008870 141 1.240000 0.075200 142 1.560000 0.032800 143 0.017000 0.031100 144 0.014600 0.034400 145 0.040600 0.058100 146 0.065900 0.109000 147 0.034600 0.001470 148 0.042900 0.020100 149 0.020700 0.054300 150 0.006530 0.043800 151 0.017400 0.043600 152 0.087600 0.101000 153 0.266000 0.122000 154 0.524000 0.016100 155 0.294000 0.044000 156 0.396000 0.084300 157 1.070000 0.192000 158 2.900000 0.224000 159 0.137000 0.061200 160 0.074500 0.070800 161 0.128000 0.059700 162 0.144000 0.071000 163 0.166000 0.083100 164 0.987000 0.124000 165 0.035200 0.068300 166 2.270000 0.206000 167 3.740000 0.204000 168 2.940000 0.171000 169 0.033700 0.067900 170 0.091500 0.089800 171 0.019700 0.037900 172 0.286000 0.170000 173 0.524000 0.154000 174 2.100000 0.158000 175 0.664000 0.161000 176 0.165000 0.111000 177 0.060400 0.091300 178 0.247000 0.065200 179 0.099200 0.070700 180 0.304000 0.123000 181 0.284000 0.128000 182 0.140000 0.104000 183 1.040000 0.185000 184 0.625000 0.078900 185 0.081300 0.044100 186 0.098900 0.118000 187 0.010200 0.027300 188 0.020500 0.049900 189 0.006910 0.026900 190 1.910000 0.103000 191 0.743000 0.184000 192 0.047300 0.072300 193 0.040200 0.054000 194 0.122000 0.062600 195 0.305000 0.094100 196 0.083800 0.098500 197 0.126000 0.079800 198 0.084500 0.103000 199 0.033700 0.028000 200 0.033100 0.034400 201 0.012100 0.018200 202 0.117000 0.089500 203 0.034200 0.021100 204 0.380000 0.002760 205 0.025100 0.034000 206 0.023800 0.024100 207 0.141000 0.086700 208 0.117000 0.049600 209 0.061700 0.028900 210 0.031700 0.038300 211 0.031900 0.000801 212 0.070400 0.000787 213 0.104000 0.000678 214 0.165000 0.000841 215 0.068200 0.001140 216 0.228000 0.001410 217 0.043900 0.001510 218 0.265000 0.001640 219 0.105000 0.000480 220 0.267000 0.001010 221 0.164000 0.000576 222 0.215000 0.001030 223 0.150000 0.000959 224 0.151000 0.001390 225 0.158000 0.001070 226 0.242000 0.000896 227 0.065900 0.000696 228 0.054600 0.000911 229 0.048000 0.000584 230 0.158000 0.000843 231 0.174000 0.000831 232 0.141000 0.000563 233 0.113000 0.000614 234 0.185000 0.000730 235 0.283000 0.001410 236 0.130000 0.001110 237 0.240000 0.001270 238 0.207000 0.000554 239 0.112000 0.000833 240 0.192000 0.000925 241 0.131000 0.000811 242 0.278000 0.001170 243 0.269000 0.000970 244 0.449000 0.000916 245 0.101000 0.000707 246 0.178000 0.000676 247 0.086000 0.001020 248 0.082600 0.000817 249 0.059900 0.000600 250 0.107000 0.000641 251 0.230000 0.000880 252 0.238000 0.001100 253 0.134000 0.000639 254 0.033900 0.011200 255 0.047300 0.037800 256 0.091100 0.038400 257 0.064700 0.041900 258 0.108000 0.034800 259 0.032500 0.017700 260 0.075400 0.019000 261 0.062900 0.023700 262 0.130000 0.034300 263 0.031300 0.020200 264 0.052800 0.013400 265 0.029500 0.021800 266 0.120000 0.053200 267 0.274000 0.056500 268 0.119000 0.042100 269 0.037700 0.022300 270 0.074800 0.035700 271 0.078000 0.025200 272 0.165000 0.052400 273 0.128000 0.042100 274 0.152000 0.064500 275 0.231000 0.045100 276 0.134000 0.034900 277 0.062400 0.026700 278 0.075800 0.033400 279 0.020200 0.015500 280 0.123000 0.051900 281 0.020500 0.014900 282 0.383000 0.090000 283 0.072300 0.032200 284 0.062400 0.038200 285 0.149000 0.086200 286 0.127000 0.066400 287 0.125000 0.063200 288 0.044900 0.019500 289 0.041600 0.032100 290 0.099300 0.045700 291 0.045600 0.018200 292 0.099000 0.064700 293 0.078200 0.025300 294 0.112000 0.055100 295 0.077600 0.051000 296 0.149000 0.057100 297 0.104000 0.047000 298 0.192000 0.061100 299 0.154000 0.086900 300 0.064200 0.039100 301 0.143000 0.048300 302 0.150000 0.048300 303 0.030900 0.015500 304 0.055400 0.024200 305 0.109000 0.035000 306 0.112000 0.046300 307 0.037700 0.015900 308 0.036900 0.018400 309 4.150000 0.000293 310 0.456000 0.005370 311 0.030200 0.003960 312 1.130000 0.008940 313 0.217000 0.004130 314 3.860000 0.000572 315 0.469000 0.000641 316 0.104000 0.000924 317 0.043900 0.000991 318 0.037700 0.000716 319 0.024900 0.000747 320 0.026400 0.000611 321 0.038700 0.000864 322 0.028600 0.000843 323 0.025300 0.000885 324 0.047300 0.001040 325 0.014000 0.001080 326 0.018300 0.000626 327 0.012600 0.000655 328 0.012200 0.000614 329 0.024200 0.000616 330 0.031700 0.000887 331 0.024900 0.000830 332 0.021900 0.000699 333 0.050900 0.000631 334 0.018200 0.000578 335 0.210000 0.001020 336 0.077300 0.000494 337 0.050000 0.000522 338 0.027600 0.000520 339 0.017900 0.000663 340 0.017600 0.000722 341 0.035100 0.000727 342 0.013100 0.000698 343 0.006180 0.000728 344 0.037800 0.000569 345 0.009540 0.000392 346 0.030800 0.000457 347 0.066200 0.000940 348 0.015300 0.000628 349 0.059500 0.000738 350 0.004620 0.000642 351 0.037100 0.000765 352 0.095800 0.000615 353 0.088200 0.000472 354 0.082800 0.000837 355 0.115000 0.000986 356 0.067700 0.000878 357 0.017700 0.001140 358 0.015900 0.000815 359 0.021300 0.000869 360 0.022000 0.000782 361 0.037400 0.000988 362 0.015200 0.000832 363 0.010400 0.000798 364 0.036900 0.000334 365 0.050100 0.001050 366 0.035100 0.000681 367 0.033700 0.000735 368 0.064000 0.000635 369 0.018300 0.000479 370 0.030535 0.000555 371 0.056700 0.000438 372 0.016600 0.000633 373 0.022400 0.000576 374 0.023900 0.000973 375 0.006720 0.000679 376 0.003220 0.000468 377 0.016200 0.000632 378 0.077100 0.000632 379 0.015900 0.000432 380 0.109000 0.000883 381 0.015100 0.001130 382 0.065800 0.000657 383 0.103000 0.000859 384 0.028800 0.000497 385 0.055100 0.001240 528 0.026200 0.017300 nd = no data - PC3 cells were seeded in 96-well black plates (Corning #3904) at 500 cells/well in 90 μl of RPMI media containing 10% heat-inactivated FBS and incubated overnight at 37° C. and 5% CO2 to allow cells to attach to wells. The following day, test compounds were serially diluted in neat DMSO to 1000× final concentrations prior to dilution with RPMI media to 10× and 1% DMSO. Ten μL of the 10× compounds were then transferred to wells containing cells to produce a dose response of 10-fold dilutions from 10 μM to 1×10−5 μM. Cells were incubated for 5 days at 37° C. and 5% CO2, then cell viability was measured using Cell Titer Glo reagent (Promega #G7571). Percent inhibition values were calculated and fitted to a sigmoidal dose response curves using Assay Explorer software to determine IC50s. To assess whether inhibition of cell viability was due to NAMPT inhibition, the proliferation assay was also performed in the presence of 0.3 mM nicotinamide mononucleotide.
- Table 2 shows the results of the cell proliferation assay.
-
TABLE 2 Cell Cell Titer- Titer- Glo- Glo- Ex- IC50 Ex- IC50 ample (μM) ample (μM) 1 0.00656 514 0.00032 2 >10 515 0.00085 3 7.33 516 0.00226 4 0.112 517 0.00921 5 0.00675 518 0.00087 6 0.0677 519 0.00321 7 0.876 520 0.00047 8 0.0708 521 0.00472 9 0.739 522 0.00078 10 0.00184 523 0.00099 11 0.0227 524 0.00573 12 0.0844 525 0.00093 13 0.0791 526 0.00094 14 0.0548 527 0.00778 15 0.0347 528 0.01923 16 0.0926 529 0.00933 17 0.0937 530 0.00202 18 0.148 531 0.0176 19 0.0564 532 0.00724 20 0.00028 533 0.0246 21 0.15 534 0.00546 22 0.00125 535 0.00939 23 0.0725 536 0.00614 24 0.169 537 0.0033 25 0.00141 538 0.0137 26 0.000682 539 0.00257 27 >10 540 0.00391 28 >10 541 0.0042 29 0.135 542 0.0676 30 0.00197 543 0.0077 31 0.0069 544 0.00717 32 0.00654 545 0.0152 33 0.00366 546 0.00141 34 0.0068 547 0.00302 35 0.00692 548 0.0649 36 0.00966 549 0.00067 37 0.00648 550 0.00821 38 0.00639 551 0.00048 39 0.00738 552 0.00332 40 0.00217 553 0.0441 41 0.00376 554 0.00263 42 0.0646 555 0.0239 43 0.00688 556 0.00598 44 0.00547 557 0.0102 45 0.00677 558 0.00066 46 0.00301 559 0.00133 47 0.00335 560 0.00585 48 0.00288 561 0.0622 49 0.00696 562 0.00945 50 0.00895 563 0.0242 51 0.00362 564 0.0792 52 0.00628 565 0.0741 53 0.00367 566 0.0822 54 0.00331 567 0.0765 55 0.0211 568 0.0482 56 0.00927 569 0.207 57 0.00875 570 0.631 58 0.00648 571 0.118 59 0.00614 572 0.0598 60 0.00507 573 0.0819 61 0.00352 574 0.0553 62 0.0142 575 0.269 63 0.00635 576 0.0848 64 0.00632 577 0.093 65 0.00638 578 0.0887 66 0.00581 579 0.267 67 0.386 580 0.078 68 0.00354 581 0.0807 69 0.00422 582 0.627 70 0.00397 583 0.0874 71 0.0729 584 0.0872 72 0.00569 585 0.283 73 1.98 586 0.107 74 0.0114 587 0.0814 75 nd 588 0.113 76 0.0191 589 0.0979 77 nd 590 0.0822 78 0.0212 591 0.0936 79 nd 592 0.62 80 0.0255 593 0.0634 81 nd 594 0.0478 82 0.00955 595 0.0806 83 nd 596 0.0846 84 0.0389 597 0.117 85 0.0205 598 0.208 86 0.0697 599 0.0797 87 0.0317 600 0.219 88 0.0663 601 0.0968 89 0.0646 602 0.002 90 0.0601 603 0.576 91 0.0599 604 8.26127 92 0.024 605 1.4 93 0.0584 606 0.0867 94 0.0657 607 7.65 95 0.0739 608 0.712 96 7.61 609 0.00205 97 0.922 610 0.0079 98 0.00605 611 0.09 99 0.00572 612 0.0536 100 0.00613 613 0.70691 101 0.00031 614 7.66 102 0.00059 615 6.15 103 0.00144 616 7.29 104 0.00018 617 1.87 105 0.00617 618 >10 106 0.0618 619 >10 107 0.00688 620 2.83 108 0.00013 621 >10 109 0.00066 622 >10 110 0.00026 623 6.17 111 0.00064 624 >10 112 0.00076 625 1.9 113 0.00634 626 5.22 114 0.0181 627 0.853 115 0.0004 628 >10 116 0.00064 629 5.01 117 0.00063 630 0.00812 118 0.00022 631 0.00958 119 0.00019 632 0.00881 120 0.00023 633 0.00895 121 0.00062 634 0.00922 122 0.00061 635 0.0416 123 0.00103 636 0.0828 124 0.00144 637 0.00124 125 0.00024 638 0.0299 126 0.00026 639 0.00816 127 0.00014 640 0.00292 128 0.00016 641 0.0726 129 0.00016 642 0.00726 130 0.00181 643 0.00846 131 0.0003 644 0.00823 132 0.00023 645 0.0033 133 0.00062 646 0.0587 134 0.00064 647 0.00573 135 0.0003 648 0.0268 136 0.00023 649 0.00111 137 0.00031 650 0.0869 138 0.00023 651 0.0276 139 0.00018 652 0.00614 140 0.00354 653 0.00972 141 0.834 654 0.00276 142 0.7406 655 0.000475 143 0.00496 656 0.061 144 0.0184 657 0.00844 145 0.0709 658 0.0144 146 0.0707 659 0.0112 147 0.00095 660 0.00523 148 0.0761 661 0.0216 149 0.058 662 0.0159 150 0.0589 663 0.0316 151 0.0609 664 1.15 152 0.116 665 7.62 153 0.699 666 0.008059 154 0.803 667 0.01248 155 0.701 668 >10 156 0.712 669 0.00188 157 0.948 670 0.00853 158 1.3 671 0.00853 159 0.182 672 0.00405 160 0.173 673 0.0116 161 0.213 674 0.00572 162 0.225 675 0.0693 163 0.12 676 0.00202 164 0.202 677 0.0093 165 0.0682 678 0.00609 166 1.07 679 0.0006 167 6.25 680 0.00355 168 1.01 681 0.00902 169 0.0654 682 0.00273 170 0.0655 683 0.00902 171 0.0681 684 0.0766 172 0.329 685 0.00828 173 0.627 686 0.0649 174 1.13 687 0.00611 175 0.683 688 0.0094 176 0.218 689 0.00968 177 0.107 690 0.00314 178 0.3 691 0.03 179 0.192 692 0.00423 180 0.164 693 0.0136 181 0.238 694 0.0716 182 0.0879 695 0.00616 183 0.346 696 0.00467 184 0.604 697 0.00596 185 0.0742 698 0.0679 186 0.627 699 0.065 187 0.0206 700 0.00876 188 0.0224 701 0.0752 189 0.0146 702 0.00207 190 0.694 703 0.00843 191 0.677 704 0.0053 192 0.0693 705 0.0202 193 0.071 706 0.0077 194 0.124 707 0.00693 195 0.701 708 0.0142 196 0.111 709 0.0145 197 0.103 710 0.0103 198 0.0716 711 0.0595 199 0.0974 712 0.00679 200 0.0719 713 0.00999 201 0.0609 714 0.0176 202 0.168 715 0.0118 203 0.606 716 0.0692 204 0.0245 717 0.0121 205 0.0387 718 0.00627 206 0.0674 719 0.00963 207 0.671 720 0.00857 208 0.593 721 0.00839 209 0.0816 722 0.0848 210 0.0627 723 0.003507 211 0.00594 724 0.0809 212 0.00579 725 0.00401 213 0.00688 726 0.0327 214 0.00909 727 0.0046 215 0.00695 728 0.00697 216 0.00599 729 0.0135 217 0.00255 730 0.00681 218 0.00886 731 0.00050 219 0.00886 732 0.0299 220 0.0132 733 0.0375 221 0.00899 734 0.00833 222 0.0155 735 0.0689 223 0.0055 736 0.00809 224 0.00752 737 1.86 225 0.00876 738 0.853926 226 0.00889 739 7.31 227 0.00453 740 0.914369 228 0.00597 741 0.181262 229 0.00646 742 0.734 230 0.00905 743 6.62 231 0.00875 744 2.72 232 0.00874 745 >10 233 0.00873 746 >10 234 0.0105 747 5.92 235 0.0124 748 0.00258 236 0.00925 749 >10 237 0.0103 750 0.226 238 0.0157 751 0.00271 239 0.0067 752 2.45 240 0.0103 753 0.00892 241 0.00773 754 0.0948 242 0.00906 755 0.19 243 0.00928 756 0.00908 244 0.0104 757 0.0677 245 0.00706 758 0.857 246 0.00965 759 0.0062 247 0.00798 760 0.253 248 0.00658 761 0.0923 249 0.00235 762 0.709 250 0.00911 763 0.00841 251 0.00787 764 0.022126 252 0.00951 765 1.02 253 0.00809 766 0.787 254 0.012 767 1.28 255 0.0241 768 0.111 256 0.145 769 0.0186 257 0.0761 770 0.138 258 0.309 771 0.0699 259 0.0726 772 0.0636 260 0.0746 773 0.0857 261 0.0715 774 0.00252 262 0.119 775 0.00215 263 0.0595 776 0.00764 264 0.1 777 0.0192 265 0.0701 778 0.0197 266 0.083 779 0.00148 267 0.622 780 0.00407 268 0.0829 781 0.01 269 0.0604 782 0.0669 270 0.0627 783 0.00646 271 0.0515 784 0.016 272 0.0795 785 0.00117 273 0.634 786 0.012 274 0.107 787 0.0639 275 0.683 788 0.00759 276 0.13 789 0.0284 277 0.0731 790 0.0746 278 0.0791 791 0.00748 279 0.00972 792 0.0088 280 0.0719 793 0.329 281 0.0169 794 0.196 282 0.629 795 0.773 283 0.0725 796 0.0117 284 0.0666 797 0.0126 285 0.0692 798 0.0664 286 0.074 799 0.0255 287 0.121 800 0.06 288 0.0248 801 0.024555 289 0.0532 802 0.0263 290 0.0807 803 0.00161 291 0.0736 804 0.00792 292 0.0934 805 0.065 293 0.0723 806 0.00313 294 0.0832 807 0.00415 295 0.0715 808 0.0411 296 0.0689 809 0.0024 297 0.0932 810 0.0611 298 0.0979 811 0.011 299 0.0846 812 0.0102 300 0.0259 813 0.0786 301 0.0905 814 0.0819 302 0.0824 815 0.185 303 0.0586 816 0.188 304 0.0332 817 0.0641 305 0.102 818 0.0294 306 0.0347 819 0.00856 307 0.0208 820 0.0754 308 0.0614 821 0.165 309 8.2 822 0.0605 310 0.0161 823 0.247 311 0.0029 824 0.0706 312 0.0217 825 0.0623 313 0.00603 826 0.0983 314 0.621 827 0.0737 315 0.0868 828 0.000826 316 0.00312 829 0.00295 317 0.00183 830 0.00796 318 0.00272 831 0.00725 319 0.00124 832 0.0167 320 0.00237 833 0.00667 321 0.00321 834 0.0144 322 0.00214 835 0.00235 323 0.00281 836 0.658 324 0.00708 837 0.769 325 0.00128 838 1.77 326 0.00577 839 2 327 0.00123 840 0.0028 328 0.00159 841 0.00355 329 0.00283 842 0.000665 330 0.00138 843 0.00061 331 0.00209 844 0.00252 332 0.00099 845 0.00209 333 0.00568 846 0.00724 334 0.00097 847 0.115 335 0.00607 848 0.609 336 0.00826 849 0.685 337 0.00694 850 0.0705 338 0.00111 851 0.00275 339 0.00183 852 0.0124 340 0.00242 853 >10 341 0.00198 854 >10 342 0.0023 855 0.747 343 0.00653 856 0.729 344 0.0089 857 0.00252 345 0.00199 858 0.00436 346 0.0038 859 0.0027 347 0.00806 860 0.01 348 0.002 861 0.00758 349 0.00728 862 0.00849 350 0.00075 863 0.00567 351 0.00236 864 0.00529 352 0.00888 865 0.00406 353 0.00715 866 0.00792 354 0.00751 867 0.00784 355 0.00979 868 0.00229 356 0.00909 869 0.00198 357 0.00147 870 0.0032 358 0.00186 871 0.00361 359 0.00177 872 0.0236 360 0.00235 873 0.675 361 0.00277 874 0.0711 362 0.00261 875 >10 363 0.0056 876 0.0292 364 0.00863 877 0.02960 365 0.00784 878 0.0706 366 0.00657 879 0.00583 367 0.00638 880 0.01540 368 0.0077 881 0.00818 369 0.00214 882 0.00643 370 0.00879 883 0.0309 371 0.00894 884 0.00275 372 0.00706 885 0.00163 373 0.00595 886 0.00766 374 0.00632 887 0.00847 375 0.00087 888 0.00976 376 0.00062 889 0.00285 377 0.00213 890 0.00409 378 0.00709 891 0.0656 379 0.00107 892 0.146 380 0.00757 893 0.681 381 0.00187 894 0.752 382 0.00899 895 0.00215 383 0.0627 896 0.00109 384 0.00827 897 0.00156 385 0.0232 898 .000851 386 0.00318 899 .000401 387 0.0022 900 0.00224 388 0.00088 901 0.00207 389 0.00717 902 0.00645 390 0.0015 903 .000618 391 0.00599 904 0.00195 392 0.00354 905 0.0133 393 0.00372 906 .000879 394 0.00199 907 6.75 395 0.00214 908 0.0925 396 0.06848 909 0.067 397 0.00335 910 0.00651 398 0.00819 911 >10 399 0.00635 912 0.0642 400 0.0068 913 0.0663 401 0.00854 914 0.0027 402 0.00168 915 0.139 403 0.0041 916 0.646 404 0.0027 917 0.101 405 0.00675 918 0.717 406 0.00742 919 0.0519 407 0.00101 920 0.00543 408 0.0299 921 0.0029 409 0.00672 922 0.00338 410 0.00868 923 0.0694 411 0.00715 924 0.00117 412 0.00137 925 0.0101 413 0.01 926 0.602 414 0.0074 927 0.0039 415 0.00228 928 0.00256 416 0.00112 929 0.0271 417 0.00645 930 0.0027 418 0.00826 931 0.00317 419 0.00217 932 0.00582 420 0.00235 933 0.00239 421 0.00372 934 0.00245 422 0.00112 935 0.002 423 0.00038 936 0.00218 424 0.0015 937 0.00262 425 0.00091 938 0.00875 426 0.00207 939 0.00296 427 0.00203 940 0.00197 428 0.00019 941 0.0021 429 0.0008 942 0.00276 430 0.00142 943 0.0076 431 0.00167 944 0.00714 432 0.008 945 0.00451 433 0.00577 946 0.00289 434 0.00635 947 0.00256 435 0.0003 948 0.00226 436 0.00067 949 0.00595 437 0.00098 950 0.00606 438 0.00196 951 0.00277 439 0.00336 952 0.00217 440 0.0018 953 0.00334 441 0.00683 954 0.00638 442 0.00625 955 0.00597 443 0.00565 956 0.00640 444 0.078 957 0.00193 445 0.0191 958 0.00263 446 0.108 959 0.00233 447 0.903 960 0.00286 448 0.00932 961 0.00557 449 0.678 962 0.0024 450 0.0509 963 0.00214 451 0.0868 964 0.00184 452 0.0632 965 0.00260 453 0.105 966 0.00323 454 0.106 967 0.00305 455 0.458 968 0.0037 456 0.0395 969 .000347 457 0.142 970 0.0285 458 0.0644 971 0.0708 459 0.0369 972 0.667 460 0.223 973 0.00553 461 0.646 974 0.00784 462 0.214 975 0.098 463 0.0709 976 0.0612 464 0.0659 977 0.0124 465 0.616 978 1.07 466 0.00807 979 0.072 467 0.0156 980 0.0822 468 0.73 981 1.06 469 0.00861 982 0.0835 470 0.715 983 0.604 471 0.072 984 0.696 472 0.00656 985 0.635 473 0.0093 986 7.47 474 0.0685 987 0.609 475 0.594 988 1.24 476 0.0174 989 0.602 477 0.235 990 6.81 478 0.0143 991 0.76 479 0.0689 992 1.51 480 0.00424 993 0.809 481 0.0121 994 0.059 482 0.0326 995 0.245 483 0.00214 996 0.104 484 0.00056 997 0.0935 485 0.00635 998 1.28 486 0.00624 999 0.25 487 0.072 1000 0.077 488 0.0642 1001 0.0532 489 0.00207 1002 0.911 490 0.00068 1003 1.07 491 0.00845 1004 7.92 492 0.00373 1005 0.592 493 0.00673 1006 0.00536 494 0.00105 1007 0.0567 495 0.00706 1008 0.299 496 0.0063 1009 0.0818 497 0.0234 1010 0.0709 498 0.00664 1011 0.113 499 0.0121 1012 0.782 500 0.00102 1013 0.213 501 0.00607 1014 0.219 502 0.00474 1015 0.0901 503 0.0582 1016 0.212 504 0.00775 1017 0.752 505 0.00684 1018 0.716 506 0.00128 1019 2.46 507 0.00834 1020 7.27 508 0.00079 1021 0.0477 509 0.00119 1022 8.16 510 0.0664 1023 0.508 511 0.00082 1024 nd 512 0.0155 1025 nd 513 0.0035 nd = no data - Compounds which inhibit NAMPT are useful for treating diseases in which activation of NF-KB is implicated. Such methods are useful in the treatment of a variety of diseases including inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukaemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia.
- Involvement of NAMPT in the treatment of cancer is described in WO 97/48696. Involvement of NAMPT in immuno-supression is described in WO 97/48397. Involvement of NAMPT for the treatment of diseases involving angiogenesis is described in WO 2003/80054. Involvement of NAMPT for the treatment of rheumatoid arthritis and septic shock is described in WO 2008/025857. Involvement of NAMPT for the prophlaxis and treatment of ischaemia is described in WO 2009/109610.
- Cancers include, but are not limited to, hematologic and solid tumor types such as acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer (including estrogen-receptor positive breast cancer), bronchogenic carcinoma, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, gastric carcinoma, germ cell testicular cancer, gestational trophobalstic disease, glioblastoma, head and neck cancer, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer (including small cell lung cancer and non-small cell lung cancer), lymphangioendothelio-sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, peripheral T-cell lymphoma, pinealoma, polycythemia vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, testicular cancer (including germ cell testicular cancer), thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer, Wilms' tumor and the like.
- The following abbreviations have the meanings indicated. ADDP means 1,1′-(azodicarbonyl)dipiperidine; AD-mix-β means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2CO3, and K2SO4; 9-BBN means 9-borabicyclo(3.3.1)nonane; Boc means tert-butoxycarbonyl; (DHQD)2PHAL means hydroquinidine 1,4-phthalazinediyl diethyl ether; DBU means 1,8-diazabicyclo[5.4.0]undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DMF means N,N-dimethylformamide; dmpe means 1,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means 1,4-bis(diphenylphosphino)-butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1′-bis(diphenylphosphino)ferrocene; dppm means 1,1-bis(diphenylphosphino)methane; EDAC HCl means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Fmoc means fluorenylmethoxycarbonyl; HATU means O-(7-azabenzotriazol-1-yl)-N,N′N′N′-tetramethyluronium hexafluorophosphate; HMPA means hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH3 means macroporous triethylammonium methylpolystyrene cyanoborohydride; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh3 means triphenylphosphine.
- The following schemes are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. Compounds of this invention may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties may be protected and deprotected, as necessary.
-
- As shown in Scheme 1, compounds of formula (1), wherein R2 is as described herein, can be reacted with acids of formula (2); wherein PG is a suitable protecting group and n is 1, 2, or 3, in the presence of a base such as but not limited to diisopropylethylamine, to provide compounds of formula (3). The reaction may involve the use of a carboxyl activating agent such as but not limited to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and a ester activating agent such as but not limited to 1-hydroxybenzotriazole hydrate. The reaction is typically performed at ambient temperature in a solvent such as but not limited to N,N-dimethylformamide, N,N-dimethylacetamide, or mixtures thereof. Compounds of formula (4) can be prepared from compounds of formula (3) after removal of the suitable protecting group using standard reaction conditions known to those skilled in the art and readily available in the literature. Compounds of formula (5), wherein X1, X2, and R1 are as described herein and X is an appropriate halide, can be reacted with compounds of formula (4) to provide compounds of formula (6) which are representative of compounds of Formula (I). This C—N cross coupling reaction typically employs a base such as but not limited to cesium carbonate, a palladium catalyst such as but not limited to bis(dibenzylideneacetone)palladium(0), and a ligand such as but not limited to (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine). The reaction is typically performed at an elevated temperature in a solvent such as but not limited to dioxane.
- tert-Butyl 4-(4-aminophenoxy)piperidine-1-carboxylate can be reacted with acids of formula (7); wherein n is 1, 2, or 3, in the presence of a base such as but not limited to diisopropylethylamine; to provide compounds of formula (8). The reaction may involve the use of a carboxyl activating agent such as but not limited to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and a ester activating agent such as but not limited to 1-hydroxybenzotriazole hydrate. The reaction is typically performed at ambient temperature in a solvent such as but not limited to N,N-dimethylformamide, N,N-dimethylacetamide, or mixtures thereof. Compounds of formula (9) can be prepared from compounds of formula (8) by reacting the latter with hydrogen in the presence of palladium hydroxide. The reaction is typically performed at ambient temperature in a solvent such as but not limited to tetrahydrofuran. Compounds of formula (5), wherein X1, X2, and R1 are as described herein and X is an appropriate halide, can be reacted with compounds of formula (9) to provide compounds of formula (10). The C—N cross coupling reaction typically employs a base such as but not limited to cesium carbonate, a palladium catalyst such as but not limited to bis(dibenzylideneacetone)palladium(0), and a ligand such as but not limited to (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine). The reaction is typically performed at an elevated temperature in a solvent such as but not limited to dioxane. Compounds of formula (11) can be prepared by treating compounds of formula (10) with an acid such as but not limited to trifluoroacetic acid in a solvent such as but not limited to dichloromethane. Compounds of formula (13), which are representative of compounds of Formula (I), can be prepared by reacting compounds of formula (11) with compounds of formula (12), wherein R10 is as described herein, in the presence of a base such as but not limited to diisopropylethylamine. The reaction may involve the use of a carboxyl activating agent such as but not limited to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and a ester activating agent such as but not limited to 1-hydroxybenzotriazole hydrate. The reaction is typically performed at ambient temperature in a solvent such as but not limited to N,N-dimethylformamide, N,N-dimethylacetamide, or mixtures thereof.
- As shown in Scheme 3, tert-Butyl 4-(4-aminophenyl)piperidine-1-carboxylate can be reacted with acids of formula (7); wherein n is 1, 2, or 3, in the presence of a base such as but not limited to diisopropylethylamine; to provide compounds of formula (14). The reaction may involve the use of a carboxyl activating agent such as but not limited to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and a ester activating agent such as but not limited to 1-hydroxybenzotriazole hydrate. The reaction is typically performed at ambient temperature in a solvent such as but not limited to N,N-dimethylformamide, N,N-dimethylacetamide, or mixtures thereof. Compounds of formula (15) can be prepared from compounds of formula (14) by reacting the latter with hydrogen in the presence of palladium hydroxide. The reaction is typically performed at ambient temperature in a solvent such as but not limited to tetrahydrofuran. Compounds of formula (5), wherein X1, X2, and R1 are as described herein and X is an appropriate halide, can be reacted with compounds of formula (15) to provide compounds of formula (16). The C—N cross coupling reaction typically employs a base such as but not limited to cesium carbonate, a palladium catalyst such as but not limited to bis(dibenzylideneacetone)palladium(0), and a ligand such as but not limited to (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine). The reaction is typically performed at an elevated temperature in a solvent such as but not limited to dioxane. Compounds of formula (17) can be prepared by treating compounds of formula (16) with an acid such as but not limited to trifluoroacetic acid in a solvent such as but not limited to dichloromethane. Compounds of formula (18), which are representative of compounds of Formula (I), can be prepared by reacting compounds of formula (17) with compounds of formula (12), wherein R10 is as described herein, in the presence of a base such as but not limited to diisopropylethylamine. The reaction may involve the use of a carboxyl activating agent such as but not limited to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and a ester activating agent such as but not limited to 1-hydroxybenzotriazole hydrate. The reaction is typically performed at ambient temperature in a solvent such as but not limited to N,N-dimethylformamide, N,N-dimethylacetamide, or mixtures thereof. Alternatively, compounds of formula (17) can be reacted with compounds of formula (19), wherein R10 is as described herein, to provide compounds of formula (20), which are representative of compounds of Formula (I). The reaction is typically performed in the presence of a reducing agent such as but not limited to sodium triacetoxyborohydride and acetic acid in a solvent such as but not limited to methanol and may be performed at an elevated temperature.
- The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. Each exemplified compound and intermediate was named using ACD/ChemSketch Version 12.5 (20 Apr. 2011) or (3 Sep. 2012), Advanced Chemistry Development Inc., Toronto, Ontario), or ChemDraw® Ver. 9.0.7 (CambridgeSoft, Cambridge, Mass.).
- 1-(Benzyloxycarbonyl)azetidine-3-carboxylic acid (5.10 g, 21.67 mmol), 1-hydroxybenzotriazole hydrate (4.15 g, 27.1 mmol) and tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate (5.28 g, 18.06 mmol) were suspended in dimethylformamide (25 ml) followed by addition of diisopropylethylamine (9.64 ml, 54.2 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (5.19 g, 27.1 mmol). The mixture was stirred at room temperature overnight and the solution was diluted with water. The resulting turbid mixture was extracted with ethyl acetate and then ethyl acetate/tetrahydrofuran. The organics were combined and dried over magnesium sulfate, filtered and concentrated to give a solid which was triturated with ether and filtered to give the title compound.
- tert-Butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate (50 mg, 0.098 mmol) and tetrahydrofuran (5 ml) were added to 20% wet palladium hydroxide on carbon (10 mg, 0.071 mmol) in a 50 ml pressure bottle and the mixture was stirred for 16 hours at 30 psi and room temperature. The mixture was filtered through a nylon membrane and the filtrate was concentrated to give the title compound.
- tert-Butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate (4.97 g, 13.24 mmol), cesium carbonate (10.78 g, 33.1 mmol), 3-bromopyridine (1.307 ml, 13.24 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.764 g, 1.32 mmol) and bis(dibenzylideneacetone)palladium(0) (0.606 g, 0.662 mmol) were suspended in dioxane (50 ml), bubbled with nitrogen for 30 minutes and heated at 100° C. overnight. The mixture was filtered through a celite pad with dichloromethane washes and the filtrate was concentrated. Normal phase chromatography provided the title compound.
- tert-Butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate (3.82 g, 8.44 mmol) was dissolved in 60 ml dichloromethane, cooled to 0° C. and treated with trifluoroacetic acid (10 ml). The mixture was allowed to warm to room temperature and was stirred for 2 hours. Removal of the solvent under vacuum provided the title compound.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yloxy)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-(tetrahydro-2H-pyran-4-yl)acetic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.95 (bs, 1H), 7.93 (d, J=4.2 Hz, 1H), 7.88-7.83 (m, 1H), 7.55-7.47 (m, 2H), 7.26-7.08 (m, 1H), 7.01-6.78 (m, 3H), 4.14-4.04 (m, 2H), 4.02-3.62 (m, 6H), 2.37-1.73 (m, 6H), 1.66-1.00 (m, 8H); MS (ESI(+)) m/e 479 (M+H)+.
-
TABLE 1 Ex Name 1H NMR MS 3 N-(4-{[1-(tetrahydro- 1H NMR (300 MHz, DMSO-d6) δ ppm (ESI(+)) 2 H-pyran-4-ylacetyl) 9.96 (s, 1H), 8.02 (dd, J = 4.3, 1.2 Hz, 1H), m/e 547 piperidin-4-yl]oxy} 7.55-7.45 (m, 3H), 7.15 (d, J = 8.5 Hz, 1H), (M + H)+ phenyl)-1-[2- 6.97-6.90 (m, 2H), 4.59-4.47 (m, 1H), (trifluoromethyl) 4.28-4.05 (m, 4H), 3.93-3.53 (m, 6H) pyridin-3-yl] 2.27 (d, J = 1.3 Hz, 2H) azetidine-3- 2.00-1.78 (m, 4H), carboxamide 1.64-1.38 (m, 5H), 1.39-1.04 (m, 3H) 4 1-(2-methylpyridin- 1 H NMR (300 MHz, DMSO-d6) δ ppm (ESI(+)) 3-yl)-N-(4-{[1- 9.92 (s, 1H), 7.88 (dd, J = 4.7, 1.4 Hz, 1H), m/e 493 (tetrahydro-2 H- 7.55-7.48 (m, 2H), (M + H)+ pyran-4-ylacetyl) 7.07 (dd, J = 8.0, 4.7 Hz, 1H), piperidin-4-yl] 6.97-6.92 (m, 1H), 6.94-6.81 (m, 2H), oxy}phenyl) 6.94-6.81 (m. 2H), azetidine-3- 4.58-4.47 (m, 1H), 4.10 (t, J = 7.7 Hz, 2H), carboxamide 3.98 (t, J = 6.8 Hz, 2H), 3.93-3.50 (m, 6H), 3.29-3.14 (m, 2H), 2.35 (s, 3H), 2.26 (d, J = 6.9 Hz, 2H), 2.05-1.79 (m, 3H), 1.66-1.32 (m, 5H), 1.31-1.06 (m, 2H) 5 1-(4-methylpyridin- 1H NMR (300 MHz, DMSO-d6) δ ppm (ESI(+)) 3-yl)-N-(4-{[1- 9.93 (s, 1H), 7.90 (d, J = 4.7 Hz, 1H), m/e 493 (tetrahydro-2 H- 7.76 (s, 1H), 7.55-7.48 (m, 2H), (M + H)+ pyran-4-ylacetyl) 7.03-6.89 (m, 3H), 4.58-4.47 (m, 1H), piperidin-4-yl]oxy} 4.20-3.26 (s, 4H), 3.95-3.53 (m, 5 H), phenyl)azetidine- 3.26-3.15 (m, 4H), 2.26 (d, J = 6.9 Hz, 2H) 3-carboxamide 2.18 (s, 3H), 2.05-1.78 (m, 3H), 1.66-1.35 (m, 4H), 1.32-1.08 (m, 2H) 6 1-(4-fluoropyridin- 1H NMR (300 MHz, DMSO-d6) δ ppm (ESI(+)) 3-yl)-N-(4-{[1- 9.93 (bs, 1H), 7.95 (t, J = 11.6 Hz, 2H), m/e 497 (tetrahydro-2 H- 7.55-7.47 (m, 2H), (M + H)+ pyran-4-ylacetyl) 7.16 (dd, J = 12.7, 5.2 Hz, 1H), piperidin-4-yl]oxy} 6.97-6.90 (m, 2H), 4.59-4.48 (m, 1H) phenyl)azetidine- 4.29-4.00 (m, 5H), 3.93-3.41 (m, 5H) 3-carboxamide 2.30-2.23 (m, 2H), 1.99-1.78 (m, 4H), 1.66-1.39 (m, 5H), 1.40-1.00 (m, 3H) 7 N-(4-{[1- 1H NMR (300 MHz, DMSO-d6) δ ppm (ESI(+)) (tetrahydro- 9.93 (bs, 1H), 7.95 (t, J = 11.6 Hz, 2H), m/e 547 2 H-pyran-4- 7.55-7.47 (m, 2H), (M + H)+ ylacetyl) 7.16 (dd, J = 12.7, 5.2 Hz, 1H), piperidin-4-yl] 6.97-6.90 (m, 2H), 4.59-4.48 (m, 1H), oxy}phenyl)- 4.29-4.00 (m, 5H), 3.93-3.41 (m, 5H) 1-[4- 2.30-2.23 (m, 2H), 1.99-1.78 (m, 4H), (trifluoromethyl) 1.66-1.39 (m, 5H), 1.40-1.00 (m, 3H) pyridin-3-yl] azetidine-3- carboxamide 31 N-(4-{[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm (ESI(+)) hydroxy-2- 9.94 (s, 1H), 7.97-7.70 (m, 2H), m/e 439 methylpropanoyl) 7.55-7.47 (m, 2H), (M + H)+ piperidin-4-yl] 7.18 (dd, J = 8.2, 4.6 Hz, 1H), oxy}phenyl)-1- 7.00-6.78 (m, 3H), 5.39 (s, 1H), (pyridin-3-yl) 4.58-4.41 (m, 1H), 4.09 (t, J = 7.8 Hz, 2H), azetidine-3- 3.95 (t, J = 6.7 Hz, 2H), 3.78-3.47 (m, 2H), carboxamide 1.99-1.82 (m, 2H), 1.62-1.34 (m, 2H), 1.35-1.02 (m, 8H) 32 N-[4-({1-[(2 S)-2- 1H NMR (300 MHz, DMSO-d6) δ ppm (ESI(+)) methylbutanoyl] 9.94 (s, 1H), 7.94 (d, J = 4.7 Hz, 1H), m/e 437 piperidin-4-yl} 7.86 (d, J = 2.8 Hz, 1H), 7.55-7.47 (m, 2H), (M + H)+ oxy)phenyl]-1- 7.24-7.04 (m, 1H), 7.02-6.80 (m, 3H), (pyridin-3-yl) 4.59-4.48 (m, 1H), 4.09 (t, J = 7.8 Hz, 2H), azetidine-3- 4.03-3.62 (m, 5H), carboxamide 3.38 (dd, J = 13.6, 6.6 Hz, 1H), 2.80-2.64 (m, 1H), 2.01-1.78 (m, 2H), 1.64-1.36 (m, 3H), 1.38-1.15 (m, 1H), 1.15-0.86 (m, 4H), 0.81 (t, J = 7.3 Hz, 3H) 33 1-(pyridin-3-yl)- 1H NMR (300 MHz, DMSO-d6) δ ppm (ESI(+)) N-[4-({1-[(2 S)- 9.94 (s, 1H), 7.98-7.82 (m, 2H), m/e 451 tetrahydrofuran- 7.55-7.48 (m, 2H), (M + H)+ 2-ylcarbonyl] 7.20 (dd, J = 8.3, 4.6 Hz, 1H), piperidin-4-yl} 7.00-6.80 (m, 3H), 4.67 (t, J = 6.5 Hz, 1H), oxy)phenyl] 4.53 (s, 1H), 4.10 (t, J = 7.8 Hz, 2H), azetidine-3- 3.96 (t, J = 6.6 Hz, 2H), 3.89-3.58 (m, 4H), carboxamide 3.46-3.08 (m, 4H), 2.12-1.68 (m, 5H), 1.66-1.38 (m, 2H) 34 N-{4-[(1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) pentanoylpipe 8.12 (d, J = 5.49 Hz, 1 H), m/e 437 ridin-4-yl]oxy] 8.04 (d, 2.75 Hz, 1 H) (M + H)+ phenyl}-1- 7.80 (dd, J = 8.85, 5.49 Hz, 1 H), (pyridin-3-yl) 7.60 (dd, J = 8.39, 2.29 Hz, 1 H), azetidine-3- 7.51 (d, J = 9.16 Hz, 2 H) carboxamide 6.96 (d, J = 8.85 Hz, 2 H), 4.51-4.59 (m, 1 H), 4.25 (t, J = 8.24 Hz, 2 H) 4.14 (dd, J = 7.93, 5.80 Hz, 2 H) 3.80-3.90 (m, 1 H) 3.73-3.79 (m, 2 H) 3.31-3.41 (m, 1 H) 3.19-3.27 (m, 1 H) 2.29-2.36 (m, 2 H) 1.83-2.00 (m, 2 H) 1.53-1.62 (m, 1 H) 1.42-1.51 (m, 3 H) 1.24-1.35 (m, 2 H) 0.87 (t, 3 H) 35 N-[4-({1-[(2- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylcyclopropyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 435 carbonyl] 8.04 (d, J = 2.44 Hz, 1 H) (M + H)+ piperidin-4-yl} 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) oxy)phenyl]-1- 7.59 (dd, J = 8.70, 1.98 Hz, 1 H) (pyridin-3-yl) 7.52 (dd, J = 8.85 Hz, 2 H) azetidine-3- 6.97 (d, J = 8.85 Hz, 2 H) carboxamide 4.51-4.62 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 5.80 Hz, 2 H) 3.79-4.01 (m, 2 H) 3.73-3.78 (m, 1 H) 3.46-3.54 (m, 1 H) 3.16-3.28 (m, 1 H) 1.89 (d, J = 1.53 Hz, 2 H) 1.70-1.76 (m, 1 H) 1.53 (d, J = 55.85 Hz, 2 H) 1.03-1.17 (m, 4 H) 0.89-0.97 (m, 1 H) 0.49-0.59 (m, 1 H) 36 N-[4-({1-(1 S,4 R)- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) bicyclo[2.2.1] 8.12 (d, J = 5.19 Hz, 1 H) m/e 489 hept-2-ylacetyl] 8.04 (d, J = 2.75 Hz, 1 H) (M + H)+ piperidin-4-yl} 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) oxy)phenyl]-1- 7.60 (dd, J = 8.54, 2.14 Hz, 1 H) (pyridin-3-yl) 7.47-7.54 (m, 2 H) 6.93-6.99 (m, 2 H) azetidine-3- 4.49-4.58 (m, 1 H) carboxamide 4.25 (t, J = 8.39 Hz, 2 H) 4.10-4.16 (m, J = 8.09, 5.95 Hz, 2 H) 3.81-3.89 (m, 1 H) 3.73-3.79 (m, 2 H) 3.18-3.39 (m, 2 H) 2.27-2.36 (m, 1 H) 2.11-2.21 (m, 2 H) 1.73-1.99 (m, 4 H) 1.38-1.60 (m, 5 H) 1.34 (d, J = 9.77 Hz, 1 H) 0.97-1.19 (m, 4 H) 37 N-(4-{[1-(4- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylpentanoyl) 8.12 (d, J = 5.19 Hz, 1 H) m/e 451 piperidin-4-yl] 8.04 (d, J = 2.75 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.70, 5.34 Hz, 1 H) (pyridin-3-yl) 7.59 (dd, J =8.70, 1.98 Hz, 1 H) azetidine-3- 7.47-7.54 (m, 2 H) carboxamide 6.93-6.99 (m, 2 H) 4.51-4.57 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.10-4.16 (m, J = 8.09, 5.95 Hz, 2 H) 3.80-3.87 (m, J = 17.70 Hz, 1 H) 3.74-3.79 (m, 2 H) 3.17-3.38 (m, 2 H) 2.27-2.36 (m, J = 8.85, 6.71 Hz, 2 H) 1.83-1.99 (m, J = 22.89 Hz, 2 H) 1.32-1.62 (m, 5 H) 0.87 (d, J = 6.41 Hz, 6 H) 38 N-(4-{[1-(3- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylpentanoyl) 8.12 (d, J = 5.19 Hz, 1 H) m/e 451 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (d, J = 8.85, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.54, 2.14 Hz, 1 H) azetidine-3- 7.49-7.53 (m, 2 H) carboxamide 6.93-6.97 (m, 2 H) 4.51-4.59 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 = (dd, J = 8.09, 5.95 Hz, 2 H) 3.83-3.91 (m, 1 H) 3.73-3.79 (m, 2 H) 3.19-3.39 (m, 2 H) 2.27-2.34 (m, 1 H) 2.10-2.18 (m, 1 H) 1.84-1.98 (m, 2 H) 1.73-1.81 (m, 1 H) 1.42-1.59 (m, 2 H) 1.29-1.39 (m, 1 H) 1.11-1.21 (m, 1 H) 0.82-0.89 (m, 6 H) 39 N-(4-{[1-(3- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) ethoxypropanoyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 453 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.85, 1.83 Hz, 1 H) azetidine-3- 7.51 (d, J = 9.16 Hz, 2 H) carboxamide 6.92-6.98 (m, 2 H) 4.49-4.59 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 5.80 Hz, 2 H) 3.80-3.89 (m, 1 H) 3.74-3.79 (m, 2 H) 3.59 (t, J = 6.56 Hz, 2 H) 3.42 (q, J = 7.02 Hz, 2 H) 3.20-3.38 (m, 2 H) 2.55-2.63 (m, 2 H) 1.83-1.99 (m, 2 H) 1.41-1.63 (m, 2 H) 1.09 (t, J = 7.02 Hz, 3 H) 40 N-(4-{[1-(2,2- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) dimethylbutanoyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 451 piperidin-4-yl] 8.05 (d, J = 2.75 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.81 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.85, 1.83 Hz, 1 H) azetidine-3- 7.49-7.53 (m, 2 H) carboxamide 6.96 (d, J = 9.16 Hz, 2 H) 4.53-4.59 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.12-4.18 (m, J = 7.93, 6.10 Hz, 2 H) 3.87-3.93 (m, 1 H) 3.75-3.80 (m, 2 H) 3.28-3.38 (m, 2 H) 1.89-1.97 (m, 2 H) 1.60 (q, J = 7.53 Hz, 2 H) 1.46-1.54 (m, 2 H) 1.16 (s, 6 H) 0.80 (t, J = 7.48 Hz, 3 H) 41 N-(4-{[1-(3,3- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) dimethylbutanoyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 451 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.70, 1.98 Hz, 1 H) azetidine-3- 7.49-7.52 (m, 2 H) carboxamide 6.92-6.99 (m, 2 H) 4.47-4.58 (m, 1 H) 4.22-4.29 (m, 2 H) 4.14 (dd, J = 8.09, 5.95 Hz, 2 H) 3.85-3.92 (m, 1 H) 3.74-3.80 (m, 2 H) 3.34-3.43 (m, 1 H) 3.20-3.27 (m, 1 H) 2.26 (s, 2 H) 1.82-2.01 (m, 2 H) 1.38-1.60 (m, 2 H) 0.99 (s, 9 H) 42 N-(4-{[1-(2,2- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) dimethylpropanoyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 437 piperidin-4-yl] 8.04 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.59-7.61 (m, 1 H) azetidine-3- 7.49-7.54 (m, 2 H) carboxamide 6.93-6.98 (m, 2 H) 4.51-4.61 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 8.09, 5.95 Hz, 2 H) 3.85-3.92 (m, 2 H) 3.73-3.79 (m, 1 H) 3.29-3.38 (m, 2 H) 1.89-1.99 (m, 2 H) 1.45-1.56 (m, 2 H) 1.20 (s, 9 H) 43 N-{4-[(1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) butanoylpiperidin- 8.12 (d, J = 5.49 Hz, 1 H) m/e 423 4-yl)oxy]phenyl}- 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ 1-(pyridin-3-yl) 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) azetidine-3- 7.60 (dd, J = 8.85, 1.83 Hz, 1 H) carboxamide 7.49-7.53 (m, 2 H) 6.93-6.98 (m, 2 H) 4.49-4.60 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J =7.93, 6.10 Hz, 2 H) 3.82-3.90 (m, 1 H) 3.73-3.79 (m, 2 H) 3.20-3.37 (m, 2 H) 2.31 (t, J = 7.17 Hz, 2 H) 1.82-1.98 (m, 2 H) 1.41-1.63 (m, 4 H) 0.89 (t, J = 7.32 Hz, 3 H) 44 N-(4-{[1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) (ethoxyacetyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 439 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.54, 1.83 Hz, 1 H) azetidine-3- 7.51 (d, J = 9.16 Hz, 2 H) carboxamide 6.96 (d, J = 9.16 Hz, 2 H) 4.50-4.59 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.10-4.16 (m, 4 H) 3.80-3.87 (m, 1 H) 3.73-3.78 (m, 2 H) 3.47 (q, J = 7.02 Hz, 2 H) 3.20-3.35 (m, 2 H) 1.86-1.98 (m, J = 21.67 Hz, 2 H) 1.45-1.64 (m, 2 H) 1.13 (t, J = 7.02 Hz, 3 H) 45 N-(4-{[1-(3- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylbutanoyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 437 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.70, 1.98 Hz, 1 H) azetidine-3- 7.47-7.55 (m, 2 H) 6.93-6.98 (m, 2 H) carboxamide 4.51-4.57 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 6.10 Hz, 2 H) 3.83-3.90 (m, 1 H) 3.74-3.79 (m, 2 H) 3.19-3.37 (m, 2 H) 2.19-2.24 (m, 2 H) 1.82-2.03 (m, 3 H) 1.41-1.60 (m, 2 H) 0.90 (d, J = 6.71 Hz, 6 H) 46 N-(4-{[1-(2- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylpropanoyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 423 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.70, 1.98 Hz, 1 H) azetidine-3- 7.49-7.54 (m, 2 H) 6.93-6.99 (m, 2 H) carboxamide 4.52-4.60 (m, 1 H) 4.25 (t, J = 8.24 Hz, 2 H) 4.14 (dd, J = 7.93, 6.10 Hz, 2 H) 3.84 (s, 1 H) 3.75-3.79 (m, 2 H) 3.18-3.42 (m, 2 H) 2.86-2.93 (m, 1 H) 1.84-1.99 (m, 2 H) 1.42-1.63 (m, 2 H) 1.00 (d, J = 6.71 Hz, 6 H) 47 N-(4-{[1-(N- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) acetyl-L-leucyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 508 piperidin-4-yl] 8.05 (d, J = 2.75 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.81 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.85, 1.83 Hz, 1 H) azetidine-3- 7.52 (d, J = 8.85 Hz, 2 H) carboxamide 6.95-6.99 (m, 2 H) 4.77 (dd, J = 9.00, 3.81 Hz, 1 H) 4.53-4.62 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.12-4.17 (m, 2 H) 3.92 (d, J = 13.12 Hz, 1 H) 3.74-3.79 (m, 2 H) 3.31-3.47 (m, 2 H) 3.14-3.21 (m, 1 H) 1.92-2.01 (m, 1 H) 1.85 (s, 3 H) 1.28-1.63 (m, 5 H) 0.85-0.91 (m, 6 H) 48 N-[4-({1-[(2- 1H NMR (500 MHz, DMSO-d6/D2O) (ESI(+)) methoxyethoxy) δ ppm 8.12 (d, J = 5.19 Hz, 1 H) m/e 469 acetyl]piperidin-4- 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ yl}oxy)phenyl]-1- 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.54, 2.14 Hz, 1 H) azetidine-3- 7.51 (d, J = 9.61 Hz, 2 H) carboxamide 6.93-6.99 (m, J = 9.61, 9.61 Hz, 2 H) 4.51-4.59 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.09-4.18 (m, 4 H) 3.80-3.86 (m, 1 H) 3.74-3.77 (m, 1 H) 3.54-3.57 (m, 2 H) 3.47 (dd, J = 5.65, 3.51 Hz, 2 H) 3.20-3.33 (m, 6 H) 1.87-1.96 (m, 2 H) 1.45-1.66 (m, 2 H) 49 N-(4-{[1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) (cyclohexylcarbonyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 463 piperidin-4-yl] 8.05 (d, J = 2.75 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.70, 1.98 Hz, 1 H) azetidine-3- 7.51 (d, J = 8.85 Hz, 2 H) carboxamide 6.94-6.97 (m, 2 H) 4.49-4.58 (m, 1 H) 4.25 (t, J = 8.24 Hz, 2 H) 4.14 (dd, J = 8.09, 5.95 Hz, 2 H) 3.84 (dd, 1 H) 3.73-3.78 (m, 2 H) 3.33-3.40 (m, J = 9.77 Hz, 1 H) 3.17-3.27 (m, 1 H) 2.58-2.63 (m, 1 H) 1.82-1.99 (m, 2 H) 1.09-1.73 (m, 12 H) 50 N-(4-{[1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) (cyclohexylacetyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 477 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.81 (dd, J = 8.85, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.85, 1.83 Hz, 1 H) azetidine-3- 7.48-7.53 (m, 2 H) carboxamide 6.91-7.00 (m, 2 H) 4.51-4.57 (m, 1 H) 4.25 (t, J = 8.24 Hz, 2 H) 4.14 (dd, J = 7.93, 6.10 Hz, 2 H) 3.84 (d, J = 4.27 Hz, 1 H) 3.74-3.79 (m, 2 H) 3.31-3.38 (m, 1 H) 3.16-3.27 (m, 1 H) 2.18-2.23 (m, J = 6.56, 2.90 Hz, 2 H) 1.83-1.97 (m, 2 H) 1.41-1.71 (m, 8 H) 1.06-1.27 (m, 3 H) 0.88-0.98 (m, 2 H) 51 1-(pyridin-3-yl)- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) N-(4-{[1-(4,4,4- 8.12 (d, J = 5.49 Hz, 1 H) m/e 477 trifluorobutanoyl) 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ piperidin-4-yl] 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) oxy}phenyl) 7.59 (dd, J = 8.70, 1.98 Hz, 1 H) azetidine-3- 7.49-7.54 (m, 2 H) carboxamide 6.93-6.99 (m, 2 H) 4.52-4.60 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 8.09, 5.95 Hz, 2 H) 3.81-3.89 (m, 1 H) 3.74-3.78 (m, 2 H) 3.25-3.39 (m, 2 H) 2.61-2.68 (m, 2 H) 2.43-2.51 (m, 2 H) 1.84-2.00 (m, 2 H) 1.44-1.65 (m, 2 H) 52 N-(4-{[1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) (cyclopentylcarbonyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 449 piperidin-4-yl] 8.05 (d, J = 2.75 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.70, 1.98 Hz, 1 H) azetidine-3- 7.51 (d, J = 8.85 Hz, 2 H) carboxamide 6.96 (d, J = 8.85 Hz, 2 H) 4.51-4.59 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.09-4.18 (m, 2 H) 3.81-3.90 (m, 1 H) 3.75-3.79 (m, 2 H) 3.33-3.42 (m, 1 H) 3.20-3.29 (m, 1 H) 2.96-3.02 (m, 1 H) 1.46-1.98 (m, 12 H) 53 N-[4-({1-[(1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylcyclohexyl) 8.12 (d, J = 5.19 Hz, 1 H) m/e 477 carbonyl]piperidin- 8.04 (d, J = 2.44 Hz, 1 H) (M + H)+ 4-yl}oxy)phenyl]-1- 7.79 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.59 (dd, J = 8.70, 1.98 Hz, 1 H) azetidine-3- 7.49-7.53 (m, 2 H) carboxamide 6.96 (d, J = 8.85 Hz, 2 H) 4.50-4.59 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 6.10 Hz, 2 H) 3.90 (dd, J = 9.00, 5.95 Hz, 2 H) 3.74-3.78 (m, 1 H) 3.27-3.36 (m, 2 H) 1.85-1.99 (m, 4 H) 1.24-1.55 (m, 10 H) 1.18 (s, 3 H) 54 N-[4-({1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) (furan-3-ylcarbonyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 447 piperidin-4-yl] 8.04 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 8.02 (s, 1 H) (pyridin-3-yl) 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) azetidine-3- 7.71-7.73 (m, 1 H) carboxamide 7.59 (dd, J = 8.70, 2.29 Hz, 1 H) 7.52 (d, J = 8.85 Hz, 2 H) 6.97 (d, J = 8.85 Hz, 2 H) 6.67 (s, 1 H) 4.56-4.62 (m, 1 H) 4.25 (t, J = 8.24 Hz, 2 H) 4.14 (dd, J = 7.93, 6.10 Hz, 2 H) 3.82-3.92 (m, 2 H) 3.73-3.77 (m, 1 H) 3.39-3.49 (m, 2 H) 1.91-2.00 (m, 2 H) 1.55-1.65 (m, 2 H) 55 1-(pyridin-3-yl)- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) N-(4-{[1-(3,3,3- 8.09 (d, J = 4.58 Hz, 1 H) m/e 463 trifluoropropanoyl) 8.02 (s, 1 H) (M + H)+ piperidin-4-yl] 7.73 (dd, J = 8.54, 5.49 Hz, 1 H) oxy}phenyl) 7.48-7.54 (m, J = 9.16 Hz, 3 H) azetidine-3- 6.96 (d, J = 8.85 Hz, 2 H) carboxamide 4.57 (s, 1 H) 4.23 (t, J = 8.24 Hz, 2 H) 4.09-4.14 (m, 2 H) 3.80-3.87 (m, 1 H) 3.72-3.78 (m, 2 H) 3.59-3.63 (m, 2 H) 3.26-3.39 (m, 2 H) 1.93 (s, 2 H) 1.51 (s, 2 H) 56 N-{4-[(1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) acetylpiperidin- 8.12 (d, J = 5.19 Hz, 1 H) m/e 395 4-yl)oxy]phenyl}- 8.05 (d, J = 2.75 Hz, 1 H) (M + H)+ 1-(pyridin-3-yl) 7.81 (dd, J = 8.85, 5.49 Hz, 1 H) azetidine-3- 7.60 (dd, J = 8.70, 1.98 Hz, 1 H) carboxamide 7.49-7.53 (m, 2 H) 6.92-6.98 (m, 2 H) 4.50-4.58 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 6.10 Hz, 2 H) 3.79-3.85 (m, 1 H) 3.75-3.79 (m, 2 H) 3.19-3.40 (m, 2 H) 2.02 (s, 3 H) 1.83-1.99 (m, 2 H) 1.41-1.68 (m, 2 H) 57 N-(4-{[1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) (methoxyacetyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 425 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)-1- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) (pyridin-3-yl) 7.60 (dd, J = 8.54, 2.44 Hz, 1 H) azetidine-3- 7.51 (d, J = 9.16 Hz, 2 H) carboxamide 6.96 (d, J = 9.16 Hz, 2 H) 4.51-4.59 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 8.09, 5.95 Hz, 2 H) 4.10 (d, J = 3.05 Hz, 2 H) 3.80-3.86 (m, 1 H) 3.74-3.77 (m, 1 H) 3.57-3.64 (m, 1 H) 3.18-3.34 (m, 5 H) 1.85-1.99 (m, 2 H) 1.44-1.64 (m, 2 H) 58 1-(pyridin-3-yl)- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) N-(4-{[1-(thiophen- 8.11 (d, J = 5.49 Hz, 1 H) m/e 463 3-ylcarbonyl) 8.04 (d, J = 2.75 Hz, 1 H) (M + H)+ piperidin-4-yl] 7.76-7.78 (m, 1 H) oxy}phenyl) 7.59-7.61 (m, 2 H) azetidine-3- 7.52 (d, J = 8.85 Hz, 2 H) carboxamide 7.44 (d, J = 4.88 Hz, 1 H) 7.22 (d, J = 5.19 Hz, 1 H) 6.97 (d, J = 9.16 Hz, 2 H) 4.56-4.62 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.12-4.16 (m, 2 H) 3.87-3.96 (m, 1 H) 3.72-3.79 (m, 2 H) 3.33-3.46 (m, 2 H) 1.90-2.01 (m, J = 1.83 Hz, 2 H) 1.54-1.70 (m, 2 H) 59 N-[4-({1-[(3- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylthiophen-2-yl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 477 carbonyl]piperidin- 8.04 (d, J = 2.75 Hz, 1 H) (M + H)+ 4-yl}oxy)phenyl]- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) 1-(pyridin-3-yl) 7.48-7.62 (m, 4 H) azetidine-3- 6.93-6.99 (m, 3 H) carboxamide 4.54-4.66 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 6.10 Hz, 2 H) 3.72-3.85 (m, 3 H) 3.34-3.45 (m, 2 H) 2.20 (s, 3 H) 1.91-2.00 (m, J = 9.77 Hz, 2 H) 1.53-1.64 (m, 2 H) 60 N-(4-{[1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) (morpholin-4- 8.13 (d, J = 5.49 Hz, 1 H) m/e 480 ylacetyl) 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ piperidin-4-yl]oxy} 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) phenyl)-1-(pyridin-3- 7.60 (dd, J =8.54, 2.14 Hz, 1 H) yl)azetidine-3- 7.53 (d, J = 8.85 Hz, 2 H) carboxamide 6.97 (d, J = 9.16 Hz, 2 H) 4.54-4.64 (m, 1 H) 4.35 (s, 2 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 8.09, 5.95 Hz, 2 H) 3.76-4.04 (m, 6 H) 3.52-3.60 (m, 1 H) 3.25-3.49 (m, 4 H) 3.08-3.22 (m, 2 H) 1.89-2.08 (m, 2 H) 1.50-1.77 (m, 2 H) 61 1-(pyridin-3-yl)- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) N-(4-{[1- 8.12 (d, J = 5.49 Hz, 1 H) m/e 463 (thiophen-2- 8.04 (d, J = 1.83 Hz, 1 H) (M + H)+ ylcarbonyl) 7.79 (dd, J = 8.85, 5.49 Hz, 1 H) piperidin-4- 7.58 (dd, J = 8.54, 2.14 Hz, 1 H) yl]oxy}phenyl) 7.52 (d, J = 9.16 Hz, 2 H) azetidine-3- 7.42 (d, J = 3.66 Hz, 1 H) carboxamide 7.18-7.22 (m, 1 H) 7.14 (dd, J = 4.88, 3.66 Hz, 1 H) 6.99 (d, 2 H) 4.58-4.66 (m, 1 H) 4.25 (t, J = 8.24 Hz, 2 H) 4.14 (dd, J = 7.93, 6.10 Hz, 2 H) 3.89-3.96 (m, 2 H) 3.74-3.80 (m, 1 H) 3.52 (m, 2 H) 1.95-2.04 (m, 2 H) 1.59-1.70 (m, 2 H) 62 N-[4-({1-[(5- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylthiophen-2- 8.12 (d, J = 5.49 Hz, 1 H) m/e 477 yl)carbonyl] 8.04 (d, J = 2.75 Hz, 1 H) (M + H)+ piperidin-4- 7.80 (dd, J = 8.54, 5.49 Hz, 1 H) yl]oxy}phenyl]-1- 7.59 (dd, J = 8.24, 2.14 Hz, 1 H) (pyridin-3-yl) 7.52 (d, J = 9.16 Hz, 2 H) azetidine-3- 7.23 (d, J = 3.36 Hz, 1 H) carboxamide 6.98 (d, J = 9.16 Hz, 2 H) 6.80-6.86 (m, 1 H) 4.56-4.65 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.12-4.17 (m, 2 H) 3.90-3.95 (m, 2 H) 3.74-3.79 (m, 1 H) 3.45 - 3.55 (m, 2 H) 2.47 (s, 3 H) 1.94 -2.05 (m, 2 H) 1.58-1.67 (m, 2 H) 63 N-(4-{[1-(furan- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) 2-ylcarbonyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 447 piperidin-4- 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ yl]oxy}phenyl)-1- 7.78-7.83 (m, 2 H) (pyridin-3-yl) 7.60 (dd, J =8.39, 2.29 Hz, 1 H) azetidine-3- 7.52 (d, J = 9.16 Hz, 2 H) carboxamide 6.96-7.02 (m, 3 H) 6.63 (dd, J = 3.36, 1.83 Hz, 1 H) 4.58-4.67 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 5.80 Hz, 2 H) 3.92-3.99 (m, 2 H) 3.75-3.80 (m, 1 H) 3.41-3.59 (m, 2 H) 1.95-2.04 (m, 2 H) 1.58-1.67 (m, 2 H) 64 N-[4-({1-[(1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methyl-1 H- 8.11 (s, 1 H) m/e 460 pyrrol-2-yl) 8.04 (d, J = 2.44 Hz, 1 H) (M + H)+ carbonyl] 7.80 (dd, J = 8.70, 5.34 Hz, 1 H) piperidin-4-yl} 7.59 (dd, J = 8.85, 1.83 Hz, 1 H) oxy)phenyl]-1- 7.52 (d, J = 9.16 Hz, 2 H) (pyridin-3-yl) 6.97 (d, J = 9.16 Hz, 2 H) azetidine-3- 6.88 (s, 1 H) carboxamide 6.33 (dd, J = 3.81, 1.68 Hz, 1 H) 6.01-6.05 (m, 1 H) 4.52-4.63 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.11-4.17 (m, 2 H) 3.90-3.96 (m, 2 H) 3.74-3.79 (m, 1 H) 3.66 (s, 3 H) 3.41-3.50 (m, 2 H) 1.91-2.04 (m, 2 H) 1.52-1.67 (m, 2 H) 65 N-{4-[(1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) propanoylpiperidin- 8.12 (d, J = 5.49 Hz, 1 H) m/e 409 4-yl)oxy]phenyl}- 8.05 (d, J = 2.75 Hz, 1 H) (M + H)+ 1-(pyridin-3-yl) 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) azetidine-3- 7.60 (dd, J = 8.39, 2.29 Hz, 1 H) carboxamide 7.51 (d, J = 8.85 Hz, 2 H) 6.96 (d, 2 H) 4.48-4.60 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 6.10 Hz, 2 H) 3.81-3.90 (m, 1 H) 3.72-3.80 (m, 2 H) 3.17-3.41 (m, 2 H) 2.34 (q, J = 7.53 Hz, 2 H) 1.82-2.01 (m, 2 H) 1.35-1.63 (m, 2 H) 1.00 (t, J = 7.48 Hz, 3 H) 66 N-[4-({1-[(1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) methylcyclopropyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 435 carbonyl] 8.05 (d, J = 2.75 Hz, 1 H) (M + H)+ piperidin-4-yl} 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) oxy)phenyl]-1- 7.60 (dd, J = 8.55, 1.83 Hz, 1 H) (pyridin-3-yl) 7.52 (d, J = 8.85 Hz, 2 H) azetidine-3- 6.96 (d, J = 8.85 Hz, 2 H) carboxamide 4.51-4.60 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 5.80 Hz, 2 H) 3.82-3.92 (m, 2 H) 3.74-3.78 (m, 1 H) 3.31-3.46 (m, 2 H) 1.85-1.96 (m, 2 H) 1.47-1.58 (m, J = 7.32 Hz, 2 H) 1.23 (s, 3 H) 0.76-0.81 (m, 2 H) 0.52-0.56 (m, 2 H) 67 N-(4-{[1-(N,N- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm N/A dimethyl-beta- 8.12 (d, J = 5.19 Hz, 1 H) alanyl)piperidin- 8.05 (d, J = 2.75 Hz, 1 H) 4-yl]oxy}phenyl)- 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) 1-(pyridin-3-yl) 7.60 (dd, J = 8.39, 2.29 Hz, 1 H) azetidine-3- 7.53 (d, J = 9.16 Hz, 2 H) carboxamide 6.99 (d, J = 8.85 Hz, 2 H) 4.56-4.64 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 7.93, 5.80 Hz, 2 H) 3.72-3.82 (m, 3 H) 3.67-3.70 (m, 2 H) 3.19-3.54 (m, J = 87.28 Hz, 4 H) 2.92 (d, J = 10.68 Hz, 6 H) 1.97-2.16 (m, 2 H) 1.66-1.85 (m, 2 H) 68 1-(pyridin-3yl)- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) N-(4-{[1- 8.12 (d, J = 5.49 Hz, 1 H) m/e 464 (1,3-thiazol-2- 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ ylcarbonyl) 7.98-8.02 (m, 2 H) piperidin-4-yl] 7.81 (dd, J = 8.85, 5.49 Hz, 1 H) oxy}phenyl) 7.60 (dd, J = 8.39, 2.29 Hz, 1 H) azetidine-3- 7.53 (d, 2 H) carboxamide 6.99 (d, 2 H) 4.55-4.69 (m, 2 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.15 (dd, J = 7.93, 5.80 Hz, 2 H) 3.94-4.08 (m, J = 41.20, 9.46 Hz, 2 H) 3.74-3.79 (m, 1 H) 3.49-3.58 (m, 1 H) 1.98-2.08 (m, 2 H) 1.67 (s, 2 H) 69 N-(4-{[1- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) (cyclopentylacetyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 463 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)- 7.77-7.82 (m, 1 H) 1-(pyridin-3-yl) 7.60 (dd, J = 8.70, 1.98 Hz, 1 H) azetidine-3- 7.51 (d, J = 8.85 Hz, 2 H) carboxamide 6.96 (d, J = 8.85 Hz, 2 H) 4.50-4.58 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.11-4.15 (m, 2 H) 3.81-3.90 (m, 1 H) 3.73-3.79 (m, 2 H) 3.18-3.40 (m, 2 H) 2.35 (dd, J = 7.17, 2.59 Hz, 2 H) 2.05-2.16 (m, 1 H) 1.83-1.98 (m, 2 H) 1.68-1.77 (m, 2 H) 1.42-1.63 (m, 6 H) 1.05- 1.19 (m, 2 H) 70 N-(4-{[1-(2,3- 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm (ESI(+)) dimethylbutanoyl) 8.12 (d, J = 5.49 Hz, 1 H) m/e 451 piperidin-4-yl] 8.05 (d, J = 2.44 Hz, 1 H) (M + H)+ oxy}phenyl)- 7.80 (dd, J = 8.85, 5.49 Hz, 1 H) 1-(pyridin-3-yl) 7.60 (dd, J = 8.70, 2.29 Hz, 1 H) azetidine-3- 7.50-7.53 (m, 2 H) carboxamide 6.96 (d, J = 9.16 Hz, 2 H) 4.50-4.61 (m, 1 H) 4.25 (t, J = 8.39 Hz, 2 H) 4.14 (dd, J = 8.09, 5.95 Hz, 2 H) 3.92-3.97 (m, 1 H) 3.74-3.87 (m, 3 H) 3.20-3.43 (m, 2 H) 2.55-2.61 (m, 1 H) 1.38-2.03 (m, 5 H) 0.95 (d, J = 6.71 Hz, 2 H) 0.81-0.88 (m, 6 H) - The following Examples were prepared essentially as described in Example 1, substituting the appropriate bromopyridine in Example 1C and the appropriate carboxylic acid in Example 1E. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described in Example 1A-C, substituting (S)-1-(benzyloxycarbonyl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid in Example 1A. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.96 (s, 1H), 7.95 (d, J=2.9 Hz, 1H), 7.85 (dd, J=4.6, 1.3 Hz, 1H), 7.54-7.48 (m, 2H), 7.15 (dd, J=8.4, 4.6 Hz, 1H), 6.98-6.86 (m, 3H), 4.53-4.41 (m, 1H), 3.73-3.46 (m, 3H), 3.45-3.30 (m, 2H), 3.24 (dd, J=17.5, 10.0 Hz, 2H), 3.12 (dd, J=24.9, 15.2 Hz, 2H), 2.35-2.10 (m, 2H), 2.01-1.78 (m, 2H), 1.68-1.42 (m, 2H), 1.40 (s, 9H); MS (ESI(+)) m/e 467 (M+H)+.
- The title compound was prepared as described in Example 1A-C, substituting (R)-1-(benzyloxycarbonyl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid in Example 1A. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.97 (s, 1H), 7.95 (d, J=2.9 Hz, 1H), 7.85 (dd, J=4.6, 1.3 Hz, 1H), 7.54-7.48 (m, 2H), 7.16 (dd, J=8.4, 4.6 Hz, 1H), 6.98-6.86 (m, 3H), 4.53-4.41 (m, 1H), 3.75-3.45 (m, 3H), 3.45-3.34 (m, 3H), 3.25 (dd, J=8.8, 6.2 Hz, 1H), 3.23-3.09 (m, 2H), 2.34-2.07 (m, 2H), 1.95-1.75 (m, 2H), 1.59-1.41 (m, 2H), 1.40 (s, 9H); MS (ESI(+)) m/e 467 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and (S)-tetrahydrofuran-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.01 (s, 1H), 7.93 (dd, J=4.6, 1.3 Hz, 1H), 7.85 (d, J=2.8 Hz, 1H), 7.57-7.49 (m, 2H), 7.22-7.14 (m, 3H), 6.86 (ddd, J=8.2, 2.9, 1.4 Hz, 1H), 4.68 (dd, J=7.5, 5.7 Hz, 1H), 4.53-4.43 (m, 1H), 4.10 (d, J=8.0 Hz, 2H), 3.95 (d, J=13.3 Hz, 2H), 3.89-3.64 (m, 3H), 3.15-3.00 (m, 1H), 2.82-2.59 (m, 2H), 2.19-1.68 (m, 6H), 1.61-1.29 (m, 3H); MS (ESI(+)) m/e 435 (M+H)+.
-
TABLE 2 Ex Name 1H NMR MS 2 1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.04 (s, (ESI(+)) cyanopyridin-3- 1H), 8.12-7.94 (m, 1H), 7.54 (d, J = 8.5 Hz, m/e 448 yl)-N-{4-[1-(2- 2H), 7.48-7.37 (m, 1H), 7.21-7.16 (m, 2H), (M + H)+ hydroxy-2- 7.14 (dt, J = 7.7, 1.9 Hz, 1H), 5.36 (s, 1H), methylpropanoyl) 4.97-4.53 (m, 2H), 4.43-4.31 (m, 2H), 4.30-4.13 piperidin-4- (m, 2H), 3.78-3.56 (m. 1H), 2.85-2.65 (m, 2H), yl]phenyl}azetidine- 1.81-1.63 (m, 2H), 1.59-1.42 (m, 2H), 3-carboxamide 1.33 (s, 6H) 20 N-{4-[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.01 (s, (ESI(+)) hydroxy-2- 1H), 7.93 (dd, J = 4.6, 1.3 Hz, 1H), 7.85 (d, J = m/e 423 methylpropanoyl) 2.8 Hz, 1H), 7.57-7.49 (m, 2H), 7.26-7.09 (m, (M + H)+ piperidin-4- 3H), 6.86 (ddd, J = 8.2, 2.9, 1.4 Hz, 1H), 5.37 (s, yl]phenyl}-1- 1H), 4.77 (bs, 1H), 4.09 (t, J = 7.8 Hz, 2H), 3.95 (pyridin-3- (t, J = 6.6 Hz, 2H), 3.77-3.55 (m, 1H), 3.18- yl)azetidine-3- 2.62 (m, 2H), 1.81-1.71 (m, 2H), 1.67-1.35 carboxamide (m, 2H), 1.33 (s, 6H), 1.30-1.00 (m, 1H) 22 N-(4-{1-[(2 S)-2- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.01 (s, (ESI(+)) methylbutanoyl] 1H), 7.93 (dd, J = 4.6, 1.4 Hz, 1H), 7.86 (d, J = m/e 421 piperidin-4- 2.8 Hz, 1H), 7.57-7.49 (m, 2H), 7.25-7.09 (m, (M + H)+ yl}phenyl)-1- 3H), 6.90-6.82 (m, 1H), 4.63-4.52 (m, 1H), (pyridin-3- 4.18-3.87 (m, 5H), 3.78-3.63 (m, 1H), 3.16-2.99 yl)azetidine-3- (m, 1H), 2.81-2.67 (m, 2H), 2.59 (d, J = carboxamide 12.4 Hz, 1H), 1.88-1.67 (m, 2H), 1.68-1.07 (m, 4H), 1.05-0.94 (m, 3H), 0.91-0.72 (m, 3H) 25 1-(pyridin-3-yl)- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.01 (s, (ESI(+)) N-{4-[1- 1H), 7.93 (dd, J = 4.6, 1.3 Hz, 1H), 7.85 (d, J = m/e 463 (tetrahydro-2H- 2.8 Hz, 1H), 7.57-7.49 (m, 2H), 7.22-7.14 (m, (M + H)+ pyran-4- 3H), 6.86 (ddd, J = 8.2, 2.8, 1.4 Hz, 1H), 4.60- ylacetyl)piperidin- 4.49 (m, 1H), 4.09 (t, J = 7.8 Hz, 2H), 3.97 (dd, 4-yl]phenyl} J = 16.6, 10.2 Hz, 2H), 3.88-3.62 (m, 3H), 3.14- azetidine-3- 3.00 (m, 1H), 2.77-2.65 (m, 1H), 2.57 (t, J = carboxamide 11.1 Hz, 1H), 2.27 (d, J = 6.8 Hz, 2H), 1.91 (dd, J = 9.4, 5.6 Hz, 1H), 1.74 (d, J = 11.3 Hz, 3H), 1.59 (d, J = 12.9 Hz, 2H), 1.43 (dd, J = 31.3, 12.2 Hz, 3H), 1.20 (dd, J = 24.5, 12.0 Hz, 3H) 26 N-[4-(1- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.01 (s, (ESI(+)) benzoylpiperidin- 1H), 7.93 (dd, J = 4.7, 1.3 Hz, 1H), 7.86 (d, J = m/e 441 4-yl)phenyl]-1- 2.7 Hz, 1H), 7.54 (d, J = 8.5 Hz, 2H), 7.48-7.36 (M + H)+ (pyridin-3- (m, 5H), 7.27-7.11 (m, 3H), 6.86 (ddd, J = 8.3, yl)azetidine-3- 2.8, 1.3 Hz, 1H), 4.62 (s, 1H), 4.13-4.01 (m, carboxamide 2H), 3.97 (dd, J = 12.1, 5.8 Hz, 2H), 3.71 (ddd, J = 14.3, 8.1, 6.1 Hz, 2H), 3.13 (s, 1H), 2.76 (t, J = 11.7 Hz, 2H), 1.85 (d, J = 32.6 Hz, 2H), 1.66-1.40 (m, 2H) 29 N-{4-[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.00 (s, (ESI(+)) methylpropanoyl) 1H), 7.88 (dd, J = 4.7, 1.4 Hz, 1H), 7.57-7.49 m/e 421 piperidin-4- (m, 2H), 7.22-7.14 (m, 2H), 7.07 (dd, J = 8.0, (M + H)+ yl]phenyl}-1-(2- 4.7 Hz, 1H), 6.85 (dd, J = 8.1, 1.4 Hz, 1H), methylpyridin-3- 4.60-4.49 (m, 1H), 4.15-3.85 (m, 4H), 3.68-3.53 yl)azetidine-3- (m, 1H), 3.21-3.02 (m, 1H), 2.97-2.61 (m, carboxamide 2H), 2.35 (s, 3H), 2.32-1.66 (m, 3H), 1.60- 1.14 (m, 3H), 1.1-0.92 (m, 6H) 30 N-{4-[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.01 (s, (ESI(+)) methylpropanoyl) 1H), 8.11-7.82 (m, 2H), 7.80-7.31 (m, 2H), m/e 407 piperidin-4- 7.33-7.07 (m, 2H), 6.86 (ddd, J = 8.3, 2.9, 1.4 (M + H)+ yl]phenyl}-1- Hz, 1H), 4.61-4.49 (m, 1H), 4.16-3.87 (m, (pyridin-3- 4H), 3.77-3.64 (m, 1H), 3.20-2.99 (m, 1H), yl)azetidine-3- 2.89 (p, J = 6.7 Hz, 1H), 2.80-2.61 (m, 1H), carboxamide 2.64-2.47 (m, 1H), 1.89-1.60 (m, 2H), 1.61- 1.30 (m, 2H), 1.08 (d, J = 6.8 Hz, 2H), 1.05- 0.97 (m, 6H) 71 N-{4-[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.00 (s, (ESI(+)) hydroxy-2- 1H), 7.88 (dd, J = 4.7, 1.4 Hz, 1H), 7.57-7.50 m/e 437 methylpropanoyl) (m, 2H), 7.21-7.14 (m, 2H), 7.07 (dd, J = 8.0, (M + H)+ piperidin-4- 4.6 Hz, 1H), 6.85 (dd, J = 8.1, 1.4 Hz, 1H), 5.37 yl]phenyl}-1-(2- (s, 1H), 4.65 (bs, 1H), 4.10 (t, J = 7.7 Hz, 2H), methylpyridin-3- 3.97 (t, J = 6.8 Hz, 2H), 3.70-3.56 (m, 1H), yl)azetidine-3- 3.05-2.63 (m, 2H), 2.35 (s, 3H), 1.81-1.71 carboxamide (m, 2H), 1.66-1.36 (m, 3H), 1.33 (s, 6H), 1.28-1.13 (m, 1H) 72 N-{4-[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.99 (s, (ESI(+)) hydroxy-2- 1H), 7.90 (d, J = 4.7 Hz, 1H), 7.76 (s, 1H), m/e 437 methylpropanoyl) 7.57-7.50 (m, 2H), 7.21-7.14 (m, 2H), 7.00 (d, J = (M + H)+ piperidin-4- 4.7 Hz, 1H), 5.35 (s, 1H), 4.71 (bs, 2H), 4.15 (t, yl]phenyl}-1-(4- J = 7.7 Hz, 2H), 4.05 (t, J = 6.8 Hz, 2H), 3.72- methylpyridin-3- 3.58 (m, 1H), 3.22-2.63 (m, 1H), 2.18 (s, 3H), yl)azetidine-3- 1.82-1.72 (m, 2H), 1.62-1.36 (m, 2H), 1.33 (s, carboxamide 6H), 1.20 (d, J = 18.3 Hz, 1H), 0.89-0.72 (m, 1H) 73 N-{4-[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.94 (s, (ESI(+)) hydroxy-2- 1H), 7.56-7.49 (m, 3H), 7.21-7.13 (m, 2H), m/e 453 methylpropanoyl) 6.84 (dd, J = 7.5, 4.9 Hz, 1H), 6.72 (dd, J = 7.5, (M + H)+ piperidin-4- 1.6 Hz, 1H), 5.35 (s, 1H), 4.72 (bs, 2H), 4.07 (t, yl]phenyl}-1-(2- J = 7.9 Hz, 2H), 3.95 (d, J = 6.9 Hz, 2H), 3.83 (s, methoxypyridin- 3H), 3.66-3.52 (m, 1H), 2.73 (t, J = 11.9 Hz, 3-yl)azetidine-3- 2H), 1.82-1.71 (m, 2H), 1.59-1.36 (m, 2H), carboxamide 1.33 (s, 6H) 96 N-{4-[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.94 (s, (ESI(+)) hydroxy-2- 1H), 7.93 (d, J = 5.3 Hz, 1H), 7.63 (s, 1H), m/e 453 methylpropanoyl) 7.56-7.49 (m, 2H), 7.21-7.13 (m, 2H), 6.88 (d, J = (M + H)+ piperidin-4- 5.4 Hz, 1H), 5.35 (s, 1H), 4.71 (bs, 1H), 4.09 (t, yl]phenyl}-1-(4- J = 7.9 Hz, 2H), 3.96 (dd, J = 12.1, 4.8 Hz, 2H), methoxypyridin- 3.79 (s, 3H), 3.71-3.54 (m, 2H), 2.73 (t, J = 3-yl)azetidine-3- 11.8 Hz, 1H), 1.76 (d, J = 11.4 Hz, 3H), 1.51 (s, carboxamide 3H), 1.33 (s, 6H) 97 1-(4- 1H NMR (300 MHz, DMSO-d6) δ ppm 10.04 (s, (ESI(+)) cyanopyridin-3- 1H), 8.09 (s, 1H), 7.96 (d, J = 5.0 Hz, 1H), 7.54 m/e 448 yl)-N-{4-[1-(2- (d, J = 8.6 Hz, 2H), 7.46 (dd, J = 5.1, 0.5 Hz, (M + H)+ hydroxy-2- 1H), 7.18 (d, J = 8.6 Hz, 2H), 5.36 (s, 1H), 4.74 methylpropanoyl) (s, 1H), 4.43 (t, J = 8.3 Hz, 2H), 4.31 (dd, J = piperidin-4- 8.0, 5.8 Hz, 2H), 3.79-3.66 (m, 1H), 2.74 (dd, J = yl]phenyl} 13.8, 10.3 Hz, 2H), 1.81-1.72 (m, 3H), 1.65- azetidine-3- 1.45 (m, 3H), 1.33 (s, 6H) carboxamide 98 N-[4-(1- (ESI(+)) pentanoylpiperidin- m/e 421 4-yl)phenyl]-1- (M + H)+ (pyridin-3- yl)azetidine-3- carboxamide 99 N-{4-[1-(3- (ESI(+)) methylpentanoyl) m/e 435 piperidin-4- (M + H)+ yl]phenyl]}-1- (pyridin-3- yl)azetidine-3- carboxamide 100 N-(4-{1- (ESI(+)) [(1 S, 4 R)- m/e 473 bicyclo[2.2.1] (M + H)+ hept-2- ylacetyl]piperidin- 4-yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 101 N-{4-[1- (ESI(+)) (cyclopentylacetyl) m/e 447 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 102 N-(4-{1-[(2- (ESI(+)) methylcyclopropyl) m/e 419 carbonyl]piperidin- (M + H)+ 4-yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 103 N-{4-[1- (ESI(+)) (morpholin-4- m/e 464 ylacetyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 104 N-{4-[1-(furan-3- (ESI(+)) ylcarbonyl) m/e 431 piperidin-4- (M + H)+ yl]phenyl}- 1-(pyridin-3- yl)azetidine-3- carboxamide 105 1-(pyridin-3-yl)- (ESI(+)) N-{4-[1- m/e 474 (pyrrolidin-1- (M + H)+ ylacetyl)piperidin- 4-yl] phenyl}azetidine-3- carboxamide 106 N-{4-[1-(5- (ESI(+)) oxo-D- m/e 448 prolyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 107 N-{4-[1-(N,N- (ESI(+)) dimethyl-beta- m/e 436 alanyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 108 1-(pyridin-3-yl)- (ESI(+)) N-{4-[1-(1,3- m/e 448 thiazol-2- (M + H)+ ylcarbonyl) piperidin-4- yl]phenyl} azetidine-3- carboxamide 109 1-(pyridin-3-yl)- (ESI(+)) N-{4-[1- m/e 447 (thiophen-3- (M + H)+ ylcarbonyl) piperidin-4- yl]phenyl} azetidine-3- carboxamide 110 N-(4-{1-[(1- (ESI(+)) methylcyclopropyl) m/e 419 carbonyl] (M + H)+ piperidin-4- yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 111 N-(4-{1-[(3- (ESI(+)) methylthiophen- m/e 461 2- (M + H)+ yl)carbonyl] piperidin-4- yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 112 1-(pyridin-3-yl)- (ESI(+)) N-{4-[1-(4,4,4- m/e 461 trifluorobutanoyl) (M + H)+ piperidin-4- yl]phenyl} azetidine-3- carboxamide 113 N-(4-{1-[(4- (ESI(+)) methylpiperazin- m/e 477 1-yl)acetyl] (M + H)+ piperidin- 4-yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 114 N-{4-[1-(5-oxo- (ESI(+)) L- m/e 448 prolyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 115 N-{4-[1-(3- (ESI(+)) ethoxypropanoyl) m/e 437 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 116 N-{4-[1-(4- (ESI(+)) methylpentanoyl) m/e 435 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 117 N-(4-{1-[(1- (ESI(+)) methylcyclohexyl) m/e 461 carbonyl]piperidin- (M + H)+ 4-yl}phenyl)- 1-(pyridin-3- yl)azetidine-3- carboxamide 118 N-[4-(1- (ESI(+)) acetylpiperidin- m/e 379 4-yl)phenyl]-1- (M + H)+ (pyridin-3- yl)azetidine-3- carboxamide 119 N-{4-[1- (ESI(+)) (cyclohexylacetyl) m/e 461 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 120 N-{4-[1-(N- (ESI(+)) acetyl-L- m/e 492 leucyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 121 N-[4-(1- (ESI(+)) propanoylpiperidin- m/e 393 4-yl)phenyl]- (M + H)+ 1-(pyridin-3- yl)azetidine-3- carboxamide 122 1-(pyridin-3-yl)- (ESI(+)) N-{4-[1-(3,3,3- m/e 447 trifluoropropanoyl) (M + H)+ piperidin-4- yl]phenyl} azetidine-3- carboxamide 123 N-(4-{1-[(2- (ESI(+)) methoxyethoxy) m/e 453 acetyl]piperidin-4- (M + H)+ yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 124 N-(4-{1-[3- (ESI(+)) (morpholin-4- m/e 478 yl)propanoyl] (M + H)+ piperidin-4- yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 125 N-{4-[1-(2,2- (ESI(+)) dimethylpropanoyl) m/e 421 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 126 N-(4-{1-[(5- (ESI(+)) methylthiophen-2- m/e 461 yl)carbonyl] (M + H)+ piperidin-4- yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 127 1-(pyridin-3-yl)- (ESI(+)) N-{4-[1- m/e 447 (thiophen-2- (M + H)+ ylcarbonyl) piperidin-4- yl]phenyl} azetidine-3- carboxamide 128 N-(4-{1-[(1- (ESI(+)) methyl-1H- m/e 444 pyrrol-2- (M + H)+ yl)carbonyl] piperidin-4- yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 129 N-{4-[1-(furan-2- (ESI(+)) ylcarbonyl) m/e 431 piperidin-4-yl] (M + H)+ phenyl)-1-(pyridin- 3-yl)azetidine-3- carboxamide 130 N-(4-{1-[3- (ESI(+)) (piperidin-1- m/e 476 yl)propanoyl] (M + H)+ piperidin-4- yl}phenyl)-1- (pyridin-3- yl)azetidine-3- carboxamide 131 N-{4-[1- (ESI(+)) (ethoxyacetyl) m/e 423 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 132 N-{4-[1-(3,3- (ESI(+)) dimethylbutanoyl) m/e 435 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 133 N-{4-[1-(2,2- (ESI(+)) dimethylbutanoyl) m/e 435 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 134 N-[4-(1- (ESI(+)) butanoylpiperidin- m/e 407 4-yl)phenyl]-1- (M + H)+ (pyridin-3- yl)azetidine-3- carboxamide 135 N-{4-[1- (ESI(+)) (methoxyacetyl) m/e 409 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 136 N-{4-[1- (ESI(+)) (cyclohexyl- m/e 447 carbonyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 137 N-{4-[1-(3- (ESI(+)) methylbutanoyl) m/e 421 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 138 N-{4-[1- (ESI(+)) (cyclopentyl- m/e 433 carbonyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 139 N-{4-[1-(2,3- (ESI(+)) dimethylbutanoyl) m/e 435 piperidin-4- (M + H)+ yl]phenyl}-1- (pyridin-3- yl)azetidine-3- carboxamide 149 N-[4-(1- (ESI(+)) benzoylpiperidin- m/e 455 4-yl)phenyl]-1-(2- (M + H)+ methylpyridin-3- yl)azetidine-3- carboxamide 150 N-{4-[1-(2- (ESI(+)) fluorobenzoyl) m/e 473 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 151 N-{4-[1-(2- (ESI(+)) chlorobenzoyl) m/e 489 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 152 N-{4-[1-(3- (ESI(+)) fluorobenzoyl) m/e 473 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 153 N-{4-[1-(3- (ESI(+)) chlorobenzoyl) m/e 489 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 154 N-{4-[1-(3,5- (ESI(+)) dichlorobenzoyl) m/e 523 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 155 N-{4-[1-(4- (ESI(+)) fluorobenzoyl) m/e 473 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 156 N-{4-[1-(4- (ESI(+)) chlorobenzoyl) m/e 489 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 157 1-(2- (ESI(+)) methylpyridin-3- m/e 523 yl)-N-(4-{1-[4- (M + H)+ (trifluoromethyl) benzoyl]piperidin- 4-yl}phenyl) azetidine-3- carboxamide 158 1-(2- (ESI(+)) methylpyridin-3- m/e 457 yl)-N-{4-[1- (M + H)+ (pyridazin-3- ylcarbonyl) piperidin-4- yl]phenyl} azetidine-3- carboxamide 159 1-(2- (ESI(+)) methylpyridin-3- m/e 435 yl)-N-[4-(1- (M + H)+ pentanoylpiperidin- 4-yl)phenyl] azetidine-3- carboxamide 160 N-{4-[1-(3- (ESI(+)) methylpentanoyl) m/e 449 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 161 N-(4-{1- (ESI(+)) [(1 S, 4 R)- m/e 487 bicyclo[2.2.1] (M + H)+ hept-2- ylacetyl]piperidin- 4-yl}phenyl)-1- (2-methylpyridin- 3-yl)azetidine-3- carboxamide 162 N-{4-[1- (ESI(+)) (cyclopentylacetyl) m/e 461 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 163 N-(4-{1-[(2- (ESI(+)) methylcyclopropyl) m/e 433 carbonyl] (M + H)+ piperidin-4- yl}phenyl)-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 164 1-(2- (ESI(+)) methylpyridin-3- m/e 478 yl)-N-{4-[1- (M + H)+ (morpholin-4- ylacetyl)piperidin- 4-yl]phenyl} azetidine-3- carboxamide 165 N-{4-[1-(furan-3- (ESI(+)) ylcarbonyl) m/e 445 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 166 1-(2- (ESI(+)) methylpyridin-3- m/e 462 yl)-N-{4-[1- (M + H)+ (pyrrolidin-1- ylacetyl)piperidin- 4-yl]phenyl} azetidine-3- carboxamide 167 1-(2- (ESI(+)) methylpyridin-3- m/e 462 yl)-N-{4-[1-(5- (M + H)+ oxo-D- prolyl)piperidin- 4-yl]phenyl} azetidine-3- carboxamide 168 N-{4-[1-(N,N- (ESI(+)) dimethyl-beta- m/e 450 alanyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (2-methylpyridin- 3-yl)azetidine-3- carboxamide 169 1-(2- (ESI(+)) methylpyridin-3- m/e 461 yl)-N-{4-[1- (M + H)+ (thiophen-3- ylcarbonyl) piperidin-4- yl]phenyl} azetidine-3- carboxamide 170 N-(4-{1-[(1- (ESI(+)) methylcyclopropyl) m/e 433 carbonyl] (M + H)+ piperidin-4- yl}phenyl)-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 171 1-(2- (ESI(+)) methylpyridin-3- m/e 475 yl)-N-(4-{1-[(3- (M + H)+ methylthiophen- 2-yl)carbonyl] piperidin-4- yl}phenyl) azetidine-3- carboxamide 172 1-(2- (ESI(+)) methylpyridin-3- m/e 475 yl)-N-{4-[1- (M + H)+ (4,4,4- trifluorobutanoyl) piperidin-4- yl]phenyl} azetidine-3- carboxamide 173 N-(4-{1-[(4- (ESI(+)) methylpiperazin- m/e 491 1-yl)acetyl] (M + H)+ piperidin-4- yl}phenyl)-1- (2-methylpyridin- 3-yl)azetidine-3- carboxamide 174 1-(2- (ESI(+)) methylpyridin-3- m/e 462 yl)-N-{4-[1-(5- (M + H)+ oxo-L- prolyl)piperidin- 4-yl]phenyl} azetidine-3- carboxamide 175 N-{4-[1-(3- (ESI(+)) ethoxypropanoyl) m/e 451 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 176 N-{4-[1-(4- (ESI(+)) methylpentanoyl) m/e 449 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 177 N-(4-{1-[(1- (ESI(+)) methylcyclohexyl) m/e 475 carbonyl]piperidin- (M + H)+ 4-yl}phenyl)- 1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 178 N-[4-(1- (ESI(+)) acetylpiperidin- m/e 393 4-yl)phenyl]-1-(2- (M + H)+ methylpyridin-3- yl)azetidine-3- carboxamide 179 N-{4-[1- (ESI(+)) (cyclohexylacetyl) m/e 475 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 180 N-{4-[1-(N- (ESI(+)) acetyl-L- m/e 506 leucyl)piperidin- (M + H)+ 4-yl]phenyl}-1- (2-methylpyridin- 3-yl)azetidine-3- carboxamide 181 1-(2- (ESI(+)) methylpyridin-3- m/e 407 yl)-N-[4-(1- (M + H)+ propanoyl- piperidin-4- yl)phenyl] azetidine-3- carboxamide 182 1-(2- (ESI(+)) methylpyridin-3- m/e 461 yl)-N-{4-[1- (M + H)+ (3,3,3- trifluoropropanoyl) piperidin-4- yl]phenyl} azetidine-3- carboxamide 183 N-(4-{1-[(2- (ESI(+)) methoxyethoxy) m/e 467 acetyl]piperidin-4- (M + H)+ yl}phenyl)-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 184 1-(2- (ESI(+)) methylpyridin-3- m/e 492 yl)-N-(4-{1-[3- (M + H)+ (morpholin-4- yl)propanoyl] piperidin-4- yl}phenyl) azetidine-3- carboxamide 185 N-{4-[1-(2,2- (ESI(+)) dimethylpropanoyl) m/e 435 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 186 1-(2- (ESI(+)) methylpyridin-3- m/e 475 yl)-N-(4-{1-[(5- (M + H)+ methylthiophen-2- yl)carbonyl] piperidin-4- yl}phenyl) azetidine-3- carboxamide 187 1-(2- (ESI(+)) methylpyridin-3- m/e 461 yl)-N-{4-[1- (M + H)+ (thiophen-2- ylcarbonyl) piperidin-4- yl]phenyl} azetidine-3- carboxamide 188 1-(2- (ESI(+)) methylpyridin-3- m/e 458 yl)-N-(4-{1-[(1- (M + H)+ methyl-1H- pyrrol-2- yl)carbonyl] piperidin-4- yl}phenyl) azetidine-3- carboxamide 189 N-{4-[1-(furan-2- (ESI(+)) ylcarbonyl) m/e 445 piperidin-4-yl] (M + H)+ phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 190 1-(2- (ESI(+)) methylpyridin-3- m/e 490 yl)-N-(4-{1-[3- (M + H)+ (piperidin-1- yl)propanoyl] piperidin-4- yl}phenyl) azetidine-3- carboxamide 191 N-{4-[1- (ESI(+)) (ethoxyacetyl) m/e 437 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 192 N-{4-[1-(3,3- (ESI(+)) dimethylbutanoyl) m/e 449 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 193 N-{4-[1-(2,2- (ESI(+)) dimethylbutanoyl) m/e 449 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 194 N-[4-(1- (ESI(+)) butanoylpiperidin- m/e 421 4-yl)phenyl]-1-(2- (M + H)+ methylpyridin-3- yl)azetidine-3- carboxamide 195 N-{4-[1- (ESI(+)) (methoxyacetyl) m/e 423 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 196 N-{4-[1- (ESI(+)) (cyclohexyl- m/e 461 carbonyl) (M + H)+ piperidin-4- yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 197 N-{4-[1-(3- (ESI(+)) methylbutanoyl) m/e 435 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide 198 N-{4-[1-(2,3- (ESI(+)) dimethylbutanoyl) m/e 449 piperidin-4- (M + H)+ yl]phenyl}-1-(2- methylpyridin-3- yl)azetidine-3- carboxamide - The following Examples were prepared essentially as described in Example 10, substituting the appropriate bromopyridine in Example 10C and the appropriate carboxylic acid in Example 10E. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described in Example 1D-E, substituting tert-butyl 4-[4-({[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate in Example 1D. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.98 (s, 1H), 7.99 (d, J=2.9 Hz, 1H), 7.91 (d, J=4.8 Hz, 1H), 7.50 (s, 2H), 7.33 (dd, J=8.5, 4.8 Hz, 1H), 7.16-7.09 (m, 1H), 6.97-6.89 (m, 2H), 4.58-4.47 (m, 1H), 3.95-3.65 (m, 4H), 3.56 (d, J=8.6 Hz, 1H), 3.50-3.32 (m, 6H), 2.36-2.11 (m, 4H), 2.01-1.79 (m, 3H), 1.66-1.38 (m, 4H), 1.32-1.08 (m, 3H); MS (ESI(+)) m/e 493 (M+H)+.
-
TABLE 3 Ex Name 1H NMR MS 12 (3 S)-N-(4-{[1-(2- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.97 (s, (ESI(+)) methylpropanoyl) 1H), 7.96 (d, J = 2.9 Hz, 1H), 7.86 (dd, J = 4.6, m/e 437 piperidin-4- 1.3 Hz, 1H), 7.55-7.48 (m, 2H), 7.19 (dd, J = (M + H)+ yl]oxy}phenyl)- 8.4, 4.6 Hz, 1H), 6.99-6.90 (m, 3H), 4.59- 1-(pyridin-3- 4.48 (m, 1H), 4.03-3.67 (m, 3H), 3.54 (d, J = yl)pyrrolidine-3- 8.6 Hz, 1H), 3.47-3.38 (m, 2H), 3.35 (d, J = 7.4 carboxamide Hz, 2H), 3.28-3.18 (m, 1H), 2.95-2.82 (m, 1H), 2.38-2.03 (m, 2H), 2.00-1.80 (m, 2H), 1.64-1.37 (m, 2H), 1.00 (d, J = 6.7 Hz, 6H) 13 (3 S)-1-(pyridin- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.97 (s, (ESI(+)) 3-yl)-N-[4-({1- 1H), 7.97 (d, J = 2.8 Hz, 1H), 7.88 (d, J = 5.1 m/e 465 [(2 S)- Hz, 1H), 7.55-7.48 (m, 2H), 7.33-7.19 (m, (M + H)+ tetrahydrofuran-2- 1H), 7.05-6.88 (m, 3H), 4.67 (t, J = 6.5 Hz, ylcarbonyl] 1H), 4.57-4.50 (m, 1H), 3.94-3.67 (m, 4H), piperidin-4- 3.55 (d, J = 8.6 Hz, 1H), 3.47-3.38 (m, 4H), yl}oxy)phenyl] 2.38-2.12 (m, 2H), 2.07-1.74 (m, 7H), 1.65- pyrrolidine-3- 1.00 (m, 3H) carboxamide 14 (3 S)-1-(pyridin- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.97 (s, (ESI(+)) 3-yl)-N-[4-({1- 1H), 7.96 (d, J = 2.9 Hz, 1H), 7.87 (dd, J = 4.6, m/e 465 [(2 R)- 1.2 Hz, 1H), 7.55-7.48 (m, 2H), 7.21 (dd, J = (M + H)+ tetrahydrofuran- 8.4, 4.6 Hz, 1H), 7.02-6.93 (m, 2H), 6.92 (s, 2-ylcarbonyl] 1H), 4.67 (t, J = 6.6 Hz, 1H), 4.57-4.50 (m, pipiperidin-4- 1H), 3.94-3.62 (m, 4H), 3.54 (d, J = 8.6 Hz yl}oxy)phenyl] 1H), 3.44 (d, J = 6.7 Hz, 2H), 3.41 (d, J = 5.4 pyrrolidine-3- Hz, 2H), 3.23 (d, J = 7.8 Hz, 1H), 2.36-2.07 carboxamide (m, 3H), 2.09-1.76 (m, 6H), 1.65-1.39 (m, 2H) 15 (3 S)-1-(pyridin- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.97 (s, (ESI(+)) 3-yl)-N-(4-{[1- 1H), 7.97 (d, J = 2.9 Hz, 1H), 7.88 (dd, J = 4.7, m/e 465 (tetrahydrofuran- 1.2 Hz, 1H), 7.55-7.48 (m, 2H), 7.25 (dd, J = (M + H)+ 3-ylcarbonyl) 8.4, 4.7 Hz, 1H), 7.02 (dd, J = 8.5, 2.8 Hz, 1H), piperidin-4- 6.97-6.90 (m, 2H), 4.60-4.48 (m, 1H), 3.98- yl]oxy}phenyl) 3.61 (m, 7H), 3.55 (d, J = 8.6 Hz, 1H), 3.45 pyrrolidine-3- (d, J = 6.9 Hz, 2H), 3.44-3.39 (m, 2H), 3.38- carboxamide 3.32 (m, 2H), 2.38-2.09 (m, 2H), 2.10-1.81 (m, 4H), 1.65-1.40 (m, 2H) 16 (3 S)-N-(4-{[1- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.96 (s, (ESI(+)) (cyclopropylacetyl) 1H), 7.99-7.93 (m, 1H), 7.85 (dd, J = 4.6, 1.3 m/e 449 piperidin-4- Hz, 1H), 7.55-7.48 (m, 2H), 7.16 (dd, J = 8.4, (M + H)+ yl)oxy}phenyl)- 4.5 Hz, 1H), 6.98-6.87 (m, 3H), 4.59-4.47 (m, 1-(pyridin-3- 1H), 3.92-3.80 (m, 1H), 3.73-3.61 (m, 1H), yl)pyrrolidine-3- 3.54 (d, J = 8.6 Hz, 1H), 3.47-3.37 (m, 2H), carboxamide 3.26-3.07 (m, 3H), 2.27 (d, J = 6.8 Hz, 3H), 2.23-2.12 (m, 1H), 1.97-1.79 (m, 2H), 1.62- 1.32 (m, 2H), 1.04-0.83 (m, 1H), 0.49-0.36 (m, 2H), 0.19-0.07 (m, 2H) 17 (3 S)-N-(4-{[1- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.96 (s, (ESI(+)) (2-hydroxy-2- 1H), 7.96 (d, J = 3.1 Hz, 1H), 7.87 (d, J = 4.7 m/e 453 methylpropanoyl) Hz, 1H), 7.57-7.39 (m, 2H), 7.21 (dd, J = 8.4, (M + H)+ piperidin-4- 4.6 Hz, 1H), 7.03-6.88 (m, 3H), 5.38 (s, 1H), yl]oxy}phenyl)- 4.59-3.79 (m, 3H), 3.65-3.38 (m, 4H), 2.35- 1-(pyridin-3- 2.10 (m, 2H), 1.99-1.84 (m, 2H), 1.63-1.34 yl)pyrrolidine-3- (m, 3H), 1.35-1.19 (m, 7H) carboxamide 18 (3 S)-1-(pyridin- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.96 (s, (ESI(+)) 3-yl)-N-(4-{[1- 1H), 7.95 (d, J = 2.9 Hz, 1H), 7.85 (dd, J = 4.6, m/e 477 (3,3,3-trifluoro- 1.3 Hz, 1H), 7.55-7.48 (m, 2H), 7.16 (dd, J = (M + H)+ propanoyl) 8.4, 4.5 Hz, 1H), 6.98-6.88 (m, 3H), 4.55 (dq, piperidin-4- J = 7.7, 3.8 Hz, 1H), 3.83 (ddd, J = 13.2, 6.8, 3.9 yl]oxy}phenyl) Hz, 1H), 3.74-3.49 (m, 5H), 3.48-3.38 (m, pyrrolidine-3- 2H), 2.38-2.06 (m, 3H), 2.02-1.80 (m, 2H), carboxamide 1.71-1.36 (m, 3H) 19 (3 S)-N-[4-({1- 1H NMR (300 MHz, DMSO-d6) δ ppm 9.96 (s, (ESI(+)) [(2 S)-2- 1H), 7.95 (d, J = 2.9 Hz, 1H), 7.85 (d, J = 4.6 m/e 451 methylbutanoyl] Hz, 1H), 7.55-7.48 (m, 2H), 7.16 (dd, J = 8.4, (M + H)+ piperidin-4- 4.5 Hz, 1H), 6.98-6.88 (m, 3H), 4.60-4.48 (m, yl}oxy)phenyl]- 1H), 4.03-3.69 (m, 2H), 3.54 (d, J = 8.6 Hz, 1-(pyridin-3- 1H), 3.47-3.37 (m, 2H), 3.33 (d, J = 4.6 Hz, yl)pyrrolidine-3- 1H), 3.27-3.17 (m, 1H), 2.72 (h, J = 6.7 Hz, carboxamide 1H), 2.35-2.01 (m, 2H), 2.02-1.79 (m, 2H), 1.65-1.10 (m, 5H), 0.98 (d, J = 6.7 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H) - The following Examples were prepared essentially as described in Example 1D-E, substituting tert-butyl 4-[4-({[(3S)-1-(pyridin-3-yl)pyrrolidin-3-yl]carbonyl}amino)phenoxy]piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate in Example 1D and the appropriate carboxylic acid for 2-(tetrahydro-2H-pyran-4-yl)acetic acid in Example 1E. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described in Example 1A, substituting benzyl 3-aminoazetidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4-(1-(tert-butoxycarbonyl)piperidin-4-yloxy)benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidin-3-ylcarbamoyl)phenoxy)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting benzyl 3-(4-(piperidin-4-yloxy)benzamido)azetidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-(tetrahydro-2H-pyran-4-yl)acetic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting benzyl 3-(4-(1-(2-(tetrahydro-2H-pyran-4-yl)acetyl)piperidin-4-yloxy)benzamido)azetidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting N-(azetidin-3-yl)-4-(1-(2-(tetrahydro-2H-pyran-4-yl)acetyl)piperidin-4-yloxy)benzamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.83 (d, J=6.8 Hz, 1H), 7.93 (d, J=4.0 Hz, 1H), 7.85 (d, J=8.4 Hz, 3H), 7.27 (s, 2H), 7.26-7.11 (m, 1H), 7.05 (d, J=8.6 Hz, 2H), 6.87 (d, J=8.1 Hz, 1H), 4.86 (d, J=6.9 Hz, 1H), 4.71 (s, 1H), 4.28-4.19 (m, 2H), 3.93-3.64 (m, 6H), 2.30-2.23 (m, 2H), 2.05-1.67 (m, 3H), 1.52 (t, J=29.3 Hz, 5H), 1.32-0.81 (m, 3H); MS (ESI(+)) m/e 479 (M+H)+.
- The title compound was prepared as described in Example 21, substituting (S)-2-methylbutanoic acid for 2-(tetrahydro-2H-pyran-4-yl)acetic acid in Example 21C. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.84 (d, J=7.0 Hz, 1H), 7.99-7.84 (m, 3H), 7.83 (s, 1H), 7.18 (dd, J=8.2, 4.6 Hz, 1H), 7.09-7.01 (m, 2H), 6.87 (ddd, J=8.2, 2.8, 1.4 Hz, 1H), 4.94-4.64 (m, 2H), 4.24 (t, J=7.5 Hz, 2H), 3.98-3.72 (m, 4H), 2.73 (h, J=6.7 Hz, 1H), 2.04-1.83 (m, 2H), 1.67-1.20 (m, 4H), 1.06-0.87 (m, 4H), 0.87-0.77 (m, 4H); MS (ESI(+)) m/e 437 (M+H)+.
- The title compound was prepared as described in Example 21, substituting 2-hydroxy-2-methylpropanoic acid for 2-(tetrahydro-2H-pyran-4-yl)acetic acid in Example 21C. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.84 (d, J=7.0 Hz, 1H), 7.93 (dd, J=4.6, 1.3 Hz, 1H), 7.87-7.86 (m, 1H), 7.86 (s, 1H), 7.84 (s, 1H), 7.18 (dd, J=8.2, 4.6 Hz, 1H), 7.08-7.02 (m, 2H), 6.87 (ddd, J=8.2, 2.8, 1.4 Hz, 1H), 5.40 (s, 1H), 4.92-4.81 (m, 1H), 4.76-4.67 (m, 1H), 4.24 (t, J=7.5 Hz, 3H), 3.82 (dd, J=7.6, 5.9 Hz, 3H), 1.98-1.94 (m, 3H), 1.72-1.41 (m, 3H), 1.32 (s, 6H); MS (ESI(+)) m/e 439 (M+H)+.
- The title compound was prepared as described in Example 21A, D and E, substituting (S)-benzyl 3-aminopyrrolidine-1-carboxylate for benzyl 3-aminoazetidine-1-carboxylate in Example 21A. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.43 (d, J=6.8 Hz, 1H), 7.94 (d, J=2.9 Hz, 1H), 7.87-7.80 (m, 3H), 7.15 (dd, J=8.4, 4.5 Hz, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 6.90 (ddd, J=8.4, 3.0, 1.3 Hz, 1H), 4.71-4.55 (m, 2H), 3.73-3.53 (m, 3H), 3.44 (t, J=7.5 Hz, 1H), 3.18 (d, J=13.4 Hz, 2H), 3.17 (d, J=12.2 Hz, 2H), 2.34-2.19 (m, 1H), 2.14-1.97 (m, 1H), 1.98-1.82 (m, 2H), 1.63-1.43 (m, 2H), 1.40 (s, 9H); MS (ESI(+)) m/e 467 (M+H)+.
- The title compound was prepared as described in Example 21A, D and E, substituting (R)-benzyl 3-aminopyrrolidine-1-carboxylate for benzyl 3-aminoazetidine-1-carboxylate in Example 21A. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.44 (d, J=6.8 Hz, 1H), 7.94 (d, J=2.9 Hz, 1H), 7.88-7.79 (m, 3H), 7.15 (dd, J=8.3, 4.5 Hz, 1H), 7.06-6.98 (m, 2H), 6.90 (ddd, J=8.4, 3.0, 1.4 Hz, 1H), 4.72-4.54 (m, 2H), 3.74-3.50 (m, 3H), 3.51-3.39 (m, 1H), 3.18 (d, J=13.6 Hz, 2H), 3.16 (d, J=11.9 Hz, 1H), 2.33-2.18 (m, 1H), 2.07 (dq, J=12.9, 6.5 Hz, 1H), 2.00-1.82 (m, 2H), 1.67-1.43 (m, 2H), 1.40 (s, 9H); MS (ESI(+)) m/e 467 (M+H)+.
- In a 20 mL vial was added N-(4-(piperidin-4-yloxy)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide bis(2,2,2-trifluoroacetate) (67 mg, 0.12 mmol) dissolved in methanol (2.0 mL) followed by the addition of cyclopropanecarbaldehyde (10 mg, 0.14 mmol) dissolved in methanol (0.45 mL), followed by the addition of neat acetic acid (66 μL, 1.2 mmol). The mixture was shaken for 1 hour at 70° C. After that, 265 mg of MP-cyanoborohydride resin (2-3 mmol/g) was added and the resulting mixture was shaken at 70° C. overnight. The reaction mixture was filtered, checked by LC/MS and concentrated to dryness. The residues were dissolved in 1:1 DMSO/CH3OH and purified by reverse phase HPLC. 1H NMR (500 MHz, pyridine-d5/D2O) δ ppm 8.20-8.25 (m, 1H) 8.13 (d, J=2.75 Hz, 1H) 7.98-8.03 (m, 2H) 7.11 (dd, J=8.24, 4.58 Hz, 1H) 7.02-7.07 (m, 2H) 6.72-6.78 (m, 1H) 4.58 (d, J=2.75 Hz, 1H) 4.34 (t, J=6.71 Hz, 2H) 4.05 (t, J=7.63 Hz, 2H) 3.80-3.92 (m, 1H) 3.34 (s, 4H) 2.92 (d, J=7.32 Hz, 2H) 2.32-2.44 (m, 2H) 2.12 (s, 2H) 1.09-1.22 (m, 1H) 0.51-0.58 (m, 2H) 0.28-0.34 (m, 2H); MS (ESI(+)) m/e 407 (M+H).
-
TABLE 4 Ex Name 1H NMR MS 75 N-(4-{[1-(2- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) methylpentyl) 27° C.) δ ppm 8.23 (dd, J = 4.58, 1.22 Hz, 1 H) m/e 437 piperidin-4- 8.13 (d, J = 2.75 Hz, 1H) 7.97-8.03 (m, 2 H) 7.06- (M + H)+ yl]oxy}phenyl)- 7.13 (m, 3 H) 6.71-6.77 (m, 1 H) 4.44 (s, 1 H) 1-(pyridin-3- 4.34 (t, J = 6.56 Hz, 2 H) 4.00-4.08 (m, 2 H) 3.78- yl)azetidine-3- 3.88 (m, 1 H) 2.96 (s, 2 H) 2.67 (s, 1 H) 2.34-2.48 carboxamide (m, J = 2.44 Hz, 3 H) 2.21 (s, 2 H) 1.97 (s, 2 H) 1.72-1.83 (m, 1 H) 1.15-1.45 (m, 3 H) 1.00-1.10 (m, 1 H) 0.96 (d, J = 6.71 Hz, 3 H) 0.85 (t, J = 7.17 Hz, 3 H) 76 N-(4-{[1-(2- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) methylpropyl) 27° C.) δ ppm 8.23 (dd, J = 4.73, 1.37 Hz, 1 H) m/e 409 piperidin-4- 8.13 (d, J = 2.75 Hz, 1 H) 7.97-8.04 (m, 2 H) 7.04- (M + H)+ yl]oxy}phenyl)- 7.15 (m, 3 H) 6.72-6.76 (m, 1 H) 4.40-4.47 (m, 1-(pyridin-3- 1 H) 4.34 (t, J = 6.56 Hz, 2 H) 3.99-4.09 (m, 2 H) yl)azetidine-3- 3.79-3.89 (m, 1 H) 2.91-3.00 (m, 2 H) 2.61-2.82 carboxamide (m, 2 H) 2.36-2.45 (m, 2 H) 2.13-2.26 (m, J = 9.46 Hz, 2 H) 1.79-2.04 (m, 3 H) 0.92 (d, J = 6.41 Hz, 6 H) 77 N-(4-{[1-(3- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) methylbutyl) 27° C.) δ ppm 8.21-8.26 (m, 1 H) 8.14 (d, J = 3.05 m/e 423 piperidin-4- Hz, 1 H) 7.98-8.03 (m, 2 H) 7.05-7.13 (m, 3 H) (M + H)+ yl]oxy}phenyl)- 6.71-6.77 (m, 1 H) 4.47-4.54 (m, 1 H) 4.34 (t, 1-(pyridin-3- J = 6.56 Hz, 2 H) 4.00-4.07 (m, 2 H) 3.80-3.89 yl)azetidine-3- (m, 1 H) 3.11 (s, 2 H) 2.87-3.06 (m, 2 H) 2.77- carboxamide 2.86 (m, 2 H) 2.22-2.33 (m, 2 H) 2.04 (s, 2 H) 1.47-1.61 (m, 3 H) 0.82 (d, J = 6.41 Hz, 6 H) 78 N-(4-{[1-(2- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) ethylbutyl) 27° C.) δ ppm 8.23 (dd, J = 4.58, 1.22 Hz, 1 H) m/e 437 piperidin-4- 8.13 (d, J = 2.75 Hz, 1 H) 7.98-8.03 (m, 2 H) (M + H)+ yl]oxy}phenyl)- 7.06-7.13 (m, 3 H) 6.71-6.76 (m, 1 H) 4.40-4.49 1-(pyridin-3- (m, 1 H) 4.34 (t, J = 6.56 Hz, 2 H) 4.00-4.06 (m, yl)azetidine-3- 2 H) 3.78-3.88 (m, 1 H) 2.91-3.03 (m, 2 H) carboxamide 2.57-2.77 (m, 2 H) 2.40-2.49 (m, J = 4.27, 2.14 Hz, 2 H) 2.14-2.28 (m, 2 H) 1.90-2.01 (m, J = 14.04 Hz, 2 H) 1.58 (s, 1 H) 1.29-1.45 (m, 4 H) 0.84 (t, J = 7.48 Hz, 6 H) 79 N-(4-{[1-(2,2- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) dimethylpropyl) 27° C.) δ ppm 8.23 (dd, J = 4.58, 1.22 Hz, 1 H) m/e 423 piperidin-4- 8.14 (d, J = 2.75 Hz, 1 H) 7.99-8.01 (m, 2 H) (M + H)+ yl]oxy}phenyl)- 7.07-7.13 (m, 3 H) 6.74 (d, J = 5.49 Hz, 1 H) 1-(pyridin-3- 4.33 (t, J = 6.56 Hz, 2 H) 4.00-4.06 (m, 2 H) yl)azetidine-3- 3.80-3.86 (m, 1 H) 2.73-2.81 (m, 2 H) 2.34-2.43 carboxamide (m, 2 H) 1.93-2.03 (m, 4 H) 1.76-1.88 (m, 2 H) 1.24-1.34 (m, 1 H) 0.87 (s, 9 H) 80 N-(4-{[1-(2- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) methylbutyl) 27° C.) δ ppm 8.21-8.24 (m, 1 H) 8.13 (d, J = 2.75 m/e 423 piperidin-4- Hz, 1 H) 8.00 (d, J = 9.16 Hz, 2 H) 7.07-7.14 (m, (M + H)+ yl]oxy}phenyl)- 3 H) 6.70-6.77 (m, 1 H) 4.29-4.39 (m, 3 H) 3.97- 1-(pyridin-3- 4.06 (m, 2 H) 3.77-3.86 (m, 1 H) 2.75-2.88 (m, yl)azetidine-3- 2 H) 2.45-2.56 (m, 4 H) 2.04-2.25 (m, 3 H) 1.85- carboxamide 1.97 (m, 2 H) 1.38-1.64 (m, 2 H) 0.81-0.93 (m, 6H) 81 N-{4-[(1- (ESI(+) propylpiperidin- m/e 395 4-yl)oxy]phenyl}- (M + H)+ 1-(pyridin-3- yl)azetidine-3- carboxamide 82 N-(4-{[1-(2- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) cyclopropylethyl) 27° C.) δ ppm 8.23 (dd, J = 4.58, 1.53 Hz, 1 H) m/e 421 piperidin-4- 8.14 (d, J = 2.44 Hz, 1 H) 7.95-8.04 (m, 2 H) (M + H)+ yl]oxy}phenyl)- 7.05-7.14 (m, 3 H) 6.69-6.78 (m, 1 H) 4.42-4.51 1-(pyridin-3- (m, 1 H) 4.34 (t, J = 6.56 Hz, 2 H) 3.95-4.11 yl)azetidine-3- (m, 2 H) 3.79-3.89 (m, J = 8.24, 8.24 Hz, 1 H) carboxamide 3.00-3.13 (m, 2 H) 2.73-2.93 (m, 3 H) 2.40-2.48 (m, 1 H) 2.15-2.30 (m, 2 H) 2.01 (s, 2 H) 1.50-1.61 (m, J = 8.54 Hz, 2 H) 0.54-0.70 (m, 1 H) 0.33-0.42 (m, 2 H) 0.06 (t, J = 4.73 Hz, 2 H) 83 1-(pyridin-3- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) yl)-N-(4-{[1- 27° C.) δ ppm 8.23 (dd, J = 4.58, 1.22 Hz, 1 H) m/e 437 (tetrahydrofuran- 8.13 (d, J = 2.75 Hz, 1 H) 7.98-8.04 (m, 2 H) (M + H)+ 3-ylmethyl) 7.03-7.15 (m, 3 H) 6.70-6.77 (m, 1 H) 4.44-4.53 piperidin-4- (m, 1 H) 4.34 (t, J = 6.56 Hz, 2 H) 3.96-4.09 yl]oxy}phenyl) (m, 3 H) 3.77-3.92 (m, 2 H) 3.55-3.74 (m, 2 H) azetidine-3- 3.03-3.19 (m, 2 H) 2.86-3.04 (m, 2 H) 2.75-2.88 carboxamide (m, 2 H) 2.57-2.72 (m, 1 H) 2.19-2.34 (m, 2 H) 1.94-2.08 (m, 3 H) 1.56-1.71 (m, 1 H) 84 N-(4-{[1-(2,2- 1H NMR (500 MHz, pyridine-d5/D2O Temp = (ESI(+)) dimethylbutyl) 27° C.) δ ppm 8.23 (dd, J = 4.73, 1.37 Hz, 1 H) m/e 437 piperidin-4- 8.14 (d, J = 2.44 Hz, 1 H) 7.97-8.02 (m, 2 H) (M + H)+ yl]oxy}phenyl)- 7.07-7.13 (m, 3 H) 6.71-6.76 (m, 1 H) 4.28-4.38 1-(pyridin-3- (m, 2 H) 4.00-4.06 (m, 2 H) 3.82 (s, 1 H) yl)azetidine-3- 2.72-2.82 (m, 2 H) 2.29-2.43 (m, 2 H) 1.91-2.07 carboxamide (m, 4 H) 1.75-1.88 (m, 2 H) 1.19-1.29 (m, J = 7.22, 7.22, 7.22 Hz, 3 H) 0.72-0.86 (m, 9 H) - The following Examples were prepared essentially as described in Example 74, substituting the appropriate aldehyde for cyclopropanecarbaldehyde. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described in Example 10, substituting 4-bromopyridazine for 3-bromopyridine in Example 10C and 2-hydroxy-2-methylpropanoic acid for (S)-tetrahydrofuran-2-carboxylic acid in Example 10E. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.04 (s, 1H), 8.60 (d, J=6.0 Hz, 1H), 8.51 (d, J=3.0 Hz, 1H), 7.57-7.50 (m, 2H), 7.22-7.14 (m, 2H), 6.54 (dd, J=6.0, 3.0 Hz, 1H), 5.36 (s, 1H), 4.73 (bs, 2H), 4.30-3.96 (m, 4H), 3.87-3.60 (m, 1H), 2.71 (d, J=11.9 Hz, 1H), 1.82-1.72 (m, 2H), 1.67-1.42 (m, 2H), 1.35-1.31 (m, 8H); MS (ESI(+)) m/e 424 (M+H)+.
-
TABLE 5 Ex Name MS 140 N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 143 N-(4-{1-[(2 S)-2-methylbutanoyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 144 N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 448 (M + H)+ 145 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4- (ESI(+)) ylacetyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 464 (M + H)+ 146 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydro-2H-pyran-4- (ESI(+)) ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 564 (M + H)+ 525 N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 526 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 449 (M + H)+ 527 N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 420 (M + H)+ 528 N-{4-[1-(2-methylpropanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 408 (M + H)+ 529 N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 460 (M + H)+ 530 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-3-ylcarbonyl) (ESI(+)) piperidin-4-yl}phenyl}azetidine-3-carboxamide m/e 448 (M + H)+ 531 N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl}phenyl)- (ESI(+)) 1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 532 N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 533 N-{4-[1-(3,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 534 N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 535 1-(pyridazin-4-yl)-N-(4-{1-[3-[-(trifluoromethyl)benzoyl] (ESI(+)) piperidin-4-yl}phenyl)azetidine-3-carboxamide m/e 510 (M + H)+ 536 N-(4-{1-[(2,4-difluorophenyl)acetyl]piperidin-4-yl}phenyl)- (ESI(+)) 1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 537 1-(pyridazin-4-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 449 (M + H)+ 538 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 436 (M + H)+ 539 N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 540 N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl}phenyl)-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 541 N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 406 (M + H)+ 542 1-(pyridazin-4-yl)-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 436 (M + H)+ 543 1-(pyridazin-4-yl)-N-{4-[1-(pyridin-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 443 (M + H)+ 544 N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 545 N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 546 N-{4-[1-(2-methyl-2-phenylpropanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 484 (M + H)+ 547 N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 548 N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}- (ESI (+)) 1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 410 (M + H)+ 549 1-(pyridazin-4-yl)-N-{4-[1-(thiophen-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 448 (M + H)+ 550 1-(pyridazin-4-yl)-N-[4-(1-{[3- (ESI(+)) (trifluoromethyl)phenyl]acetyl}piperidin-4- m/e 524 yl)phenyl]azetidine-3-carboxamide (M + H)+ 551 N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 460 (M + H)+ 552 N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 553 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethyl)benzoyl] (ESI(+)) piperidin-4-yl}phenyl)azetidine-3-carboxamide m/e 510 (M + H)+ 554 N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 460 (M + H)+ 555 1-(pyridazin-4-yl)-N-(4-{1-[4-(trifluoromethoxy) (ESI(+)) benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide m/e 526 (M + H)+ 556 N-{4-[1-methylbutanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 557 1-(pyridazin-4-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 448 (M + H)+ 558 N-(4-{1-[difluoro(phenyl)acetyl]piperidin-4-yl}phenyl)-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 559 N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 560 N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin- (ESI(+)) 4-yl}phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 484 (M + H)+ 561 1-(pyridazin-4-yl)-N-[4-(1-{[4- (ESI(+)) (trifluoromethoxy)phenyl]acetyl}piperidin-4-yl) m/e 540 phenyl]azetidine-3-carboxamide (M + H)+ 562 1-(pyridazin-4-yl)-N-(4-{1-[3-(trifluoromethoxy) (ESI(+)) benzoyl]piperidin-4-yl}phenyl)azetidine-3-carboxamide m/e 526 (M + H)+ 563 1-(pyridazin-4-yl)-N-[4-(1-{[4- (ESI(+)) (trifluoromethyl)phenyl]acetyl}piperidin-4-yl) m/e 524 phenyl]azetidine-3-carboxamide (M + H)+ - The following Examples were essentially prepared as described in Example 10, substituting 4-bromopyridazine for 3-bromopyridine in Example 10C and the appropriate acid for (S)-tetrahydrofuran-2-carboxylic acid in Example 10E. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described in Example 74, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide for N-(4-(piperidin-4-yloxy)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide and cyclohexanecarbaldehyde for cyclopropanecarbaldehyde. 1H NMR (500 MHz, pyridine-d5/D2O) δ ppm 8.23 (dd, J=4.58, 1.22 Hz, 1H) 8.13 (d, J=2.75 Hz, 1H) 7.99 (d, J=8.54 Hz, 2H) 7.31-7.36 (m, 2H) 7.11 (dd, J=8.24, 4.27 Hz, 1H) 6.71-6.75 (m, 1H) 4.32 (t, J=6.56 Hz, 2H) 3.98-4.05 (m, 2H) 3.79-3.89 (m, 1H) 3.62-3.71 (m, 2H) 2.69-2.95 (m, 5H) 2.37-2.49 (m, 2H) 1.75-2.00 (m, 5H) 1.46-1.65 (m, 3H) 0.90-1.24 (m, 5H); (ESI(+)) m/e 433 (M+H).
-
TABLE 6 Ex Name 1H NMR MS 87 N-{4-[1-(3,3- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) dimethylbutyl) δ ppm 8.23 (dd, J = 4.73, 1.37 Hz, 1H) m/e 421 piperidin-4- 8.13 (d, J = 2.75 Hz, 1H) 7.98 (d, J = (M + H)+ yl]phenyl}-1- 8.54 Hz, 2H) 7.29-7.32 (m, 2H) 7.11 (pyridin-3- (dd, J = 7.93, 4.88 Hz, 1H) 6.69-6.75 yl)azetidine- (m, 1H) 4.32 (t, J = 6.71 Hz, 2H) 3.98- 3- 4.04 (m, 2H) 3.79-3.87 (m, 1H) 3.68 carboxamide (s, 2H) 3.08-3.15 (m, 2H) 2.80-2.92 (m, 2H) 2.71-2.79 (m, 1H) 2.34-2.46 (m, 2H) 1.90-1.99 (m, 2H) 1.71-1.78 (m, 2H) 0.87 (s, 9H) 88 N-{4-[1- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) (cyclopentyl δ ppm 8.23 (dd, J = 4.88, 1.22 Hz, 1H) m/e 419 methyl) 8.13 (d, J = 2.75 Hz, 1H) 7.99 (d, J = (M + H)+ piperidin-4- 8.54 Hz, 2H) 7.31-7.35 (m, 2H) 7.11 yl]phenyl}-1- (dd, J = 8.09, 4.73 Hz, 1H) 6.70-6.75 (pyridin-3- (m, 1H) 4.33 (t, J = 6.56 Hz, 2H) 3.97- yl)azetidine- 4.05 (m, 2H) 3.77-3.85 (m, 1H) 3.56- 3- 3.71 (m, 2H) 2.98 (d, J = 6.71 Hz, 2H) carboxamide 2.69-2.86 (m, J = 12.21, 12.21 Hz, 3H) 2.34-2.49 (m, 2H) 2.19-2.31 (m, 1H) 1.78-1.97 (m, 4H) 1.35-1.57 (m, 4H) 1.17-1.28 (m, 2H) 89 N-{4-[1-(2,2- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) dimethylbutyl) δ ppm 8.23 (dd, J = 4.58, 1.22 Hz, 1H) m/e 421 piperidin-4- 8.14 (d, J = 2.75 Hz, 1H) 8.02 (d, J = (M + H)+ yl]phenyl}-1- 8.54 Hz, 2H) 7.32 (d, J = 8.24 Hz, 2H) (pyridin-3- 7.11 (dd, J = 8.24, 4.58 Hz, 1H) 6.71- yl)azetidine- 6.75 (m, 1H) 4.33 (t, J = 6.56 Hz, 2H) 3- 3.99-4.05 (m, 2H) 3.79-3.86 (m, 1H) carboxamide 2.89-2.97 (m, 2H) 2.29-2.50 (m, J = 59.51 Hz, 3H) 2.14 (d, J = 3.97 Hz, 2H) 1.84-1.97 (m, 2H) 1.71-1.78 (m, 2H) 1.30 (q, J = 7.63 Hz, 2H) 0.88 (s, 6H) 0.82 (t, J = 7.48 Hz, 3H) 90 N-{4-[1-(2- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) methylpentyl) δ ppm 8.23 (dd, J = 4.73, 1.37 Hz, 1H) m/e 421 piperidin-4- 8.13 (d, J = 2.75 Hz, 1H) 7.99 (d, J = (M + H)+ yl]phenyl}-1- 8.54 Hz, 2H) 7.30-7.37 (m, 2H) 7.11 (pyridin-3- (dd, J = 8.24, 4.27 Hz, 1H) 6.69-6.77 yl)azetidine- (m, 1H) 4.28-4.36 (m, 2H) 3.96-4.06 3- (m, 2H) 3.77-3.87 (m, 1H) 3.53 (s, 2H) carboxamide 2.55-2.91 (m, 5H) 2.23-2.42 (m, 2H) 1.81-1.95 (m, J = 6.71 Hz, 3H) 1.04- 1.47 (m, 4H) 1.03 (t, J = 6.41 Hz, 3H) 0.85 (t, J = 7.17 Hz, 3H) 91 N-[4-(1- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) butylpiperidin- δ ppm 8.20-8.27 (m, 1H) 8.13 (d, J = m/e 393 4- 3.05 Hz, 1H) 7.99 (d, J = 8.54 Hz, 2H) (M + H)+ yl)phenyl]-1- 7.30-7.35 (m, 2H) 7.08-7.12 (m, 1H) (pyridin-3- 6.68-6.74 (m, 1H) 4.32 (t, J = 6.56 Hz, yl)azetidine- 2H) 3.97-4.06 (m, 2H) 3.78-3.86 (m, 3- 1H) 3.56-3.69 (m, 2H) 2.92-3.03 (m, carboxamide 2H) 2.66-2.87 (m, 3H) 2.29-2.45 (m, 2H) 1.91 (d, J = 13.73 Hz, 2H) 1.65- 1.77 (m, 2H) 1.10-1.31 (m, 2H) 0.79 (t, J = 7.32 Hz, 3H) 92 N-{4-[1-(2- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) ethylbutyl) δ ppm 8.23 (d, J = 4.58 Hz, 1H) 8.13 m/e 421 piperidin-4- (d, J = 2.75 Hz, 1H) 7.99 (d, J = 8.54 (M + H)+ yl]phenyl}-1- Hz, 2H) 7.33 (d, J = 8.54 Hz, 2H) 7.09- (pyridin-3- 7.11 (m, 1H) 6.70-6.74 (m, 1H) 4.32 (t, yl)azetidine- J = 6.56 Hz, 2H) 3.97-4.05 (m, 2H) 3- 3.78-3.86 (m, 1H) 3.43-3.61 (m, 2H) carboxamide 2.55-2.95 (m, 5H) 2.22-2.43 (m, 2H) 1.90 (d, J = 13.12 Hz, 2H) 1.67-1.78 (m, 1H) 1.30-1.50 (m, 4H) 0.85 (t, J = 7.48 Hz, 6H) 93 N-{4-[1-(3- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) methylbutyl) δ ppm 8.19-8.26 (m, 1H) 8.13 (d, J = m/e 407 piperidin-4- 2.75 Hz, 1H) 7.99 (d, J = 8.54 Hz, 2H) (M + H)+ yl]phenyl}-1- 7.29-7.34 (m, 2H) 7.11 (dd, J = 8.24, (pyridin-3- 4.58 Hz, 1H) 6.67-6.76 (m, 1H) 4.32 yl)azetidine- (t, J = 6.56 Hz, 2H) 3.98-4.04 (m, 2H) 3- 3.77-3.87 (m, 1H) 3.57-3.69 (m, 2H) carboxamide 2.95-3.05 (m, 2H) 2.67-2.87 (m, 3H) 2.29-2.44 (m, 2H) 1.84-1.98 (m, 2H) 1.60-1.71 (m, 2H) 1.39-1.58 (m, 1H) 0.82 (d, J=6.71 Hz, 6H) 94 N-{4-[1-(2- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) methylpropyl) δ ppm 8.21-8.27 (m, 1H) 8.14 (d, J = m/e 393 piperidin-4- 2.75 Hz, 1H) 7.99 (d, J = 8.54 Hz, 2H) (M + H)+ yl]phenyl}-1- 7.32 (d, J = 8.54 Hz, 2H) 7.11 (dd, J = (pyridin-3- 8.09, 4.73 Hz, 1H) 6.70-6.75 (m, 1H) yl)azetidine- 4.33 (t, J = 6.56 Hz, 2H) 3.97-4.04 (m, 3- 2H) 3.78-3.87 (m, 1H) 3.27-3.41 (m, carboxamide 2H) 2.62 (s, 1H) 2.38-2.52 (m, 4H) 2.10-2.26 (m, J = 22.28 Hz, 2H) 1.90- 1.99 (m, 1H) 1.81-1.88 (m, 2H) 0.95 (d, J = 6.41 Hz, 6H) 95 N-[4-(1- 1H NMR (500 MHz, pyridine-d5/D2O) (ESI(+)) propylpiperidin- δ ppm 8.21-8.25 (m, 1H) 8.10-8.15 m/e 379 4- (m, 1H) 7.98 (d, J = 8.54 Hz, 2H) 7.31 (M + H)+ yl)phenyl]-1- (d, J = 8.54 Hz, 2H) 7.11 (dd, J = 8.24, (pyridin-3- 4.58 Hz, 1H) 6.71-6.76 (m, 1H) 4.32 yl)azetidine- (t, J = 6.56 Hz, 2H) 3.99-4.04 (m, 2H) 3- 3.77-3.89 (m, 1H) 3.55-3.66 (m, 2H) carboxamide 2.86-2.98 (m, 2H) 2.64-2.86 (m, 3H) 2.30-2.46 (m, 2H) 1.90 (d, J = 14.04 Hz, 2H) 1.70-1.81 (m, 2H) 0.78 (t, J = 7.32 Hz, 3H) - The following Examples were prepared essentially as described in Example 74, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide for N-(4-(piperidin-4-yloxy)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide and the appropriate aldehyde for cyclopropanecarbaldehyde. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described in Example 1A, substituting (S)-1-((benzyloxy)carbonyl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid and tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1B, substituting (S)-tert-butyl 4-(4-(1-((benzyloxy)carbonyl)pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate and 4-bromopyridazine for 3-bromopyridine.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)—N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-hydroxy-2-methylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.07 (s, 1H), 8.68-8.61 (m, 1H), 8.61-8.50 (m, 1H), 7.52 (t, J=6.8 Hz, 2H), 7.17 (d, J=8.6 Hz, 2H), 6.62 (dd, J=6.3, 3.2 Hz, 1H), 5.35 (s, 1H), 3.73-3.34 (m, 8H), 2.73 (dd, J=13.9, 10.2 Hz, 2H), 2.40-2.06 (m, 2H), 1.76 (d, J=11.0 Hz, 2H), 1.64-1.38 (m, 2H), 1.33 (s, 6H); MS (ESI(+)) m/e 438 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)—N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-4-yl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and cyclopentylacetic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.07 (s, 1H), 8.64 (dd, J=3.1, 0.9 Hz, 1H), 8.57 (dd, J=6.2, 0.9 Hz, 1H), 7.54 (s, 1H), 7.51 (s, 1H), 7.21-7.13 (m, 2H), 6.61 (dd, J=6.2, 3.1 Hz, 1H), 3.68-3.41 (m, 8H), 3.18-3.00 (m, 1H), 2.78-2.64 (m, 1H), 2.42-2.06 (m, 5H), 1.83-1.69 (m, 4H), 1.65-1.20 (m, 6H), 1.22-1.04 (m, 2H); MS (ESI(+)) m/e 462 (M+H)+.
- In a 50 mL round-bottomed flask was added tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate (918 mg, 2.55 mmol) and diisopropylethylamine (0.558 ml, 3.19 mmol) in ethanol (10.6 ml). 3,6-dichloropyridazine (317 mg, 2.128 mmol) was added as a solid in a single portion. The reaction was stirred overnight at 45° C.; and the reaction was cooled and concentrated. Dichloromethane and water were added and the layers were separated. The aqueous layer was extracted three times with dichloromethane and the combined organics were dried with magnesium sulfate, filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography to give the title compound.
- To a 50 mL round-bottomed flask was added tert-butyl 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate (550 mg, 1.165 mmol) and Pd/C (93 mg, 0.087 mmol). The flask was flushed with nitrogen for 10 minutes and ethanol (11.7 ml) was added. Triethylamine (0.162 ml, 1.165 mmol) and cyclohexa-1,4-diene (654 mg, 8.16 mmol) were added and the reaction was stirred at 80° C. for 1 hour, cooled and filtered through diatomaceous earth. The filtrate was concentrated in vacuo and the residue was purified by regular phase flash column chromatography to give the title compound.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-methylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.52 (dd, J=9.2, 4.7 Hz, 2H), 7.40 (ddd, J=13.5, 7.9, 2.8 Hz, 1H), 7.18 (d, J=8.6 Hz, 2H), 6.82 (dd, J=8.9, 1.3 Hz, 1H), 4.55 (d, J=12.0 Hz, 1H), 4.32-3.90 (m, 5H), 3.83-3.54 (m, 1H), 3.10 (t, J=12.9 Hz, 1H), 2.89 (hept, J=6.7 Hz, 1H), 2.71 (ddd, J=28.5, 16.0, 11.7 Hz, 1H), 1.77 (d, J=12.3 Hz, 2H), 1.60-1.10 (m, 4H), 1.01 (t, J=6.0 Hz, 6H); MS (ESI(+)) m/e 408 (M+H)+.
-
TABLE 7 Ex Name MS 316 N-[4-(1-acetylpiperidin-4-yl)phenyl]-1-(pyridazin-3- (ESI(+)) yl)azetidine-3-carboxamide m/e 380 (M + H)+ 317 N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1-(pyridazin- (ESI(+)) 3-yl)azetidine-3-carboxamide m/e 408 (M + H)+ 318 N-[4-(1-pentanoylpiperidin-4-yl)phenyl]-1-(pyridazin- (ESI(+)) 3-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 319 N-{4-[1-(2-methylbutanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 320 N-{4-[1-(3-methylbutanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 321 N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1-(pyridazin- (ESI(+)) 3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 322 N-{4-[1-(2-methylpentanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 323 N-{4-[1-(3-methylpentanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 324 N-{4-[1-(4-methylpentanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 325 N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 326 N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 327 N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 328 N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 329 N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1-(pyridazin- (ESI(+)) 3-yl)azetidine-3-carboxamide m/e 450 (M + H)+ 330 N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 406 (M + H)+ 331 N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 420 (M + H)+ 332 1-(pyridazin-3-yl)-N-{4-[1-(3,3,3-trifluoropropanoyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 448 (M + H)+ 333 N-{4-[1-(methoxyacetyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 410 (M + H)+ 334 N-(4-{1-[(methylsulfanyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 426 (M + H)+ 335 N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 454 (M + H)+ 336 N-{4-[1-(3-nitropropanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 439 (M + H)+ 337 N-(4-{1-[3-(methylsulfanyl)propanoyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 440 (M + H)+ 338 N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 418 (M + H)+ 339 N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 448 (M + H)+ 340 N-{4-[1-(cyclohexylacetyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 341 N-{4-[1-(3-methylbenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 456 (M + H)+ 342 N-{4-[1-(2-hydroxybenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 458 (M + H)+ 343 N-{4-[1-(3-hydroxybenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 458 (M + H)+ 344 N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 458 (M + H)+ 345 N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 472 (M + H)+ 346 N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 472 (M + H)+ 347 N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 472 (M + H)+ 348 N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 460 (M + H)+ 349 N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 460 (M + H)+ 350 N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 351 N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 352 N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 467 (M + H)+ 353 N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 467 (M + H)+ 354 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethyl) (ESI(+)) benzoyl]piperidin-4-yl}phenyl)azetidine-3- m/e 510 carboxamide (M + H)+ 355 1-(pyridazin-3-yl)-N-(4-{1-[4-(trifluoromethyl) (ESI(+)) benzoyl]piperidin-4-yl}phenyl)azetidine-3- m/e 510 carboxamide (M + H)+ 356 1-(pyridazin-3-yl)-N-(4-{1-[3-(trifluoromethoxy) (ESI(+)) benzoyl]piperidin-4-yl}phenyl)azetidine-3- m/e 526 carboxamide (M + H)+ 357 N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 470 (M + H)+ 358 N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 470 (M + H)+ 359 N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 470 (M + H)+ 360 N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 470 (M + H)+ 361 N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 470 (M + H)+ 362 N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 510 (M + H)+ 363 N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 510 (M + H)+ 364 N-{4-[1-(3,4-dichlorobenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 510 (M + H)+ 365 N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 510 (M + H)+ 366 N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 367 N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 368 N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 369 N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 490 (M + H)+ 370 N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 490 (M + H)+ 371 1-(pyridazin-3-yl)-N-[4-[1-{[4-(trifluoromethyl) (ESI(+)) phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3- m/e 524 carboxamide (M + H)+ 372 N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 484 (M + H)+ 373 N-(4-{1-[(2,5-difluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 374 N-(4-{1-[(3,4-dichlorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 525 (M + H)+ 375 N-{4-[1-(furan-3-ylcarbonyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 432 (M + H)+ 376 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 448 (M + H)+ 377 N-(4-{1-[(5-methylthiophen-2-yl)carbonyl]piperidin- (ESI(+)) 4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 462 carboxamide (M + H)+ 378 N-(4-{1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4- ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 458 (M + H)+ 379 N-(4-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 420 (M + H)+ 380 N-{4-[1-(3-ethoxypropanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 438 (M + H)+ 381 N-(4-{1-[(1-phenylcyclopropyl)carbonyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 482 (M + H)+ 382 1-(pyridazin-3-yl)-N-(4-{1-[(pyrimidin-2- (ESI(+)) ylsulfanyl)acetyl]piperidin-4-yl}phenyl)azetidine-3- m/e 490 carboxamide (M + H)+ 383 N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 491 (M + H)+ 384 N-(4-{1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 385 N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 493 (M + H)+ 386 N-{4-[1-(diphenylacetyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 532 (M + H)+ 387 N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 388 N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 389 N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 390 N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 391 N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 392 N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 484 (M + H)+ 393 N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 498 (M + H)+ 394 N-(4-{1-[2-fluoro-5-(trifluoromethyl)benzoyl] (ESI(+)) piperidin-4-yl})phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 528 carboxamide (M + H)+ 395 N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 544 carboxamide (M + H)+ 397 N-{4-[1-(cyclopentylacetyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 448 (M + H)+ 398 N-(4-{1-[(4-methylphenoxy)acetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 486 (M + H)+ 399 N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 484 (M + H)+ 400 N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 401 N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 402 N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 403 1-(pyridazin-3-yl)-N-[4-(1-{[3-(trifluoromethyl) (ESI(+)) phenyl]acetyl}piperidin-4-yl)phenyl]azetidine-3- m/e 524 carboxamide (M + H)+ 404 N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 490 (M + H)+ 405 N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 524 (M + H)+ 406 N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 407 N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 486 (M + H)+ 408 N-(4-{1-[N-(furan-2-ylcarbonyl)glycyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 489 (M + H)+ 409 N-(4-{1-[(benzyloxy)acetyl]piperidin-4-yl}phenyl)-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 486 (M + H)+ 410 N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 506 (M + H)+ 411 N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 406 (M + H)+ 412 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-2- (ESI(+)) ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3- m/e 436 carboxamide (M + H)+ 413 N-{4-[1-(N-benzoylglycyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 499 (M + H)+ 414 1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3- (ESI(+)) ylcarbonyl)piperidin-4-yl]phenyl}azetidine-3- m/e 436 carboxamide (M + H)+ 415 1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl) (ESI(+)) butanoyl]piperidin-4-yl}phenyl)azetidine-3- m/e 490 carboxamide (M + H)+ 416 N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 417 N-{4-[1-(cyclobutylcarbonyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 420 (M + H)+ 418 N-[4-(1-{N-[(4-methylphenyl)sulfonyl]glycyl} (ESI(+)) piperidin-4-yl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 549 carboxamide (M + H)+ 419 N-(4-{1-[(2,3-difluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 420 N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 486 (M + H)+ 421 N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 506 (M + H)+ 422 N-{4-[1-(3-phenylpropanoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 470 (M + H)+ 423 N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin-4-yl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 524 (M + H)+ 424 N-(4-{1-[3-(phenylsulfonyl)propanoyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 534 (M + H)+ 425 1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 448 (M + H)+ 426 N-(4-{1-[(2,5-dimethylfuran-3-yl)carbonyl]piperidin- (ESI(+)) 4-yl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 460 carboxamide (M + H)+ 427 N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 420 (M + H)+ 428 N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 460 (M + H)+ 429 N-{4-[1-(2-methylbenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 456 (M + H)+ 430 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-4-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 449 (M + H)+ 431 1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5-ylcarbonyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 449 (M + H)+ 432 N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 424 (M + H)+ 433 1-(pyridazin-3-yl)-N-{4-[1-(4,4,4-trifluorobutanoyl) (ESI(+)) piperidin-4-yl]phenyl}azetidine-3-carboxamide m/e 462 (M + H)+ 434 N-(4-{1-[(6-methylpyridin-3-yl)carbonyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 457 (M + H)+ 435 N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(pyridazin-3- (ESI(+)) yl)azetidine-3-carboxamide m/e 442 (M + H)+ 436 N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 432 (M + H)+ 437 N-(4-{1-[(1-methylcyclohexyl)carbonyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 438 N-{4-[1-(2-oxopropanoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 408 (M + H)+ 439 N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 434 (M + H)+ 440 N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1-(pyridazin- (ESI(+)) 3-yl)azetidine-3-carboxamide m/e 394 (M + H)+ 441 N-{4-[1-(4-methylbenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 456 (M + H)+ - The following Examples were prepared essentially as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and the appropriate carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- A suspension of 4-bromoaniline (406 mg, 2.362 mmol), 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (650 mg, 2.60 mmol), PdCl2(dppf)-dichloromethane adduct (57.9 mg, 0.071 mmol) and sodium carbonate (526 mg, 4.96 mmol) in a 6:2:1 mixture of tetrahydrofuran/methanol/water (12 ml) was taken through three vacuum/nitrogen purge cycles; and the reaction mixture was heated in an oil bath at 85° C. overnight. The mixture was diluted with ethyl acetate and water; the separated aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with brine, dried with magnesium sulfate, filtered and concentrated. The residue was purified by normal phase chromatography to give the title compound.
- The title compound was prepared as described in Example 1A, substituting 4-(1-isobutyl-1H-pyrazol-4-yl)aniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1B, substituting benzyl 3-((4-(1-isobutyl-1H-pyrazol-4-yl)phenyl)carbamoyl)azetidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting 4-bromopyridazine for 3-bromopyridine and N-(4-(1-isobutyl-1H-pyrazol-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.10 (s, 1H), 8.61 (d, J=6.0 Hz, 1H), 8.51 (d, J=3.0 Hz, 1H), 8.08 (s, 1H), 7.81 (s, 1H), 7.64-7.56 (m, 2H), 7.55-7.48 (m, 2H), 6.55 (dd, J=6.0, 3.0 Hz, 1H), 4.31-3.96 (m, 4H), 3.91 (d, J=7.1 Hz, 2H), 3.74 (s, 1H), 2.12 (dd, J=13.3, 6.5 Hz, 1H), 0.86 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 377 (M+H)+.
- The title compound was prepared as described in Example 1, substituting tert-butyl 4-(4-aminophenoxy)azetidinyl-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate in Example 1A, 4-bromopyridazine for 3-bromopyridyl in Example 1C and 4-fluorobenzoic acid for 2-(tetrahydro-2H-pyran-4-yl)acetic acid in Example 1E. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.01 (s, 1H), 8.67-8.44 (m, 1H), 7.83-7.63 (m, 2H), 7.62-7.43 (m, 2H), 7.43-7.18 (m, 2H), 6.90-6.77 (m, 2H), 6.55 (dd, J=6.1, 3.1 Hz, 1H), 5.13-4.94 (m, 1H), 4.61 (d, J=52.0 Hz, 2H), 4.36-4.04 (m, 4H), 3.99 (s, 1H), 3.70 (ddt, J=33.0, 30.2, 15.0 Hz, 1H), 1.21 (t, J=15.0+)) m/e 448 (M+H)+.
-
TABLE 8 Ex Name MS 200 N-(4-{[1-(2,4-difluorobenzoyl)azetidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 466 (M + H)+ 201 N-[4-({1-[difluoro(phenyl)acetyl]azetidin-3-yl}oxy) (ESI(+)) phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 480 (M + H)+ 202 N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]azetidin- (ESI(+)) 3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 472 carboxamide (M + H)+ 203 N-[4-({1-[(4-fluorophenyl)acetyl]azetidin-3-yl}oxy) (ESI(+)) phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 205 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl) (ESI(+)) benzoyl]azetidin-3-yl}oxy)phenyl]azetidine-3- m/e 498 carboxamide (M + H)+ 206 N-{4-[(1-benzoylazetidin-3-yl)oxy]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 430 (M + H)+ 207 N-(4-{[1-(2-hydroxy-2-methylpropanoyl)azetidin- (ESI(+)) 3-yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 412 carboxamide (M + H)+ 208 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3- (ESI(+)) ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3- m/e 424 carboxamide (M + H)+ 209 N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 420 (M + H)+ 210 N-{4-[(1-pentanoylazetidin-3-yl)oxy]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 410 (M + H)+ 254 N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 424 (M + H)+ 255 N-(4-{[1-(cyclohexylcarbonyl)azetidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 256 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4- (ESI(+)) ylacetyl)azetidin-3-yl]oxy}phenyl)azetidine-3- m/e 452 carboxamide (M + H)+ 257 N-[4-({1-[(2-methylcyclopropyl)carbonyl]azetidin- (ESI(+)) 3-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 408 carboxamide (M + H)+ 258 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl) (ESI(+)) azetidin-3-yl]oxy}phenyl)azetidine-3-carboxamide m/e 436 (M + H)+ 259 N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 260 N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 452 (M + H)+ 261 N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 408 (M + H)+ 262 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2- (ESI(+)) ylcarbonyl)azetidin-3-yl]oxy}phenyl)azetidine-3- m/e 424 carboxamide (M + H)+ 263 N-(4-{[1-(4-methylpentanoyl)azetidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 424 (M + H)+ 264 N-(4-{[1-(2-methylpropanoyl)azetidin-3-yl]oxy} (ESI(+)) phenyl)-1-pyridazin-4-yl)azetidine-3-carboxamide m/e 396 (M + H)+ 265 N-[4-({1-[(2S)-2-methylbutanoyl]azetidin-3-yl}oxy) (ESI(+)) phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 410 (M + H)+ 266 N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 438 (M + H)+ 267 N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)- (ESI(+)) 1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 426 (M + H)+ 268 1-(pyridazin-4-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl) (ESI(+)) piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide m/e 464 (M + H)+ 269 N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl}oxy) (ESI(+)) phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 508 (M + H)+ 270 N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]piperidin- (ESI(+)) 4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 500 carboxamide (M + H)+ 271 N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 272 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl) (ESI(+)) piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide m/e 465 (M + H)+ 273 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethyl) (ESI(+)) phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine- m/e 540 3-carboxamide (M + H)+ 274 N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 494 (M + H)+ 275 1-(pyridazin-4-yl)-N-{4-[(1-{[4-(trifluoromethoxy) (ESI(+)) phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine- m/e 556 3-carboxamide (M + H)+ 276 N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 490 carboxamide (M + H)+ 277 N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 508 carboxamide (M + H)+ 278 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl) (ESI(+)) piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide m/e 464 (M + H)+ 279 N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 280 N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 438 carboxamide (M + H)+ 281 N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin-4- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 500 carboxamide (M + H)+ 282 N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1- (ESI(+)) (pyridazin-4-yl)azetidine-3-carboxamide m/e 396 (M + H)+ 283 1-(pyridazin-4-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide m/e 465 (M + H)+ 284 N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 494 (M + H)+ 285 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethyl) (ESI(+)) benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3- m/e 526 carboxamide (M + H)+ 286 N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 287 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethyl) (ESI(+)) benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3- m/e 526 carboxamide (M + H)+ 288 N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl}oxy) (ESI(+)) phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 490 (M + H)+ 289 N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 290 1-(pyridazin-4-yl)-N-[4-({1-[4-(trifluoromethoxy) (ESI(+)) benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3- m/e 542 carboxamide (M + H)+ 291 N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 508 carboxamide (M + H)+ 292 1-(pyridazin-4-yl)-N-[4-({1-[3-(trifluoromethoxy) (ESI(+)) benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3- m/e 542 carboxamide (M + H)+ 293 N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 294 N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 424 (M + H)+ 295 N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 296 1-(pyridazin-4-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide m/e 459 (M + H)+ 297 N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 298 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-3- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 452 carboxamide (M + H)+ 299 N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 494 (M + H)+ 300 N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 452 (M + H)+ 301 N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 302 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydrofuran-2- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 452 carboxamide (M + H)+ 303 1-(pyridazin-4-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]oxy}phenyl)azetidine-3-carboxamide m/e 464 (M + H)+ 304 N-[4-({1-[(5-methylthiophen-2-yl)carbonyl]piperidin- (ESI(+)) 4-yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 478 carboxamide (M + H)+ 305 1-(pyridazin-4-yl)-N-{4-[(1-{[3-(trifluoromethyl) (ESI(+)) phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine- m/e 540 3-carboxamide (M + H)+ 306 1-(pyridazin-4-yl)-N-(4-{[1-(tetrahydro-2H-pyran-4- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 466 carboxamide (M + H)+ 307 N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy) (ESI(+)) phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 438 (M + H)+ 308 N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl}oxy) (ESI(+)) phenyl]-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 490 (M + H)+ 396 N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 442 N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 443 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 451 carboxamide (M + H)+ 444 N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 422 carboxamide (M + H)+ 445 N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin-3- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 424 carboxamide (M + H)+ 446 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydro-2H- (ESI(+)) pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl) m/e 452 azetidine-3-carboxamide (M + H)+ 447 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4- (ESI(+)) (trifluoromethoxy)phenyl]acetyl}pyrrolidin-3-yl]oxy} m/e 542 phenyl)azetidine-3-carboxamide (M + H)+ 448 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-3- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 450 carboxamide (M + H)+ 449 N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 476 carboxamide (M + H)+ 450 N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl] (ESI(+)) pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl) m/e 494 azetidine-3-carboxamide (M + H)+ 451 N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 480 carboxamide (M + H)+ 452 N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin-3- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 476 carboxamide (M + H)+ 453 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3-(trifluoromethyl) (ESI(+)) benzoyl]pyrrolidin-3-yl}oxy)phenyl]azetidine-3- m/e 512 carboxamide (M + H)+ 454 N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl] (ESI(+)) pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl) m/e 494 azetidine-3-carboxamide (M + H)+ 455 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[4- (ESI(+)) (trifluoromethyl)phenyl]acetyl}pyrrolidin-3- m/e 526 yl]oxy}phenyl)azetidine-3-carboxamide (M + H)+ 456 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 451 carboxamide (M + H)+ 457 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran- (ESI(+)) 2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine- m/e 438 3-carboxamide (M + H)+ 458 N-[4-({(3R)-1-[(5-methylthiophen-2-yl) (ESI(+)) carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin- m/e 464 4-yl)azetidine-3-carboxamide (M + H)+ 459 N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin-3- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 476 carboxamide (M + H)+ 460 N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 408 carboxamide (M + H)+ 461 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(tetrahydrofuran-3- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 438 carboxamide (M + H)+ 462 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[3- (ESI(+)) (trifluoromethoxyl)benzoyl]pyrrolidin-3-yl}oxy) m/e 528 phenyl]azetidine-3-carboxamide (M + H)+ 463 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(pyridin-2- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 445 carboxamide (M + H)+ 464 N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 465 N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 466 N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl) (ESI(+)) pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-4-yl) m/e 486 azetidine-3-carboxamide (M + H)+ 467 N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 480 carboxamide (M + H)+ 468 N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 412 (M + H)+ 469 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(thiophen-2- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 450 carboxamide (M + H)+ 470 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-{[3- (ESI(+)) (trifluoromethyl)phenyl]acetyl}pyrrolidin-3-yl]oxy} m/e 526 phenyl)azetidine-3-carboxamide (M + H)+ 471 N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-[(pyridazin-4-yl)azetidine-3- m/e 410 carboxamide (M + H)+ 472 N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 473 N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 438 carboxamide (M + H)+ 474 N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-pyridazin-4-yl)azetidine-3- m/e 480 carboxamide (M + H)+ 475 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4- (ESI(+)) (trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy)phenyl] m/e 512 azetidine-3-carboxamide (M + H)+ 476 N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 477 1-(pyridazin-4-yl)-N-[4-({(3R)-1-[4- (ESI(+)) (trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy) m/e 528 phenyl]azetidine-3-carboxamide (M + H)+ 478 N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 424 carboxamide (M + H)+ 479 1-(pyridazin-4-yl)-N-(4-{[(3R)-1-(3,3,3- (ESI(+)) trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl) m/e 450 azetidine-3-carboxamide (M + H)+ 480 N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin-3- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-4-yl)azetidine-3- m/e 494 carboxamide (M + H)+ 481 N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-4-yl)azetidine-3- m/e 424 carboxamide (M + H)+ 482 N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl] (ESI(+)) pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-4-yl) m/e 486 azetidine-3-carboxamide (M + H)+ - The following Examples were prepared essentially as described in Example 1, substituting the appropriate amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate in Example 1A, 4-bromopyridazine for 3-bromopyridyl in Example 1C and the appropriate carboxylic acid for 2-(tetrahydro-2H-pyran-4-yl)acetic acid in Example 1E. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described in Example 1, substituting (S)-1-((benzyloxy)carbonyl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid acid and tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate in Example 1A, and cyclopentylbenzoic acid for 2-(tetrahydro-2H-pyran-4-yl)acetic acid in Example 1E. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 7.95 (d, J=2.8 Hz, 1H), 7.85 (dd, J=4.6, 1.2 Hz, 1H), 7.55 (t, J=10.1 Hz, 2H), 7.16 (dd, J=8.3, 4.3 Hz, 3H), 6.92 (ddd, J=8.4, 2.9, 1.3 Hz, 1H), 4.54 (d, J=12.7 Hz, 1H), 3.98 (d, J=13.7 Hz, 1H), 3.64-3.48 (m, 1H), 3.48-3.38 (m, 1H), 3.22-2.87 (m, 2H), 2.68 (dd, J=24.3, 12.3 Hz, 1H), 2.41-2.01 (m, 6H), 1.77 (s, 4H), 1.68-1.04 (m, 9H); MS (ESI(+)) m/e 461 (M+H)+.
- The title compound was prepared as described in Example 147, substituting tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate for 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate in Example 147A and 2-chlorobenzoic acid for 2-methylpropanoic acid in Example 147D. 1H NMR (400 MHz, DMSO/D2O) δ ppm 8.51 (dd, J=4.4, 1.2 Hz, 1H), 7.78-7.66 (m, 1H), 7.55-7.45 (m, 3H), 7.45-7.37 (m, 2H), 7.37-7.28 (m, 2H), 7.01-6.89 (m, 2H), 4.63-4.34 (m, 6H), 4.03-3.86 (m, 1H), 3.86-3.72 (m, 1H), 3.63-3.43 (m, 1H), 3.43-3.31 (m, 1H), 3.26-3.07 (m, 1H), 2.06-1.80 (m, 2H), 1.80-1.53 (m, 2H), 1.28-1.21 (m, 1H); MS (ESI(+)) m/e 492 (M+H)+.
-
TABLE 9 Ex Name MS 212 N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl} (ESI(+)) oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 438 carboxamide (M + H)+ 213 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 465 carboxamide M + H)+ 214 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydro-2H-pyran- (ESI(+)) 4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 466 carboxamide (M + H)+ 215 N-[4-({1-[difluoro(phenyl)acetyl]piperidin-4-yl} (ESI(+)) oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 508 carboxamide (M + H)+ 216 N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl] (ESI(+)) piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl) m/e 500 azetidine-3-carboxamide (M + H)+ 217 N-(4-{[1-(2-methyl-2-phenylpropanoyl)piperidin- (ESI(+)) 4-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 500 carboxamide (M + H)+ 218 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 465 carboxamide (M + H)+ 219 N-[4-({1-[(5-methylthiophen-2-yl)carbonyl] (ESI(+)) piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl) m/e 478 azetidine-3-carboxamide (M + H)+ 220 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethyl) (ESI(+)) phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine- m/e 540 3-carboxamide (M + H)+ 221 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 452 carboxamide (M + H)+ 222 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethyl) (ESI(+)) benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3- m/e 526 carboxamide (M + H)+ 223 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 464 carboxamide (M + H)+ 224 1-(pyridazin-3-yl)-N-[4-({1-[3-(trifluoromethoxy) (ESI(+)) benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3- m/e 542 carboxamide (M + H)+ 225 N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 438 (M + H)+ 226 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-3- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 452 carboxamide (M + H)+ 227 N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 490 carboxamide (M + H)+ 228 N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 229 N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 494 carboxamide (M + H)+ 230 N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 231 N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 476 (M + H)+ 232 N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 490 carboxamide (M + H)+ 233 N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 234 N-(4-{[1-(3,4-difluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 494 (M + H)+ 235 1-(pyridazin-3-yl)-N-[4-({1-[4- (ESI(+)) (trifluoromethoxy)benzoyl]piperidin-4-yl}oxy) m/e 542 phenyl]azetidine-3-carboxamide (M + H)+ 236 N-[4-({1-[(2,4-difluorophenyl)acetyl]piperidin-4- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 508 carboxamide (M + H)+ 237 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl) (ESI(+)) benzoyl]piperidin-4-yl}oxy)phenyl]azetidine-3- m/e 526 carboxamide (M + H)+ 238 1-(pyridazin-3-yl)-N-{4-[(1-{[4-(trifluoromethoxy) (ESI(+)) phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine- m/e 556 3-carboxamide (M + H)+ 239 N-[4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 508 carboxamide (M + H)+ 240 1-(pyridazin-3-yl)-N-{4-[(1-{[3-(trifluoromethyl) (ESI(+)) phenyl]acetyl}piperidin-4-yl)oxy]phenyl}azetidine- m/e 540 3-carboxamide (M + H)+ 241 N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 438 carboxamide (M + H)+ 242 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 459 carboxamide (M + H)+ 243 N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 494 (M + H)+ 244 -{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 396 (M + H)+ 245 N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 246 N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 426 (M + H)+ 247 N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 490 carboxamide (M + H)+ 248 N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 452 carboxamide (M + H)+ 249 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2- (ESI(+)) ylcarbonyl)piperidin-4-yl]oxy}phenyl)azetidine-3- m/e 464 carboxamide (M + H)+ 250 N-(4-{[1-(3-chlorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 492 (M + H)+ 251 N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 422 carboxamide (M + H)+ 252 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3- (ESI(+)) trifluoropropanoyl)piperidin-4-yl]oxy}phenyl) m/e 464 azetidine-3-carboxamide (M + H)+ 253 N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 424 (M + H)+ 483 N-(4-{[(3R)-1-(2-chlorobenzoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 478 carboxamide (M + H)+ 484 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-2- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 451 carboxamide (M + H)+ 485 N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 422 carboxamide (M + H)+ 486 N-[4-({(3R)-1-[(2S)-2-methylbutanoyl]pyrrolidin- (ESI(+)) 3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 424 carboxamide (M + H)+ 487 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydro-2H- (ESI(+)) pyran-4-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl) m/e 452 azetidine-3-carboxamide (M + H)+ 488 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4- (ESI(+)) (trifluoromethoxy)phenyl]acetyl}pyrrolidin-3- m/e 542 yl]oxy}phenyl)azetidine-3-carboxamide (M + H)+ 489 N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 462 carboxamide (M + H)+ 490 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-3- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 450 carboxamide (M + H)+ 491 N-[4-({(3R)-1-[(4-fluorophenyl)acetyl]pyrrolidin-3- (ESI(+)) yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 476 carboxamide (M + H)+ 492 N-[4-({(3R)-1-[(3,5-difluorophenyl)acetyl] (ESI(+)) pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl) m/e 494 azetidine-3-carboxamide (M + H)+ 493 N-(4-{[(3R)-1-(3,4-difluorobenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 480 carboxamide (M + H)+ 494 N-[4-({(3R)-1-[(3-fluorophenyl)acetyl]pyrrolidin- (ESI(+)) 3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 476 carboxamide (M + H)+ 495 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3- (ESI(+)) (trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy) m/e 512 phenyl]azetidine-3-carboxamide (M + H)+ 496 N-[4-({(3R)-1-[(2,4-difluorophenyl)acetyl] (ESI(+)) pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl) m/e 494 azetidine-3-carboxamide (M + H)+ 497 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[4- (ESI(+)) (trifluoromethyl)phenyl]acetyl}pyrrolidin-3- m/e 526 yl]oxy}phenyl)azetidine-3-carboxamide (M + H)+ 498 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(1,3-thiazol-4- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 451 carboxamide (M + H)+ 499 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran- (ESI(+)) 2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine- m/e 438 3-carboxamide (M + H)+ 500 N-[4-({(3R)-1-[(5-methylthiophen-2-yl)carbonyl] (ESI(+)) pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl) m/e 464 azetidine-3-carboxamide (M + H)+ 501 N-[4-({(3R)-1-[(2-fluorophenyl)acetyl]pyrrolidin- (ESI(+)) 3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 476 carboxamide (M + H)+ 502 N-(4-{[(3R)-1-(cyclopropylcarbonyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 408 carboxamide (M + H)+ 503 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(tetrahydrofuran- (ESI(+)) 3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine- m/e 438 3-carboxamide (M + H)+ 504 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[3- (ESI(+)) (trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy) m/e 528 phenyl]azetidine-3-carboxamide (M + H)+ 505 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(pyridin-2- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine- m/e 445 3-carboxamide (M + H)+ 506 N-(4-{[(3R)-1-(3-chlorobenzoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 478 carboxamide (M + H)+ 507 N-(4-{[(3R)-1-(4-chlorobenzoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 478 carboxamide (M + H)+ 508 N-(4-{[(3R)-1-(2-methyl-2-phenylpropanoyl) (ESI(+)) pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3- m/e 486 yl)azetidine-3-carboxamide (M + H)+ 509 N-(4-{[(3R)-1-(2,4-difluorobenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 480 carboxamide (M + H)+ 510 N-(4-{[(3R)-1-(methoxyacetyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 412 carboxamide (M + H)+ 511 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(thiophen-2- (ESI(+)) ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)azetidine-3- m/e 450 carboxamide (M + H)+ 512 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-{[3- (ESI(+)) (trifluoromethyl)phenyl]acetyl}pyrrolidin-3- m/e 526 yl]oxy}phenyl)azetidine-3-carboxamide (M + H)+ 513 N-(4-{[(3R)-1-(2-methylpropanoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 410 carboxamide (M + H)+ 514 N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 462 carboxamide (M + H)+ 515 N-(4-{[(3R)-1-(2,2-dimethylbutanoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 438 carboxamide (M + H)+ 516 N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 480 carboxamide (M + H)+ 517 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4- (ESI(+)) (trifluoromethyl)benzoyl]pyrrolidin-3-yl}oxy) m/e 512 phenyl]azetidine-3-carboxamide (M + H)+ 518 N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 462 carboxamide (M + H)+ 519 1-(pyridazin-3-yl)-N-[4-({(3R)-1-[4- (ESI(+)) (trifluoromethoxy)benzoyl]pyrrolidin-3-yl}oxy) m/e 528 phenyl]azetidine-3-carboxamide (M + H)+ 520 N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 424 carboxamide (M + H)+ 521 1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(3,3,3- (ESI(+)) trifluoropropanoyl)pyrrolidin-3-yl]oxy}phenyl) m/e 450 azetidine-3-carboxamide (M + H)+ 522 N-[4-({(3R)-1-[difluoro(phenyl)acetyl]pyrrolidin- (ESI(+)) 3-yl}oxy)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 494 carboxamide (M + H)+ 523 N-(4-{[(3R)-1-(2,2-dimethylpropanoyl)pyrrolidin- (ESI(+)) 3-yl]oxy}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 424 carboxamide (M + H)+ 524 N-[4-({(3R)-1-[(4,4-difluorocyclohexyl)carbonyl] (ESI(+)) pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin-3-yl) m/e 486 azetidine-3-carboxamide (M + H)+ - The following Examples were prepared essentially as described in Example 147, substituting the appropriate amine in Example 147A and the appropriate carboxylic acid in Example 147D. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- tert-Butyl azetidin-3-ylcarbamate (500 mg, 2.90 mmol) and 3,6-dichloropyridazine (454 mg, 3.05 mmol) were combined in DMSO (5 mL) and N-ethyl-N-isopropylpropan-2-amine (563 mg, 4.35 mmol), and the mixture was heated overnight at 100° C. The mixture was cooled to room temperature and diluted with water. Filtration provided the title compound.
- A mixture of tert-butyl 1-(6-chloropyridizan-3-yl)azetidin-3-ylcarbamate (413 mg, 1.45 mmol), 1,4-cyclohexadiene (1.10 mL, 11.6 mmol) and triethylamine (0.61 mL, 1.45 mmol) was purged with nitrogen and 5% palladium on carbon (20 mg) was added. The reaction mixture was heated to 80° C. overnight, cooled to room temperature and filtered through diatomaceous earth, rinsing with methanol. Concentration provided the title compound.
- Tert-butyl 1-(pyridazin-3-yl)azetidin-3-ylcarbamate.triethylamine hydrochloride (200 mg, 0.516 mmol) was dissolved in methanol (1.5 mL) and a 4N solution of HCl in dioxane (1.5 mL, 6.00 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 1 hour then concentrated to dryness to give the title compound.
- The title compound was prepared as described as described in Example 148A, substituting 5-bromofuran-2-carboxylic acid for 4-bromoaniline.
- The title compound was prepared as described in Example 1A, substituting 1-(pyridazin-3-yl)azetidin-3-amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-isobutyl-1H-pyrazol-4-yl)furan-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.83 (d, J=7.5 Hz, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 8.15 (d, J=0.7 Hz, 1H), 7.88 (d, J=0.7 Hz, 1H), 7.39 (dd, J=8.9, 4.5 Hz, 1H), 7.16 (d, J=3.5 Hz, 1H), 6.84 (dd, J=8.9, 1.4 Hz, 1H), 6.64 (d, J=3.5 Hz, 1H), 4.97-4.84 (m, 1H), 4.38 (t, J=8.1 Hz, 2H), 4.06 (dd, J=8.6, 5.7 Hz, 2H), 3.95 (d, J=7.2 Hz, 2H), 2.21-2.05 (m, 1H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 367 (M+H)+.
- The title compound was prepared as described in Example 147, substituting (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate in Example 147A. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.06 (s, 1H), 8.48 (dd, J=4.4, 1.2 Hz, 1H), 7.54 (d, J=8.5 Hz, 2H), 7.43-7.25 (m, 1H), 7.18 (d, J=8.6 Hz, 2H), 6.87 (dd, J=9.2, 1.2 Hz, 1H), 4.64-4.48 (m, 1H), 4.15-3.97 (m, 1H), 3.76 (dd, J=10.4, 8.0 Hz, 1H), 3.69-3.54 (m, 2H), 3.54-3.38 (m, 1H), 3.20-3.03 (m, 1H), 3.02-2.83 (m, 2H), 2.79-2.64 (m, 1H), 2.64-2.52 (m, 1H), 2.37-2.13 (m, 2H), 1.90-1.68 (m, 2H), 1.59-1.29 (m, 2H), 0.99 (dt, J=14.5, 7.0 Hz, 6H); MS (ESI(+)) m/e 422 (M+H)+.
- The title compound was prepared as described in Example 147, substituting (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate in Example 147A and benzoic acid for 2-methylpropanoic acid in Example 147D. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.06 (s, 1H), 8.48 (dd, J=4.4, 1.3 Hz, 1H), 7.55 (d, J=8.6 Hz, 1H), 7.51-7.39 (m, 5H), 7.34 (dd, J=9.1, 4.5 Hz, 1H), 7.25-7.19 (m, 2H), 6.87 (dd, J=9.1, 1.3 Hz, 1H), 4.65-4.48 (m, 1H), 3.84-3.53 (m, 4H), 3.48 (dt, J=10.2, 7.4 Hz, 1H), 3.22-2.69 (m, 3H), 2.36-2.13 (m, 2H), 1.98-1.48 (m, 4H); MS (ESI(+)) m/e 456 (M+H)+.
- The title compound was prepared as described in Example 147, substituting (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate in Example 147A and tetrahydro-2H-pyran-4-ylacetic acid for 2-methylpropanoic acid in Example 147D. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.06 (s, 1H), 8.48 (dd, J=4.4, 1.2 Hz, 1H), 7.54 (d, J=8.6 Hz, 2H), 7.39-7.27 (m, 1H), 7.17 (d, J=8.6 Hz, 2H), 6.87 (dd, J=9.2, 1.2 Hz, 1H), 4.65-4.45 (m, 1H), 4.07-3.92 (m, 1H), 3.89-3.68 (m, 3H), 3.68-3.54 (m, 2H), 3.54-3.39 (m, 1H), 3.22-2.93 (m, 2H), 2.80-2.65 (m, 1H), 2.64-2.52 (m, 1H), 2.38-2.13 (m, 4H), 2.00-1.84 (m, 1H), 1.80 (dt, J=27.7, 7.7 Hz, 2H), 1.68-1.14 (m, 7H); MS (ESI(+)) m/e 478 (M+H)+.
- The title compound was prepared as described in Example 147, substituting (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate in Example 147A and 2,2-dimethylpropanoic acid for 2-methylpropanoic acid in Example 147D. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.05 (s, 1H), 8.47 (dd, J=4.4, 1.0 Hz, 1H), 7.52 (d, J=8.5 Hz, 2H), 7.32 (dd, J=9.1, 4.5 Hz, 1H), 7.16 (d, J=8.5 Hz, 2H), 6.86 (dd, J=9.2, 1.0 Hz, 1H), 4.39 (d, J=13.2 Hz, 2H), 3.75 (dd, J=10.4, 8.0 Hz, 1H), 3.69-3.54 (m, 2H), 3.46 (dt, J=10.1, 7.5 Hz, 1H), 3.27 (dd, J=14.8, 7.4 Hz, 1H), 2.96 (dd, J=12.8, 7.0 Hz, 1H), 2.84 (dd, J=22.1, 9.6 Hz, 2H), 2.78-2.64 (m, 1H), 2.27 (dt, J=7.1, 5.0 Hz, 1H), 2.18 (ddd, J=14.3, 11.6, 7.3 Hz, 1H), 1.77 (d, J=11.3 Hz, 2H), 1.54-1.31 (m, 3H), 1.18 (d, J=16.8 Hz, 9H); MS (ESI(+)) m/e 436 (M+H)+.
-
TABLE 10 Ex Name MS 630 (3S)-1-(pyridazin-3-yl)-N-{4-[1-(1,3-thiazol-5- (ESI(+)) ylcarbonyl)piperidine-4-yl]phenyl}pyrrolidine-3- m/e 463 carboxamide (M + H)+ 631 (3S)-N-{4-[1-(4-methylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 470 (M + H)+ 632 (3S)-N-(4-{1-[(2S)-2-phenylbutanoyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 498 carboxamide (M + H)+ 633 (3S)-N-(4-{1-[(2S)-2-methoxy-2-phenylacetyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 500 pyrrolidine-3-carboxamide (M + H)+ 634 (3S)-N-(4-{1-[(2R)-2-methoxy-2-phenylacetyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 500 pyrrolidine-3-carboxamide (M + H)+ 635 (3S)-N-{4-[1-(ethoxyacetyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 438 (M + H)+ 636 (3S)-N-(4-{1-[(4-methylphenoxy)acetyl]piperidin- (ESI(+)) 4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 500 carboxamide (M + H)+ 637 (3S)-N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 474 carboxamide (M + H)+ 638 (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran-3- (ESI(+)) ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3- m/e 450 carboxamide (M + H)+ 639 (3S)-N-{4-[1-(naphthalen-1-ylcarbonyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 506 carboxamide (M + H)+ 640 (3S)-N-(4-{1-[(2,6-dichlorophenyl)acetyl]piperidin- (ESI(+)) 4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 538 carboxamide (M + H)+ 641 (3S)-N-{4-[1-(naphthalen-1-ylacetyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 520 carboxamide (M + H)+ 642 (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4-(thiophen-2-yl) (ESI(+)) butanoyl]piperidin-4-yl}phenyl)pyrrolidine-3- m/e 504 carboxamide (M + H)+ 643 (3S)-N-{4-[1-(cyclopropylacetyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 434 carboxamide (M + H)+ 644 (3S)-N-{4-[1-(cyclopentylacetyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 462 carboxamide (M + H)+ 645 (3S)-N-{4-[1-(2,5-difluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 492 carboxamide (M + H)+ 646 (3S)-N-{4-[1-(naphthalen-2-ylacetyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 520 carboxamide (M + H)+ 647 (3S)-N-(4-{1-[3-(phenylsulfonyl)propanoyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 548 pyrrolidine-3-carboxamide (M + H)+ 648 (3S)-1-(pyridazin-3-yl)-N-[4-(1-{[3- (ESI(+)) (trifluoromethyl)phenyl]acetyl}piperidin-4-yl) m/e 538 phenyl]pyrrolidine-3-carboxamide (M + H)+ 649 (3S)-N-{4-[1-(furan-2-ylcarbonyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 446 carboxamide (M + H)+ 650 (3S)-N-{4-[1-(N-benzoylglycyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 513 carboxamide (M + H)+ 651 (3S)-N-(4-{1-[(2,4-dichlorophenyl)acetyl]piperidin- (ESI(+)) 4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 538 carboxamide (M + H)+ 652 (3S)-N-{4-[1-(2-methylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 470 carboxamide (M + H)+ 653 (3S)-1-(pyridazin-3-yl)-N-{4-[1-(4,4,4- (ESI(+)) trifluorobutanoyl)piperidin-4-yl]phenyl}pyrrolidine- m/e 476 3-carboxamide (M + H)+ 654 (3S)-N-(4-{1-[(1-methylcyclohexyl)carbonyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 476 pyrrolidine-3-carboxamide (M + H)+ 655 (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-3- (ESI(+)) ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3- m/e 462 carboxamide (M + H)+ 656 (3S)-N-(4-{1-[(6-methylpyridin-3-yl)carbonyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 471 pyrrolidine-3-carboxamide (M + H)+ 657 (3S)-N-(4-{1-[(3-chlorophenyl)acetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 504 carboxamide (M + H)+ 658 (3S)-N-[4-(1-propanoylpiperidin-4-yl)phenyl]-1- (ESI(+)) (pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 408 (M + H)+ 659 (3S)-N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 492 (M + H)+ 660 (3S)-N-{4-[1-(cyclopentylcarbonyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 448 carboxamide (M + H)+ 661 (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydrofuran- (ESI(+)) 2-ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3- m/e 450 carboxamide (M + H)+ 662 (3S)-N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 420 (M + H)+ 663 (3S)-N-{4-[1-(4-chlorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 490 (M + H)+ 669 (3S)-N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 490 (M + H)+ 670 (3S)-N-{4-[1-(2-methylpentanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 450 (M + H)+ 671 (3S)-N-{4-[1-(4-methylpentanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 450 (M + H)+ 672 (3S)-N-{4-[1-(2,4-dimethylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 484 (M + H)+ 673 (3S)-N-[4-(1-heptanoylpiperidin-4-yl)phenyl]-1- (ESI(+)) (pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 464 (M + H)+ 674 (3S)-N-{4-[1-(2,4-dichlorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 524 (M + H)+ 675 (3S)-N-(4-{1-[(4-fluorophenyl)acetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 488 carboxamide (M + H)+ 676 (3S)-N-{4-[1-(2,3-difluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 492 (M + H)+ 677 (3S)-N-{4-[1-(3-methylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 470 (M + H)+ 678 (3S)-N-[4-(1-hexanoylpiperidin-4-yl)phenyl]-1- (ESI(+)) (pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 450 (M + H)+ 679 (3S)-N-(4-{1-[(3-methylthiophen-2-yl)carbonyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 476 pyrrolidine-3-carboxamide (M + H)+ 680 (3S)-N-{4-[1-(2,3-dimethylbutanoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 450 carboxamide (M + H)+ 681 (3S)-N-[4-(1-butanoylpiperidin-4-yl)phenyl]-1- (ESI(+)) (pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 422 (M + H)+ 682 (3S)-N-{4-[1-(3-methylpentanoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 450 carboxamide (M + H)+ 683 (3S)-N-(4-{1-[(3,5-dimethylphenyl)acetyl]piperidin- (ESI(+)) 4-yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 498 carboxamide (M + H)+ 684 (3S)-N-{4-[1-(3,5-dichlorobenzoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 524 carboxamide (M + H)+ 685 (3S)-N-{4-[1-(3-fluoro-2-methylbenzoyl)piperidin- (ESI(+)) 4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 488 carboxamide (M + H)+ 686 (3S)-N-(4-{1-[(4-chlorophenyl)acetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 504 carboxamide (M + H)+ 687 (3S)-N-{4-[1-(furan-3-ylcarbonyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 446 carboxamide (M + H)+ 688 (3S)-N-{4-[1-(3,4-dimethylbenzoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 484 carboxamide (M + H)+ 689 (3S)-N-{4-[1-(4-fluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 474 carboxamide (M + H)+ 690 (3S)-N-(4-{1-[2-chloro-5-(trifluoromethyl)benzoyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 558 pyrrolidine-3-carboxamide (M + H)+ 691 (3S)-N-[4-(1-acetylpiperidin-4-yl)phenyl]-1- (ESI(+)) (pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 394 (M + H)+ 692 (3S)-N-{4-[1-(2,4-difluorobenzoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 492 carboxamide (M + H)+ 693 (3S)-N-{4-[1-(3,5-dimethylbenzoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 484 carboxamide (M + H)+ 694 (3S)-N-{4-[1-(3-ethoxypropanoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 452 carboxamide (M + H)+ 695 (3S)-N-{4-[1-(2,5-dichlorobenzoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 524 carboxamide (M + H)+ 696 (3S)-N-{4-[1-(2,5-dimethylbenzoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 484 carboxamide (M + H)+ 697 (3S)-N-{4-[1-(5-fluoro-2-methylbenzoyl)piperidin- (ESI(+)) 4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 488 carboxamide (M + H)+ 698 (3S)-N-{4-[1-(diphenylacetyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 546 carboxamide (M + H)+ 699 (3S)-1-(pyridazin-3-yl)-N-(4-{1-[4- (ESI(+)) (trifluoromethyl)benzoyl]piperidin-4-yl}phenyl) m/e 524 pyrrolidine-3-carboxamide (M + H)+ 700 (3S)-N-{4-[1-(pent-4-enoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 434 (M + H)+ 701 (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3- (ESI(+)) (trifluoromethoxy)benzoyl]piperidin-4- m/e 540 yl}phenyl)pyrrolidine-3-carboxamide (M + H)+ 702 (3S)-N-(4-{1-[(1-phenylcyclopropyl)carbonyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 496 pyrrolidine-3-carboxamide (M + H)+ 703 (3S)-N-(4-{1-[2-fluoro-5-(trifluoromethyl) (ESI(+)) benzoyl]piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 542 pyrrolidine-3-carboxamide (M + H)+ 704 (3S)-N-{4-[1-(cyclohexylacetyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 476 (M + H)+ 705 (3S)-N-{4-[1-(4-methoxybenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 486 (M + H)+ 706 (3S)-N-{4-[1-(2-methylbutanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 436 (M + H)+ 707 (3S)-N-{4-[1-(2-ethylbutanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 450 (M + H)+ 708 (3S)-N-{4-[1-(4-tert-butylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 512 (M + H)+ 709 (3S)-N-{4-[1-(3-chlorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 490 (M + H)+ 710 (3S)-N-(4-{1-[(2-fluorophenyl)acetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 488 carboxamide (M + H)+ 711 (3S)-1-(pyridazin-3-yl)-N-(4-{1-[3- (ESI(+)) (trifluoromethyl)benzoyl]piperidin-4-yl}phenyl) m/e 524 pyrrolidine-3-carboxamide (M + H)+ 712 (3S)-N-(4-{1-[(1-methylcyclopropyl)carbonyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 434 pyrrolidine-3-carboxamide (M + H)+ 713 (3S)-N-{4-[1-(pent-4-ynoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 432 (M + H)+ 714 (3S)-N-(4-{1-[(3-fluorophenyl)acetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 488 carboxamide (M + H)+ 715 (3S)-N-(4-{1-[3-(methylsulfanyl)propanoyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 454 pyrrolidine-3-carboxamide (M + H)+ 716 (3S)-N-(4-{1-[(1-acetylpiperidin-4-yl)carbonyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl) m/e 505 pyrrolidine-3-carboxamide (M + H)+ 717 (3S)-N-{4-[1-(but-3-enoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 420 (M + H)+ 718 (3S)-N-{4-[1-(2,2-dimethylbutanoyl)piperidin-4- (ESI(+)) yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 450 carboxamide (M + H)+ 719 (3S)-N-{4-[1-(3-fluoro-4-methylbenzoyl)piperidin- (ESI(+)) 4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 488 carboxamide (M + H)+ 720 (3S)-N-{4-[1-(3-methoxybenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 486 carboxamide (M + H)+ 721 (3S)-N-(4-{1-[(2-chlorophenyl)acetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 504 carboxamide (M + H)+ 722 (3S)-N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 468 carboxamide (M + H)+ 723 (3S)-N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 450 carboxamide (M + H)+ 724 (3S)-N-{4-[1-(N-acetyl-L-leucyl)piperidin-4-yl] (ESI(+)) phenyl}-1(pyridazin-3-yl)pyrrolidine-3- m/e 507 carboxamide (M + H)+ 725 (3S)-N-{4-[1-(3-fluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 474 (M + H)+ 726 (3S)-N-{4-[1-(4-cyanobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 481 (M + H)+ 727 (3S)-N-{4-[1-(2-methoxybenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1(pyridazin-3-yl)pyrrolidine-3- m/e 486 carboxamide (M + H)+ 728 (3S)-N-{4-[1-(2,3-dimethylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 484 carboxamide (M + H)+ 729 (3S)-N-(4-{1-[4-(propan-2-yl)benzoyl]piperidin-4- (ESI(+)) yl}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 498 carboxamide (M + H)+ 730 (3S)-N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 462 carboxamide (M + H)+ 731 (3S)-1-(pyridazin-3-yl)-N-{4-[1-(thiophen-2- (ESI(+)) ylcarbonyl)piperidin-4-yl]phenyl}pyrrolidine-3- m/e 462 carboxamide (M + H)+ 732 (3S)-N-{4-[1-(4-hydroxybenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 472 (M + H)+ 733 (3S)-N-{4-[1-(3-cyanobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 481 (M + H)+ 734 (3S)-1-(pyridazin-3-yl)-N-{4-[1-(3,3,3- (ESI(+)) trifluoropropanoyl)piperidin-4-yl]phenyl} m/e 462 pyrrolidine-3-carboxamide (M + H)+ 735 (3S)-N-{4-[1-(methoxyacetyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 424 (M + H)+ 736 (3S)-N-{4-[1-(3-methylbutanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 436 carboxamide (M + H)+ - The following Examples were essentially prepared as described in Example 313, substituting the appropriate carboxylic acid for 2,2-dimethylpropanoic acid.
- The title compound was prepared as described in Example 1A, substituting 1-(pyridazin-3-yl)azetidin-3-amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.96 (d, J=7.0 Hz, 1H), 8.56 (dd, J=4.6, 1.3 Hz, 1H), 7.82 (d, J=8.3 Hz, 2H), 7.41-7.31 (m, 3H), 6.83 (dd, J=9.0, 1.3 Hz, 1H), 4.96-4.85 (m, 1H), 4.37 (t, J=8.1 Hz, 2H), 4.16-3.97 (m, 4H), 2.88-2.65 (m, 3H), 1.80-1.70 (m, 2H), 1.60-1.43 (m, 2H), 1.41 (s, 9H); MS (ESI(+)) m/e 438 (M+H)+.
- The title compound was prepared as described as described in Example 148A, substituting 5-bromothiophene-2-carboxylic acid for 4-bromoaniline.
- The title compound was prepared as described in Example 1A, substituting 1-(pyridazin-3-yl)azetidin-3-amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.99 (d, J=7.1 Hz, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 8.14 (d, J=0.8 Hz, 1H), 7.81-7.79 (m, 1H), 7.72 (d, J=3.9 Hz, 1H), 7.39 (dd, J=8.9, 4.5 Hz, 1H), 7.21 (d, J=3.8 Hz, 1H), 6.84 (dd, J=9.0, 1.4 Hz, 1H), 4.92-4.81 (m, 1H), 4.37 (t, J=8.1 Hz, 2H), 4.03 (dd, J=8.6, 5.5 Hz, 2H), 3.92 (d, J=7.1 Hz, 2H), 2.19-2.04 (m, 1H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 383 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminophenylthio)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- To a 20 mL vial was added tert-butyl 4-((4-(1-((benzyloxy)carbonyl)azetidine-3-carboxamido)phenyl)thio)piperidine-1-carboxylate (8.3 g, 15.79 mmol) in dichloromethane (79 ml). The reaction mixture was cooled to ca −20° C. in a methanol/dry ice bath treated with m-chloroperbenzoic acid (8.17 g, 47.4 mmol) and was allowed to warm slowly to room temperature. When complete, the reaction mixture was treated with 1N aqueous sodium hydroxide and extracted with dichloromethane. The combined organics were dried with sodium sulfate, filtered and concentrated by rotary evaporation. The residue was purified by regular phase chromatography to give the title compound.
- tert-Butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenylsulfonyl)piperidine-1-carboxylate (7.94 g, 14.24 mmol) and ethanol (160 ml) were added to 20% Pd(OH)2/C, wet (1.5 g, 1.089 mmol) in a 250 mL SS pressure bottle and the mixture was stirred for 16 hours at 30 psi and room temperature. The mixture was filtered through a nylon membrane and concentrated to give the title compound.
- The title compound was prepared as described in Example 147A, substituting tert-butyl 4-(4-(azetidine-3-carboxamido)phenylsulfonyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting tert-butyl 4-((4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)sulfonyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-((4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)sulfonyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-ylsulfonyl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 3-chlorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO/D2O) δ ppm 8.53 (dd, J=4.4, 1.2 Hz, 1H), 7.93-7.84 (m, 2H), 7.84-7.77 (m, 2H), 7.72 (dd, J=9.3, 4.4 Hz, 1H), 7.58-7.38 (m, 2H), 7.40-7.21 (m, 3H), 4.58-4.37 (m, 5H), 4.02 (d, J=31.5 Hz, 3H), 3.88 (tt, J=8.8, 5.9 Hz, 1H), 3.48 (ddd, J=11.6, 7.7, 3.9 Hz, 1H), 2.99 (t, J=11.9 Hz, 2H), 1.92 (d, J=10.6 Hz, 2H), 1.53 (qd, J=12.2, 4.5 Hz, 3H); MS (ESI(+)) m/e 540 (M+H)+.
-
TABLE 11 Ex Name MS 565 N-(4-{[1-(4-tert-butylbenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 562 (M + H)+ 566 N-(4-{[1-(4-methoxybenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 536 (M + H)+ 567 N-(4-{[1-(4-methylbenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 520 (M + H)+ 568 N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 512 (M + H)+ 569 N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 484 (M + H)+ 570 N-(4-{[1-(2-methoxybenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 536 (M + H)+ 571 N-[4-({1-[(2S)-2-phenylbutanoyl]piperidin-4-yl} (ESI(+)) sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 548 carboxamide (M + H)+ 572 N-[4-({1-[4-(propan-2-yl)benzoyl]piperidin-4-yl} (ESI(+)) sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 548 carboxamide (M + H)+ 573 N-(4-{[1-(4-chlorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 540 (M + H)+ 574 N-{4-{(1-benzoylpiperidin-4-yl)sulfonyl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 506 (M + H)+ 575 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl) (ESI(+)) piperidin-4-yl]sulfonyl}phenyl]azetidine-3- m/e 526 carboxamide (M + H)+ 576 N-(4-{[1-(2,5-difluorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 542 (M + H)+ 577 N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 524 (M + H)+ 578 N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 520 (M + H)+ 579 N-[4-({1-[(4-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 538 carboxamide (M + H)+ 580 N-(4-{[1-(3-methylbenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 520 (M + H)+ 581 N-(4-{[1-(2,3-dimethylbenzoyl]piperidin-4-yl] ESI(+)) sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 534 carboxamide (M + H)+ 582 N-[4-({1-[(3-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 538 carboxamide (M + H)+ 583 N-(4-{[1-3-fluorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 524 (M + H)+ 584 1-(pyridazin-3-yl)-N-[4-({l-[3-(trifluoromethyl) (ESI(+)) benzoyl]piperidin-4-yl}sulfonyl)phenyl]azetidine-3- m/e 575 carboxamide (M + H)+ 585 N-(4-({1-[(3,5-difluorophenyl)acetyl]piperidin-4- (ESI(+)) yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 556 carboxamide (M + H)+ 586 N-(4-{[1-(2,4-difluorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 542 (M + H)+ 587 1-(pyridazin-3-yl)-N-[4-({1-[4-(trifluoromethyl) (ESI(+)) benzoyl)piperidin-4-yl}sulfonyl)phenyl]azetidine-3- m/e 574 carboxamide (M + H)+ 588 N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 524 (M + H)+ 589 N-(4-{[1-(2,3-difluorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 542 (M + H)+ 590 N-(4-{[1-(2,4-dichlorobenzoyl)piperidin-4-yl] (ESI(+)) sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 574 carboxamide (M + H)+ 591 N-(4-{[1-(naphthalen-1-ylcarbonyl)piperidin-4-yl] (ESI(+)) sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 556 carboxamide (M + H)+ 592 N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl] (ESI(+)) sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 470 carboxamide (M + H)+ 593 N-(4-{[1-(3,5-difluorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 542 (M + H)+ 594 N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl] (ESI(+)) sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 486 carboxamide (M + H)+ 595 N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl] (ESI(+)) sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 500 carboxamide (M + H)+ 596 N-(4-{[1-(3-methoxybenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 536 (M + H)+ 597 N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 486 (M + H)+ 598 N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 472 (M + H)+ 599 N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl] (ESI(+)) sulfonyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 498 carboxamide (M + H)+ 600 N-(4-{[1-(phenylacetyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 520 (M + H)+ 601 N-[4-({1-[(1-phenylcyclopropyl)carbonyl]piperidin- (ESI(+)) 4-yl}sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 546 carboxamide (M + H)+ 611 N-(4-{[1-(2-chlorobenzoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 540 (M + H)+ 612 N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]sulfonyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 500 (M + H)+ 613 N-[4-({1-[(2-fluorophenyl)acetyl]piperidin-4-yl} (ESI(+)) sulfonyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 538 carboxamide (M + H)+ - The following Examples were prepared essentially as described in Example 564, substituting the appropriate carboxylic acid in Example 564F. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-methylalanine for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.14 (s, 1H), 8.18-8.11 (m, 4H), 8.07 (d, J=2.5 Hz, 1H), 7.74 (dd, J=8.6, 5.4 Hz, 1H), 7.55 (d, J=8.5 Hz, 2H), 7.52 (dd, J=8.7, 2.3 Hz, 1H), 7.21 (d, J=8.5 Hz, 2H), 4.41-3.68 (m, 7H), 3.10-2.89 (m, 2H), 2.89-2.74 (m, 1H), 1.85 (d, J=12.3 Hz, 2H), 1.58 (s, 6H), 1.52-1.37 (m, 2H); MS (ESI(+)) m/e 422 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (R)-tert-butyl 3-aminopyrrolidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (R)-tert-butyl 3-(5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-2-carboxamido)pyrrolidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.85 (d, J=6.78 Hz, 6H) 1.90-2.38 (m, 3H) 3.16-3.66 (m, 4H) 3.92 (d, J=7.12 Hz, 2H) 4.59 (d, J=5.76 Hz, 1H) 6.92 (dd, J=8.48, 1.70 Hz, 1H) 7.08-7.27 (m, 2H) 7.72 (d, J=3.73 Hz, 1H) 7.79 (s, 1H) 7.85 (d, J=3.73 Hz, 1H) 7.95 (d, J=2.71 Hz, 1H) 8.13 (s, 1H) 8.54 (d, J=7.12 Hz, 1H); MS (ESI(+)) m/e 396 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting 4-bromopyridazine for 3-bromopyridine and (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.85 (d, J=6.44 Hz, 6H) 1.90-2.39 (m, 3H) 3.38-3.75 (m, 4H) 3.92 (d, J=7.12 Hz, 2H) 4.43-4.71 (m, 1H) 6.62 (dd, J=6.44, 3.05 Hz, 1H) 7.19 (d, J=3.73 Hz, 1H) 7.71 (d, J=4.07 Hz, 1H) 7.79 (s, 1H) 8.13 (s, 1H) 8.55 (dd, J=8.99, 6.95 Hz, 2H) 8.64 (d, J=2.71 Hz, 1H); MS (ESI(+)) m/e 397 (M+H)+.
- The title compound was prepared as described in Example 147A, substituting (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1B, substituting (R)—N-(1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl)-5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (400 MHz, DMSO-d6) δ ppm 0.85 (d, J=6.71 Hz, 6H) 1.94-2.38 (m, 3H) 3.39-3.84 (m, 4H) 3.92 (d, J=7.32 Hz, 2H) 4.45-4.66 (m, 1H) 6.88 (d, J=8.24 Hz, 1H) 7.19 (d, J=3.97 Hz, 1H) 7.34 (dd, J=9.00, 4.43 Hz, 1H) 7.73 (d, J=3.97 Hz, 1H) 7.80 (s, 1H) 8.14 (s, 1H) 8.49 (d, J=3.66 Hz, 1H) 8.56 (d, J=6.71 Hz, 1H); MS (ESI(+)) m/e 397 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-tert-butyl 3-aminopyrrolidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 3-(5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-2-carboxamido)pyrrolidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147A, substituting (S)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1B, substituting (S)—N-(1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl)-5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.85 (d, J=6.78 Hz, 6H) 1.91-2.42 (m, 3H) 3.49-3.88 (m, 4H) 3.87-4.07 (m, 2H) 4.30-4.81 (m, 1H) 7.20 (d, J=3.73 Hz, 1H) 7.68 (d, J=8.82 Hz, 1H) 7.74-7.94 (m, 3H) 8.14 (s, 1H) 8.58 (d, J=3.05 Hz, 1H) 8.71 (d, J=6.44 Hz, 1H); MS (ESI(+)) m/e 397 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting 4-bromopyridazine for 3-bromopyridine and (S)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.75-0.98 (m, 6H) 1.98-2.44 (m, 3H) 3.67-4.18 (m, 6H) 4.66 (s, 1H) 7.15 (dd, J=7.12, 3.05 Hz, 1H) 7.21 (d, J=3.73 Hz, 1H) 7.54-7.91 (m, 2H) 8.14 (s, 1H) 8.56-8.95 (m, 3H); MS (ESI(+)) m/e 397 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting (S)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.85 (d, J=6.78 Hz, 6H) 1.88-2.38 (m, 3H) 3.11-3.67 (m, 4H) 3.92 (d, J=7.46 Hz, 2H) 4.45-4.76 (m, 1H) 6.75-7.01 (m, 1H) 7.03-7.25 (m, 2H) 7.73 (d, J=4.07 Hz, 1H) 7.79 (s, 1H) 7.81-7.93 (m, 1H) 7.95 (d, J=2.71 Hz, 1H) 8.13 (s, 1H) 8.54 (d, J=7.12 Hz, 1H); MS (ESI(+)) m/e 396 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-methylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.00 (s, 1H), 7.93 (dd, J=4.6, 1.4 Hz, 1H), 7.85 (d, J=2.5 Hz, 1H), 7.53 (d, J=8.6 Hz, 2H), 7.23-7.13 (m, 3H), 6.86 (ddd, J=8.3, 2.9, 1.4 Hz, 1H), 5.43 (bs, 1H), 4.59 (bs, 1H), 4.15-4.03 (m, 2H), 4.02-3.90 (m, 2H), 3.71 (tt, J=8.3, 6.1 Hz, 1H), 3.42-3.32 (m, 4H), 3.04 (bs, 1H), 2.80-2.62 (m, 2H), 2.39 (bs, 4H), 1.78 (d, J=11.1 Hz, 2H), 1.57-1.42 (m, 2H), 1.39 (s, 9H), 1.17 (s, 6H); MS (ESI(+)) m/e 591 (M+H)+.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(2-methyl-1-oxo-1-{4-[4-({[1-(pyridin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidin-1-yl}propan-2-yl)piperazine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.08 (s, 1H), 8.52 (s, 1H), 8.14 (d, J=5.2 Hz, 1H), 8.07 (d, J=2.6 Hz, 1H), 7.76 (dd, J=8.7, 5.4 Hz, 1H), 7.54 (d, J=8.6 Hz, 2H), 7.20 (d, J=8.6 Hz, 2H), 4.88 (bs, 4H), 4.23 (t, J=8.4 Hz, 2H), 4.12 (dd, J=7.9, 5.9 Hz, 2H), 3.87-3.66 (m, 1H), 3.10 (bs, 4H), 2.85-2.54 (m, 5H), 1.79 (d, J=13.1 Hz, 2H), 1.61-1.32 (m, 2H), 1.21 (s, 6H); MS (ESI(+)) m/e 491 (M+H)+.
- To 3,4,5-trichloropyridazine (1.624 g, 8.85 mmol) and N-ethyl-N-isopropylpropan-2-amine (2.289 g, 17.71 mmol) in 50 mL N,N-dimethylformamide at 0° C. was added tert-butyl 4-(4-(azetidine-3-carboxamido)phenylsulfonyl)piperidine-1-carboxylate (2.5 g, 5.90 mmol) in 10 ml N,N-dimethylformamide, dropwise. The reaction mixture was stirred from 0° C. to room temperature overnight, diluted with water and extracted with ethyl acetate. The organic layer was dried with magnesium sulfate, filtered, concentrated and purified by flash chromatography to give the title compound.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 4-((4-(1-(5,6-dichloropyridazin-4-yl)azetidine-3 carboxamido)phenyl)sulfonyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3 carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-((4-(1-(pyridazin-4-yl)azetidine-3-carboxamido)phenyl)sulfonyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-ylsulfonyl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and isobutyric acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.70 (s, 1H), 8.79 (d, J=7.2 Hz, 1H), 8.55 (d, J=3.1 Hz, 1H), 7.93-7.86 (m, 2H), 7.85-7.78 (m, 2H), 7.00 (dd, J=7.2, 3.1 Hz, 1H), 4.65-4.36 (m, 5H), 4.09-3.82 (m, 2H), 3.35-2.67 (m, 4H), 1.95-1.76 (m, 2H), 1.48-0.99 (m, 2H), 0.95 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 472 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-ylsulfonyl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.70 (s, 1H), 8.79 (d, J=7.2 Hz, 1H), 8.55 (d, J=3.3 Hz, 1H), 7.93-7.86 (m, 2H), 7.85-7.78 (m, 2H), 7.49-7.29 (m, 5H), 7.00 (dd, J=7.2, 3.1 Hz, 1H), 4.65-4.35 (m, 4H), 3.99-3.83 (m, 1H), 3.73-3.50 (m, 1H), 3.28-2.65 (m, 4H), 2.37-1.59 (m, 2H), 1.56-1.06 (m, 2H); MS (ESI(+)) m/e 506 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-ylsulfonyl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.70 (s, 1H), 8.79 (d, J=6.9 Hz, 1H), 8.55 (d, J=3.1 Hz, 1H), 7.93-7.86 (m, 2H), 7.85-7.78 (m, 2H), 7.52-7.38 (m, 2H), 7.31-7.20 (m, 2H), 7.00 (dd, J=7.2, 3.1 Hz, 1H), 4.63-4.19 (m, 4H), 3.99-3.83 (m, 1H), 3.73-3.46 (m, 2H), 3.23-2.65 (m, 3H), 2.37-1.60 (m, 2H), 1.56-1.06 (m, 2H); MS (ESI(+)) m/e 524 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-ylsulfonyl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and cyclopentanecarboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.69 (s, 1H), 8.79 (d, J=7.2 Hz, 1H), 8.55 (d, J=3.1 Hz, 1H), 7.97-7.77 (m, 4H), 7.00 (dd, J=7.2, 3.1 Hz, 1H), 4.67-4.37 (m, 5H), 4.11-4.01 (m, 1H), 3.99-3.84 (m, 1H), 3.35-2.71 (m, 4H), 1.95-1.06 (m, 10H), 1.07-0.97 (m, 2H); MS (ESI(+)) m/e 498 (M+H)+.
- 3,4,5-Trichloropyridazine (269 mg, 1.464 mmol) was dissolved in 5 ml N,N-dimethylformamide and triethylamine (370 mg, 3.66 mmol) was added. The solution was cooled with an ice-bath when (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide bistrifluoroacetate (400 mg, 0.732 mmol) in N,N-dimethylformamide was added dropwise. The reaction mixture was stirred from 0° C. to room temperature overnight, diluted with water and extracted with ethyl acetate. The organic layer was dried with magnesium sulfate, filtered, concentrated, and purified by flash chromatography to give the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.66 (s, 1H), 8.49 (d, J=6.5 Hz, 1H), 8.14 (s, 1H), 7.79 (s, 1H), 7.70 (d, J=3.9 Hz, 1H), 7.20 (d, J=3.8 Hz, 1H), 4.59-4.45 (m, 1H), 4.05 (dd, J=11.0, 6.4 Hz, 1H), 4.01-3.66 (m, 5H), 2.30-1.94 (m, 3H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 465 (M+H)+.
- The title compound was prepared as described in Example 147A, substituting (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (d, J=6.6 Hz, 1H), 8.14 (s, 1H), 7.80 (s, 1H), 7.72 (d, J=3.9 Hz, 1H), 7.49 (d, J=9.4 Hz, 1H), 7.20 (d, J=3.8 Hz, 1H), 7.03 (d, J=9.4 Hz, 1H), 4.64-4.52 (m, 1H), 3.92 (d, J=7.2 Hz, 2H), 3.76 (dd, J=11.0, 6.6 Hz, 1H), 3.69-3.41 (m, 3H), 2.34-2.21 (m, 1H), 2.19-2.02 (m, 2H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 431 (M+H)+.
- The title compound was prepared as described in Example 618, substituting (S)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.70 (s, 1H), 8.55 (d, J=6.5 Hz, 1H), 8.19 (s, 1H), 7.85 (s, 1H), 7.75 (d, J=3.9 Hz, 1H), 7.25 (d, J=3.8 Hz, 1H), 4.64-4.47 (m, 1H), 4.10 (dd, J=10.9, 6.4 Hz, 1H), 4.07-3.67 (m, 5H), 2.32-2.02 (m, 3H), 0.94-0.75 (m, 6H); MS (ESI(+)) m/e 465 (M+H)+.
- The title compound was prepared as described in Example 147A, substituting (S)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.54 (d, J=6.7 Hz, 1H), 8.13 (d, J=0.8 Hz, 1H), 7.79 (d, J=0.8 Hz, 1H), 7.72 (d, J=3.9 Hz, 1H), 7.49 (d, J=9.4 Hz, 1H), 7.19 (d, J=3.8 Hz, 1H), 7.03 (d, J=9.4 Hz, 1H), 4.63-4.53 (m, 1H), 3.92 (d, J=7.2 Hz, 2H), 3.76 (dd, J=11.0, 6.6 Hz, 1H), 3.71-3.39 (m, 3H), 2.37-2.00 (m, 3H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 431 (M+H)+.
- The title compound was prepared as described as described in Example 148A, substituting 5-bromothiophene-3-carboxylic acid for 4-bromoaniline.
- The title compound was prepared as described in Example 1A, substituting (R)-tert-butyl 3-aminopyrrolidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (R)-tert-butyl 3-(5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-3-carboxamido)pyrrolidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 618, substituting (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-3-carboxamide for (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.66 (s, 1H), 8.37 (d, J=6.5 Hz, 1H), 8.08 (d, J=0.8 Hz, 1H), 7.94 (d, J=1.4 Hz, 1H), 7.74 (d, J=0.8 Hz, 1H), 7.51 (d, J=1.4 Hz, 1H), 4.53 (q, J=5.4 Hz, 1H), 4.06 (dd, J=10.9, 6.4 Hz, 1H), 3.98-3.66 (m, 5H), 2.30-1.96 (m, 3H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 465 (M+H)+.
- The title compound was prepared as described in Example 147A, substituting (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-3-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting (R)—N-(1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl)-5-(1-isobutyl-1H-pyrazol-4-yl)thiophene-3-carboxamide for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.49 (dd, J=4.5, 1.3 Hz, 1H), 8.41 (d, J=6.7 Hz, 1H), 8.08 (s, 1H), 7.96 (d, J=1.4 Hz, 1H), 7.73 (s, 1H), 7.54 (d, J=1.4 Hz, 1H), 7.37 (dd, J=9.1, 4.4 Hz, 1H), 6.92 (d, J=9.1 Hz, 1H), 4.67-4.55 (m, 1H), 3.92 (d, J=7.2 Hz, 2H), 3.78 (dd, J=10.9, 6.6 Hz, 1H), 3.72-3.41 (m, 3H), 2.40-1.98 (m, 3H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 397 (M+H)+.
- The title compound was prepared as described in Example 1B, substituting N-[(3R)-1-(5,6-dichloropyridazin-4-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-3-carboxamide for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.86-8.69 (m, 2H), 8.58 (d, J=6.6 Hz, 1H), 8.08 (d, J=0.8 Hz, 1H), 8.01 (d, J=1.4 Hz, 1H), 7.74 (d, J=0.8 Hz, 1H), 7.55 (d, J=1.4 Hz, 1H), 7.15 (dd, J=7.3, 3.1 Hz, 1H), 4.72-4.59 (m, 1H), 4.08-3.47 (m, 6H), 2.37-1.97 (m, 3H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 397 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(benzyloxycarbonyl)piperidine-4-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting benzyl 4-((4-(1-(tert-butoxycarbonyl)piperidin-4-yl)phenyl)carbamoyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147A, substituting tert-butyl 4-(4-(piperidine-4-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, tert-butyl 4-(4-(1-(6-chloropyridazin-3-yl)piperidine-4-carboxamido)phenyl)piperidine-1-carboxylate for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(pyridazin-3-yl)piperidine-4-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)piperidine-4-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.86 (s, 1H), 8.51 (d, J=3.6 Hz, 1H), 7.53-7.47 (m, 2H), 7.43-7.31 (m, 1H), 7.26 (d, J=8.6 Hz, 1H), 7.17-7.11 (m, 2H), 4.45-4.34 (m, 4H), 2.94 (t, J=11.6 Hz, 1H), 2.82 (t, J=12.5 Hz, 1H), 2.66 (dddd, J=33.0, 15.2, 8.0, 3.6 Hz, 1H), 1.89-1.81 (m, 2H), 1.80-1.71 (m, 2H), 1.70-1.53 (m, 2H), 1.51-1.33 (m, 2H), 1.20 (s, 9H), MS (ESI(+)) m/e 450 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)piperidine-4-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.87 (s, 1H), 8.51 (d, J=4.8 Hz, 1H), 7.54-7.48 (m, 2H), 7.47-7.36 (m, 5H), 7.35 (dd, J=9.3, 4.4 Hz, 1H), 7.26 (d, J=8.7 Hz, 1H), 7.21-7.15 (m, 2H), 4.60 (s, 1H), 4.46-4.37 (m, 2H), 3.63 (s, 1H), 3.24-2.56 (m, 6H), 1.89-1.80 (m, 2H), 1.80-1.46 (m, 5H), MS (ESI(+)) m/e 470 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)piperidine-4-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.87 (s, 1H), 8.51 (d, J=4.4 Hz, 1H), 7.56-7.38 (m, 4H), 7.35 (dd, J=9.3, 4.4 Hz, 1H), 7.32-7.21 (m, 3H), 7.16 (d, J=8.5 Hz, 2H), 4.64 (d, J=13.1 Hz, 1H), 4.41 (d, J=13.3 Hz, 2H), 3.15 (t, J=12.3 Hz, 1H), 2.93 (dd, J=18.0, 7.3 Hz, 2H), 2.70 (dddd, J=15.1, 11.4, 10.1, 7.0 Hz, 3H), 1.86 (t, J=13.8 Hz, 3H), 1.76-1.39 (m, 5H); MS (ESI(+)) m/e 488 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)piperidine-4-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4,4,4-trifluorobutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.86 (s, 1H), 8.51 (d, J=4.3 Hz, 1H), 7.49 (t, J=8.9 Hz, 2H), 7.41-7.30 (m, 1H), 7.25 (d, J=9.3 Hz, 1H), 7.14 (d, J=8.5 Hz, 2H), 4.51 (d, J=13.0 Hz, 1H), 4.41 (d, J=13.3 Hz, 2H), 3.94 (d, J=13.4 Hz, 1H), 3.07 (t, J=12.0 Hz, 1H), 2.94 (dd, J=18.1, 7.3 Hz, 2H), 2.77-2.40 (m, 9H), 1.93-1.80 (m, 2H), 1.71 (d, J=25.3 Hz, 2H), 1.58 (dqd, J=29.0, 12.7, 4.0 Hz, 3H), 1.39 (qd, J=12.7, 4.1 Hz, 1H); MS (ESI(+)) m/e 490 (M+H)+.
- The title compound was prepared as described in Example 147A, substituting (S)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-3-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.42 (d, J=6.7 Hz, 1H), 8.08 (s, 1H), 7.96 (d, J=1.3 Hz, 1H), 7.74 (d, J=0.5 Hz, 1H), 7.54 (d, J=1.3 Hz, 1H), 7.49 (d, J=9.5 Hz, 1H), 7.02 (d, J=9.5 Hz, 1H), 4.87-4.44 (m, 1H), 3.92 (d, 2H), 3.94-3.38 (m, 4H), 2.50-1.87 (m, 3H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 431 (M+H)+.
- The title compound was prepared as described in Example 147B, substituting N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]thiophene-3-carboxamide for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (dd, J=4.3, 1.2 Hz, 2H), 8.08 (d, J=0.8 Hz, 1H), 8.02 (d, J=1.4 Hz, 1H), 7.86 (dd, J=9.5, 4.3 Hz, 1H), 7.77-7.66 (m, 2H), 7.57 (d, J=1.4 Hz, 1H), 4.70-4.61 (m, 1H), 3.92 (d, J=7.2 Hz, 2H), 3.67-2.93 (m, 4H), 2.41-2.00 (m, 3H), 0.88-0.81 (m, 6H); MS (ESI(+)) m/e 397 (M+H)+.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting benzyl 3-((4-(piperidin-4-yl)phenyl)carbamoyl)azetidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting benzyl 3-((4-(1-benzoylpiperidin-4-yl)phenyl)carbamoyl)azetidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting 3-bromo-6-fluoro-5-methylpyridine for 3-bromopyridine and N-(4-(1-benzoylpiperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (400 MHz, DMSO-d6D2O) δ ppm 7.55-7.34 (m, 7H), 7.26-7.14 (m, 3H), 6.98-6.86 (m, 1H), 4.21-4.01 (m, 3H), 3.95 (dd, J=8.8, 4.6 Hz, 2H), 3.69 (ddd, J=8.5, 7.4, 4.3 Hz, 1H), 3.09-2.95 (m, 2H), 2.80 (d, J=0.6 Hz, 1H), 2.23-2.14 (m, 3H), 1.87-1.75 (m, 2H), 1.58 (tt, J=12.8, 6.1 Hz, 2H), 1.11-1.01 (m, 1H); MS (ESI(+)) m/e 473 (M+H)+.
-
TABLE 12 Ex Name MS 666 N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5- (ESI(+)) fluoropyridin-3-yl)azetidine-3-carboxamide m/e 459 (M + H)+ 668 N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2- (ESI(+)) fluoro-6-methylpyridin-3-yl)azetidine-3- m/e 473 carboxamide (M + H)+ 737 N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(2- (ESI(+)) cyanopyridin-3-yl)azetidine-3-carboxamide m/e 466 (M + H)+ 738 N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(4- (ESI(+)) cyanopyridin-3-yl)azetidine-3-carboxamide m/e 466 (M + H)+ 739 N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(6- (ESI(+)) fluoro-4-methylpyridin-3-yl)azetidine-3- m/e 473 carboxamide (M + H)+ 740 N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5- (ESI(+)) cyanopyridin-3-yl)azetidine-3-carboxamide m/e 466 (M + H)+ 741 N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1-(5- (ESI(+)) methylpyridin-3-yl)azetidine-3-carboxamide m/e 455 (M + H)+ - The following Examples were essentially prepared as described in Example 665, substituting an appropriate bromoheterocycle in Example 665D.
- The title compound was prepared as described in Example 1C, substituting 3-bromo-6-methylpyridazine for 3-bromopyridine and tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(6-methylpyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 1-(6-methylpyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.02 (s, 1H), 7.54 (d, J=8.5 Hz, 2H), 7.49-7.39 (m, 5H), 7.28 (d, J=9.1 Hz, 1H), 7.22 (d, J=8.5 Hz, 2H), 6.79 (d, J=9.0 Hz, 1H), 4.72-4.51 (m, 1H), 4.19 (t, J=8.2 Hz, 2H), 4.10 (dd, J=7.8, 6.2 Hz, 2H), 3.71 (tt, J=8.5, 6.1 Hz, 2H), 3.21-2.95 (m, 1H), 2.95-2.64 (m, 2H), 2.44 (s, 3H), 1.93-1.46 (m, 4H); (ESI(+)) m/e 456 (M+H)+.
-
TABLE 13 Ex Name MS 851 N-{4-[1-(2-fluorobenzoyl)piperidin-4-yl]phenyl}-1- (ESI(+)) (6-methylpyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 852 N-{4-[-(2,2-dimethylpropanoyl)piperidin-4-yl]phenyl}- (ESI(+)) 1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ - The following Examples were essentially prepared as described in Example 667, substituting the appropriate carboxylic acid in Example 667C.
- The title compound was prepared as described in Example 148A, substituting 2-bromothiazole-5-carboxylic acid for 4-bromoaniline.
- The title compound was prepared as described in Example 1A, substituting (S)-tert-butyl 3-aminopyrrolidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-(1-isobutyl-1H-pyrazol-4-yl)thiazole-5-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 3-(2-(1-isobutyl-1H-pyrazol-4-yl)thiazole-5-carboxamido)pyrrolidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147A, substituting (S)-2-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiazole-5-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting (S)—N-(1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl)-2-(1-isobutyl-1H-pyrazol-4-yl)thiazole-5-carboxamide for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.80 (d, 1H), 8.41 (d, J=0.8 Hz, 1H), 8.30 (s, 1H), 8.28 (s, 1H), 7.90 (s, 1H), 7.34 (dd, J=9.1, 4.5 Hz, 1H), 6.88 (dd, J=9.1, 1.3 Hz, 1H), 4.67-4.52 (m, 1H), 4.03-3.93 (m, 2H), 3.90-3.40 (m, 4H), 2.36-2.02 (m, 3H), 0.89-0.82 (m, 6H); MS (ESI(+)) m/e 398 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and (S)-1-((benzyloxy)carbonyl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting (S)-tert-butyl 4-(4-(1-((benzyloxy)carbonyl)pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting 3-bromo-2-methylpyridine for 3-bromopyridine and (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 4-(4-(1-(2-methylpyridin-3-yl)pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(2-methylpyridin-3-yl)-N-(4-(piperidin-4-yl)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.98 (s, 1H), 7.97 (ddd, J=5.1, 2.2, 1.3 Hz, 2H), 7.69 (dt, J=8.4, 0.9 Hz, 1H), 7.56-7.51 (m, 2H), 7.47-7.41 (m, 5H), 7.24-7.18 (m, 3H), 7.09 (dd, J=8.0, 4.7 Hz, 1H), 4.62 (s, 1H), 3.65 (s, 1H), 3.19 (ddd, J=14.2, 10.1, 6.4 Hz, 4H), 2.76 (t, J=11.9 Hz, 2H), 2.47 (s, 3H), 2.26-2.06 (m, 2H), 1.93-1.49 (m, 4H), 1.23 (s, 1H), MS (ESI(+)) m/e 469.3 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(2-methylpyridin-3-yl)-N-(4-(piperidin-4-yl)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.98 (s, 1H), 8.01-7.93 (m, 2H), 7.58-7.45 (m, 2H), 7.44-7.37 (m, 1H), 7.30 (tdd, J=6.6, 3.7, 2.8 Hz, 2H), 7.20 (dd, J=11.4, 4.7 Hz, 2H), 7.09 (dd, J=8.1, 4.6 Hz, 1H), 4.66 (d, J=13.1 Hz, 1H), 3.49-3.14 (m, 8H), 2.90-2.69 (m, 2H), 2.47 (s, 3H), 2.31-2.06 (m, 2H), 1.92-1.80 (m, 1H), 1.70 (s, 1H), 1.64-1.41 (m, 2H); MS (ESI(+)) m/e 487.3 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(2-methylpyridin-3-yl)-N-(4-(piperidin-4-yl)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4,4,4-trifluorobutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.97 (s, 1H), 7.97 (dd, J=4.8, 3.6 Hz, 2H), 7.53 (d, J=8.3 Hz, 3H), 7.24-7.13 (m, 3H), 4.53 (d, J=12.9 Hz, 1H), 3.97 (d, J=13.3 Hz, 1H), 3.39 (d, J=7.5 Hz, 3H), 3.36-3.29 (m, 2H), 3.25-3.16 (m, 2H), 3.11 (dd, J=24.4, 11.8 Hz, 1H), 2.70 (ddd, J=15.1, 11.8, 8.3 Hz, 1H), 2.67-2.57 (m, 3H), 2.47 (s, 3H), 2.27-2.07 (m, 2H), 1.75 (s, 2H), 1.56 (dt, J=12.5, 8.7 Hz, 1H), 1.41 (qd, J=12.8, 4.3 Hz, 1H), MS (ESI(+)) m/e 489.3 (M+H)+.
- The title compound was prepared as described in Example 148A, substituting 5-bromofuran-2-carboxylic acid for 4-bromoaniline.
- The title compound was prepared as described in Example 1A, substituting (S)-tert-butyl 3-aminopyrrolidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-isobutyl-1H-pyrazol-4-yl)furan-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 3-(5-(1-isobutyl-1H-pyrazol-4-yl)furan-2-carboxamido)pyrrolidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147A, substituting (S)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)furan-2-carboxamide for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.37 (d, J=6.9 Hz, 1H), 8.14 (s, 1H), 7.87 (s, 1H), 7.49 (d, J=9.4 Hz, 1H), 7.17 (d, J=3.5 Hz, 1H), 7.03 (d, J=9.4 Hz, 1H), 6.63 (d, J=3.5 Hz, 1H), 4.69-4.54 (m, 1H), 3.95 (d, J=7.2 Hz, 2H), 3.79 (dd, J=11.0, 6.8 Hz, 1H), 3.72-3.58 (m, 1H), 3.60-3.39 (m, 2H), 2.36-2.19 (m, 1H), 2.22-2.03 (m, 2H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 415 (M+H)+.
- The title compound was prepared as described in Example 147B, substituting N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]furan-2-carboxamide for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.49 (dd, J=4.5, 1.2 Hz, 1H), 8.38 (d, J=7.0 Hz, 1H), 8.15 (s, 1H), 7.87 (s, 1H), 7.34 (dd, J=9.1, 4.4 Hz, 1H), 7.17 (d, J=3.5 Hz, 1H), 6.88 (dd, J=9.1, 1.3 Hz, 1H), 6.63 (d, J=3.5 Hz, 1H), 4.70-4.54 (m, 1H), 3.95 (d, J=7.2 Hz, 2H), 3.79 (dd, J=10.8, 6.9 Hz, 1H), 3.75-3.61 (m, 1H), 3.61-3.39 (m, 2H), 2.37-2.01 (m, 3H), 0.85 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 381 (M+H)+.
- The title compound was prepared as described in Example 147A, substituting azetidine-3-carboxylic acid for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting 1-(6-chloropyridazin-3-yl)azetidine-3-carboxylic acid for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 4-bromoaniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 148A, substituting 1-((4-methyltetrahydro-2H-pyran-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and N-(4-bromophenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.09 (s, 1H), 8.56 (dd, J=4.5, 1.2 Hz, 1H), 8.06 (s, 1H), 7.82 (s, 1H), 7.61 (d, J=8.7 Hz, 2H), 7.52 (d, J=8.6 Hz, 2H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.83 (dd, J=9.0, 1.2 Hz, 1H), 4.25 (t, J=8.3 Hz, 2H), 4.16 (dd, J=8.0, 6.0 Hz, 2H), 4.02 (s, 2H), 3.84-3.62 (m, 3H), 3.52 (ddd, J=11.8, 9.2, 3.0 Hz, 2H), 1.51 (ddd, J=13.3, 9.0, 4.2 Hz, 2H), 1.32-1.17 (m, 2H), 0.97 (s, 3H); MS (ESI(+)) m/e 433 (M+H)+.
- The title compound was prepared as described in Example 147A, substituting (S)-tert-butyl pyrrolidin-3-ylcarbamate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl (1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl)carbamate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4-(1-isobutyrylpiperidin-4-yl)benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.53 (d, J=6.6 Hz, 1H), 7.83-7.76 (m, 2H), 7.48 (d, J=9.4 Hz, 1H), 7.37-7.30 (m, 2H), 7.01 (d, J=9.5 Hz, 1H), 4.68-4.49 (m, 2H), 4.12-4.00 (m, 1H), 3.77 (dd, J=11.0, 6.6 Hz, 1H), 3.68-3.39 (m, 3H), 3.19-3.00 (m, 1H), 3.02-2.50 (m, 3H), 2.35-2.19 (m, 1H), 2.08 (dq, J=12.5, 6.3 Hz, 1H), 1.91-1.70 (m, 2H), 1.65-1.07 (m, 2H). 1.05-0.88 (m, 6H); MS (ESI(+)) m/e 456 (M+H)+.
- The title compound was prepared as described in Example 148A, substituting tert-butyl 4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethyl)piperazine-1-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and N-(4-bromophenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(2-(4-(4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)-1H-pyrazol-1-yl)ethyl)piperazine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.20 (s, 1H), 8.71 (s, 2H), 8.57 (dd, J=4.3, 1.0 Hz, 1H), 8.14 (s, 1H), 7.86 (s, 1H), 7.80 (dd, J=9.4, 4.4 Hz, 1H), 7.66-7.58 (m, 2H), 7.57-7.49 (m, 2H), 7.45 (d, J=9.2 Hz, 1H), 4.56-4.36 (m, 4H), 4.31 (t, J=6.3 Hz, 2H), 3.91-3.73 (m, 1H), 3.25-3.09 (m, 4H), 3.04 (t, J=6.1 Hz, 2H), 2.83 (s, 4H); MS (ESI(+)) m/e 433 (M+H)+.
- The title compound was prepared as described in Example 148A, substituting 1-neopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and N-(4-bromophenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.14 (s, 1H), 8.57 (dd, J=4.5, 1.2 Hz, 1H), 8.05 (s, 1H), 7.82 (s, 1H), 7.66-7.58 (m, 2H), 7.55-7.51 (m, 2H), 7.48 (dd, J=9.1, 4.5 Hz, 1H), 6.98 (dd, J=9.1, 1.1 Hz, 1H), 4.30 (t, J=8.6 Hz, 2H), 4.22 (dd, J=8.4, 6.0 Hz, 2H), 3.90 (s, 2H), 3.77 (tt, J=8.6, 5.9 Hz, 1H), 0.92 (s, 9H); MS (ESI(+)) m/e 391 (M+H)+.
- The title compound was prepared as described in Example 147B, substituting N-[(3S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl]-4-[1-(2-methylpropanoyl)piperidin-4-yl]benzamide for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.69 (d, J=6.6 Hz, 1H), 8.57 (dd, J=4.3, 1.2 Hz, 1H), 8.16-7.75 (m, 3H), 7.69 (dd, J=9.5, 1.2 Hz, 1H), 7.37-7.31 (m, 2H), 4.90-4.41 (m, 2H), 4.33-3.60 (m, 5H), 3.20-2.50 (m, 4H), 2.37-2.14 (m, 2H), 1.87-1.74 (m, 2H), 1.63-1.20 (m, 2H), 1.02 (bs, J=7.4 Hz, 6H); MS (ESI(+)) m/e 422 (M+H)+.
- The title compound was prepared as described in Example 148A, substituting 2-methyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propan-2-ol for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and N-(4-bromophenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.09 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 8.01 (s, 1H), 7.81 (s, 1H), 7.69-7.57 (m, 2H), 7.57-7.44 (m, 2H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.83 (dd, J=9.0, 1.3 Hz, 1H), 4.70 (s, 1H), 4.25 (t, J=8.4 Hz, 2H), 4.16 (dd, J=8.0, 6.0 Hz, 2H), 4.01 (s, 2H), 3.74 (tt, J=8.5, 6.0 Hz, 1H), 1.08 (s, 6H); MS (ESI(+)) m/e 393 (M+H)+.
- The title compound was prepared as described in Example 147B, substituting (S)-tert-butyl (1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl)carbamate for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl (1-(pyridazin-3-yl)pyrrolidin-3-yl)carbamate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 148A, substituting tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 5-bromothiophene-2-carboxylic acid for 4-bromoaniline.
- The title compound was prepared as described in Example 1B, substituting 5-(1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)thiophene-2-carboxylic acid for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(pyridazin-3-yl)pyrrolidin-3-amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)thiophene-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 4-(5-((1-(pyridazin-3-yl)pyrrolidin-3-yl)carbamoyl)thiophen-2-yl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-5-(piperidin-4-yl)-N-(1-(pyridazin-3-yl)pyrrolidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 3-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.63-8.44 (m, 2H), 7.66 (d, J=3.8 Hz, 1H), 7.58-7.44 (m, 1H), 7.41-7.19 (m, 4H), 6.95 (d, J=3.8 Hz, 1H), 6.87 (dd, J=9.1, 1.4 Hz, 1H), 4.66-4.19 (m, 2H), 3.85-3.38 (m, 5H), 3.20-2.72 (m, 3H), 2.34-2.15 (m, 1H), 2.17-1.78 (m, 3H), 1.72-1.46 (m, 2H); MS (ESI(+)) m/e 480 (M+H)+.
-
TABLE 14 Ex Name MS 755 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1- (ESI(+)) (pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2- m/e 480 carboxamide (M + H)+ 758 N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1- (ESI(+)) (tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4- m/e 470 yl]thiophene-2-carboxamide (M + H)+ 760 5-[1-(2-methylpropanoyl)piperidin-4-yl]-N-[(3S)-1- (ESI(+)) (pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2- m/e 428 carboxamide (M + H)+ 761 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[(3S)-1- (ESI(+)) (pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2- m/e 498 carboxamide (M + H)+ 762 5-{1-[(2-methylcyclopropyl)carbonyl]piperidin-4- (ESI(+)) yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl] m/e 440 thiophene-2-carboxamide (M + H)+ 763 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[(3S)-1- (ESI(+)) (pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2- m/e 480 carboxamide (M + H)+ 764 5-(1-benzoylpiperidin-4-yl)-N-[(3S)-1-(pyridazin-3- (ESI(+)) yl)pyrrolidin-3-yl]thiophene-2-carboxamide m/e 462 (M + H)+ 765 N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1- (ESI(+)) (tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl] m/e 456 thiophene-2-carboxamide (M + H)+ 766 N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-{1- (ESI(+)) [(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl} m/e 456 thiophene-2-carboxamide (M + H)+ 767 5-{1-[(1-methylpiperidin-4-yl)acetyl]piperidin-4-yl}- (ESI(+)) N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene- m/e 498 2-carboxamide (M + H)+ 768 N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1-(1,3- (ESI(+)) thiazol-4-ylcarbonyl)piperidin-4-yl]thiophene-2- m/e 469 carboxamide (M + H)+ 1013 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[(3S)- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2- m/e 442 carboxamide (M + H)+ 1014 5-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-N-[(3S)- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2- m/e 456 carboxamide (M + H)+ 1015 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[(3S)- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2- m/e 456 carboxamide (M + H)+ 1016 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4- (ESI(+)) yl}-N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl] m/e 440 thiophene-2-carboxamide (M + H)+ 1017 N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]-5-[1- (ESI(+)) (3,3,3-trifluoropropanoyl)piperidin-4-yl]thiophene- m/e 468 2-carboxamide (M + H)+ 1018 5-[1-(cyclopropylacetyl)piperidin-4-yl]-N-[(3S)-1- (ESI(+)) (pyridazin-3-yl)pyrrolidin-3-yl]thiophene-2- m/e 440 carboxamide (M + H)+ 1019 5-[1-(bicyclo[2.2.1]hept-2-ylacetyl)piperidin-4-yl]- (ESI(+)) N-[(3S)-1-(pyridazin-3-yl)pyrrolidin-3-yl]thiophene- m/e 494 2-carboxamide (M + H)+ - The following Examples were essentially prepared as described in Example 754, substituting an appropriate carboxylic acid in Example 754G.
- The title compound was prepared as described in Example 147A, substituting (S)-pyrrolidine-3-carboxylic acid for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting (S)-1-(6-chloropyridazin-3-yl)pyrrolidine-3-carboxylic acid for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 4-bromoaniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and (S)-1-(pyridazin-3-yl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 148A, substituting 1-((4-methyltetrahydro-2H-pyran-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and (S)—N-(4-bromophenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide for 4-bromoaniline. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.11 (s, 1H), 8.48 (dd, J=4.5, 1.2 Hz, 1H), 8.07 (s, 1H), 7.82 (s, 1H), 7.64-7.58 (m, 2H), 7.54-7.49 (m, 2H), 7.34 (dd, J=9.1, 4.4 Hz, 1H), 6.88 (dd, J=9.2, 1.3 Hz, 1H), 4.02 (s, 2H), 3.78 (dd, J=10.5, 7.9 Hz, 1H), 3.72-3.58 (m, 4H), 3.56-3.45 (m, 3H), 3.37-3.32 (m, 1H), 2.42-2.09 (m, 2H), 1.51 (ddd, J=13.4, 9.1, 4.2 Hz, 2H), 1.32-1.12 (m, 2H), 0.97 (s, 3H); MS (ESI(+)) m/e 447 (M+H)+.
-
TABLE 15 Ex Name MS 757 (3S)-N-{4-[1-(2-hydroxy-2-methylpropyl)-1H-pyrazol- (ESI(+)) 4-yl]phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 407 carboxamide (M + H)+ 759 (3S)-N-{4-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 405 carboxamide (M + H)+ 769 (3S)-N-{4-[1-(2-methylpropyl)-1H-pyrazol-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 391 carboxamide (M + H)+ 770 (3S)-N-{4-[1-(propan-2-yl)-1H-pyrazol-4-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 377 (M + H)+ 771 (3S)-N-{4-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 389 carboxamide (M + H)+ 772 (3S)-1-(pyridazin-3-yl)-N-{4-[1-(tetrahydro-2H-pyran- (ESI(+)) 2-ylmethyl)-1H-pyrazol-4-yl]phenyl}pyrrolidine-3- m/e 433 carboxamide (M + H)+ 773 (3S)-N-[4-[1-tert-butyl-1H-pyrazol-4-yl)phenyl]-1- (ESI(+)) (pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 391 (M + H)+ - The following Examples were essentially prepared as described in Example 756, substituting an appropriate boronate in Example 756D.
- The title compound was prepared as described in Example 1A, substituting (R)-tert-butyl 3-(4-aminophenoxy)pyrrolidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and (S)-1-(pyridazin-3-yl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (R)-tert-butyl 3-(4-((S)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamido)phenoxy)pyrrolidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(pyridazin-3-yl)-N-(4-((R)-pyrrolidin-3-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.03 (d, J=18.3 Hz, 1H), 8.51 (d, J=4.2 Hz, 1H), 7.46 (tdt, J=21.9, 19.2, 10.8 Hz, 8H), 7.13-7.02 (m, 1H), 6.96 (d, J=8.9 Hz, 1H), 6.86 (d, J=8.9 Hz, 1H), 5.00 (d, J=34.1 Hz, 1H), 3.88-3.74 (m, 2H), 3.65 (dd, J=12.1, 7.4 Hz, 4H), 3.51 (d, J=7.3 Hz, 2H), 2.37-1.98 (m, 4H), MS (ESI(+)) m/e 458 (M+H)+.
-
TABLE 16 Ex Name MS 775 (3S)-N-(4-{[(3R)-1-(2-fluorobenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 476 carboxamide (M + H)+ 776 (3S)-N-(4-{[(3R)-1-(3-fluorobenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 476 carboxamide (M + H)+ 777 (3S)-N-(4-{[(3R)-1-(4-fluorobenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 476 carboxamide (M + H)+ 778 (3S)-N-(4-{[(3R)-1-(3,5-difluorobenzoyl)pyrrolidin- (ESI(+)) 3-yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 494 carboxamide (M + H)+ 779 (3S)-N-(4-{[(3R)-1-(2-methylbenzoyl)pyrrolidin-3- (ESI(+)) yl]oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 472 carboxamide (M + H)+ 780 (3S)-N-(4-{[(3R)-1-(2,2-dimethylpropanoyl) (ESI(+)) pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3- m/e 438 yl)pyrrolidine-3-carboxamide (M + H)+ 781 (3S)-N-[4-({(3R)-1-[(4,4-difluorocyclohexyl) (ESI(+)) carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1-(pyridazin- m/e 500 3-yl)pyrrolidine-3-carboxamide (M + H)+ 782 (3S)-1-(pyridazin-3-yl)-N-(4-{[(3R)-1-(4,4,4- (ESI(+)) trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl] m/e 478 pyrrolidine-3-carboxamide (M + H)+ 783 (3S)-N-(4-{[(3R)-1-(2,4-difluorobenzoyl) (ESI(+)) pyrrolidin-3-yl]oxy}phenyl)-1-(pyridazin-3-yl) m/e 494 pyrrolidine-3-carboxamide (M + H)+ - The following Examples were essentially prepared as described in Example 774, substituting an appropriate carboxylic acid in Example 774C.
- The title compound was prepared as described in Example 806, substituting butanoyl chloride for 3,3-dimethylbutanoyl chloride in Example 806A. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.39 (s, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 8.04-7.89 (m, 2H), 7.89-7.74 (m, 2H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.84 (dd, J=8.9, 1.4 Hz, 1H), 4.26 (t, J=8.4 Hz, 2H), 4.18 (dd, J=8.2, 5.9 Hz, 2H), 3.79 (tt, J=8.6, 5.9 Hz, 1H), 2.96 (t, J=7.4 Hz, 2H), 1.81 (h, J=7.4 Hz, 2H), 0.99 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 365 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 3-(4-aminophenyl)azetidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and substituting (S)-1-(pyridazin-3-yl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 3-(4-(1-(pyridazin-3-yl)pyrrolidine-3-carboxamido)phenyl)azetidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)—N-(4-(azetidin-3-yl)phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.15 (bs, 1H), 8.51-8.46 (m, 1H), 7.67-7.40 (m, 4H), 7.40-7.24 (m, 5H), 6.90-6.85 (m, 1H), 4.50-4.42 (m, 1H), 4.41-4.34 (m, 1H), 4.02-3.96 (m, 2H), 3.93-3.83 (m, 1H), 3.81-3.73 (m, 1H), 3.67-3.58 (m, 2H), 3.53-3.44 (m, 1H), 3.40-3.30 (m, 1H), 2.43-2.12 (m, 2H); MS (ESI(+)) m/e 446 (M+H)+.
-
TABLE 17 Ex Name MS 786 (3S)-N-{4-[1-(3-fluorobenzoyl)azetidin-3-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 446 (M + H)+ 787 (3S)-N-{4-[1-(4-fluorobenzoyl)azetidin-3-yl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 446 (M + H)+ 788 (3S)-N-[4-(1-benzoylazetidin-3-yl)phenyl]-1- (ESI(+)) (pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 428 (M + H)+ 789 (3S)-N-{4-[1-(2,2-dimethylpropanoyl)azetidin-3-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 408 (M + H)+ 790 (3S)-N-{4-[1-(3,5-difluorobenzoyl)azetidin-3-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 464 (M + H)+ 791 3S)-N-{4-[1-(2-methylbenzoyl)azetidin-3-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3- m/e 442 carboxamide (M + H)+ 792 (3S)-N-{4-[1-(2,4-difluorobenzoyl)azetidin-3-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 464 (M + H)+ - The following Examples were essentially prepared as described in Example 785, substituting an appropriate carboxylic acid in Example 785C.
- The title compound was prepared as described in Example 147A, substituting (R)-pyrrolidine-3-carboxylic acid for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting (R)-1-(6-chloropyridazin-3-yl)pyrrolidine-3-carboxylic acid for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and (R)-1-(pyridazin-3-yl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (R)-tert-butyl 4-(4-(1-(pyridazin-3-yl)pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (R)—N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.06 (s, 1H), 8.48 (dd, J=4.4, 0.9 Hz, 1H), 7.54 (t, J=6.3 Hz, 2H), 7.47-7.40 (m, 5H), 7.35 (dd, J=9.1, 4.5 Hz, 1H), 7.22 (d, J=8.6 Hz, 2H), 6.89 (dd, J=9.2, 1.1 Hz, 1H), 4.62 (s, 1H), 3.75 (dt, J=25.9, 12.9 Hz, 1H), 3.62 (td, J=10.2, 5.8 Hz, 3H), 3.55-3.41 (m, 1H), 3.13 (s, 1H), 2.98-2.69 (m, 2H), 2.39-2.11 (m, 2H), 1.90-1.48 (m, 4H), MS (ESI(+)) m/e 456 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (R)—N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.06 (s, 1H), 8.48 (dd, J=4.5, 1.2 Hz, 1H), 7.59-7.40 (m, 4H), 7.41-7.23 (m, 3H), 7.19 (d, J=8.5 Hz, 2H), 6.89 (dd, J=9.2, 1.2 Hz, 1H), 4.66 (d, J=13.1 Hz, 1H), 3.77 (dd, J=10.5, 7.9 Hz, 1H), 3.73-3.56 (m, 2H), 3.48 (dt, J=10.2, 7.4 Hz, 2H), 3.17 (t, J=12.1 Hz, 1H), 2.82 (dt, J=24.1, 11.3 Hz, 2H), 2.38-2.09 (m, 2H), 1.97-1.79 (m, 1H), 1.69 (t, J=17.4 Hz, 1H), 1.52 (ddd, J=20.9, 12.0, 6.1 Hz, 2H), MS (ESI(+)) m/e 474 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (R)—N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.04 (s, 1H), 8.48 (dd, J=4.5, 1.3 Hz, 1H), 7.54 (t, J=6.4 Hz, 1H), 7.34 (dd, J=9.1, 4.5 Hz, 1H), 7.21-7.14 (m, 2H), 6.87 (dd, J=9.1, 1.3 Hz, 1H), 4.46-4.35 (m, 2H), 3.76 (dd, J=10.5, 7.9 Hz, 1H), 3.69-3.54 (m, 2H), 3.48 (dt, J=10.2, 7.4 Hz, 1H), 2.94-2.63 (m, 3H), 2.39-2.07 (m, 2H), 1.83-1.73 (m, 2H), 1.50 (s, 1H), 1.22 (s, 9H), MS (ESI(+)) m/e 436 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and (S)-1-(pyridazin-3-yl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 4-(4-(1-(pyridazin-3-yl)pyrrolidine-3-carboxamido)phenoxy)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)—N-(4-(piperidin-4-yloxy)phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and cyclohexanecarboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.97 (s, 1H), 8.48 (dd, J=4.5, 1.3 Hz, 1H), 7.55-7.48 (m, 2H), 7.34 (dd, J=9.1, 4.4 Hz, 1H), 6.97-6.84 (m, 3H), 4.58-4.47 (m, 1H), 3.88-3.40 (m, 6H), 3.40-3.20 (m, 2H), 2.60-2.50 (m, 1H), 2.41-2.08 (m, 2H), 2.00-1.80 (m, 2H), 1.77-1.07 (m, 13H); MS (ESI(+)) m/e 478 (M+H)+.
-
TABLE 18 Ex Name MS 797 (3S)-N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 490 (M + H)+ 798 (3S)-N-(4-{[1-(3-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 490 (M + H)+ 799 (3S)-N-{4-[(1-benzoylpiperidin-4-yl)oxy]phenyl}-1- (ESI(+)) (pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 472 (M + H)+ 800 (3S)-N-(4-{[1-(4-fluorobenzoyl)piperidin-4-yl]oxy} (ESI(+)) phenyl)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamide m/e 490 (M + H)+ 801 (3S)-N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl] (ESI(+)) oxy}phenyl)-1-(pyridazin-3-yl)pyrrolidine-3- m/e 452 carboxamide (M + H)+ 802 (3S)-N-(4-({1-[(2-methylcyclopropyl)carbonyl] (ESI(+)) piperidin-4-yl}oxy)phenyl]-1-(pyridazin-3-yl) m/e 450 pyrrolidine-3-carboxamide (M + H)+ - The following Examples were essentially prepared as described in Example 796, substituting an appropriate carboxylic acid in Example 796C.
- A suspension of 4-nitrobenzohydrazide (0.500 g, 2.76 mmol), and 4-methylmorpholine (0.455 ml, 4.14 mmol) were stirred in dichloromethane (20 ml). 3,3-Dimethylbutanoyl chloride (0.422 ml, 3.04 mmol) was added and the reaction mixture was stirred for 2 hours. Normal phase chromatography of the crude reaction mixture gave the title compound.
- A mixture of N′-(3,3-dimethylbutanoyl)-4-nitrobenzohydrazide (0.556 g, 1.991 mmol) and methyl N-(triethylammoniumsulfonyl)carbamate (0.572 g, 2.389 mmol) in tetrahydrofuran (10 ml) was heated to 120° C. in a microwave for 45 minutes. The crude reaction mixture was concentrated and purified by normal phase chromatography to give the title compound.
- The title compound was prepared as described in Example 1B, substituting 2-neopentyl-5-(4-nitrophenyl)-1,3,4-oxadiazole for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 4-(5-neopentyl-1,3,4-oxadiazol-2-yl)aniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.45 (s, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 7.97-7.91 (m, 2H), 7.88-7.82 (m, 2H), 7.39 (dd, J=9.0, 4.5 Hz, 1H), 6.84 (dd, J=9.0, 1.4 Hz, 1H), 4.26 (t, J=8.4 Hz, 2H), 4.18 (dd, J=8.2, 5.9 Hz, 2H), 3.79 (tt, J=8.6, 5.9 Hz, 1H), 2.82 (s, 2H), 1.03 (s, 9H); MS (ESI(+)) m/e 393 (M+H)+.
- To a solution of 4-(4-nitrophenyl)-1H-imidazole (0.500 g, 2.64 mmol) in N,N-dimethylformamide (10 ml) was added cesium carbonate (1.292 g, 3.96 mmol) followed by 1-bromo-2,2-dimethylpropane (0.366 ml, 2.91 mmol). After heating at 850 overnight, the reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate, filtered and concentrated. Normal phase chromatography provided the title compound.
- The title compound was prepared as described in Example 1B, substituting 1-neopentyl-4-(4-nitrophenyl)-1H-imidazole for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 4-(1-neopentyl-1H-imidazol-4-yl)aniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.08 (s, 1H), 8.56 (dd, J=4.6, 1.3 Hz, 1H), 7.73-7.66 (m, 2H), 7.64-7.58 (m, 2H), 7.57 (d, J=1.2 Hz, 1H), 7.49 (d, J=1.1 Hz, 1H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.83 (dd, J=9.0, 1.4 Hz, 1H), 4.25 (t, J=8.3 Hz, 2H), 4.16 (dd, J=8.1, 6.0 Hz, 2H), 3.77 (s, 2H), 3.77-3.69 (m, 1H), 0.91 (s, 9H); MS (ESI(+)) m/e 391 (M+H)+.
- A 250-mL round bottom flask was charged with bis(triphenylphosphine)palladium bischloride (151 mg, 0.216 mmol) and copper iodide (82 mg, 0.431 mmol), and the flask was degassed with nitrogen. Tetrahydrofuran (40 mL) was added through a septum, and nitrogen was bubbled through the mixture for 30 minutes. To this was added dropwise a nitrogen-degassed solution of 4-nitrobenzoyl chloride (2 g, 10.8 mmol), ethynylcyclopropane (784 mg, 11.9 mmol) and triethylamine (1.31 g, 12.9 mmol) in tetrahydrofuran (15 mL). The reaction mixture was stirred at room temperature for 2 hours and then concentrated to dryness. The residue was purified by normal phase chromatography to give the title compound.
- 3-Cyclopropyl-1-(4-nitrophenyl)prop-2-yn-1-one (500 mg, 2.323 mmol) was dissolved in N,N-dimethylformamide (7.75 mL), and the solution was chilled to 0° C. Methylhydrazine (118 mg, 2.56 mmol) was added dropwise. The mixture was stirred overnight at room temperature then diluted with water (25 mL) and stirred for 45 minutes. The resulting precipitate was collected by filtration to give the title compound.
- The title compound was prepared as described in Example 1B, substituting 3-cyclopropyl-1-methyl-5-(4-nitrophenyl)-1H-pyrazole for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)aniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.11 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.69-7.58 (m, 4H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.83 (dd, J=9.0, 1.3 Hz, 1H), 6.28 (s, 1H), 4.25 (t, J=8.3 Hz, 2H), 4.16 (dd, J=8.1, 6.0 Hz, 2H), 3.84 (s, 3H), 3.75 (dq, J=8.3, 5.9 Hz, 1H), 1.95-1.82 (m, 1H), 1.02-0.92 (m, 2H), 0.71-0.62 (m, 2H); MS (ESI(+)) m/e 375 (M+H)+.
- To a suspension of (Z)—N′-hydroxy-4-nitrobenzimidamide (0.500 g, 2.76 mmol) in dichloromethane (6 ml) was added 4-methylmorpholine (0.455 ml, 4.14 mmol) followed by 3,3-dimethylbutanoyl chloride (0.422 ml, 3.04 mmol). After 1 hour, the crude reaction mixture was purified by normal phase chromatography and the collected intermediate was dissolved in dichloromethane (8 ml) and treated with tetrabutylammonium fluoride (1.0M in THF) (8.28 ml, 8.28 mmol). After 3 hours at room temperature, the mixture was diluted with ethyl acetate, washed with water, dried over magnesium sulfate, filtered, and concentrated. Normal phase chromatography provided the title compound.
- The title compound was prepared as described in Example 1B, substituting 5-neopentyl-3-(4-nitrophenyl)-1,2,4-oxadiazole for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 4-(5-neopentyl-1,2,4-oxadiazol-3-yl)aniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.40 (s, 1H), 8.57 (dd, J=4.6, 1.3 Hz, 1H), 8.05-7.89 (m, 2H), 7.89-7.75 (m, 2H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.84 (dd, J=9.0, 1.3 Hz, 1H), 4.26 (t, J=8.4 Hz, 2H), 4.18 (dd, J=8.1, 5.9 Hz, 2H), 3.79 (tt, J=8.5, 5.9 Hz, 1H), 2.90 (s, 2H), 1.04 (s, 9H); MS (ESI(+)) m/e 393 (M+H)+.
- The title compound was prepared as described in Example 805, substituting (2-methoxyethyl)hydrazine for methylhydrazine in Example 805B. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.20 (s, 1H), 8.56 (d, J=4.5 Hz, 1H), 7.72-7.57 (m, 4H), 7.55-7.48 (m, 1H), 7.07-6.99 (m, 1H), 6.28 (s, 1H), 4.38-4.18 (m, 6H), 3.83-3.69 (m, 3H), 3.25 (s, 3H), 1.98-1.87 (m, 1H), 1.00-0.91 (m, 2H), 0.67 (d, J=2.3 Hz, 2H); MS (ESI(+)) m/e 419 (M+H)+.
- The title compound was prepared as described in Example 147A, substituting tert-butyl azetidin-3-ylcarbamate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting tert-butyl (1-(6-chloropyridazin-3-yl)azetidin-3-yl)carbamate for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl (1-(pyridazin-3-yl)azetidin-3-yl)carbamate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 1-(pyridazin-3-yl)azetidin-3-amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)thiophene-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.95 (d, J=7.2 Hz, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.65 (d, J=3.8 Hz, 1H), 7.38 (dd, J=8.9, 4.5 Hz, 1H), 6.95 (dd, J=3.8, 0.8 Hz, 1H), 6.83 (dd, J=9.0, 1.4 Hz, 1H), 4.92-4.77 (m, 1H), 4.36 (t, J=8.1 Hz, 2H), 4.05-3.97 (m, 4H), 3.09-2.66 (m, 3H), 1.98-1.88 (m, 2H), 1.40 (s, 11H); MS (ESI(+)) m/e 444 (M+H)+.
- N-(4-Bromophenyl)-1,1,1-trimethyl-N-(trimethylsilyl)silanamine (7 g, 22.12 mmol) in tetrahydrofuran (100 mL) was treated with a solution of n-BuLi (1M, 22 mL) at −78° C. The reaction mixture was stirred an additional hour at −78° C. and then treated with a solution of tert-butyl 4-oxopiperidine-1-carboxylate (3.97 g, 19.91 mmol) in tetrahydrofuran (20 mL). The reaction mixture was stirred at −78° C. for 30 minutes and then warmed to room temperature. The reaction was quenched by addition of saturated ammonium chloride solution (100 mL) and then was extracted with ethyl acetate. The combined organics were washed with water, brine, dried with magnesium sulfate, filtered and concentrated. The crude tert-butyl 4-(4-(bis(trimethylsilyl)amino)phenyl)-4-hydroxypiperidine-1-carboxylate was treated with a solution of tetrabutylammonium fluoride (1M THF, 40 mL) at room temperature for 1 hour. The reaction mixture was diluted with water and extracted with ethyl acetate. The organics were washed with water and brine, dried with magnesium sulfate, filtered and concentrated. Purification by normal phase chromatography provided the title compound.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminophenyl)-4-hydroxypiperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-((benzyloxy)carbonyl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- tert-Butyl 4-(4-(1-((benzyloxy)carbonyl)azetidine-3-carboxamido)phenyl)-4-hydroxypiperidine-1-carboxylate (2.5 g, 4.91 mmol) in 50 mL dichloromethane was cooled to −78° C. and diethylaminosulfur trifluoride was added dropwise via a syringe. The reaction solution was stirred at −78° C. for an additional 1 hour and then warmed to 0° C. The reaction was allowed to stir at 0° C. for 1 hour and was cooled back down to −78° C. The reaction mixture was diluted with 50 mL of dichloromethane followed by quenching with 10 mL methanol. The solution was washed with saturated sodium bicarbonate and brine, dried with magnesium sulfate and filtered. Concentration and normal phase chromatography provided the title compound.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 4-(4-(1-((benzyloxy)carbonyl)azetidine-3-carboxamido)phenyl)-4-fluoropiperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147A, substituting tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)-4-fluoropiperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting tert-butyl 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)-4-fluoropiperidine-1-carboxylate for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.18-10.08 (m, 1H), 8.55 (dd, J=4.5, 1.4 Hz, 1H), 7.65-7.56 (m, 2H), 7.40-7.33 (m, 3H), 6.82 (dd, J=8.9, 1.4 Hz, 1H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.2, 5.7 Hz, 2H), 4.08-3.91 (m, 2H), 3.81-3.68 (m, 1H), 3.17-2.70 (m, 2H), 2.07-1.82 (m, 3H), 1.42-1.35 (s, 10H); MS (ESI(+)) m/e 456 (M+H)+.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(5-{[1-(pyridazin-3-yl)azetidin-3-yl]carbamoyl}thiophen-2-yl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 5-(piperidin-4-yl)-N-(1-(pyridazin-3-yl)azetidin-3-yl)thiophene-2-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.96 (d, J=7.2 Hz, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.66 (d, J=3.8 Hz, 1H), 7.51-7.34 (m, 6H), 6.98 (dd, J=3.8, 0.8 Hz, 1H), 6.84 (dd, J=9.0, 1.4 Hz, 1H), 4.92-4.77 (m, 1H), 4.6 (bs, 1H), 4.36 (t, J=8.1 Hz, 2H), 4.01 (dd, J=8.6, 5.6 Hz, 2H), 3.64 (bs, 1H), 3.23-2.83 (m, 3H), 2.10-1.84 (m, 2H), 1.67-1.48 (m, 2H); MS (ESI(+)) m/e 448 (M+H)+.
-
TABLE 19 Ex Name MS 811 5-[1-(2-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin- (ESI(+)) 3-yl)azetidin-3-yl]thiophene-2-carboxamide m/e 466 (M + H)+ 812 5-[1-(2-methylbenzoyl)piperidin-4-yl]-N-[1-(pyridazin- (ESI(+)) 3-yl)azetidin-3-yl]thiophene-2-carboxamide m/e 462 (M + H)+ 813 5-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-N-[1- (ESI(+)) (pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide m/e 484 (M + H)+ 814 5-[1-(3-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin- (ESI(+)) 3-yl)azetidin-3-yl]thiophene-2-carboxamide m/e 466 (M + H)+ 815 5-[1-(4-fluorobenzoyl)piperidin-4-yl]-N-[1-(pyridazin- (ESI(+)) 3-yl)azetidin-3-yl]thiophene-2-carboxamide m/e 466 (M + H)+ 816 5-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-N-[1- (ESI(+)) (pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide m/e 484 (M + H)+ 847 5-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-N-[1- (ESI(+)) (pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide m/e 428 (M + H)+ 848 5-{1-[(1-methylcyclopropyl)carbonyl]piperidin-4-yl}- (ESI(+)) N-[1-(pyridazin-3-yl)azetidin-3-yl]thiophene-2- m/e 426 carboxamide (M + H)+ 849 N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(3,3,3- (ESI(+)) trifluoropropanoyl)piperidin-4-yl]thiophene-2- m/e 454 carboxamide (M + H)+ 850 5-[1-(2,2-dimethylbutanoyl)piperidin-4-yl]-N-[1- (ESI(+)) (pyridazin-3-azetidin-3-yl]thiophene-2-carboxamide m/e 442 (M + H)+ 855 N-[1-(pyridazin-3-yl)azetidin-3-yl]-5-[1-(4,4,4- (ESI(+)) trifluorobutanoyl)piperidin-4-yl]thiophene-2- m/e 468 carboxamide (M + H)+ 856 5-[1-(cyclopropylcarbonyl)piperidin-4-yl]-N-[1- ESI(+)) (pyridazin-3-yl)azetidin-3-yl]thiophene-2-carboxamide m/e 412 (M + H)+ - The following Examples were essentially prepared as described in Example 810, substituting an appropriate carboxylic acid in Example 810B.
- The title compound was prepared as described in Example 805, substituting 2-hydrazinylethanol for methylhydrazine in 805B. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.14 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.72-7.58 (m, 4H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.83 (dd, J=9.0, 1.4 Hz, 1H), 6.27 (s, 1H), 4.90 (br s, 1H), 4.31-4.08 (m, 6H), 3.84-3.69 (m, 3H), 2.01-1.88 (m, 1H), 1.01-0.89 (m, 2H), 0.72-0.62 (m, 2H); MS (ESI(+)) m/e 405 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-((benzyloxy)carbonyl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 4-(4-(1-((benzyloxy)carbonyl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147A, substituting tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate and 3,6-difluoropyridazine for 3,6-dichloropyridazine.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(6-fluoropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 1-(6-fluoropyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 7.54 (d, J=8.6 Hz, 2H), 7.49-7.38 (m, 6H), 7.22 (d, J=8.6 Hz, 2H), 7.12 (dd, J=9.5, 6.8 Hz, 1H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.0, 6.0 Hz, 2H), 3.71 (ddd, J=14.4, 8.4, 5.9 Hz, 2H), 2.86 (dd, J=67.9, 55.9 Hz, 3H), 2.04-1.43 (m, 4H); MS (ESI(+)) m/e 460 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting 1-(6-fluoropyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.04 (s, 1H), 7.58-7.34 (m, 5H), 7.35-7.25 (m, 2H), 7.23-7.17 (m, 2H), 7.12 (dd, J=9.4, 6.7 Hz, 1H), 4.70-4.61 (m, 1H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (d, J=13.9 Hz, 2H), 3.77-3.66 (m, 1H), 3.50-3.41 (m, 1H), 3.23-3.09 (m, 1H), 2.95-2.72 (m, 2H), 1.91-1.82 (m, 1H), 1.79-1.42 (m, 3H); MS (ESI(+)) m/e 478 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting 1-(6-fluoropyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 7.57-7.50 (m, 2H), 7.41 (dd, J=9.4, 1.9 Hz, 1H), 7.22-7.15 (m, 2H), 7.12 (dd, J=9.4, 6.7 Hz, 1H), 4.45-4.36 (m, 2H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.0, 5.9 Hz, 2H), 3.77-3.66 (m, 1H), 2.93-2.66 (m, 3H), 1.82-1.74 (m, 2H), 1.52-1.35 (m, 2H), 1.22 (s, 9H); MS (ESI(+)) m/e 440 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting 1-(6-fluoropyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and isobutyric acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 7.54 (d, J=8.5 Hz, 2H), 7.41 (dd, J=9.5, 1.9 Hz, 1H), 7.18 (d, J=8.5 Hz, 2H), 7.12 (dd, J=9.5, 6.8 Hz, 1H), 4.62-4.45 (m, 1H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (dd, J=7.9, 6.1 Hz, 2H), 4.10-3.97 (m, 1H), 3.72 (ddd, J=8.4, 7.2, 4.2 Hz, 1H), 3.10 (s, 1H), 2.89 (dt, J=13.4, 6.7 Hz, 1H), 2.81-2.64 (m, 1H), 2.57 (s, 1H), 1.79 (ddd, J=16.4, 10.0, 2.9 Hz, 2H), 1.58-1.25 (m, 2H), 1.12-0.92 (m, 6H); MS (ESI(+)) m/e 426 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting 1-(6-fluoropyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-ethylbutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 7.57-7.51 (m, 2H), 7.41 (dd, J=9.4, 1.9 Hz, 1H), 7.21-7.08 (m, 3H), 4.68-4.59 (m, 1H), 4.31-4.06 (m, 1H), 3.77-3.66 (m, 1H), 3.15-3.04 (m, 1H), 2.66 (ddt, J=25.3, 20.0, 12.2 Hz, 1H), 1.87-1.74 (m, 2H), 1.64-1.27 (m, 6H), 0.87-0.76 (m, 6H); MS (ESI(+)) m/e 454 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting 1-(6-fluoropyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.04 (s, 1H), 7.59-7.46 (m, 4H), 7.41 (dd, J=9.4, 1.9 Hz, 1H), 7.32-7.17 (m, 4H), 7.13 (dd, J=9.4, 6.7 Hz, 1H), 4.70-4.48 (m, 1H), 4.24 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.0, 5.9 Hz, 2H), 4.06-3.53 (m, 2H), 3.22-2.68 (m, 3H), 2.04-1.50 (m, 4H); MS (ESI(+)) m/e 478 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (R)-tert-butyl 3-(4-aminophenoxy)pyrrolidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and (S)-1-(pyridazin-3-yl)pyrrolidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 3-(4-((S)-1-(pyridazin-3-yl)pyrrolidine-3-carboxamido)phenoxy)pyrrolidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(pyridazin-3-yl)-N-(4-((S)-pyrrolidin-3-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.04-9.95 (m, 1H), 8.51-8.45 (m, 1H), 7.61-7.37 (m, 7H), 7.37-7.30 (m, 1H), 6.99-6.92 (m, 1H), 6.90-6.83 (m, 2H), 5.07-4.92 (m, 1H), 3.88-3.70 (m, 2H), 3.71-3.38 (m, 6H), 2.37-1.97 (m, 4H); MS (ESI(+)) m/e 458 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(pyridazin-3-yl)-N-(4-((S)-pyrrolidin-3-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.04-9.96 (m, 1H), 8.48 (d, J=4.5 Hz, 1H), 7.59-7.37 (m, 4H), 7.37-7.22 (m, 3H), 6.94 (d, J=8.7 Hz, 1H), 6.87 (dd, J=8.9, 4.4 Hz, 2H), 3.86-3.52 (m, 5H), 3.54-3.37 (m, 2H), 2.37-1.97 (m, 4H); MS (ESI(+)) m/e 476 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(pyridazin-3-yl)-N-(4-((S)-pyrrolidin-3-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,4-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.07-9.93 (m, 1H), 8.47 (t, J=4.6 Hz, 1H), 7.54 (dt, J=12.8, 10.3 Hz, 2H), 7.44-7.18 (m, 4H), 7.02-6.80 (m, 3H), 5.16-4.85 (m, 1H), 3.91-3.70 (m, 2H), 3.70-3.35 (m, 7H), 2.43-1.97 (m, 4H); MS (ESI(+)) m/e 494 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(pyridazin-3-yl)-N-(4-((S)-pyrrolidin-3-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.99 (s, 1H), 8.48 (dd, J=4.5, 1.3 Hz, 1H), 7.57-7.50 (m, 2H), 7.33 (dd, J=9.1, 4.5 Hz, 1H), 6.95-6.83 (m, 4H), 4.95 (bs, 1H), 3.86-3.39 (m, 8H), 2.39-1.92 (m, 4H), 1.15 (s, 9H); MS (ESI(+)) m/e 438. (M+H)+.
- The title compound was prepared as described in Example 148A, substituting tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 4-bromo-2-fluoroaniline for 4-bromoaniline.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 4-(4-amino-3-fluorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-amino-3-fluorophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-((benzyloxy)carbonyl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 4-(4-(1-((benzyloxy)carbonyl)azetidine-3-carboxamido)-3-fluorophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147A, substituting tert-butyl 4-(4-(azetidine-3-carboxamido)-3-fluorophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting tert-butyl 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)-3-fluorophenyl)piperidine-1-carboxylate for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(3-fluoro-4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(2-fluoro-4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.86 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.79 (t, J=8.3 Hz, 1H), 7.58-7.41 (m, 2H), 7.42-7.25 (m, 3H), 7.23-7.14 (m, 1H), 7.11-7.03 (m, 1H), 6.83 (dd, J=9.0, 1.4 Hz, 1H), 4.70-4.61 (m, 1H), 4.24 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.1, 5.8 Hz, 2H), 3.92-3.81 (m, 1H), 3.51-3.42 (m, 1H), 3.23-3.10 (m, 1H), 2.92-2.76 (m, 2H), 1.94-1.81 (m, 1H), 1.83-1.44 (m, 3H); MS (ESI(+)) m/e 478 (M+H)+.
-
TABLE 20 Ex Name MS 829 N-[4-(1-benzoylpiperidin-4-yl)-2-fluorophenyl]-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 460 (M + H)+ 830 N-{2-fluoro-4-[1-(3-fluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 831 N-{2-fluoro-4-[1-(2-methylbenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 832 N-{2-fluoro-4-[1-(4-fluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 833 N-{4-[1-(2,4-difluorobenzoyl)piperidin-4-yl]-2- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 496 carboxamide (M + H)+ 834 N-{4-[1-(3,5-difluorobenzoyl)piperidin-4-yl]-2- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 460 carboxamide (M + H)+ 835 N-{4-[1-(3,3-dimethylbutanoyl)piperidin-4-yl]-2- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 454 carboxamide (M + H)+ 858 N-{2-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 426 (M + H)+ 859 N-{4-[1-(2,2-dimethylpropanoyl)piperidin-4-yl]-2- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 440 carboxamide (M + H)+ 860 N-{4-[1-(cyclopropylcarbonyl)piperidin-4-yl]-2- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 424 carboxamide (M + H)+ 861 N-(2-fluoro-4-{1-[(1-methylcyclopropyl)carbonyl] (ESI(+)) piperidin-4-yl}phenyl)-1-(pyridazin-3-yl]azetidine- m/e 438 3-carboxamide (M + H)+ 862 N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]-2- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 438 carboxamide (M + H)+ - The following Examples were essentially prepared as described in Example 828, substituting the appropriate carboxylic acid in Example 828H.
- The title compound was prepared as described in Example 1A, substituting (S)-1-benzyl 3-tert-butyl pyrrolidine-1,3-dicarboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting (S)-tert-butyl 4-(4-(1-((benzyloxy)carbonyl)pyrrolidine-3-carboxamido)phenoxy)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting 3-bromo-6-methylpyridazine for 3-bromopyridine and (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenoxy)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 4-(4-(1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamido)phenoxy)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-methylpyridazin-3-yl)-N-(4-(piperidin-4-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.98 (s, 1H), 7.57-7.45 (m, 3H), 7.42 (td, J=7.2, 1.8 Hz, 1H), 7.35-7.20 (m, 3H), 6.98-6.91 (m, 2H), 6.83 (d, J=9.1 Hz, 1H), 4.63-4.54 (m, 1H), 4.05-3.95 (m, 1H), 3.74 (dd, J=10.3, 7.9 Hz, 1H), 3.64-3.42 (m, 3H), 3.31-3.03 (m, 3H), 2.40 (s, 3H), 2.36-2.08 (m, 2H), 2.07-1.76 (m, 2H), 1.78-1.19 (m, 4H); MS (ESI(+)) m/e 504 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-methylpyridazin-3-yl)-N-(4-(piperidin-4-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.98 (s, 1H), 7.55-7.48 (m, 2H), 7.48-7.37 (m, 5H), 7.23 (d, J=9.1 Hz, 1H), 6.97-6.91 (m, 2H), 6.83 (d, J=9.1 Hz, 1H), 4.57 (dq, J=7.7, 3.8 Hz, 1H), 4.04-3.42 (m, 8H), 3.26 (p, J=7.4 Hz, 1H), 2.41 (s, 3H), 2.35-2.08 (m, 2H), 2.09-1.84 (m, 2H), 1.68-1.51 (m, 2H); MS (ESI(+)) m/e 486 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-methylpyridazin-3-yl)-N-(4-(piperidin-4-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.98 (s, 1H), 7.55-7.48 (m, 2H), 7.24 (d, J=9.1 Hz, 1H), 6.96-6.90 (m, 2H), 6.83 (d, J=9.1 Hz, 1H), 4.59-4.50 (m, 1H), 3.94-3.80 (m, 2H), 3.74 (dd, J=10.3, 7.9 Hz, 1H), 3.65-3.52 (m, 2H), 3.32-3.18 (m, 4H), 2.40 (s, 3H), 2.34-2.08 (m, 2H), 1.97-1.83 (m, 2H), 1.58-1.43 (m, 2H), 1.20 (s, 9H); MS (ESI(+)) m/e 466 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-methylpyridazin-3-yl)-N-(4-(piperidin-4-yloxy)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and cyclohexanecarboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.98 (s, 1H), 7.55-7.48 (m, 2H), 7.24 (d, J=9.1 Hz, 1H), 6.97-6.90 (m, 2H), 6.83 (d, J=9.2 Hz, 1H), 4.52 (dq, J=7.8, 3.9 Hz, 1H), 3.89-3.66 (m, 3H), 3.68-3.49 (m, 2H), 3.45-3.13 (m, 3H), 2.61-2.55 (m, 1H), 2.40 (s, 3H), 2.36-2.11 (m, 2H), 2.04-1.80 (m, 2H), 1.74-1.08 (m, 13H); MS (ESI(+)) m/e 492 (M+H)+.
- The title compound was prepared as described in Example 148A, substituting 2,2-dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-azabicyclo[3.2.1]oct-3-en-8-yl)propan-1-one for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 1-bromo-4-nitrobenzene for 4-bromoaniline.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 3-(4-nitrophenyl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 3-(4-aminophenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-((benzyloxy)carbonyl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 3-(4-(1-((benzyloxy)carbonyl)azetidine-3-carboxamido)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147A, substituting tert-butyl 3-(4-(azetidine-3-carboxamido)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 147B, substituting tert-butyl 3-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 3-(4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(8-azabicyclo[3.2.1]octan-3-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and isobutyric acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.52 (dd, J=7.4, 3.4 Hz, 2H), 7.37 (dd, J=9.0, 4.5 Hz, 1H), 7.18 (dd, J=17.7, 8.6 Hz, 2H), 6.82 (dd, J=9.0, 1.3 Hz, 1H), 4.51 (ddd, J=15.0, 5.1, 4.4 Hz, 1H), 4.43-4.29 (m, 1H), 4.18 (dt, J=14.0, 8.1 Hz, 4H), 3.72 (ddd, J=8.4, 5.9, 2.5 Hz, 1H), 2.77 (dt, J=13.4, 6.7 Hz, 1H), 2.48-2.14 (m, 3H), 2.04-1.37 (m, 7H), 1.15-0.94 (m, 6H); MS (ESI(+)) m/e 434 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(8-azabicyclo[3.2.1]octan-3-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4,4,4-trifluorobutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.03 (d, J=3.6 Hz, 1H), 8.56 (dd, J=4.5, 1.1 Hz, 1H), 7.53 (dd, J=8.6, 2.7 Hz, 2H), 7.37 (dt, J=14.0, 7.0 Hz, 1H), 7.21 (dd, J=23.0, 8.6 Hz, 2H), 6.80 (dd, J=19.3, 8.9 Hz, 1H), 4.61-4.47 (m, 1H), 4.32 (dd, J=16.5, 8.6 Hz, 1H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (t, J=7.0 Hz, 2H), 3.82-3.62 (m, 1H), 3.22-3.04 (m, 1H), 3.04-2.90 (m, 1H), 2.78-2.50 (m, 6H), 2.41-2.12 (m, 1H), 2.05-1.38 (m, 8H); MS (ESI(+)) m/e 488 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(8-azabicyclo[3.2.1]octan-3-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.04 (d, J=2.4 Hz, 1H), 8.56 (dt, J=9.1, 4.5 Hz, 1H), 7.63-7.42 (m, 7H), 7.37 (dt, J=14.0, 7.0 Hz, 1H), 7.29 (d, J=8.5 Hz, 1H), 7.23 (d, J=8.5 Hz, 1H), 6.91-6.70 (m, 1H), 4.69 (d, J=6.1 Hz, 1H), 4.24 (t, J=8.3 Hz, 2H), 4.19-4.11 (m, 2H), 4.01 (d, J=14.9 Hz, 1H), 3.85-3.61 (m, 1H), 2.47-2.22 (m, 1H), 2.02-1.53 (m, 7H); MS (ESI(+)) m/e 468 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(8-azabicyclo[3.2.1]octan-3-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.04 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.59-7.44 (m, 4H), 7.46-7.16 (m, 5H), 6.82 (dd, J=9.0, 1.4 Hz, 1H), 4.73-4.65 (m, 1H), 4.24 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.0, 5.9 Hz, 2H), 3.81-3.67 (m, 2H), 2.10 (s, 1H), 2.05-1.35 (m, 8H); MS (ESI(+)) m/e 486 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(8-azabicyclo[3.2.1]octan-3-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.02 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.56-7.49 (m, 2H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 7.24-7.14 (m, 2H), 6.82 (dd, J=9.0, 1.4 Hz, 1H), 4.66-4.51 (m, 2H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.1, 5.9 Hz, 2H), 3.72 (tt, J=8.5, 5.9 Hz, 1H), 2.43-2.07 (m, 3H), 1.92-1.39 (m, 8H), 1.23-1.17 (m, 9H); MS (ESI(+)) m/e 448 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(8-azabicyclo[3.2.1]octan-3-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-methylcyclopropylacetic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.56-7.49 (m, 2H), 7.38 (dd, J=8.9, 4.5 Hz, 1H), 7.26-7.15 (m, 2H), 6.82 (dd, J=8.9, 1.4 Hz, 1H), 4.62-4.38 (m, 2H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.1, 5.9 Hz, 2H), 3.72 (tt, J=8.5, 5.9 Hz, 1H), 2.37-2.21 (m, 1H), 1.93-1.45 (m, 8H), 1.28 (d, J=5.7 Hz, 3H), 1.02-0.72 (m, 2H), 0.51 (dd, J=6.2, 2.1 Hz, 2H); MS (ESI(+)) m/e 446 (M+H)+.
- The title compound was prepared as described in Example 805, substituting 4-methylpent-1-yne for ethynylcyclopropane in Example 805A and (2-methoxyethyl)hydrazine for methylhydrazine in 805B. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.21 (s, 1H), 8.56 (dd, J=4.4, 1.2 Hz, 1H), 7.78-7.58 (m, 4H), 7.24 (d, J=8.5 Hz, 1H), 6.42 (s, 1H), 4.45-4.25 (m, 3H), 4.18 (t, J=5.5 Hz, 2H), 3.87-3.73 (m, 1H), 3.69 (t, J=5.5 Hz, 2H), 3.46-3.30 (m, 4H), 3.22 (s, 3H), 2.01-1.84 (m, 1H), 0.95 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 435 (M+H)+.
- The title compound was prepared as described in Example 809C, substituting benzyl 4-[4-({[1-(6-chloropyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]-4-hydroxypiperidine-1-carboxylate for tert-butyl 4-(4-(1-((benzyloxy)carbonyl)azetidine-3-carboxamido)phenyl)-4-hydroxypiperidine-1-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.18-10.11 (m, 1H), 7.67-7.57 (m, 2H), 7.53 (d, J=9.3 Hz, 1H), 7.47-7.23 (m, 7H), 6.96 (d, J=9.3 Hz, 1H), 5.14-5.08 (m, 2H), 4.26 (t, J=8.4 Hz, 2H), 4.17 (dd, J=8.3, 5.8 Hz, 2H), 4.09-3.98 (m, 2H). 3.80-3.60 (m, 2H), 3.30-3.20 (m, 2H), 2.2-1.8 (m, 3H); MS (ESI(+)) m/e 524 (M+H)+.
- The title compound was prepared as described in Example 809A, substituting benzyl 4-oxopiperidine-1-carboxylate for tert-butyl 4-oxopiperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting benzyl 4-(4-aminophenyl)-4-hydroxypiperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(6-chloropyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.06 (s, 1H), 7.59-7.49 (m, 3H), 7.41-7.28 (m, 7H), 6.96 (d, J=9.3 Hz, 1H), 5.09 (s, 2H), 5.04 (s, 1H), 4.26 (t, J=8.4 Hz, 2H), 4.16 (dd, J=8.3, 5.8 Hz, 2H), 3.97-3.86 (m, 2H), 3.73 (tt, J=8.5, 5.8 Hz, 1H), 3.3-3.0 (m, 2H), 1.91-1.70 (m, 2H), 1.63-1.54 (m, 2H); MS (ESI(+)) m/e 522.0 (M+H)+.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-fluoro-4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)phenyl]piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(4-fluoropiperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.06 (s, 1H), 7.59-7.49 (m, 3H), 7.41-7.28 (m, 7H), 6.96 (d, J=9.3 Hz, 1H), 5.09 (s, 2H), 5.04 (s, 1H), 4.26 (t, J=8.4 Hz, 2H), 4.16 (dd, J=8.3, 5.8 Hz, 2H), 3.97-3.86 (m, 2H), 3.73 (tt, J=8.5, 5.8 Hz, 1H), 3.3-3.0 (m, 2H), 1.91-1.70 (m, 2H), 1.63-1.54 (m, 2H); MS (ESI(+)) m/e 478 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(4-fluoropiperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.20-10.03 (m, 1H), 8.57 (d, J=4.5 Hz, 1H), 7.68-7.59 (m, 2H), 7.60-7.30 (m, 8H), 6.87-6.80 (m, 1H), 4.78-4.09 (m, 5H), 4.10-3.44 (m, 3H), 3.14-3.01 (m, 1H), 2.25-1.51 (m, 4H); MS (ESI(+)) m/e 460 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(4-fluoropiperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethypropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.20-10.02 (m, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.67-7.58 (m, 2H), 7.47-7.30 (m, 3H), 6.83 (dd, J=8.9, 1.4 Hz, 1H), 4.48-4.10 (m, 6H), 3.80-3.69 (m, 1H), 3.23-2.96 (m, 2H), 2.07-1.60 (m, 4H), 1.23 (s, 9H); MS (ESI(+)) m/e 440 (M+H)+.
- The title compound was prepared as described in Example 805, substituting 3,3-dimethylbut-1-yne for ethynylcyclopropane in Example 805A and (2-methoxyethyl)hydrazine for methylhydrazine in Example 805B. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.14 (s, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 7.70 (d, J=8.7 Hz, 2H), 7.64 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.9, 4.5 Hz, 1H), 6.84 (d, J=8.9 Hz, 1H), 6.40 (s, 1H), 4.31 (t, J=6.0 Hz, 2H), 4.25 (t, J=8.3 Hz, 2H), 4.17 (dd, J=8.0, 6.0 Hz, 2H), 3.83 (t, J=6.0 Hz, 2H), 3.75 (tt, J=8.7, 6.1 Hz, 1H), 3.25 (s, 3H), 1.37 (s, 9H); MS (ESI(+)) m/e 435 (M+H)+.
- The title compound was prepared as described in Example 805, substituting 3,3-dimethylbut-1-yne for ethynylcyclopropane in Example 805A and butylhydrazine for methylhydrazine in 805B. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.14 (s, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 7.69 (d, J=8.7 Hz, 2H), 7.63 (d, J=8.8 Hz, 2H), 7.39 (dd, J=8.9, 4.5 Hz, 1H), 6.84 (dd, J=8.9, 1.3 Hz, 1H), 6.38 (s, 1H), 4.25 (t, J=8.3 Hz, 2H), 4.21-4.09 (m, 4H), 3.81-3.70 (m, 1H), 1.92-1.77 (m, 2H), 1.46-1.37 (m, 2H), 1.36 (s, 9H), 0.94 (t, J=7.3 Hz, 3H); MS (ESI(+)) m/e 433 (M+H)+.
- The title compound was prepared as described in Example 805, substituting 3,3-dimethylbut-1-yne for ethynylcyclopropane in Example 805A and (tetrahydro-2H-pyran-4-ylmethyl)hydrazine for methylhydrazine in Example 805B. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.14 (s, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 7.70 (d, J=8.7 Hz, 2H), 7.63 (d, J=8.8 Hz, 2H), 7.39 (dd, J=8.9, 4.5 Hz, 1H), 6.83 (dd, J=8.9, 1.4 Hz, 1H), 6.41 (s, 1H), 4.25 (t, J=8.3 Hz, 2H), 4.16 (dd, J=8.1, 5.9 Hz, 2H), 4.03 (d, J=7.0 Hz, 2H), 3.85 (dd, J=11.3, 3.0 Hz, 2H), 3.80-3.71 (m, 1H), 3.32-3.22 (m, 2H), 2.39-2.25 (m, 1H), 1.55 (dd, J=12.8, 1.9 Hz, 2H), 1.37 (s, 9H), 1.42-1.30 (m, 2H); MS (ESI(+)) m/e 475 (M+H)+.
- The title compound was prepared as described in Example 618, substituting tert-butyl 4-(4-(azetidine-3-carboxamido)-3-fluorophenyl)piperidine-1-carboxylate for (R)-5-(1-isobutyl-1H-pyrazol-4-yl)-N-(pyrrolidin-3-yl)thiophene-2-carboxamide.
- The title compound was prepared as described in Example 147B, substituting tert-butyl 4-(4-(1-(5,6-dichloropyridazin-4-yl)azetidine-3-carboxamido)-3-fluorophenyl)piperidine-1-carboxylate for 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(3-fluoro-4-(1-(pyridazin-4-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(2-fluoro-4-(piperidin-4-yl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.39 (s, 1H), 8.66 (d, J=6.3 Hz, 1H), 8.52 (d, J=3.0 Hz, 1H), 7.66-7.37 (m, 4H), 7.35-7.27 (m, 3H), 6.68 (dd, J=6.3, 3.2 Hz, 1H), 4.71-4.62 (m, 1H), 4.37-3.92 (m, 4H), 3.94-2.70 (m, 5H), 1.88-12 (m, 4H); MS (ESI(+)) m/e 478 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(2-fluoro-4-(piperidin-4-yl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.27 (s, 1H), 8.61 (dd, J=6.0, 0.9 Hz, 1H), 8.51 (dd, J=3.0, 0.9 Hz, 1H), 7.57 (dd, J=12.9, 2.0 Hz, 1H), 7.51-7.38 (m, 5H), 7.34 (t, J=8.4 Hz, 1H), 7.28 (dd, J=8.4, 2.0 Hz, 1H), 6.55 (dd, J=6.0, 3.0 Hz, 1H), 4.71-4.51 (m, 1H), 4.22 (t, J=8.4 Hz, 2H), 4.12 (dd, J=8.2, 5.7 Hz, 2H), 4.04-3.45 (m, 2H), 3.22-2.76 (m, 3H), 2.08-1.33 (m, 4H); MS (ESI(+)) m/e 460 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(2-fluoro-4-(piperidin-4-yl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.28 (s, 1H), 8.61 (dd, J=6.0, 0.9 Hz, 1H), 8.51 (d, J=3.4 Hz, 1H), 7.68-7.24 (m, 3H), 6.57 (dd, J=6.1, 3.0 Hz, 1H), 4.5 (d, 2H), 4.30-4.13 (m, 4H), 3.90-2.78 (m, 4H), 1.79-1.71 (m, 2H), 1.72-1.44 (m, 2H), 1.21 (s, 9H); MS (ESI(+)) m/e 440 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(2-fluoro-4-(piperidin-4-yl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 3,3,-dimethylbutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.28 (s, 1H), 8.62 (d, J=6.1 Hz, 1H), 8.51 (d, J=3.4 Hz, 1H), 7.60-7.23 (m, 3H), 6.57 (dd, J=6.1, 3.0 Hz, 1H), 4.65-4.58 (m, 1H), 4.30-4.00 (m, 5H), 3.85-2.83 (m, 3H), 2.60-2.50 (m, 1H), 2.30 (d, J=14.0 Hz, 1H), 2.21 (d, J=14.0 Hz, 1H), 1.79-1.40 (m, 4H), 1.00 (s, 9H); MS (ESI(+)) m/e 454 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(2-fluoro-4-(piperidin-4-yl)phenyl)-1-(pyridazin-4-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4,4,4-trifluorobutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.3 (s, 1H), 8.70-8.50 (m, 2H), 7.90-7.20 (m, 3H), 6.55-6.65 (m, 1H), 4.6 (d, 1H), 4.30-3.90 (m, 5H), 3.80-2.90 (m, 3H), 2.80-2.50 (m, 5H), 1.80-1.40 (m, 4H); MS (ESI(+)) m/e 480 (M+H)+.
- The title compound was prepared as described as described in Example 148A, substituting N-(4-bromophenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline and tert-butyl 4-methyl-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole followed by TFA deprotection as described in Example 1D to give the title compound as a TFA salt. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.24 (s, 1H), 8.57 (d, J=4.0 Hz, 1H), 8.52 (s, 1H), 8.40 (s, 1H), 8.11 (s, 1H), 7.87 (s, 1H), 7.80 (dd, J=9.3, 4.3 Hz, 1H), 7.63 (d, J=8.6 Hz, 2H), 7.55 (d, J=8.5 Hz, 2H), 7.45 (d, J=9.3 Hz, 1H), 4.47 (t, J=9.1 Hz, 2H), 4.43-4.34 (m, 2H), 4.08 (s, 2H), 3.81 (ddd, J=14.5, 8.7, 6.0 Hz, 1H), 3.27-3.13 (m, 2H), 3.13-2.97 (m, 2H), 1.73-1.58 (m, 2H), 1.57-1.42 (m, 2H), 0.98 (s, 3H); MS (ESI(+)) m/e 432 (M+H)+.
- The title compound was prepared as described in Example 805, substituting 3,3,3-trifluoroprop-1-yne for ethynylcyclopropane in Example 805A. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.47 (s, 1H), 8.57 (d, J=3.8 Hz, 1H), 7.80 (d, J=8.4 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.56-7.49 (m, 1H), 7.06 (d, J=8.6 Hz, 1H), 6.87 (s, 1H), 4.34 (t, J=8.4 Hz, 2H), 4.29-4.22 (m, 2H), 3.92 (s, 3H), 3.86-3.78 (m, 1H); MS (ESI(+)) m/e 403 (M+H)+.
- The title compound was prepared as described as described in Example 148A, substituting 1-neopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
- The title compound was prepared as described in Example 1A, substituting 4-(1-neopentyl-1H-pyrazol-4-yl)aniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(6-chloropyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.10 (s, 1H), 8.04 (s, 1H), 7.82 (s, 1H), 7.61 (d, J=8.7 Hz, 2H), 7.56-7.50 (m, 3H), 6.98 (d, J=9.3 Hz, 1H), 4.27 (t, J=8.5 Hz, 2H), 4.19 (dd, J=8.3, 5.9 Hz, 2H), 3.90 (s, 2H), 3.74 (tt, J=8.6, 5.9 Hz, 1H), 0.92 (s, 9H); MS (ESI(+)) m/e 425 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting 5-bromo-2-methylpyridine for 3-bromopyridine and tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(6-methylpyridin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 1-(6-methylpyridin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.99 (s, 1H), 7.73 (d, J=2.8 Hz, 1H), 7.53 (d, J=8.5 Hz, 2H), 7.48-7.39 (m, 5H), 7.22 (d, J=8.6 Hz, 2H), 7.04 (d, J=8.3 Hz, 1H), 6.80 (dd, J=8.3, 2.9 Hz, 1H), 4.62 (s, 1H), 4.05 (t, J=7.7 Hz, 2H), 3.90 (t, J=6.7 Hz, 2H), 3.69 (ddd, J=14.5, 8.1, 6.3 Hz, 2H), 3.13 (s, 1H), 2.99-2.69 (m, 2H), 2.34 (s, 3H), 1.89-1.47 (m, 4H), MS (ESI(+)) m/e 455 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting tert-butyl azetidine-3-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 1-(pyridin-3-yl)azetidine-3-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 4-bromoaniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound as described as described in Example 148A, substituting N-(4-bromophenyl)-1-(pyridin-3-yl)azetidine-3-carboxamide for 4-bromoaniline and tert-butyl 4-methyl-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole followed by TFA deprotection as described in Example 1D to give the title compound as a TFA salt. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.21 (s, 1H), 8.58 (s, 1H), 8.45 (s, 1H), 8.15 (d, J=5.3 Hz, 1H), 8.10 (s, 1H), 8.08 (d, J=2.6 Hz, 1H), 7.86 (s, 1H), 7.77 (dd, J=8.6, 5.4 Hz, 1H), 7.62 (d, J=8.7 Hz, 2H), 7.58-7.51 (m, 3H), 4.24 (t, J=8.3 Hz, 2H), 4.15 (dd, J=7.9, 6.0 Hz, 2H), 4.08 (s, 2H), 3.79 (dq, J=8.6, 5.9 Hz, 1H), 3.28-3.12 (m, 2H), 3.12-2.95 (m, 2H), 1.65 (ddd, J=13.4, 9.3, 3.8 Hz, 2H), 1.56-1.40 (m, 2H), 0.97 (s, 3H); MS (ESI(+)) m/e 431 (M+H)+.
- To 1-(6-chloropyridazin-3-yl)-N-(4-(1-neopentyl-1H-pyrazol-4-yl)phenyl)azetidine-3-carboxamide (0.076 g, 0.179 mmol) was added methylzinc(II) chloride (2.0M in THF) (0.179 ml, 0.358 mmol) and 5 mg of palladium catalyst. The reaction mixture was heated to 60° C. and a thick precipitate developed. N-methylpyrrolidine (0.2 ml) was added and the mixture was heated to 85° C. for 2 hours. The mixture was diluted with dichloromethane and purified by normal phase chromatography to give the title compound. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.11 (s, 1H), 8.04 (s, 1H), 7.82 (s, 1H), 7.61 (d, J=8.7 Hz, 2H), 7.53 (d, J=8.7 Hz, 2H), 7.43 (d, J=9.2 Hz, 1H), 6.99 (d, J=9.1 Hz, 1H), 4.27 (t, J=8.5 Hz, 2H), 4.19 (dd, J=8.2, 6.1 Hz, 2H), 3.90 (s, 2H), 3.75 (ddd, J=17.0, 8.5, 6.0 Hz, 1H), 2.45 (s, 3H), 0.92 (s, 9H); MS (ESI(+)) m/e 405 (M+H)+.
- The title compound was prepared as described as described in Example 148A, substituting 4-bromo-3-fluoroaniline for 4-bromoaniline and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
- The title compound was prepared as described in Example 1B, substituting tert-butyl 4-(4-amino-2-fluorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-amino-2-fluorophenyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(2-fluoro-4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(3-fluoro-4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 3-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.86 (s, 1H), 8.56 (dd, J=4.5, 1.1 Hz, 1H), 7.79 (t, J=8.3 Hz, 1H), 7.56-7.45 (m, 1H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 7.25 (ddd, J=20.2, 14.3, 8.7 Hz, 4H), 7.10 (d, J=8.2 Hz, 1H), 6.83 (dd, J=8.9, 1.0 Hz, 1H), 4.60 (s, 1H), 4.19 (dt, J=14.0, 8.2 Hz, 4H), 3.99-3.74 (m, 1H), 3.59 (s, 1H), 3.07 (d, J=59.7 Hz, 1H), 2.85 (dd, J=39.3, 27.7 Hz, 2H), 2.08-1.43 (m, 4H); MS (ESI(+)) m/e 478.3 (M+H)+.
-
TABLE 21 Ex Name MS 880 N-{3-fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 426 (M + H)+ 881 N-{3-fluoro-4-[1-(3,3,3-trifluoropropanoyl)piperidin- (ESI(+)) 4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 466 carboxamide (M + H)+ 882 N-{4-[1-3,3-dimethylbutanoyl)piperidin-4-yl]-3- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 454 carboxamide (M + H)+ 883 N-{3-fluoro-4-[1-(4,4,4-trifluorobutanoyl)piperidin- (ESI(+)) 4-yl]phenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 480 carboxamide (M + H)+ 884 N-[4-(1-benzoylpiperidin-4-yl)-3-fluorophenyl]-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 460 (M + H)+ 885 N-{3-fluoro-4-[1-(2-fluorobenzoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 478 (M + H)+ 886 N-{4-[-(2,2-dimethylpropanoyl)piperidin-4-yl]-3- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 440 carboxamide (M + H)+ 887 N-{3-fluoro-4-[1-(3-methylbutanoyl)piperidin-4-yl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 440 (M + H)+ 888 N-{4-[-(cyclopropylacetyl)piperidin-4-yl]-3- (ESI(+)) fluorophenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 438 carboxamide (M + H)+ - The following Examples were essentially prepared as described in Example 879, substituting an appropriate carboxylic acid in Example 879E.
- The title compound was prepared as described in Example 1A, substituting benzyl 4-(4-aminophenyl)-4-hydroxypiperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(6-chloropyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting benzyl 4-(4-(1-(6-chloropyridazin-3-yl)azetidine-3-carboxamido)phenyl)-4-hydroxypiperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(4-hydroxypiperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.08 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.61-7.54 (m, 2H), 7.55-7.33 (m, 5H), 7.35-7.22 (m, 2H), 6.83 (dd, J=8.9, 1.3 Hz, 1H), 5.16 (s, 1H), 4.50-4.42 (m, 1H), 4.24 (t, J=8.3 Hz, 2H), 4.15 (dd, J=8.1, 5.9 Hz, 2H), 3.79-3.68 (m, 1H), 3.52-3.41 (m, 1H), 3.27-3.13 (m, 2H), 2.07-1.65 (m, 3H), 1.66-1.40 (m, 1H); MS (ESI(+)) m/e 476.1 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(4-hydroxypiperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.06 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.59-7.53 (m, 2H), 7.46-7.33 (m, 3H), 6.83 (dd, J=8.9, 1.3 Hz, 1H), 5.06 (s, 1H), 4.30-4.08 (m, 6H), 3.79-3.68 (m, 1H), 3.25-3.13 (m, 2H), 1.83-1.68 (m, 2H), 1.66-1.58 (m, 2H), 1.22 (s, 9H); MS (ESI(+)) m/e 438.2 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting 3-chloro-6-methylpyridazine for 3-bromopyridine and tert-butyl azetidine-3-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 1-(6-methylpyridazin-3-yl)azetidine-3-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 4-bromoaniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(6-methylpyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described as described in Example 148A, substituting N-(4-bromophenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline and 1-((4-methyltetrahydro-2H-pyran-4-yl)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.08 (s, 1H), 8.06 (s, 1H), 7.82 (s, 1H), 7.61 (d, J=8.7 Hz, 2H), 7.52 (d, J=8.6 Hz, 2H), 7.29 (d, J=9.1 Hz, 1H), 6.79 (d, J=9.0 Hz, 1H), 4.20 (t, J=8.2 Hz, 2H), 4.12 (dd, J=7.8, 6.2 Hz, 2H), 4.02 (s, 2H), 3.78-3.64 (m, 3H), 3.52 (ddd, J=11.8, 9.3, 2.9 Hz, 2H), 2.44 (s, 3H), 1.51 (ddd, J=13.3, 9.1, 4.1 Hz, 2H), 1.30-1.19 (m, 2H), 0.97 (s, 3H); MS (ESI(+)) m/e 447 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting 3-bromo-6-methylpyridazine for 3-bromopyridine and (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 4-(4-(1-(6-methylpyridazin-3-yl)pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-methylpyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.25-9.59 (m, 1H), 7.63-7.39 (m, 4H), 7.38-7.11 (m, 5H), 6.84 (dd, J=10.8, 7.3 Hz, 1H), 4.79-4.47 (m, 1H), 3.85-3.39 (m, 6H), 3.25-3.07 (m, 1H), 3.00-2.68 (m, 2H), 2.42 (s, 3H), 2.37-2.09 (m, 2H), 1.97-1.37 (m, 4H); MS (ESI(+)) m/e 488.3 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-methylpyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.25-9.84 (m, 1H), 7.62-7.51 (m, 2H), 7.50-7.36 (m, 5H), 7.31-7.12 (m, 3H), 6.91-6.76 (m, 1H), 4.77-4.30 (m, 1H), 3.98-3.37 (m, 7H), 3.02-2.62 (m, 2H), 2.42 (s, 3H), 2.38-2.01 (m, 2H), 1.97-1.43 (m, 4H); MS (ESI(+)) m/e 470.2 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-methylpyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.04 (s, 1H), 7.56-7.50 (m, 2H), 7.23 (d, J=9.1 Hz, 1H), 7.21-7.14 (m, 2H), 6.83 (d, J=9.1 Hz, 1H), 4.45-4.36 (m, 2H), 3.74 (dd, J=10.3, 7.9 Hz, 1H), 3.64-3.52 (m, 2H), 3.50-3.39 (m, 1H), 3.35-3.25 (m, 1H), 2.93-2.66 (m, 3H), 2.40 (s, 3H), 2.37-2.11 (m, 2H), 1.82-1.74 (m, 2H), 1.53-1.35 (m, 2H), 1.22 (s, 9H); MS (ESI(+)) m/e 450.3 (M+H)+.
- The title compound was prepared as described in Example 1B, substituting 4-(4-nitrobenzyl)pyridine for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- A solution of 4-(pyridin-4-ylmethyl)aniline (21.6 g, 117 mmol) and triethylamine (19.61 ml, 141 mmol) in dichloromethane (586 ml) was cooled to 0° C. Trifluoroacetic anhydride (19.87 ml, 141 mmol) was added dropwise via additional funnel over a period of 20 minutes. The mixture was stirred at 0° C. for 1 hour and then at room temperature for 2 hours. The reaction mixture was then concentrated in vacuo and the resulting residue was purified by regular phase column chromatography to give the title compound.
- 2,2,2-Trifluoro-N-(4-(pyridin-4-ylmethyl)phenyl)acetamide (28.5 g, 102 mmol) and acetic acid (205 ml) were added to platinum(IV) oxide (3.42 g, 15.06 mmol) in a 500 mL stainless steel pressure bottle and the mixture was stirred for 16 hours at 40 psi. The mixture was filtered through a nylon membrane and concentrated in vacuo; and the resulting residue was taken up in methanol (100 mL) and poured into diethyl ether (600 mL). The precipitate was filtered, washed with ether and dried with sodium sulfate to afford the title compound.
- A solution of 2,2,2-trifluoro-N-(4-(piperidin-4-ylmethyl)phenyl)acetamide (26.4 g, 92 mmol) in dichloromethane (369 ml) was cooled to 0° C. and triethylamine (19.28 ml, 138 mmol) was added slowly. To the resulting solution was added di-tert-butyl dicarbonate (22.14 g, 101 mmol) in dichloromethane (75 ml) via addition funnel over 10 minutes. The 0° C. mixture was stirred for 2 hours and warmed slowly overnight. The reaction mixture was recooled to 0° C., treated with 1 N aqueous sodium hydroxide (100 ml), warmed to room temperature and stirred for 1 hour. The bilayer was separated and the organics were washed with water and brine, dried with magnesium sulfate, filtered and concentrated in vacuo. The residue was purified by normal phase chromatography to give the title compound.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-aminobenzyl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)benzyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-ylmethyl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.52 (d, J=8.5 Hz, 2H), 7.47-7.28 (m, 6H), 7.11 (d, J=8.5 Hz, 2H), 6.83 (dd, J=9.0, 1.3 Hz, 1H), 4.58-4.34 (m, 1H), 4.23 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.1, 6.0 Hz, 2H), 3.72 (tt, J=8.6, 6.0 Hz, 1H), 3.66-3.47 (m, 1H), 3.08-2.83 (m, 1H), 2.83-2.59 (m, 1H), 1.87-1.69 (m, 1H), 1.69-1.57 (m, 1H), 1.57-1.41 (m, 1H), 1.31-0.90 (m, 2H); MS (ESI(+)) m/e 456 (M+H)+.
-
TABLE 22 Ex Name MS 896 N-(4-{[1-(2-fluorobenzoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 474 (M + H)+ 897 N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl] (ESI(+)) methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 436 carboxamide (M + H)+ 898 N-(4-{[1-(3,3-dimethylbutanoyl)piperidin-4-yl] (ESI(+)) methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 450 carboxamide (M + H)+ 899 N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 450 (M + H)+ 900 1-(pyridazin-3-yl)-N-(4-{[1-(4,4,4-trifluorobutanoyl) (ESI(+)) piperidin-4-yl]methyl}phenyl)azetidine-3- m/e 476 carboxamide (M + H)+ 901 N-(4-{[1-(2-methylpropanoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 902 N-{4-[(1-acetylpiperidin-4-yl)methyl}phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 394 (M + H)+ 903 N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl} (ESI(+)) methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 436 carboxamide (M + H)+ 904 N-[4-({1-[(1-methylcyclopropyl)carbonyl]piperidin- (ESI(+)) 4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 434 carboxamide (M + H)+ 927 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-5-ylcarbonyl) (ESI(+)) piperidin-4-yl]methyl}phenyl)azetidine-3- m/e 463 carboxamide (M + H)+ 928 N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 448 (M + H)+ 929 N-(4-{[1-(1H-pyrazol-4-ylcarbonyl)piperidin-4-yl] (ESI(+)) methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 446 carboxamide (M + H)+ 930 N-(4-{[1-(2,2-dimethylbutanoyl)piperidin-4-yl] (ESI(+)) methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 450 carboxamide (M + H)+ 931 N-[4-({1-[(2-methylcyclopropyl)carbonyl]piperidin- (ESI(+)) 4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 434 carboxamide (M + H)+ 932 N-[4-({1-[(methylsulfanyl)acetyl]piperidin-4-yl} (ESI(+)) methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 440 carboxamide (M + H)+ 933 N-[4-({1-[(1S,4R)-bicyclo[2.2.1]hept-2-ylacetyl] (ESI(+)) piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl) m/e 488 azetidine-3-carboxamide (M + H)+ 934 N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 450 (M + H)+ 935 N-(4-{[1-(4-methylpentanoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 450 (M + H)+ 936 N-[4-({1-[3-(methylsulfanyl)propanoyl]piperidin-4- (ESI(+)) yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 454 carboxamide (M + H)+ 937 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-4-ylcarbonyl) (ESI(+)) piperidin-4-yl]methyl}phenyl)azetidine-3- m/e 463 carboxamide (M + H)+ 938 N-(4-{[1-(1H-pyrazol-5-ylcarbonyl)piperidin-4-yl] (ESI(+)) methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 446 carboxamide (M + H)+ 939 N-[4-({1-[(6-methylpyridin-3-yl)carbonyl]piperidin- (ESI(+)) 4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 471 carboxamide (M + H)+ 940 N-[4-({1-[(3-methylthiophen-2-yl)carbonyl]piperidin- (ESI(+)) 4-yl}methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 476 carboxamide (M + H)+ 941 N-(4-{[1-(pent-4-ynoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 432 (M + H)+ 942 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-3-ylcarbonyl) (ESI(+)) piperidin-4-yl]methyl}phenyl)azetidine-3- m/e 462 carboxamide (M + H)+ 943 N-(4-{[1-(methoxyacetyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e XXX (M + H)+ 944 1-(pyridazin-3-yl)-N-(4-{[1-(tetrahydrofuran-2- (ESI(+)) ylcarbonyl)piperidin-4-yl]methyl}phenyl)azetidine- m/e 424 3-carboxamide (M + H)+ 945 N-[4-({1-[(2-methoxyethoxy)acetyl]piperidin-4-yl} (ESI(+)) methyl)phenyl]-1-(pyridazin-3-yl)azetidine-3- m/e 468 carboxamide (M + H)+ 946 N-(4-{[1-(ethoxyacetyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 438 (M + H)+ 947 1-(pyridazin-3-yl)-N-(4-{[1-(thiophen-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]methyl}phenyl)azetidine-3- m/e 462 carboxamide (M + H)+ 948 N-{4-[(1-hexanoylpiperidin-4-yl)methyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 450 (M + H)+ 949 N-[4-({1-[(1-methyl-1H-pyrrol-2-yl)carbonyl] (ESI(+)) piperidin-4-yl}methyl)phenyl]-1-(pyridazin-3-yl) m/e 459 azetidine-3-carboxamide (M + H)+ 950 N-(4-{[1-(but-3-enoyl)piperidin-4-yl]methyl}phenyl)- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 420 (M + H)+ 951 1-(pyridazin-3-yl)-N-(4-{[1-(1,3-thiazol-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]methyl}phenyl)azetidine-3- m/e 463 carboxamide (M + H)+ 952 N-(4-{[1-(furan-2-ylcarbonyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 446 (M + H)+ 953 N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl] (ESI(+)) methyl}phenyl)-1-(pyridazin-3-yl)azetidine-3- m/e 447 carboxamide (M + H)+ 954 1-(pyridazin-3-yl)-N-(4-{[1-(pyridin-2-ylcarbonyl) (ESI(+)) piperidin-4-yl]methyl}phenyl)azetidine-3- m/e 457 carboxamide (M + H)+ 955 N-(4-{[1-(furan-3-ylcarbonyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 446 (M + H)+ 956 N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 434 (M + H)+ 957 N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 958 N-{4-[(1-propanoylpiperidin-4-yl)methyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 408 (M + H)+ 959 N-{4-[(1-butanoylpiperidin-4-yl)methyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 422 (M + H)+ 960 N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 434 (M + H)+ 961 N-{4-[(1-pentanoylpiperidin-4-yl)methyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 962 N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 963 N-(4-{[1-(2-methylbenzoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 470 (M + H)+ 964 N-(4-{[1-(3-methylpentanoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 450 (M + H)+ 965 N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 462 (M + H)+ 966 N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 436 (M + H)+ 967 N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]methyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 420 (M + H)+ 968 1-(pyridazin-3-yl)-N-(4-{[1-(3,3,3-trifluoropropanoyl) (ESI(+)) piperidin-4-yl]methyl}phenyl)azetidine-3- m/e 462 carboxamide (M + H)+ - The following Examples were essentially prepared as described in Example 895, substituting an appropriate carboxylic acid in Example 895G. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- The title compound was prepared as described as described in Example 148A, substituting N-(4-bromophenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline and tert-butyl 4-methyl-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-methyl-4-((4-(4-(1-(6-methylpyridazin-3-yl)azetidine-3-carboxamido)phenyl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- N-(4-(1-((4-Methylpiperidin-4-yl)methyl)-1H-pyrazol-4-yl)phenyl)-1-(6-methylpyridazin-3-yl)azetidine-3-carboxamide was dissolved in methanol (3 ml) and treated with oxetan-3-one (0.022 ml, 0.338 mmol) and sodium cyanoborohydride (0.021 g, 0.338 mmol) and stirred overnight. The mixture was was concentrated, purified by normal phase chromatography, triturated with ether and concentrated to give the title compound. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.09 (s, 1H), 8.05 (s, 1H), 7.82 (s, 1H), 7.64-7.58 (m, 2H), 7.56-7.49 (m, 2H), 7.29 (d, J=9.1 Hz, 1H), 6.80 (d, J=9.0 Hz, 1H), 4.51 (t, J=6.4 Hz, 2H), 4.40 (t, J=5.8 Hz, 2H), 4.20 (t, J=8.3 Hz, 2H), 4.12 (dd, J=7.9, 6.1 Hz, 2H), 3.98 (s, 2H), 3.73 (tt, J=8.5, 6.1 Hz, 1H), 3.48-3.39 (m, 1H), 2.44 (s, 3H), 2.42-2.33 (m, 2H), 2.16-1.99 (m, 2H), 1.58-1.46 (m, 2H), 1.30 (d, J=12.6 Hz, 2H), 0.89 (s, 3H); MS (ESI(+)) m/e 502 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting 3-chloro-4-methylpyridazine for 3-bromopyridine and tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(4-methylpyridazin-3-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 1-(4-methylpyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 8.49 (d, J=4.6 Hz, 1H), 7.58-7.52 (m, 2H), 7.53-7.37 (m, 5H), 7.25-7.17 (m, 3H), 4.81-4.37 (m, 1H), 4.39-4.25 (m, 4H), 4.26-3.38 (m, 2H), 3.24-2.58 (m, 3H), 2.19 (s, 3H), 2.10-1.11 (m, 4H); MS (ESI(+)) m/e 456.2 (M+H)+
- The title compound was prepared as described as described in Example 148A, substituting 5-bromofuran-2-carboxylic acid for 4-bromoaniline and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
- The title compound was prepared as described in Example 1B, substituting 5-(1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)furan-2-carboxylic acid for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1C, substituting 3,6-dichloropyridazine for 3-bromopyridine and (S)-tert-butyl pyrrolidin-3-ylcarbamate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate followed by TFA deprotection as described in Example 1D.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(6-chloropyridazin-3-yl)pyrrolidin-3-amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 5-(1-(tert-butoxycarbonyl)piperidin-4-yl)furan-2-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1B, substituting (S)-tert-butyl 4-(5-((1-(6-chloropyridazin-3-yl)pyrrolidin-3-yl)carbamoyl)furan-2-yl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 4-(5-((1-(pyridazin-3-yl)pyrrolidin-3-yl)carbamoyl)furan-2-yl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-5-(piperidin-4-yl)-N-(1-(pyridazin-3-yl)pyrrolidin-3-yl)furan-2-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.48 (dd, J=4.4, 0.9 Hz, 1H), 8.40 (d, J=7.0 Hz, 1H), 7.55-7.46 (m, 1H), 7.41 (t, J=6.9 Hz, 1H), 7.37-7.24 (m, 3H), 7.06 (d, J=3.4 Hz, 1H), 6.86 (dd, J=9.1, 0.8 Hz, 1H), 6.31 (d, J=3.4 Hz, 1H), 4.67-4.47 (m, 2H), 3.76 (dd, J=10.8, 6.9 Hz, 1H), 3.70-3.59 (m, 1H), 3.59-3.48 (m, 1H), 3.48-3.39 (m, 2H), 3.19 (t, J=12.1 Hz, 1H), 3.08-2.89 (m, 2H), 2.33-2.19 (m, 1H), 2.13-2.02 (m, 2H), 1.99-1.88 (m, 1H), 1.67-1.41 (m, 2H); MS (ESI(+)) m/e 464 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting 4-chloro-3-methylpyridazine for 3-bromopyridine and tert-butyl 4-(4-(azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(4-(1-(3-methylpyridazin-4-yl)azetidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting 1-(3-methylpyridazin-4-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.05 (s, 1H), 8.55 (d, J=5.8 Hz, 1H), 7.57-7.51 (m, 2H), 7.49-7.33 (m, 5H), 7.26-7.19 (m, 2H), 6.45 (d, J=5.8 Hz, 1H), 4.62 (s, 1H), 4.31 (t, J=8.4 Hz, 2H), 4.24 (dd, J=20.4, 14.1 Hz, 3H), 3.66 (ddd, J=14.6, 8.5, 6.1 Hz, 2H), 2.76 (t, J=11.9 Hz, 2H), 2.52 (s, 3H), 2.13-1.45 (m, 5H); MS (ESI(+)) m/e 456.3 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting 1-(3-methylpyridazin-4-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.08 (s, 1H), 8.55 (d, J=5.8 Hz, 1H), 7.76-7.24 (m, 8H), 6.45 (d, J=5.8 Hz, 1H), 4.50-4.45 (m, 1H), 4.32 (t, J=8.3 Hz, 2H), 4.23 (d, J=13.9 Hz, 2H), 3.73-3.62 (m, 1H), 3.50-3.41 (m, 1H), 3.26-3.07 (m, 2H), 2.94-2.56 (m, 3H), 2.45-1.03 (m, 5H); MS (ESI(+)) m/e 474.2 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-aminonicotinic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.04 (s, 1H), 8.56 (dd, J=4.5, 1.1 Hz, 1H), 8.00 (dd, J=4.9, 1.8 Hz, 1H), 7.54 (d, J=8.5 Hz, 2H), 7.46-7.32 (m, 2H), 7.21 (d, J=8.5 Hz, 2H), 6.83 (dd, J=9.0, 1.2 Hz, 1H), 6.59 (dd, J=7.3, 4.9 Hz, 1H), 5.92 (s, 2H), 4.24 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.0, 6.0 Hz, 2H), 4.09-3.84 (m, 2H), 3.73 (tt, J=8.5, 6.0 Hz, 1H), 2.99 (bs, 2H), 2.74 (tt, J=11.7, 3.2 Hz, 1H), 1.76 (d, J=11.8 Hz, 2H), 1.70-1.52 (m, 2H); MS (ESI(+)) m/e 458 (M+H)+.
- Ethyl 1-methyl-5-(4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)-1H-pyrazole-3-carboxylate (368 mg, 0.905 mmol) was taken up in tetrahydrofuran (3.38 mL), and methanol (3.38 mL) then 1N aqueous lithium hydroxide (1.35 mL, 1.350 mmol) was added. The mixture was heated at 60° C. for 2 hours. The mixture was concentrated to dryness, suspended in water and treated with 1N aqueous HCl to pH 2. The solution was extracted with ethyl acetate and the organic layers were dried with sodium sulfate, filtered, and concentrated to give a colorless syrup that solidified upon standing. This solid was triturated with ether and collected by filtration to give the title compound. 1H NMR (400 MHz, DMSO-d6) δ ppm 12.67 (s, 1H), 10.32 (bs, 1H), 8.60-8.55 (m, 1H), 7.77 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 7.42 (dd, J=9.0, 4.5 Hz, 1H), 6.89 (d, J=8.9 Hz, 1H), 6.80 (s, 1H), 4.34-4.13 (m, 4H), 3.91 (s, 3H), 3.83-3.74 (m, 1H); MS (ESI(+)) m/e 379 (M+H)+.
- 1-(4-Nitrophenyl)ethanone (2 g, 12.11 mmol) was dissolved in tetrahydrofuran (20 mL) and chilled to 0° C. Sodium ethanolate (21% in ethanol) (7.85 g, 24.22 mmol) was added dropwise and the resulting solution was stirred for 15 minutes at 0° C. Diethyl oxylate (1.947 g, 13.32 mmol) was added dropwise and the ice bath was removed. The mixture was stirred at room temperature for 3 hours and diluted with 1N aqueous HCl (125 mL). The resulting suspension was stirred for 30 minutes and collected by filtration to give the title compound.
- Ethyl 4-(4-nitrophenyl)-2,4-dioxobutanoate (500 mg, 1.885 mmol) was dissolved in hexafluoroisopropanol (4 ml) and methylhydrazine (87 mg, 1.885 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 3 hours, concentrated to dryness, triturated with ether; and filtered to provide the title compound.
- The title compound was prepared as described in Example 1B, substituting ethyl 1-methyl-5-(4-nitrophenyl)-1H-pyrazole-3-carboxylate for tert-butyl 4-(4-(1-(benzyloxycarbonyl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting ethyl 5-(4-aminophenyl)-1-methyl-1H-pyrazole-3-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.31 (s, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 7.77 (d, J=8.7 Hz, 2H), 7.54 (d, J=8.6 Hz, 2H), 7.39 (dd, J=8.9, 4.5 Hz, 1H), 6.84 (s, 1H), 6.84 (dd, J=9.0, 1.4 Hz, 1H), 4.32-4.22 (m, 4H), 4.18 (dd, J=8.1, 5.8 Hz, 2H), 3.92 (s, 3H), 3.84-3.72 (m, 1H), 1.30 (t, J=7.1 Hz, 3H); MS (ESI(+)) m/e 407 (M+H)+.
- The title compound was prepared as described in Example 912, substituting phenylhydrazine for methylhydrazine in Example 912B. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.24 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.60 (d, J=8.7 Hz, 2H), 7.51-7.41 (m, 3H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 7.34-7.30 (m, 2H), 7.20 (d, J=8.7 Hz, 2H), 7.08 (s, 1H), 6.82 (dd, J=9.0, 1.3 Hz, 1H), 4.33 (q, J=7.1 Hz, 2H), 4.24 (t, J=8.4 Hz, 2H), 4.14 (dd, J=8.0, 6.0 Hz, 2H), 3.77-3.69 (m, 1H), 1.32 (t, J=7.1 Hz, 3H); MS (ESI(+)) m/e 469 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(5-aminopyridin-2-yl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(5-(1-(pyridazin-3-yl)azetidine-3-carboxamido)pyridin-2-yl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(6-(piperidin-4-yl)pyridin-3-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.27 (s, 1H), 8.67 (d, J=2.5 Hz, 1H), 8.57 (dd, J=4.5, 1.2 Hz, 1H), 8.01 (dd, J=8.5, 2.5 Hz, 1H), 7.56-7.46 (m, 1H), 7.46-7.35 (m, 2H), 7.35-7.23 (m, 3H), 6.83 (dd, J=9.0, 1.2 Hz, 1H), 4.64 (d, J=13.0 Hz, 1H), 4.26 (t, J=8.4 Hz, 2H), 4.16 (dd, J=8.0, 6.0 Hz, 2H), 3.76 (tt, J=8.5, 5.9 Hz, 1H), 3.47 (d, J=12.6 Hz, 1H), 3.19 (t, J=12.3 Hz, 1H), 3.01-2.85 (m, 2H), 1.94 (d, J=13.0 Hz, 1H), 1.79 (d, J=12.1 Hz, 1H), 1.73-1.53 (m, 2H); MS (ESI(+)) m/e 461 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (R)-tert-butyl 3-(4-aminophenoxy)pyrrolidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(6-methylpyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described in Example 1D, substituting (R)-tert-butyl 3-(4-(1-(6-methylpyridazin-3-yl)azetidine-3-carboxamido)phenoxy)pyrrolidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (R)-1-(6-methylpyridazin-3-yl)-N-(4-(pyrrolidin-3-yloxy)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 3-methylbutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6, T=90° C.) 8 ppm 9.63 (s, 1H), 7.49 (d, J=8.9 Hz, 2H), 7.21 (d, J=9.0 Hz, 1H), 6.88 (d, J=8.7 Hz, 2H), 6.71 (d, J=9.0 Hz, 1H), 5.03-4.85 (m, 1H), 4.16 (dt, J=14.0, 8.0 Hz, 4H), 3.69 (tt, J=8.5, 6.1 Hz, 1H), 3.62-3.34 (m, 3H), 2.43 (s, 3H), 2.23-1.98 (m, 6H), 0.91 (d, J=6.2 Hz, 6H); MS (ESI(+)) m/e 438 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (R)-1-(6-methylpyridazin-3-yl)-N-(4-(pyrrolidin-3-yloxy)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and isobutyric acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6, T=90° C.) 6 ppm 9.63 (s, 1H), 7.50 (d, J=9.0 Hz, 2H), 7.21 (d, J=9.0 Hz, 1H), 6.88 (d, J=8.9 Hz, 2H), 6.71 (d, J=9.0 Hz, 1H), 5.01-4.86 (m, 1H), 4.23-4.10 (m, 4H), 3.74-3.64 (m, 1H), 3.64-3.40 (m, 4H), 2.72-2.58 (m, 1H), 2.43 (s, 3H), 2.26-1.98 (m, 2H), 1.03 (dd, J=9.7, 4.0 Hz, 6H); MS (ESI(+)) m/e 424 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (R)-1-(6-methylpyridazin-3-yl)-N-(4-(pyrrolidin-3-yloxy)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,4-difluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6, T=90° C.) 6 ppm 9.63 (bs, 1H), 7.53-7.44 (m, 3H), 7.25-7.18 (m, 2H), 7.14-7.03 (m, 1H), 6.95-6.80 (m, 2H), 6.71 (d, J=8.9 Hz, 1H), 5.05-4.92 (m, 1H), 4.19 (t, J=8.2 Hz, 2H), 4.13 (t, J=7.0 Hz, 2H), 3.68 (tdd, J=10.3, 5.0, 1.7 Hz, 1H), 3.82-3.22 (m, 4H), 2.43 (s, 3H), 2.32-2.05 (m, 2H); MS (ESI(+)) m/e 494 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (R)-1-(6-methylpyridazin-3-yl)-N-(4-(pyrrolidin-3-yloxy)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and thiazole-4-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6, T=90° C.) 6 ppm 9.63 (s, 1H), 9.09 (d, J=1.6 Hz, 1H), 8.19 (d, J=2.0 Hz, 1H), 7.49 (d, J=8.7 Hz, 2H), 7.21 (d, J=9.0 Hz, 1H), 6.89 (d, J=8.6 Hz, 2H), 6.71 (d, J=9.0 Hz, 1H), 5.00 (dt, J=4.5, 2.2 Hz, 1H), 4.16 (dt, J=14.0, 8.0 Hz, 4H), 4.09-3.57 (m, 4H), 3.69 (tt, J=8.4, 6.1 Hz, 1H), 2.43 (s, 3H), 2.20 (dd, J=33.6, 24.3 Hz, 2H); MS (ESI(+)) m/e 465.2 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(6-(piperidin-4-yl)pyridin-3-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4,4,4-trifluorobutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.27 (s, 1H), 8.67 (d, J=2.6 Hz, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 8.00 (dd, J=8.5, 2.6 Hz, 1H), 7.40 (dd, J=9.0, 4.5 Hz, 1H), 7.26 (d, J=8.5 Hz, 1H), 6.86 (dd, J=9.0, 1.3 Hz, 1H), 4.50 (d, J=13.0 Hz, 1H), 4.26 (t, J=8.4 Hz, 2H), 4.17 (dd, J=8.2, 5.9 Hz, 2H), 3.97 (d, J=13.6 Hz, 1H), 3.76 (tt, J=8.6, 5.9 Hz, 1H), 3.11 (dd, J=18.5, 7.6 Hz, 1H), 2.90 (tt, J=11.7, 3.6 Hz, 1H), 2.76-2.59 (m, 2H), 2.59-2.43 (m, 2H), 1.91-1.77 (m, 2H), 1.66 (qd, J=12.6, 4.0 Hz, 1H), 1.51 (qd, J=12.7, 4.1 Hz, 1H); MS (ESI(+)) m/e 463 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(6-(piperidin-4-yl)pyridin-3-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 3,3-dimethylbutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.26 (s, 1H), 8.66 (d, J=2.5 Hz, 1H), 8.57 (dd, J=4.5, 1.1 Hz, 1H), 8.00 (dd, J=8.5, 2.6 Hz, 1H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 7.25 (d, J=8.5 Hz, 1H), 6.83 (dd, J=9.0, 1.2 Hz, 1H), 4.58 (d, J=12.9 Hz, 1H), 4.26 (t, J=8.4 Hz, 2H), 4.16 (dd, J=8.0, 6.0 Hz, 2H), 4.07 (d, J=13.4 Hz, 1H), 3.76 (tt, J=8.5, 5.9 Hz, 1H), 3.10 (t, J=12.1 Hz, 1H), 2.88 (tt, J=11.7, 3.6 Hz, 1H), 2.59 (t, J=11.8 Hz, 1H), 2.29 (d, J=14.0 Hz, 1H), 2.22 (d, J=14.0 Hz, 1H), 1.84 (t, J=10.8 Hz, 2H), 1.60 (qd, J=12.7, 3.8 Hz, 1H), 1.48 (qd, J=12.7, 4.0 Hz, 1H), 1.00 (s, 9H); MS (ESI(+)) m/e 437 (M+H)+.
- The title compound was prepared as described in Example 1C, substituting 3-chloro-4-methylpyridazine for 3-bromopyridine and (S)-tert-butyl 4-(4-(pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1D, substituting (S)-tert-butyl 4-(4-(1-(4-methylpyridazin-3-yl)pyrrolidine-3-carboxamido)phenyl)piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(4-methylpyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.03 (s, 1H), 8.46 (d, J=4.6 Hz, 1H), 7.58-7.52 (m, 2H), 7.50-7.37 (m, 5H), 7.28-7.15 (m, 3H), 4.71-4.55 (m, 1H), 3.89-3.38 (m, 5H), 3.28-2.58 (m, 4H), 2.34 (s, 3H), 2.32-1.98 (m, 2H), 2.00-1.49 (m, 4H); MS (ESI(+)) m/e 470.2 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting (S)-1-(4-methylpyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)pyrrolidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2,2-dimethylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.02 (s, 1H), 8.46 (d, J=4.6 Hz, 1H), 7.57-7.51 (m, 2H), 7.22-7.13 (m, 3H), 4.45-4.36 (m, 2H), 3.85-3.72 (m, 2H), 3.68 (dd, J=7.9, 5.7 Hz, 2H), 3.21 (p, J=7.7 Hz, 1H), 2.93-2.66 (m, 3H), 2.34 (s, 3H), 2.31-2.05 (m, 2H), 1.82-1.74 (m, 2H), 1.53-1.34 (m, 2H), 1.22 (s, 9H); MS (ESI(+)) m/e 450.3 (M+H)+.
- The title compound was prepared as described in Example 805, substituting 3,3,3-trifluoroprop-1-yne for ethynylcyclopropane in Example 805A and phenylhydrazine for methylhydrazine in Example 805B. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.26 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.61 (d, J=8.7 Hz, 2H), 7.50-7.44 (m, 3H), 7.41-7.31 (m, 3H), 7.23 (d, J=8.7 Hz, 2H), 7.14 (s, 1H), 6.83 (dd, J=8.9, 1.4 Hz, 1H), 4.24 (t, J=8.3 Hz, 2H), 4.14 (dd, J=8.1, 5.8 Hz, 2H), 3.74 (tt, J=8.5, 5.8 Hz, 1H); MS (ESI(+)) m/e 465.1 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting 6-chloropyridin-3-amine for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The title compound was prepared as described as described in Example 148A, substituting N-(6-chloropyridin-3-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline and 1-neopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.31 (s, 1H), 8.69 (d, J=2.6 Hz, 1H), 8.57 (dd, J=4.5, 1.3 Hz, 1H), 8.18 (s, 1H), 8.06 (dd, J=8.6, 2.6 Hz, 1H), 7.95 (d, J=0.4 Hz, 1H), 7.63 (dd, J=8.6, 0.4 Hz, 1H), 7.39 (dd, J=8.9, 4.5 Hz, 1H), 6.84 (dd, J=9.0, 1.4 Hz, 1H), 4.27 (t, J=8.4 Hz, 2H), 4.18 (dd, J=8.2, 5.9 Hz, 2H), 3.94 (s, 2H), 3.78 (tt, J=8.6, 5.9 Hz, 1H), 0.93 (s, 9H); MS (ESI(+)) m/e 392 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting tert-butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.15 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.98-7.90 (m, 1H), 7.47 (d, J=0.5 Hz, 1H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.82 (dd, J=9.0, 1.4 Hz, 1H), 4.31 (tt, J=11.3, 3.9 Hz, 1H), 4.22 (t, J=8.3 Hz, 2H), 4.12 (dd, J=8.1, 6.0 Hz, 2H), 4.02 (d, J=12.3 Hz, 2H), 3.67 (tt, J=8.6, 6.0 Hz, 1H), 2.88 (bs, 2H), 1.95 (dd, J=12.4, 2.4 Hz, 2H), 1.74 (qd, J=12.4, 4.4 Hz, 2H), 1.41 (s, 9H); MS (ESI(+)) m/e 428 (M+H)+.
- The title compound was prepared as described as described in Example 148A, substituting N-(6-chloropyridin-3-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline and tert-butyl 4-methyl-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)piperidine-1-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole followed by TFA deprotection as described in Example 1D to give the title compound as a TFA salt. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.63 (s, 1H), 8.79 (d, J=2.5 Hz, 1H), 8.67-8.54 (m, 2H), 8.52-8.39 (m, 1H), 8.31 (s, 1H), 8.13 (dd, J=8.7, 2.5 Hz, 1H), 8.05 (s, 1H), 7.84 (dd, J=9.4, 4.4 Hz, 1H), 7.76 (d, J=8.7 Hz, 1H), 7.51 (dd, J=9.4, 0.9 Hz, 1H), 4.51 (t, J=9.3 Hz, 2H), 4.44 (dd, J=9.5, 5.9 Hz, 2H), 4.14 (s, 2H), 3.87 (tt, J=8.8, 5.9 Hz, 1H), 3.29-3.14 (m, 2H), 3.14-2.96 (m, 2H), 1.74-1.58 (m, 2H), 1.56-1.42 (m, 2H), 0.98 (s, 3H); MS (ESI(+)) m/e 433 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting 1-(4-methylpyridazin-3-yl)-N-(4-(piperidin-4-yl)phenyl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 3,3-dimethylbutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.02 (s, 1H), 8.49 (d, J=4.6 Hz, 1H), 7.57-7.51 (m, 2H), 7.22-7.14 (m, 3H), 4.65-4.57 (m, 1H), 4.39-4.24 (m, 4H), 4.12-4.03 (m, 1H), 3.68 (p, J=7.4 Hz, 1H), 3.07 (t, J=12.0 Hz, 1H), 2.77-2.64 (m, 1H), 2.34-2.26 (m, 1H), 2.25-2.16 (m, 4H), 2.12-1.56 (m, 2H), 1.58-1.07 (m, 3H), 1.09-0.87 (m, 9H); MS (ESI(+)) m/e 450.3 (M+H)+.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-[4-({[1-(pyridazin-3-yl)azetidin-3-yl]carbonyl}amino)-1H-pyrazol-1-yl]piperidine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate.
- The title compound was prepared as described in Example 1A, substituting N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 3,3-dimethylbutanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.16 (s, 1H), 8.56 (dd, J=4.5, 1.1 Hz, 1H), 7.95 (s, 1H), 7.46 (s, 1H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 6.83 (dd, J=9.0, 1.2 Hz, 1H), 4.53 (d, J=13.3 Hz, 1H), 4.38 (tt, J=11.3, 4.0 Hz, 1H), 4.23 (t, J=8.3 Hz, 2H), 4.12 (dd, J=8.0, 6.1 Hz, 2H), 4.07 (d, J=13.6 Hz, 1H), 3.67 (tt, J=8.5, 6.0 Hz, 1H), 3.15 (t, J=12.1 Hz, 1H), 2.66 (t, J=11.9 Hz, 1H), 2.30 (d, J=14.1 Hz, 1H), 2.23 (d, J=14.1 Hz, 1H), 1.98 (t, J=10.7 Hz, 2H), 1.80 (qd, J=12.3, 4.1 Hz, 1H), 1.68 (qd, J=12.3, 4.2 Hz, 1H), 1.00 (s, 9H); MS (ESI(+)) m/e 426 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-fluorobenzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.15 (s, 1H), 8.56 (dd, J=4.5, 1.3 Hz, 1H), 7.98 (s, 1H), 7.54-7.42 (m, 3H), 7.38 (dd, J=9.0, 4.5 Hz, 1H), 7.34-7.26 (m, 2H), 6.82 (dd, J=9.0, 1.3 Hz, 1H), 4.59 (d, J=13.3 Hz, 1H), 4.45 (tt, J=11.2, 3.9 Hz, 1H), 4.23 (t, J=8.3 Hz, 2H), 4.12 (dd, J=8.0, 6.0 Hz, 2H), 3.67 (tt, J=8.5, 6.0 Hz, 1H), 3.47 (d, J=13.3 Hz, 1H), 3.22 (t, J=12.2 Hz, 1H), 2.98 (td, J=13.0, 2.7 Hz, 1H), 2.09 (d, J=11.2 Hz, 1H), 2.00-1.91 (m, 1H), 1.90-1.74 (m, 2H); MS (ESI(+)) m/e 450 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting methyl 4-aminobenzoate for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 1-(pyridazin-3-yl)azetidine-3-carboxylic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid.
- The procedure was followed as described in Example 911, substituting methyl 4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)benzoate for ethyl 1-methyl-5-(4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)-1H-pyrazole-3-carboxylate.
- The title compound was prepared as described in Example 1A, substituting aniline for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)benzoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid. 1H NMR (400 MHz, DMSO-d6/D2O) δ ppm 8.53 (dd, J=4.4, 1.3 Hz, 1H), 7.98-7.92 (m, 2H), 7.77-7.65 (m, 5H), 7.38-7.24 (m, 3H), 7.15-7.07 (m, 1H), 4.49 (t, J=9.0 Hz, 2H), 4.46-4.38 (m, 2H), 4.00-3.81 (m, 1H); MS (ESI(+)) m/e 374 (M+H)+.
-
TABLE 23 Ex Name MS 973 N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 368 (M + H)+ 974 N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 398 (M + H)+ 975 N-{4-[(2-cyclopropylethyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e XXX (M + H)+ 976 N-(4-{[2-(2-ethylpiperidin-1-yl)ethyl]carbamoyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 366 (M + H)+ 977 N-{4-[(cyclobutylmethyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 366 (M + H)+ 978 N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 354 (M + H)+ 979 N-[4-(butylcarbamoyl)phenyl]-1-(pyridazin-3-yl) (ESI(+)) azetidine-3-carboxamide m/e 354 (M + H)+ 980 N-{4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl) (ESI(+)) carbamoyl]phenyl}-1-(pyridazin-3-yl)azetidine-3- m/e 410 carboxamide (M + H)+ 981 N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 366 (M + H)+ 982 N-[4-({2-[methyl(phenyl)amino]ethyl]carbamoyl) (ESI(+)) phenyl]-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 430 (M + H)+ 983 N-{4-[1,1′-bi(cyclopropyl)-1-ylcarbamoyl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 378 (M + H)+ 984 1-(pyridazin-3-yl)-N-[4-(thiophen-3-ylcarbamoyl) (ESI(+)) phenyl]azetidine-3-carboxamide m/e 366 (M + H)+ 985 N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 366 (M + H)+ 986 N-{4-[(1-methylpiperidin-4-yl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 395 (M + H)+ 987 N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 354 (M + H)+ 988 N-[4-(1-azabicyclo[2.2.2]oct-3-ylcarbamoyl)phenyl]- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 407 (M + H)+ 989 1-(pyridazin-3-yl)-N-{4-[(tetrahydrofuran-3- (ESI(+)) ylmethyl)carbamoyl]phenyl}azetidine-3- m/e 382 carboxamide (M + H)+ 990 N-{4-[(oxetan-3-ylmethyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 368 (M + H)+ 991 N-{4-[(2-methylcyclopropyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 352 (M + H)+ 992 N-(4-(cyclobutylcarbamoyl)phenyl]-1-(pyridazin-3- (ESI(+)) yl)azetidine-3-carboxamide m/e 352 (M + H)+ 993 N-{4-[(1-methylcyclopropyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 352 (M + H)+ 994 N-{4-[(2-methoxy-2-methylpropyl)carbamoyl] (ESI(+)) phenyl}-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 384 (M + H)+ 995 N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 352 (M + H)+ 996 1-(pyridazin-3-yl)-N-(4-{[(2R)-tetrahydrofuran-2- (ESI(+)) ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide m/e 382 (M + H)+ 997 1-(pyridazin-3-yl)-N-{4-[(3,3,3-trifluoropropyl) (ESI(+)) carbamoyl]phenyl}azetidine-3-carboxamide m/e 394 (M + H)+ 998 N-{4-[(1-methylpiperidin-3-yl)carbamoyl]phenyl}- (ESI(+)) 1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 395 (M + H)+ 999 N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 382 (M + H)+ 1000 1-(pyridazin-3-yl)-N-(4-{[(2S)-tetrahydrofuran-2- (ESI(+)) ylmethyl]carbamoyl}phenyl)azetidine-3-carboxamide m/e 382 (M + H)+ 1001 1-(pyridazin-3-yl)-N-{4-[(tetrahydro-2H-pyran-4- (ESI(+)) ylmethyl)carbamoyl]phenyl}azetidine-3-carboxamide m/e 396 (M + H)+ 1002 1-(pyridazin-3-yl)-N-[4-(tetrahydro-2H-pyran-4- (ESI(+)) ylcarbamoyl)phenyl]azetidine-3-carboxamide m/e 382 (M + H)+ 1003 N-(4-{[(1-methylpiperidin-3-yl)methyl]carbamoyl} (ESI(+)) phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide m/e 409 (M + H)+ 1004 N-[4-(cyclopropylcarbamoyl)phenyl]-1-(pyridazin-3- (ESI(+)) yl)azetidine-3-carboxamide m/e 338 (M + H)+ 1005 N-(4-(cyclopentylcarbamoyl)phenyl]-1-(pyridazin-3- (ESI(+)) yl)azetidine-3-carboxamide m/e 366 (M + H)+ 1006 N-[4-(benzylcarbamoyl)phenyl]-1-(pyridazin-3-yl) (ESI(+)) azetidine-3-carboxamide m/e 388 (M + H)+ 1007 N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 392 (M + H)+ 1008 N-[4-(propylcarbamoyl)phenyl]-1-(pyridazin-3-yl) (ESI(+)) azetidine-3-carboxamide m/e 340 (M + H)+ 1009 N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 392 (M + H)+ 1010 N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 392 (M + H)+ 1011 N-{4-[(1-methylcyclobutyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 366 (M + H)+ 1012 N-[4-(prop-2-en-1-ylcarbamoyl)phenyl]-1-(pyridazin- (ESI(+)) 3-yl)azetidine-3-carboxamide m/e 338 (M + H)+ 1020 1-(pyridazin-3-yl)-N-{4-[(3S)-tetrahydrofuran-3- (ESI(+)) ylcarbamoyl]phenyl}azetidine-3-carboxamide m/e 368 (M + H)+ 1021 N-[4-({4-[2-(dimethylamino)ethyl]phenyl}carbamoyl) (ESI(+)) phenyl]-1(pyridazin-3-yl)azetidine-3-carboxamide m/e 445 (M + H)+ 1022 1-(pyridazin-3-yl)-N-{4-[(3R)-tetrahydrofuran-3- (ESI(+)) ylcarbamoyl]phenyl}azetidine-3-carboxamide m/e 368 (M + H)+ 1023 N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1- (ESI(+)) (pyridazin-3-yl)azetidine-3-carboxamide m/e 356 (M + H)+ - The following Examples were essentially prepared as described in Example 972, substituting an appropriate amine in Example 972C. Some products were purified by flash chromatography while others were purified by reverse-phase HPLC. Accordingly, some Examples were isolated as trifluoroacetic acid salts.
- A solution of tert-butyl (3-hydroxy-2,2-dimethylpropyl)carbamate (1.000 g, 4.92 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.145 g, 5.90 mmol) and 2-(tributylphosphoranylidene)acetonitrile (1.425 g, 5.90 mmol) were stirred together in toluene (20 ml) at 90° C. overnight. The reaction mixture was concentrated and purified by normal phase chromatography to give the title compound.
- The title compound was prepared as described as described in Example 148A, substituting N-(4-bromophenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline and tert-butyl (2,2-dimethyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propyl)carbamate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
- The title compound was prepared as described in Example 1D, substituting tert-butyl (2,2-dimethyl-3-(4-(4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)-1H-pyrazol-1-yl)propyl)carbamate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate to give the title compound as a TFA salt. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.26 (s, 1H), 8.57 (dd, J=4.4, 1.1 Hz, 1H), 8.12 (s, 1H), 7.95 (bs, 3H), 7.92 (s, 1H), 7.74 (dd, J=9.3, 4.4 Hz, 1H), 7.64 (d, J=8.7 Hz, 2H), 7.55 (d, J=8.6 Hz, 2H), 7.36 (d, J=9.2 Hz, 1H), 4.44 (t, J=9.1 Hz, 2H), 4.37 (dd, J=9.2, 5.9 Hz, 2H), 4.10 (s, 2H), 3.81 (tt, J=8.8, 5.9 Hz, 1H), 2.83-2.70 (m, 2H), 0.96 (s, 6H); MS (ESI(+)) m/e 406 (M+H)+.
- The title compound was prepared as described in Example 1024A, substituting tert-butyl 4-(3-hydroxy-2,2-dimethylpropyl)piperidine-1-carboxylate for tert-butyl (3-hydroxy-2,2-dimethylpropyl)carbamate.
- The title compound was prepared as described as described in Example 148A, substituting N-(4-bromophenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for 4-bromoaniline and tert-butyl 4-(2,2-dimethyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propyl)piperidine-1-carboxylate for 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
- The title compound was prepared as described in Example 1D, substituting tert-butyl 4-(2,2-dimethyl-3-(4-(4-(1-(pyridazin-3-yl)azetidine-3-carboxamido)phenyl)-1H-pyrazol-1-yl)propyl)piperazine-1-carboxylate for tert-butyl 4-(4-(1-(pyridin-3-yl)azetidine-3-carboxamido)phenoxy)piperidine-1-carboxylate to give the title compound as a TFA salt. 1H NMR (500 MHz, DMSO-d6) δ ppm 10.25 (s, 1H), 8.81 (s, 2H), 8.57 (dd, J=4.3, 1.0 Hz, 1H), 8.07 (s, 1H), 7.86 (s, 1H), 7.80 (dd, J=9.3, 4.4 Hz, 1H), 7.62 (d, J=8.7 Hz, 2H), 7.54 (d, J=8.6 Hz, 2H), 7.45 (d, J=8.9 Hz, 1H), 4.47 (t, J=9.2 Hz, 2H), 4.40 (dd, J=9.3, 5.9 Hz, 2H), 4.03 (s, 2H), 3.87-3.74 (m, 1H), 3.19 (s, 4H), 2.92 (s, 4H), 2.45 (s, 2H), 0.89 (s, 6H); MS (ESI(+)) m/e 475 (M+H)+.
- The title compound was prepared as described in Example 1A, substituting N-(4-(piperidin-4-yl)phenyl)-1-(pyridazin-3-yl)azetidine-3-carboxamide for tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate and 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)-2-methylpropanoic acid for 1-(benzyloxycarbonyl)azetidine-3-carboxylic acid, followed by TFA deprotection as described in Example 1D to give the title compound as a TFA salt. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.17 (s, 1H), 8.67 (s, 2H), 8.56 (d, J=4.3 Hz, 1H), 7.77 (dd, J=9.3, 4.4 Hz, 1H), 7.55 (d, J=8.4 Hz, 2H), 7.42 (d, J=9.3 Hz, 1H), 7.21 (d, J=8.5 Hz, 2H), 5.27 (s, 1H), 4.59 (s, 1H), 4.45 (t, J=9.1 Hz, 2H), 4.37 (dd, J=9.2, 5.9 Hz, 2H), 3.91-3.71 (m, 1H), 3.11 (s, 5H), 2.81-2.53 (m, 6H), 1.80 (d, J=12.0 Hz, 2H), 1.45 (td, J=12.3, 9.1 Hz, 2H), 1.21 (s, 6H); MS (ESI(+)) m/e 492 (M+H)+.
Claims (2)
1. A method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of formula (IC), or a therapeutically acceptable salt thereof,
X1 is N and X2 is CR1; or
X1 is CR1 and X2 is N; or
X1 is CR1 and X2 is CR1;
Y1 is C(O)NH, or NHC(O);
Z1 is
wherein indicates the point of attachment to Y1 and indicates the point of attachment to the nitrogen containing heteroaryl;
R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R12)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); Z1 is
and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups.
2. A method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of formula (IC), or a therapeutically acceptable salt thereof,
X1 is N and X2 is CR1; or
X1 is CR1 and X2 is N; or
X1 is CR1 and X2 is CR1;
Y1 is C(O)NH, or NHC(O);
Z1 is
wherein indicates the point of attachment to Y1 and indicates the point of attachment to the nitrogen containing heteroaryl;
R1, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydoxyalkyl, alkoxy, OH, NH2, CN, NO2, F, Cl, Br and I;
R2 is independently selected from the group consisting of C4-C6-alkyl, C4-C6-alkenyl, C4-C6-alkynyl, aryl, and 5-6 membered heteroaryl; wherein each R2 C4-C6-alkyl, C4-C6-alkenyl, and C4-C6-alkynyl is substituted with one or more substituents independently selected from the group consisting of R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, CO(O)R3, OC(O)R3, OC(O)OR3, NH2, NHR3, N(R3)2, NHC(O)R3, NR3C(O)R3, NHS(O)2R3, NR3S(O)2R3, NHC(O)OR3, NR3C(O)OR3, NHC(O)NH2, NHC(O)NHR3, NHC(O)N(R3)2, NR3C(O)NHR3, NR3C(O)N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, C(O)NHOH, C(O)NHOR3, C(O)NHSO2R3, C(O)NR3SO2R3, SO2NH2, SO2NHR3, SO2N(R3)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR3, C(N)N(R3)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R2 aryl and 5-6 membered heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR4, C(N)N(R4)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, and I;
R3, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, and heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR5, C(N)N(R5)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R3 aryl, cycloalkyl, cycloalkenyl, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR6, C(N)N(R6)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
R4, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR7, C(N)N(R7)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I;
R5, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R8, OR8, SR8, S(O)R8, SO2R8, NHR8, N(R8)2, C(O)R8, C(O)NH2, C(O)NHR8, C(O)N(R8)2, NHC(O)R8, NR8C(O)R8, NHSO2R8, NHC(O)OR8, SO2NH2, SO2NHR8, SO2N(R8)2, NHC(O)NH2, NHC(O)NHR8, OH, (O), C(O)OH, N3, CN, NH2, F, Cl, Br and I;
R6, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R9, OR9, SR9, S(O)R9, SO2R9, NHR9, N(R9)2, C(O)R9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, NHC(O)R9, NR9C(O)R9, NHSO2R9, NHC(O)OR9, SO2NH2, SO2NHR9, SO2N(R9)2, NHC(O)NH2, NHC(O)NHR9, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br and I;
R7, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
R8, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
R9, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
wherein the cyclic moieties represented by R4, R5, R6, R7, R8, and R9 are independently optionally substituted with one or more substituents independently selected from the group consisting of R10, OR10, SR10, S(O)R10, SO2R10, C(O)R10, CO(O)R10, OC(O)R10, OC(O)OR10, C(O)C(O)R10, NH2, NHR10, N(R10)2, NHC(O)R10, NR10C(O)R10, NHS(O)2R10, NR10S(O)2R10, NHC(O)OR10, NR10C(O)OR10, NHC(O)NH2, NHC(O)NHR10, NHC(O)N(R10)2, NR10C(O)NHR10, NR10C(O)N(R10)2, C(O)NH2, C(O)NHR10, C(O)N(R10)2, C(O)NHOH, C(O)NHOR10, C(O)NHSO2R10, C(O)NR10SO2R10, SO2NH2, SO2NHR10, SO2N(R10)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR10, C(N)N(R10)2, CNOH, CNOCH3, OH, CN, N3, NO2, F, Cl, Br and I;
R10, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R10 alkyl, alkenyl, and alkynyl is optionally substituted with one or more substituents independently selected from the group consisting of R11, OR11, SR11, S(O)R11, SO2R11, C(O)R11, CO(O)R11, OC(O)R11, OC(O)OR11, NH2, NHR11, N(R11)2, NHC(O)R11, NR11C(O)R11, NHS(O)2R11, NR11S(O)2R11, NHC(O)OR11, NR11C(O)OR11, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)NHR11, NR11C(O)N(R11)2, C(O)NH2, C(O)NHR11, C(O)N(R11)2, C(O)NHOH, C(O)NHOR11, C(O)NHSO2R11, C(O)NR11SO2R11, SO2NH2, SO2NHR11, SO2N(R11)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR11, C(N)N(R11)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, F, Cl, Br and I; wherein each R10 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R12, OR12, SR12, S(O)R12, SO2R12, C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, NHR12, N(R12)2, NHC(O)R12, NR12C(O)R12, NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)NHR12, NHC(O)N(R12)2, NR12C(O)NHR12, NR12C(O)N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, C(O)NHOH, C(O)NHOR12, C(O)NHSO2R12, C(O)NR12SO2R12, SO2NH2, SO2NHR12, SO2N(R2)2, C(O)H, C(O)OH, C(N)NH2, C(N)NHR12, C(N)N(R12)2, CNOH, CNOCH3, OH, CN, N3, NO2, CF3, OCF3, F, Cl, Br and I;
R11, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; wherein each R11 alkyl, alkenyl, and alkynyl is optionally substituted with alkoxy or aryl; wherein each R11 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more substituents independently selected from the group consisting of R13, OR13, C(O)OR13, OCF3, CF3, F, Cl, Br and I;
R12, at each occurrence, is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl; and
R13, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and cycloalkenyl;
with the proviso that
when X1 is CR1 and X2 is CR1; R1 is hydrogen; Y1 is NHC(O); Z1 is
and R2 is pyrrolyl; the R2 pyrrolyl is not substituted with two alkyl groups; and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/357,383 US20170065575A1 (en) | 2012-05-11 | 2016-11-21 | Nampt inhibitors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261645692P | 2012-05-11 | 2012-05-11 | |
US201261719013P | 2012-10-26 | 2012-10-26 | |
US201361779756P | 2013-03-13 | 2013-03-13 | |
US13/891,357 US8975398B2 (en) | 2012-05-11 | 2013-05-10 | NAMPT inhibitors |
US14/603,832 US20150141398A1 (en) | 2012-05-11 | 2015-01-23 | Nampt inhibitors |
US15/357,383 US20170065575A1 (en) | 2012-05-11 | 2016-11-21 | Nampt inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/891,357 Division US8975398B2 (en) | 2012-05-11 | 2013-05-10 | NAMPT inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170065575A1 true US20170065575A1 (en) | 2017-03-09 |
Family
ID=48539390
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/891,354 Abandoned US20130303509A1 (en) | 2012-05-11 | 2013-05-10 | Nampt inhibitors |
US13/891,357 Active US8975398B2 (en) | 2012-05-11 | 2013-05-10 | NAMPT inhibitors |
US14/603,832 Abandoned US20150141398A1 (en) | 2012-05-11 | 2015-01-23 | Nampt inhibitors |
US15/357,383 Abandoned US20170065575A1 (en) | 2012-05-11 | 2016-11-21 | Nampt inhibitors |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/891,354 Abandoned US20130303509A1 (en) | 2012-05-11 | 2013-05-10 | Nampt inhibitors |
US13/891,357 Active US8975398B2 (en) | 2012-05-11 | 2013-05-10 | NAMPT inhibitors |
US14/603,832 Abandoned US20150141398A1 (en) | 2012-05-11 | 2015-01-23 | Nampt inhibitors |
Country Status (11)
Country | Link |
---|---|
US (4) | US20130303509A1 (en) |
EP (1) | EP2847181A1 (en) |
JP (1) | JP2015520752A (en) |
CN (1) | CN104583194A (en) |
AR (1) | AR091023A1 (en) |
CA (1) | CA2873097A1 (en) |
HK (1) | HK1209739A1 (en) |
MX (1) | MX2014013751A (en) |
TW (1) | TW201350478A (en) |
UY (1) | UY34804A (en) |
WO (1) | WO2013170115A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021007313A1 (en) * | 2019-07-08 | 2021-01-14 | Mayo Foundation For Medical Education And Research | Wnt activators and methods of use |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013170115A1 (en) * | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Pyridazine and pyridine derivatives as nampt inhibitors |
AU2015231001A1 (en) | 2014-03-21 | 2016-09-29 | Abbvie Inc. | Anti-EGFR antibodies and antibody drug conjugates |
KR102359214B1 (en) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
US10144742B2 (en) | 2014-04-18 | 2018-12-04 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
MA40240B1 (en) | 2014-06-19 | 2019-03-29 | Ariad Pharma Inc | Heteroaryl compounds of kinase inhibition |
CN107438598A (en) | 2015-01-20 | 2017-12-05 | 米伦纽姆医药公司 | Quinazoline and quinoline compound and application thereof |
SI3464336T1 (en) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Compounds |
CN109600993A (en) | 2016-06-08 | 2019-04-09 | 艾伯维公司 | Anti-egfr antibodies drug conjugates |
JP6751165B2 (en) | 2016-06-08 | 2020-09-02 | アッヴィ・インコーポレイテッド | Anti-B7-H3 antibody and antibody drug conjugate |
BR112018075630A2 (en) | 2016-06-08 | 2019-03-19 | Abbvie Inc. | anti-cd98 antibodies and antibody drug conjugates |
CA3027044A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
US20190153108A1 (en) | 2016-06-08 | 2019-05-23 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
BR112018075649A2 (en) | 2016-06-08 | 2019-04-09 | Abbvie Inc. | anti-b7-h3 antibodies and antibody drug conjugates |
BR112018076441A2 (en) | 2016-06-23 | 2019-04-09 | St. Jude Children´S Research Hospital | pantothenate kinases small molecule modulators |
SG11201903013SA (en) | 2016-10-18 | 2019-05-30 | Seattle Genetics Inc | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
WO2018124001A1 (en) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Bmp-signal-inhibiting compound |
WO2018177993A1 (en) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazoles for controlling arthropods |
EP3612567B1 (en) | 2017-04-19 | 2024-09-11 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
BR112019022445A2 (en) | 2017-04-27 | 2020-05-12 | Seattle Genetics, Inc. | COMPOSITION OF BINDER-DRUG CONJUGATE, FORMULATION, METHOD TO INHIBIT THE TUMOR CELL OR CANCER CELL MULTIPLICATION OR CAUSE APOPTOSIS IN A TUMOR OR CANCER CELL, AND, PHARMACEUTICAL CONNECTOR COMPOUND |
CA3086671A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
EP3731859A4 (en) | 2017-12-27 | 2021-09-22 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
WO2019149637A1 (en) * | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
PL3752501T3 (en) | 2018-02-13 | 2023-08-21 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
JP7242702B2 (en) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | PD-1/PD-L1 inhibitor |
CA3099737A1 (en) | 2018-05-14 | 2019-11-21 | Ariad Pharmaceuticals, Inc. | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders |
KR20230159715A (en) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 inhibitors |
US20210388018A1 (en) * | 2018-10-01 | 2021-12-16 | Cornell University | Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof |
KR102635333B1 (en) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | PD-1/PD-L1 inhibitors |
JP7413346B2 (en) | 2019-03-06 | 2024-01-15 | 第一三共株式会社 | Pyrrolopyrazole derivative |
US11807626B2 (en) | 2020-04-23 | 2023-11-07 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
CN114660219A (en) * | 2020-12-23 | 2022-06-24 | 安徽古特生物科技有限公司 | Method for detecting beta-nicotinamide mononucleotide |
AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
WO2024127366A1 (en) | 2022-12-16 | 2024-06-20 | Pheon Therapeutics Ltd | Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof |
CN117285573B (en) * | 2023-09-26 | 2024-03-26 | 长沙兴嘉生物工程股份有限公司 | Beta-nicotinamide mononucleotide metal complex and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8975398B2 (en) * | 2012-05-11 | 2015-03-10 | Abbvie Inc. | NAMPT inhibitors |
US9296723B2 (en) * | 2012-05-11 | 2016-03-29 | Abbvie Inc. | NAMPT inhibitors |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ262942A (en) | 1993-03-29 | 1997-07-27 | Zeneca Ltd | Pyridyl substituted piperazine and various other derivatives of azaheteroaryl substituted piperazines; pharmaceutical compositions |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
PT1019385E (en) | 1995-09-15 | 2004-06-30 | Upjohn Co | AMINOARYL-OXAZOLIDINONE N-OXIDES |
DE19624668A1 (en) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Use of pyridylalkane, pyridylalken or pyridylalkynamides |
DE19624659A1 (en) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | New pyridylalkene and pyridylalkanoic acid amides |
AU8270298A (en) | 1997-06-26 | 1999-01-19 | Eli Lilly And Company | Antithrombotic agents |
CA2294042A1 (en) | 1997-06-26 | 1999-01-07 | David Kent Herron | Antithrombotic agents |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
DE60231880D1 (en) | 2001-08-07 | 2009-05-20 | Banyu Pharma Co Ltd | SPIRO ISOBENZOFURANE AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
HUP0200849A2 (en) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them |
DK1485348T3 (en) | 2002-03-13 | 2008-09-29 | Janssen Pharmaceutica Nv | Carbonylamino derivatives as novel inhibitors of histane deacetylase |
EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
GB0319150D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
WO2005030704A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
EP1697375A2 (en) | 2003-12-02 | 2006-09-06 | Vertex Pharmaceuticals Incorporated | Heterocyclic protein kinase inhibitors and uses thereof |
EP1700856B1 (en) | 2003-12-26 | 2015-11-11 | Kyowa Hakko Kirin Co., Ltd. | Thiazole derivative |
EP1737850B1 (en) | 2004-04-19 | 2007-10-03 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
DE602004020812D1 (en) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | NEW INTERMEDIATE PRODUCTS FOR LINEZOLID AND RELATED COMPOUNDS |
US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
WO2006058338A2 (en) | 2004-11-29 | 2006-06-01 | Janssen Pharmaceutica N.V. | 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor |
MX2007010215A (en) * | 2005-02-24 | 2007-11-07 | Millennium Pharm Inc | Pgd2 receptor antagonists for the treatment of inflammatory diseases. |
JP2008531673A (en) | 2005-03-04 | 2008-08-14 | アストラゼネカ アクチボラグ | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
AU2007294686B2 (en) * | 2006-09-15 | 2013-10-31 | Equinox Sciences, Llc | Kinase inhibitor compounds |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
WO2008075172A2 (en) * | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
MX2009008465A (en) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | 2-aminooxazolines as taar1 ligands. |
JP2010524972A (en) | 2007-04-19 | 2010-07-22 | コンサート ファーマシューティカルズ インコーポレイテッド | Deuterated morpholinyl compounds |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
US20090113874A1 (en) | 2007-11-02 | 2009-05-07 | Caterpillar Inc. | System and method for electrically regenerating a particulate filter assembly of a generator set |
AR070479A1 (en) | 2008-02-26 | 2010-04-07 | Takeda Pharmaceutical | FUSIONED HETEROCICLIC DERIVATIVE AND ITS USE |
EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
EP2303889A1 (en) | 2008-06-18 | 2011-04-06 | F. Hoffmann-La Roche AG | Halo-substituted pyrimidodiazepines as plkl inhibitors |
JP5575799B2 (en) | 2008-12-22 | 2014-08-20 | アレイ バイオファーマ、インコーポレイテッド | 7-phenoxycyclomancarboxylic acid derivative |
WO2011025799A1 (en) * | 2009-08-26 | 2011-03-03 | Glaxo Group Limited | Cathepsin c inhibitors |
EP2611778B1 (en) * | 2010-09-03 | 2015-08-05 | Forma TM, LLC. | Guanidine compounds and compositions for the inhibition of nampt |
US9499533B2 (en) * | 2012-03-27 | 2016-11-22 | Shionogi & Co., Ltd. | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity |
US9260441B2 (en) * | 2012-03-28 | 2016-02-16 | Intervet Inc. | Heteroaryl compounds with cyclic bridging unit |
-
2013
- 2013-05-10 WO PCT/US2013/040481 patent/WO2013170115A1/en active Application Filing
- 2013-05-10 UY UY0001034804A patent/UY34804A/en not_active Application Discontinuation
- 2013-05-10 US US13/891,354 patent/US20130303509A1/en not_active Abandoned
- 2013-05-10 JP JP2015511730A patent/JP2015520752A/en active Pending
- 2013-05-10 CA CA2873097A patent/CA2873097A1/en not_active Abandoned
- 2013-05-10 EP EP13726339.8A patent/EP2847181A1/en not_active Withdrawn
- 2013-05-10 AR ARP130101637A patent/AR091023A1/en unknown
- 2013-05-10 TW TW102116746A patent/TW201350478A/en unknown
- 2013-05-10 MX MX2014013751A patent/MX2014013751A/en unknown
- 2013-05-10 US US13/891,357 patent/US8975398B2/en active Active
- 2013-05-10 CN CN201380036867.6A patent/CN104583194A/en active Pending
-
2015
- 2015-01-23 US US14/603,832 patent/US20150141398A1/en not_active Abandoned
- 2015-10-28 HK HK15110586.2A patent/HK1209739A1/en unknown
-
2016
- 2016-11-21 US US15/357,383 patent/US20170065575A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8975398B2 (en) * | 2012-05-11 | 2015-03-10 | Abbvie Inc. | NAMPT inhibitors |
US9296723B2 (en) * | 2012-05-11 | 2016-03-29 | Abbvie Inc. | NAMPT inhibitors |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021007313A1 (en) * | 2019-07-08 | 2021-01-14 | Mayo Foundation For Medical Education And Research | Wnt activators and methods of use |
Also Published As
Publication number | Publication date |
---|---|
JP2015520752A (en) | 2015-07-23 |
MX2014013751A (en) | 2015-08-07 |
HK1209739A1 (en) | 2016-04-08 |
US20150141398A1 (en) | 2015-05-21 |
US8975398B2 (en) | 2015-03-10 |
WO2013170115A1 (en) | 2013-11-14 |
TW201350478A (en) | 2013-12-16 |
EP2847181A1 (en) | 2015-03-18 |
CA2873097A1 (en) | 2013-11-14 |
AR091023A1 (en) | 2014-12-30 |
US20130303510A1 (en) | 2013-11-14 |
US20130303509A1 (en) | 2013-11-14 |
CN104583194A (en) | 2015-04-29 |
UY34804A (en) | 2013-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8975398B2 (en) | NAMPT inhibitors | |
US10093624B2 (en) | NAMPT and ROCK inhibitors | |
US9187472B2 (en) | NAMPT inhibitors | |
WO2013170113A1 (en) | Nampt inhibitors | |
EP2776393B1 (en) | Nampt inhibitors | |
US20120122924A1 (en) | Nampt inhibitors | |
US9796708B2 (en) | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | |
US9334264B2 (en) | NAMPT inhibitors | |
US9758511B2 (en) | NAMPT inhibitors | |
US20170253562A1 (en) | Nampt Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |